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Abstract 
 
The immune and reproductive systems have long been known to be inextricably linked, 
with components of immune pathways, particularly cytokines, mediating processes 
such as ovarian/menstrual cyclicity, endometrial remodelling, mating-induced 
immunomodulation, implantation, pregnancy, parturition and lactation. The nature of 
this involvement has often been investigated at the level of single mediators, with little 
consideration of the fact that cytokines are increasingly understood to function as 
complex networks. This study aimed to characterise inflammatory networks using both 
traditional and novel machine-learning Bayesian network-based methods in the context 
of keystone aspects of reproduction, viz., in the endometrial response to seminal 
plasma, cytokine:hormone interactions during lactation, and oocyte maturation 
following controlled ovarian hyperstimulation.  
 
‘Traditional’ pathway analyses used to examine the murine endometrial response to 
seminal plasma revealed previously unidentified mediators and showed 
compartmentalised epithelium/stroma-specific responses. However, they proved 
ineffective in describing novel cytokine interactions.  This led to the development a 
highly effective novel Bayesian network-based approach to explore cytokine:hormone 
networks during murine lactation. This revealed that prolactin, a putative potent 
immunomodulator, was far less influential than expected in vivo. The method also 
identified previously unknown cytokine interactions and described features such as 
synergy and antagonism. Further refinement of these network analyses as modified 
variational Bayesian state space models enabled the display of core, conserved 
subnetworks (communities) of human follicular fluid cytokines whose interactions 
varied with oocyte maturity. Moreover, these cytokine signatures also allowed the 
prediction of an oocytes’ fertilisability potential, with potential attendant benefits to 
assisted conception.  
 
This thesis represents the first endeavour to model inflammatory networks in vivo in 
any setting to date. It has revealed their central role, functional conservation and key 
features of cytokine interactions across a spectrum of reproductive processes. Further 
development of this methodology appears set to offer invaluable new insights into the 
complex immune signalling that underpins reproductive biology. 
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1. Introduction 
 
1.1 The role of immune networks in reproductive physiology 
The immune system underpins many physiological processes, and reproduction is no 
exception. In all animals, reproductive organs play host to a large population of 
leukocytes, which change dynamically in composition in response to the hormonal 
environment [1-5]. Tissue responses to reproductive events such as ovulation, 
implantation and parturition are akin to an inflammatory response, with both leukocytes 
and reproductive tissues themselves producing, and exhibiting functional responses to, 
bioactive proteins such as cytokines [6]. This results in a complex network of 
interactions between host tissue cells (including resident macrophages), fibroblasts and 
immune effector cells via the intermediary of these agents. These mediators also have 
neuroendocrine effects, thereby implicating the immune system in all aspects of 
reproductive function [7, 8]. Indeed, both the innate and adaptive systems (Figure 1-1) 
influence reproductive outcome from conception to adulthood in women and other 
mammalian dams (Table 1-1).  
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Figure 1-1: Schematic showing the components of the immune system. MΦ – 
macrophage, N – neutrophil, Ba – basophil, Eo – eosinophil, NK – natural killer cell, DC 
– dendritic cell, HSP – heat shock protein. Adapted from Muehlebein et al 2010 [9]. 
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Reproductive Event Roles of the immune System Mechanism 
Puberty Unknown Unknown 
Ovulation Oocyte release 
Priming of the endometrium 
Ovarian repair 
Leukocytes and cytokines 
T cells and NK cells 
Neutrophil 
Pregnancy Implantation Mediate tolerance 
Facilitate implantation 
Uterine NK cells, leukocytes 
 Pregnancy 
maintenance 
Mediate tolerance 
Placentation 
Immunoeducation of the newborn 
T regs, endometrial NK cells, IgG 
 Birth Induction of labour Increase in inflammatory cells and 
processes 
Lactation Direct transfer of immune factors 
Immunoeducation of the newborn 
Production and secretion of IgA 
lactoferrin and lysosyme in breast 
milk 
Menopause Unknown Unknown 
Table 1-1: Immune system involvement in major reproductive events.  
IgG – Immunoglobulin G, NK – natural killer cells, T regs – regulatory T cells. Adapted 
from Abrams and Miller (2011) [6]. 
 
1.1.1 The ovarian cycle 
The ovarian and menstrual cycles provide a prime example of the multiple roles of the 
immune system in reproductive physiology. Folliculogenesis, the concurrent production 
of mature oocytes capable of fertilization, ovulation and formation of the corpus luteum 
(CL) are all mediated by a coordinated network of hormones, cytokines, 
gonadotrophins and an array of other factors (described in more detail in Chapter 4) [2, 
10-14]. A wide array of immune effector cells are permanently present in the ovary. 
They surround follicles from their primordial stage of development through to the 
formation of the Graafian follicle and subsequent ovulation, providing regulatory 
cytokine support, thereby actively mediating both ongoing follicle growth and parallel 
attrition through atresia [2, 15, 16]. Ovulation itself has often been noted to be an 
inflammatory event, mediated by cells of the immune system and the cytokines, 
prostaglandins and matrix metalloproteinases that they produce in order to break down 
the follicular wall and release the oocyte to the oviduct [13, 17-21]. 
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Once ovulation has occurred, the formation of the corpus luteum (CL - whose role is to 
produce high levels of progesterone to support the subsequent pregnancy until this role 
is taken over by the foetoplacental unit) is mediated by leukocytes such as 
macrophages and T cells [22-25]. Cytokines such as vascular endothelial growth factor 
(VEGF) [26], interferon (IFN)-γ [27-29] and tumour necrosis factor (TNF)-α [30, 31] are 
critical to ensuring the adequate vascularization and structural integrity of the CL, such 
that failures in these signaling mechanisms can lead to luteal phase defects and 
infertility in women [32-34]. Subsequent regression of the corpus luteum into the corpus 
albicans is also mediated by leukocytes and the cytokines they produce [35, 36].  
 
Immune cells and their effector cytokines are intimately linked with reproductive 
hormones, particularly estradiol (E2) and progesterone (P4), varying alongside these 
throughout the menstrual or oestrus cycle [6]. This leads to an apparent conflict 
between the reproductive and immune systems, as it has been shown that the low E2 
levels seen throughout the follicular phase lead to a higher risk of autoimmune disease, 
while the higher levels at ovulation and during pregnancy provide an 
immunosuppressive environment which increases the risk of infection [37, 38].  
 
1.1.2 Endometrial remodelling and response to mating 
Alongside folliculogenesis, the endometrium undergoes significant remodelling in 
response to hormonal signals in order to prepare for an impending pregnancy. This 
involves growth, remodelling and breakdown governed by a complex interplay of 
hormones, cytokines, eicosanoids and matrix metalloproteinases [5, 7, 39-42]. This 
process is evident in the majority of mammalian species to a greater or lesser extent 
and is described in more detail in Chapter 2. If mating and subsequent implantation of 
a blastocyst do not occur, regression of the corpus luteum in the absence of embryo-
derived human chorionic gonadotrophin (hCG) or species-sepcific equivalent (platelet 
activating factor in mice, interferon-tau in bovids and ovids) leads to a fall in P4, which 
triggers menstruation in women, and endometrial remodelling in other species which do 
not shed their endometrium. These processes are driven by an influx of leukocytes, 
drawn by chemotactic cytokines [43]. 
Following mating, as well as providing protection from invading pathogens in the 
female genital tract, the endometrium must adapt to tolerate the non-self antigens of 
the sperm and conceptus allograft. Seminal plasma proteins induce a coordinated 
maternal inflammatory response which recruits leukocytes to the endometrium [5, 15, 
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44-46], subsequently culminating in a selective systemic immunomodulation geared at 
tolerating paternal antigens and enabling successful fertilization and implantation [47-
49]. 
 
1.1.3 Pregnancy 
Despite the fact that maternal and foetal cells differ in their genetic constitution by 50%, 
the maternal immune system does not reject the foetal allograft during pregnancy. 
Trowsdale and Betz (2006) coined the phrase ‘temporary self’ to describe this situation 
where the maternal immune system demonstrates tolerance to the presence of foreign 
antigens and treats the foetus as ‘self’ for the period of pregnancy [50]. This 
modification of the maternal immune system is made even more remarkable by the fact 
that foetal cells cross into the maternal bloodstream and can persist for many 
years/lifelong, a phenomenon known as microchimaerism [51-53]. This process is 
facilitated by the fact that the conceptus trophoblast is uniquely designed to minimise 
maternal immune activation due to a lack of constitutive and inducible major 
histocompatibility complex (MHC) molecules on the presenting villous surface [50, 54], 
while alterations in the maternal T cell pool reduce the likelihood of an immune 
response at the materno-foetal interface [54]. In addition to the local changes in the 
endometrium, the maternal immune system dampens cell-mediated immunity 
systemically whilst maintaining antibody-mediated immunity, a change which protects 
the developing foetus but leaves the mother vulnerable to infection [55]. For example, if 
a woman becomes infected with Toxoplasma gondii during pregnancy, she is more 
likely to pass the infection to her foetus during late gestation when E2 levels are at their 
highest [56]. 
 
1.1.4 Parturition 
The initiation of labour was traditionally considered to be an endocrine-mediated event, 
although evidence increasingly suggests that the trigger may actually be inflammatory 
in nature [57, 58]. The foetus is thought to provide many of these signals, for example 
through the production of phospholipids and pulmonary-derived surfactant proteins 
which mediate lung maturation. In turn, this triggers foetal macrophages to migrate to 
the uterine wall where they participate in increasing local levels of prostaglandins and 
cytokines. [58, 59]. On the other hand, phospholipids increase corticotrophin releasing 
hormone, further contributing to membrane rupture, cervical effacement and increased 
myometrial contractility [60-62]. Cervical and myometrial changes are mediated by a 
rapid influx of leukocytes, with concurrent cytokine, prostaglandin and hormone 
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production driving cervical ripening and myometrial activity as a functional syncytium 
[63-65]. The role of the inflammatory/immune system in this process is perhaps best 
exemplified in women by the fact that if a mother contracts an infectious disease during 
late pregnancy, the resulting inflammatory reaction can trigger labour and result in a 
pre-term birth, with its attendant sequelae in both the mother and foetus [66]. 
 
1.1.5 Lactation 
Nourishment of the newborn is costly to the mother, in humans amounting to an 
additional daily energy expenditure of approximately 500kcal [67, 68]. However, a large 
body of evidence suggests that this expenditure has immunological benefits for both 
the mother and the newborn. For example, provision of maternal milk has been shown 
to protect the newborn from infectious disease, and also confers protection against 
allergy and asthma in later life [69-74]. In the foetus, immunologic defence is present, 
although this is immature. During pregnancy, IgG antibodies cross the placenta to 
provide the foetus with a passive immunity which is depleted in the first 6-12 months of 
life. Furthermore, during birth, the foetal gut is colonised by maternal vaginal and faecal 
bacteria, establishing a competent mucosal surface which offers some degree of 
microbiomial protection against enteric pathogens. This colonisation is continued in the 
breastfed infant by transfer of live bacteria through breast milk, such that the infant gut 
microbiome resembles that of adults by the age of 2 [75, 76]. Breast milk provides 
additional maternal immune resources in the form of secretory IgA, leukocytes and 
non-specific anti-microbial factors which supplement pregnancy-acquired immunity [73, 
74, 77-81]. These factors combine to influence subsequent immune development in the 
newborn, improving thymic production of T cells and infant responses to vaccination 
[77, 82].  
 
In terms of maternal benefits, lactation confers a change on the cyclicity of the 
endometrium creating lactational amenorrhoea in women, where the menstrual cycle is 
suspended, providing a natural break in fertility. Suckling delays the resumption of 
normal ovarian cycles by disrupting the pattern of pulsatile hypothalamic GnRH release 
and pituitary LH production [83]. Although the mechanisms behind this are not fully 
understood, the change in ovarian cyclicity is believed to involve a modulation of the 
functional immune cells and cytokines which mediate follicular growth.  
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1.1.6 Menopause 
Involvement of the immune system in the onset of menopause is subject to 
speculation. Although the onset of menopause may not be directly immune-mediated, 
severe or repeated infection during the life of a woman can result in late-onset menses 
and early menopause, leading to a reduced reproductive lifespan. Certain autoimmune 
diseases, such as Type I diabetes and rheumatoid arthritis, as well as sporadic 
infection with mumps virus exhibit an increased risk of early menopause [84-88]. The 
menopause itself is associated with a reduction in E2 and P4 with a concomitant 
general trend towards immune senescence [89]. Figure 1-2 represents a schematic 
demonstrating this global interaction of the immune system with the reproductive cycle 
of the female. 
 
 
 
Figure 1-2: Schematic diagram illustrating the multiple reproductive processes 
influenced by the immune system in women. 
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1.2 Molecular mediators  
As outlined above, immune processes are key to all facets of the reproductive cycle. 
These multiple effects are mediated by signalling molecules, principally cytokines, 
matrix metalloproteinases and prostanoids under the influence of both peptide and 
steroid hormones. The following sections will introduce these mediators which take 
centre stage throughout the various chapters of this thesis. 
1.2.1 Cytokines 
Cytokines are small soluble signalling glycoproteins probably best known for their 
immunoregulatory properties [90]. However, in recent years, cytokines have 
increasingly been recognised as growth factors governing cell proliferation, 
differentiation, function and fate [91, 92]. Cytokines are produced by more than one cell 
type and, in the same vein, commonly have more than one target tissue, although they 
can also operate in an autocrine or paracrine manner. Cytokines are also characterised 
by a specific array of singular functional adaptations (viz., synergy, antagonism, 
functional redundancy) whose characterisation will form a core part of this thesis. There 
is a plethora of cytokines which ranges from the better known interleukins (ILs), colony 
stimulating factors (CSFs), tumour necrosis factors (TNFs) and transforming growth 
factors (TGFs) through to perhaps less familiar growth factors and peptide hormones 
such as prolactin (PRL). As integral signalling proteins to the orchestration of an array 
of physiological processes, deregulations in cytokine production and imbalances in 
their relative interactions underlie pathophysiological processes as diverse as cancer, 
autoimmunity and cardiovascular disease [93-102]. Analogously, their central role in 
reproductive success in creating an immunopermissive and embryotrophic environment 
supporting gametogenesis, fertilisation, pre-implantation embryo development, 
blastocyst implantation, placentation, foetal development and lactation highlights the 
fact that inflammatory dysfunctions underpin a broad spectrum of reproductive 
disorders [92, 103-107]. 
 
1.2.2 Prostanoids 
Prostanoids are a subgroup of the eicosanoid family of lipid mediators, comprising 
prostaglandins, thromboxanes and prostacyclins. This group of mediators is formed by 
the de novo conversion of free fatty acid substrates (e.g. arachidonic acid) by 
cyclooxygenase (COX) in response to exogenous stimuli. Prostaglandins mediate 
many physiological processes, but are intrinsic participants in inflammatory reactions. 
In the reproductive setting, prostaglandins are best known for their involvement in the 
onset of labour, particularly in terms of promoting cervical ripening and myometrial 
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contractility [108]. Moreover, prostanoids (and in particular prostaglandins) are induced 
by cytokines and vice versa, thereby highlighting the breadth of mediators actively 
involved in physiological reproductive inflammatory networks [109-111]. 
 
1.2.3 Matrix metalloproteinases 
Although their name implies a role in the turnover and degradation of the extracellular 
matrix (ECM), MMPs serve a much wider function as immune mediators [112]. These 
zinc-independent endopeptidases have the ability to directly modulate cytokine activity, 
particularly in terms of the repression of chemokine activity by proteolysis [113-115]. 
MMP activity can be induced by prostaglandins, a function typically exhibited in the 
decidua where leukocyte migration and cytokine release is increased as a result of 
their activity [116]. 
  
These key mediators act in a coordinated network to promote an environment 
conducive to oocyte maturation, fertilisation, implantation, pregnancy maintenance and 
parturition. However, much of the research conducted to date in the reproductive arena 
has broadly focussed on these molecules in isolation such that comparatively little is 
known about the networks/pathways implicated when these are investigated in the 
context of their interactions with other inflammatory mediators. 
 
1.3 Clinical relevance 
1.3.1 Female infertility 
Subfertility affects one in seven couples in the UK according to the Human Fertilisation 
and Embryology Authority (HFEA, 2011/12). Infertility is caused by a complex 
interaction of factors, including genetics, lifestyle, environment, physiology and 
pathology, although in many cases the condition remains idiopathic. There are 
significant medical, psychosocial, ethicolegal, religious and economic implications 
associated with infertility and its treatment. High multiple birth rates can result from the 
latter, which have considerable health risks for the mother and baby, resulting in 
significant financial burden to the healthcare system [117-120]. Female factor infertility 
accounts for a third of all infertility cases and results from a variety of pathologies 
including ovulatory dysfunction, (hypothalamic pituitary dysfunction or hypothalamic 
pituitary failure), endometriosis, polycystic ovary syndrome (PCOS), pelvic 
inflammatory disease (PID), and premature ovarian failure (POF)/reduced ovarian 
reserve (ROR). Table 1-2 demonstrates the aetiology of infertility according the HFEA. 
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Aetiology % of all subfertility 
cases 
References 
Female Factor infertility 29 [121, 122] 
Male Factor Infertility (MFI) 30 [121, 123, 
124] 
Unexplained Infertility 25 [121, 123, 
125, 126] 
Multiple Infertility Causes 9-15 [121, 123, 
127] 
Ovarian 
Dysfunction 
Polycystic ovarian syndrome  (PCOS) 7 [121, 128] 
Premature ovarian Failure (POF) 1 [121] 
Pelvic inflammatory disease (PID) 12-16 [121, 129] 
Endometriosis 3.5 [121, 130, 
131] 
Uterine factors 0.4 [121, 123] 
Table 1-2: Aetiology of infertility.  
Distribution of various aetiologies involved in infertility, data from HFEA (2011/12) 
relates to women undergoing assisted conception. 
1.3.2 Treatment for female infertility 
Treatment options for female infertility include surgery (e.g. ablation of endometriosis), 
hormone therapy, ovulation induction (using anti-oestrogens or gonadotrophins) and 
assisted conception techniques such as in vitro fertilisation (IVF) and intracytoplasmic 
sperm injection (ICSI). Since the success of the first IVF live birth (Louise Brown in 
1978), assisted conception now accounts for approximately 1-2% of all live births within 
the UK [132]. Assisted conception often includes several processes, such as ovulation 
induction, oocyte collection and fertilisation, and embryo transfer. Success rates for 
these treatments are variable, with IVF live birth rates in the UK remaining at 25% per 
cycle (HFEA, 2011/12).  
 
Much research is focused on improving assisted conception success rates, particularly 
in terms of understanding the complex mechanisms which provide competent oocytes 
for fertilisation and embryo development. The reduction in the number of embryos 
transferred is a prime target for the lowering of the number of multiple pregnancies, 
with some success. In the USA, when clinics were discouraged from transferring 3 or 
more embryos following IVF in 1998, the triplet or higher order multiple rate attributable 
to IVF dropped from 48% to 34%, although the number of twin births continues to rise 
[133]. Recent guidelines suggest moving towards elective single embryo transfer 
(eSET), a choice which more parents are selecting due to the risks of multiple 
pregnancy [133]. The success rates of eSET vary from clinic to clinic, although in the 
UK around 16% of women who choose this treatment option attain a live birth (HFEA, 
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2011/12). With the drive towards eSET, there is an additional focus on the choice of the 
best oocyte to fertilise, and the best embryo to transfer in order to maximise the chance 
of achieving a viable pregnancy and live birth.  
 
Recently, in order to improve the quality of oocytes collected, there has been a rise in 
the popularity of so called natural cycle (NC)-IVF. This approach aims to reduce the 
risk of side effects of controlled ovarian hyperstimulation (COH) such as ovarian 
hyperstimulation syndrome (OHSS), and to provide the highest quality oocyte for 
subsequent fertilisation [134]. The International Society for Mild Approaches in Assisted 
Reproduction (ISMAAR) defines NC-IVF as oocytes collected within a spontaneous 
menstrual cycle without the assistance of medication [135]. However, this approach 
has its failings; spontaneous cycles often only yield only one oocyte, inherently 
reducing the chances of successful fertilisation and implantation. Moreover, 
intervention is often required in terms of the administration of exogenous human 
chorionic gonadotrophin (hCG) to promote oocyte maturation in a timely manner for 
collection. Oocyte collection fails in as many as 43% of all cycles started, contributing 
to the low NC-IVF success rates [136, 137]. Notwithstanding, the oocytes retrieved are 
typically of a higher quality than those obtained following COH[138, 139]. The 
implications of this will be discussed further in Chapter 4. 
 
An alternative approach is modified natural cycle IVF (MNC-IVF), where the risk of 
premature luteinisation is mitigated by the administration of a GnRH antagonist for a 
short period of time (usually 2-4 days) and/or hCG to initiate final oocyte maturation 
prior to oocyte collection [135, 140, 141]. Comparison of success rates with COH is 
difficult, as NC-IVF is often considered in terms of cumulative pregnancy rates rather 
than pregnancy rates per started cycle. Nonetheless, a 43% pregnancy rate after 3 
started cycles remains low [137] such that the drive to improve success rates within 
COH cycles remains. In line with this, a requirement to understand the changes in the 
microenvironment of the follicle and oocyte quality following COH in order to optimise 
the stimulation protocols is much needed. 
 
1.3.3 Embryo transfer and implantation 
Another area presenting an opportunity for the improvement of assisted conception 
success rates is the preparation of the endometrium for implantation. Implantation of an 
embryo requires the synchronised development of both the embryo and endometrium. 
Once an oocyte has been fertilised and has developed into a blastocyst, it must attach 
to the luminal endometrial epithelium and invade the underlying decidualising stroma 
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over the course of a very small window of opportunity [41]. Studies which have 
assessed implantation rates following embryo transfer estimate that around 26-35% of 
all transfers result in a clinical pregnancy, with a pre-clinical pregnancy loss of 
approximately 19% [142-144]. This compares to an implantation rate in NC/MNC-IVF of 
up to 50% [136, 137]. This suggests an asynchrony between folliculogenesis and 
endometrial remodelling in stimulated cycles, which subsequently reduces the chance 
of achieving a pregnancy/live birth.  
 
Coordinated preparation of the endometrium for implantation is driven by oestrogen 
(E2) and progesterone (P4), and these hormones can be used at supraphysiological 
levels to prepare the endometrium for embryo transfer either with or without prior 
gonadotrophin stimulation [145, 146]. However, there are a number of processes which 
occur prior to the embryo reaching the uterus in natural cycles. It is thought that semen 
(its seminal plasma fraction in particular) provides a signal to the female reproductive 
tract to prepare for implantation, and to induce maternal immunotolerance of the sperm 
surface paternal antigens [147]. To date, the mechanisms governing this induction of 
tolerance, endometrial priming and subsequent receptivity remain very poorly 
understood, and will be the focus of Chapter 2 [148]. 
 
1.3.4 Role of the immune system in infertility 
The immune system has been implicated in various pathologies and dysregulations 
which contribute to infertility. These are often mediated by communication failures 
between the immune and endocrine systems which result in difficulties in conception, 
implantation and the maintenance of pregnancy. From the quality of oocytes produced 
through folliculogenesis to implantation and subsequent pregnancy, disruption to the 
immune system can result in failures which affect fertility to a lesser or greater degree, 
as discussed below. 
 
1.3.4.1 Oocyte quality 
Immune/inflammatory mediators (cytokines, MMPs, prostaglandins) have been shown 
to influence oocyte quality. Studies involving controlled ovarian hyperstimulation have 
sought to determine whether intrafollicular cytokine profiles in particular can be used as 
predictive markers to determine the developmental competence of an oocyte and, in 
certain cases, even predict the outcome of assisted conception cycles [149-151]. 
However, most studies have been limited by focussing on single or small groups of 
mediators, disregarding the fact that cytokines are increasingly believed to operate as 
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part of complex network systems [91, 92, 152-154]. This approach will form part of the 
remit of Chapter 4, where follicular fluid (FF) cytokine signatures will be related to the 
fertilisation potential of oocytes collected during ICSI-based assisted conception cycles.  
 
1.3.4.2 Fertilisation 
Post coitum, immunological and neuroendocrine systems are activated to prevent the 
maternal immune system attacking the foreign antigens present in sperm. In some 
situations, this development of sperm-specific immunotolerance fails to occur and 
sperm are destroyed in the maternal tract before they reach the oocyte, causing 
infertility. In this respect, infertile women have been shown to have a higher prevalence 
of anti-sperm antibodies and/or seminal plasma hypersensitivity compared to their 
fertile counterparts. However, when these women are treated with assisted conception 
techniques which allow bypass of the maternal tract mucosal defences, their live birth 
rates are comparable to those of controls [155-158].  
 
1.3.4.3 Implantation 
The preparation of the endometrium for implantation and immune tolerance is mediated 
by a range of immune effector cells, such as natural killer (NK) cells. A failure at any 
stage of this process has been suggested to be one of the contributory mechanisms 
underlying recurrent miscarriage. Recent research has shown that couples who share 
human leukocyte antigen (HLA) alleles are at high risk of recurrent implantation failure, 
indicating that the similarity between male and female antigens does not activate the 
initial inflammatory response in the female tract responsible for conferring 
immunotolerance [159, 160]. Indeed, there appears to be an evolutionary mechanism 
which favours the selection of mates who are immunologically different, in that both 
mice and women prefer the pheromones in the body odour of prospective sexual 
partners with dissimilar MHC alleles [161-165]. Thus, although an immunological basis 
for implantation failure is an accepted proposition, there remains a paucity of studies 
which explore the underlying physiological response to insemination and implantation 
[166]. 
 
1.3.4.4 Maintenance of pregnancy 
Once implantation has occurred, the maternal immune system is geared to maintain 
the allograft tolerance developed following exposure to seminal plasma. However, this 
represents walking an immunological tightrope such that any mild 
immune/inflammatory deviations during pregnancy alone can result in miscarriage and 
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premature labour. For example, the complement system (which forms part of the innate 
immune system) must be tightly regulated to maintain a successful pregnancy; a lack 
of decay accelerating factor (encoded by the CD55 gene) results in recurrent early 
miscarriage in women, likely due to an overactive complement system [167, 168]. 
Similarly, the premature activation of the primed uterus in late pregnancy by 
inflammation/immune system stimulation can lead to an untimely rupture of the foetal 
membranes and uterine contractions, resulting in premature labour and birth. Oft-
quoted examples in this context include bacterial vaginosis, sexually transmitted 
diseases and group B streptococci, which have all been linked to premature birth in 
women via immune system activation [169-171]. 
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1.4 Rationale, hypothesis and aims 
The immune system is involved at all stages of the reproductive cycle, from the ovarian 
cycle and menarche through to pregnancy and birth, lactation and menopause. 
However, the physiological basis of both the identity and the interactions of its multiple 
mediators remains remarkably poorly understood. The central unifying theme in this 
thesis is thus to explore the mechanisms providing the basis of immune mediator 
involvement at select, landmark points in female reproductive life.  
 
1.4.1 Research hypothesis 
Throughout the theme of this thesis, the following research hypothesis was tested: 
 
“cytokine-based immune networks underpin the physiological processes governing the 
endometrial response to seminal plasma, lactation and oocyte maturation following 
ovarian stimulation. The structure of these networks can be revealed, displayed and 
explored using both traditional and novel machine-learning data handling 
methodologies”. 
 
This hypothesis was tested using a number of reproductive systems and 
methodologies. The aims of each Chapter is presented below. 
 
1.4.2 Aims of studies 
1.4.2.1 Inflammatory pathways in the murine endometrial response to seminal plasma 
(Chapter 2) 
The aim of the studies contained within this first experimental chapter was to discover 
the immune pathways involved in the endometrial response to seminal plasma 
(including its selectively epithelial and stromal components) and the establishment of 
foetal allograft immunotolerance using a murine model system.  
 
1.4.2.2 Bayesian modelling of cytokine interactions in vivo (Chapter 3) 
The aim of the studies contained within chapter 3 was to develop novel methods of 
discovering, displaying and exploring mediator (specifically cytokine) interactions with 
peptide and steroid hormones in vivo by using murine lactation as a model system. 
This required moving away from conventional, basic analysis to develop Bayesian 
machine learning-based mathematical models. 
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1.4.2.3 Modelling follicular fluid cytokines in relation to oocyte maturation (Chapter 4) 
The aims of the studies contained within the final experimental chapter were: 
 to use the mathematical methodologies developed in chapter 3 as a basis for 
improved modelling strategies; 
 to discover, display and explore cytokine networks within human follicular fluid 
surrounding oocytes exposed to ovarian stimulation, thereby highlighting their 
likely involvement in maturation, and 
 to classify maturation and the developmental viability of those oocytes based 
on their follicular fluid cytokine profile. 
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2. Inflammatory pathways in the murine uterine response to 
seminal fluid 
 
2.1 Introduction 
The endometrium is a dynamic tissue which undergoes growth, remodelling and 
breakdown (to a lesser or greater degree in different species) on a cyclical basis, in 
preparation for blastocyst implantation. Although implantation is a rate limiting step in 
the improvement of assisted conception success rates, the molecular mechanisms 
underlying the endometrial changes in readiness for implantation remain a poorly 
understood aspect of reproductive physiology. Various factors influence the rate of 
implantation in assisted conception, including the quality of the embryo transferred 
[172] and the synchronous endometrial receptivity [148, 173]. In rodents and various 
ungulates, constituents of seminal plasma are thought to prepare the endometrium for 
implantation in a concept dubbed ‘seminal priming’, a process which modifies 
components of the immune system and can influence subsequent events in pregnancy 
[174]. Although exposure to semen affects the endometrium directly in species such as 
rodents and swine, this priming phenomenon is likely to operate indirectly through a 
more widespread alteration of reproductive mucosal response in species such as 
humans, where ejaculate volumes are more modest and where seminal plasma 
remains largely confined to the vaginal vault and cervix. As the exploration of the 
response of the endometrium to seminal plasma in humans presents ethical and 
logistic issues, the mouse presents a convenient physiological system within which 
these responses can be explored. This section of the thesis will explore the global 
changes in gene expression of murine endometrial epithelial and stromal cells in 
response to coitus and exposure to seminal plasma, with a particular focus on the 
changes elicited in inflammatory and immune pathways in preparation for implantation. 
 
2.1.1 Murine reproductive physiology 
2.1.1.1 Uterine structure 
In the mouse, the uterus is a bicornuate organ with two uterine horns joined to a single 
corpus. This organ comprises a muscle layer (myometrium) covered by a mucosal 
endometrial layer, featuring simple columnar epithelial cells (both ciliated and 
secretory) which involute into the underlying stroma and exhibit changing morphology 
according to cycle stage (Figure 2-1). The cells of endometrial layer undergo 
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proliferation, differentiation and regression/death on a cyclical basis (i.e. the menstrual 
cycle in humans and the oestrus cycle in rodents and other species), a process mainly 
regulated by changes in ovarian steroid hormones. 
 
 
Figure 2-1: Gross anatomy of the murine uterus. The expanded panel displays the 
microscopic structure of the endometrium. Frozen sections were stained with cresyl 
violet and imaged at 20x magnification (image captured by the author). The scale bar 
indicates 150µm. 
 
2.1.1.2 Murine oestrus cycle 
The murine oestrus cycle generally lasts 4-5 days [175], and consists of four distinct 
stages, comprising dioestrus, proestrus, oestrus and metoestrus [176], each displaying 
distinct vaginal cytological characteristics [177] (Table 2-1). In response to dynamic 
changes in P4 and E2, the endometrium undergoes extensive remodelling (Figure 2-2), 
involving proliferation, differentiation and apoptosis alongside ECM remodelling, 
angiogenesis and immune cell infiltration [178, 179]. This immune cell influx is 
mediated by E2, which draws macrophages, neutrophils and eosinophils into the 
uterine stroma [180-183]. It is noteworthy that the murine cycle does not involve 
19 
 
Chapter 2. Inflammatory pathways in the murine uterine response to seminal fluid 
endometrial shedding/menstruation as featured in women. At oestrus, the female 
mouse becomes sexually receptive in response to E2, although this phenomenon may 
also occur during late proestrus or early metoestrus [184]. 
 
 
Stage Vaginal characteristics Endometrial characteristics Hormone profile 
Dioestrus Quiescent tissue, 
predominantly leukocytes 
Low epithelial and stromal 
proliferation, neutrophils and 
macrophages present in stroma only, 
high numbers of mitotic bodies  
E2 low but rising, 
P4 high 
Proestrus Predominance of nucleated 
epithelial cells, appearing in 
clusters or individually; some 
cornified cells 
High glandular epithelium 
proliferation, low stromal 
proliferation, high apoptosis of 
glandular epithelium, neutrophils and 
macrophages present in stroma only, 
increased luminal dilation 
E2 rising, P4 
falling, FSH/LH 
surge at the end 
of this stage 
Oestrus Clusters of cornified 
squamous epithelial cells, 
with no visible nucleus and  
granular cytoplasm 
Endometrium at its thickest, luminal 
epithelium proliferation at its highest, 
glandular epithelium proliferation low, 
elevated stromal proliferation, 
reduction in epithelial cell collagen 
type-IV, increased extracellular fluid, 
neutrophils and macrophages 
present in stroma only, evidence of 
apoptotic cells in the endometrium, 
increase luminal dilation 
E2 high then falling 
to basal levels, P4 
low 
Metoestrus Mix of cell types with a 
predominance of leucocytes 
and a few nucleated epithelial 
and/or cornified squamous 
epithelial cells 
Glandular epithelium proliferation 
high, low stromal proliferation, 
highest apoptosis of 
luminal/glandular epithelium and 
stroma, neutrophils present in 
luminal epithelium and stroma, 
macrophages present in stroma and 
adjacent to luminal epithelial cells 
E2 falling, P4 rising 
Table 2-1: Characteristics of the vagina and endometrium at each stage of the murine 
oestrous cycle. E2 - 17β-estradiol, P4 – progesterone, LH – luteinising hormone, FSH – 
follicle stimulating hormone [185-187].  
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Figure 2-2: Schematic diagram representing hormone (E2 and P4) profiles throughout 
the murine oestrus cycle and early pregnancy. Adapted from Emanuele 2002 [45]. 
 
2.1.1.3 Murine mating 
Mating behaviour consists of the male sniffing, following, mounting, mounting-with-
intromission, and post-copulatory grooming of the female [188, 189]. Ejaculation may 
take place after one to more than 100 intromissions, marked by the male rolling over on 
his side, and usually occurs only once per day. The male accessory glands produce a 
secretion which hardens to form the vaginal plug, which may be used to confirm 
ejaculation. This persists for 16-24 hours and presents an obstacle to the female 
mating with other males [190]. 
 
2.1.1.4 Ejaculate constituents 
The ejaculate comprises several constituents which are essential for the establishment 
of pregnancy. These components vary across species, but in general comprise sperm 
and seminal plasma arising from various accessory glands (Table 2-2). The main 
functions of seminal plasma are to support spermatozoa survival whilst inducing a 
concurrent alteration of the female reproductive tract microenvironment [191]. 
Interestingly, the ejaculate is not uniform in vivo, consisting of a pre-ejaculate from the 
urethral glands, followed by release of sperm from the epididymis/secretions from the 
prostate with subsequent ejaculation proper in a series of spurts, meaning that the 
female tract receives signals in a temporal and spatial manner which is difficult to 
replicate in vitro [192]. 
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Source Percentage Component Function 
Testes 2-5% Spermatozoa: 2-16x10
6 
sperm per 
ejaculate in mice [193] 
Fertilisation of the oocyte 
Seminal 
vesicles 
65-75% Amino acids, citrate, enzymes, flavins, 
fructose, prostaglandins, proteins 
(including semenoclotin and TGF-β), 
transglutaminase, vitamin C [194-197] 
Spermatozoa support and 
nutrition; suppression of the 
female inflammatory 
response; vaginal plug 
formation 
Prostate 25-30% Acid phosphatase, citric acid, 
fibrinolysin, prostate specific antigen, 
proteolytic enzymes, zinc [198] 
Alkaline fluid neutralises the 
female reproductive tract; 
stabilisation of spermatozoa 
chromatin 
Coagulating 
gland 
<1% Galactose, mucus, pre-ejaculate, sialic 
acid [199] 
Increases sperm motility; 
vaginal plug formation 
Table 2-2: Murine accessory glands and their contribution to the ejaculate. 
 
2.1.1.5 Seminal plasma 
Seminal plasma constitutes 95-98% of the ejaculate volume; this small variation being 
accounted for by the presence and size of accessory glands in different species [200]. 
Proteins comprise a large fraction of seminal plasma which are largely attributable to 
one of three families – spermadhesins, proteins containing fibronectin type II modules, 
or cysteine-rich secretory proteins [201, 202]. In addition, blood plasma proteins are 
also present in seminal plasma, including albumin, globulins, transferrin, 
immunoglobulins, complement factors and immune mediators such as cytokines and 
chemokines. These immunological factors include monocyte chemotactic protein 
(MCP)-1, macrophage inhibitory protein (MIP)-1α/β, regulated upon activation normal T 
cell expressed and secreted (RANTES), prostaglandins and TGF-β, all of which are 
believed to modulate endometrial function [197]. 
 
2.1.2 Importance of seminal plasma in the uterine response 
Although traditionally viewed as a survival and transport medium for sperm, seminal 
plasma is now considered to have an equally significant role in preparing the uterus for 
pregnancy. The concept of seminal priming of the uterus has been prevalent in the 
literature for a number of years now, where evidence that the uterine response to 
mating originates from seminal plasma has been shown in experiments in hamsters, 
mice and rats [191]. In mice, laboratory protocols utilise the uterine response to 
seminal fluid to induce pseudopregnancy by mating females to vasectomised males. 
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This improves implantation rates at embryo transfer into surrogate dams, reduces 
miscarriage rates and prevents abnormalities which might otherwise occur in females 
not exposed to male reproductive fluids [203].  
 
Each accessory gland appears to influence fertility to a greater or lesser extent. In 
female mice mated with seminal vesicle-deficient males, embryos implant at normal 
rates but foetoplacental growth is retarded and live birth rates are reduced [204-206]. 
Where the coagulating glands, prostate and/or seminal vesicles are surgically 
removed, successful pregnancy is significantly reduced such that the impact on fertility 
is attributed to reduced sperm motility and survival resulting in poor fertilisation rates 
[199, 206-208]. Comparable surgical interventions in hamsters results in slower embryo 
cleavage and increased miscarriage rates post-implantation [209]. Interestingly, female 
mice establishing a successful pregnancy without exposure to the fraction of seminal 
plasma derived from the seminal vesicles exhibit a longer gestation without a reduction 
in litter size [206]. The prostate gland component of seminal plasma influences 
pregnancy to a lesser extent in rodents where its removal results in slightly lower 
pregnancy rates, a feature not noted with the removal of coagulating glands [199]. 
Thus, these studies indicate that seminal plasma performs a greater function than that 
of a simple, passive carrier fluid for spermatozoa. Indeed, uterine physiological 
changes can be induced by semen and/or seminal plasma, indicating that the physical 
stimulation of the mating act is not required [210]. 
 
2.1.3 Maternal immune response to seminal plasma 
Post coitum, the first response of the uterus to seminal fluid exposure is that of 
endometrial cytokine synthesis, a process followed by an influx of leukocytes (Figure 
2-3) [211]. Seminal plasma proteins interact with E2-primed uterine epithelial cells, 
resulting in the synthesis of a large array of cytokines and other immune factors, 
including granulocyte macrophage colony stimulating factor (GM-CSF), IL-6, IL-8, 
monocyte chemoattactant protein (MCP-1), MMPs and prostaglandins (PGs) amongst 
others [212, 213]. Within hours of this peak in cytokine production, inflammatory cells, 
particularly leukocytes, invade the cervix as the primary site of semen deposition in 
humans, pigs, rabbits and rodents [147, 214-219]. Studies involving the artificial 
transfer of seminal plasma into gilts have demonstrated that this maternal response is 
evident without the physical act of mating [210]. Beyond the immediate uterine 
environment, seminal plasma can influence other maternal structures, including newly 
formed corpora lutea where macrophage populations are indirectly modulated to 
mediate tissue remodelling [45]. 
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Figure 2-3: Schematic diagram representing the murine uterine response to seminal 
plasma. Adapted from Robertson (2007) [220] 
 
2.1.3.1 Myeloid cells 
As has been shown in mice and swine, myeloid lineage cells such as macrophages, 
dendritic cells and granulocytes of circulatory origin accumulate in the uterine stromal 
tissue, while macrophages, neutrophils and granulocytes traverse the epithelium and 
accumulate in the uterine cavity post coitum (Figure 2-4) [216, 221, 222]. This initial 
neutrophil response resolves prior to implantation, with a concurrent drop in cytokine 
profiles and rise in P4 [213]. However, leukocytes residing within the endometrium 
remain for several days, proliferating throughout the peri-implantation period [210]. 
Maternal macrophages and neutrophils within the uterine lumen following semen 
deposition phagocytose slow-moving or damaged sperm, thereby increasing the 
likelihood of fertilisation by competent sperm [147, 191]. There is also evidence to 
suggest that the female response to seminal plasma is male partner-specific in mice, 
providing a potential mechanism for an increased chance of successful pregnancy from 
the fittest male [223]. The immune tolerance conferred by seminal plasma in mice is in 
part MHC class II+ specific, meaning that subsequent sperm depositions by a different 
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male may be subject to immune attack [211, 224, 225]. Figure 2-4 depicts the relative 
distribution of myeloid cells through the post mating period. 
 
 
 
Figure 2-4: Schematic diagram showing the relative distribution of immune cells across 
the first five days of murine pregnancy. M – myometrium, S – stroma, E – epithelium, 
UL – uterine lumen, DC – dendritic cell, G – granulocyte, MO – macrophage, N – 
neutrophil, B – blastocyst. 
 
2.1.3.2 Role of T cells in the uterine response to seminal plasma  
In mice, the main function of this influx of immune cells is to prepare the maternal 
immune system for paternal antigen tolerance upon implantation of the conceptus. 
Modulation of the T cell response in the uterus is essential in this process. Upon initial 
semen deposition in the female reproductive tract, paternal antigens are presented to 
maternal CD4+ and CD8+ T cells by antigen presenting cells (APCs) within the lymph 
nodes which drain the uterus [46, 224]. These cells then become functionally 
anergic/hyporesponsive, enabling tolerance of the conceptus [226]. A concurrent 
expansion of the CD4+CD25+Foxp3+ regulatory T cell (Treg) pool facilitates embryo 
implantation [54, 227]. The strength of this maternal response depends on the 
composition of seminal plasma, particularly the paternal antigen content and 
concentrations of TGF-β [225]. Seminal plasma TGF-β in humans and pigs is largely of 
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the TGF-β1 isoform (although TGF-β2 and 3 are also present) which is secreted in an 
inactive form which is activated in the acidic environment of the vagina [228]. In the 
presence of activated TGF-β, naïve CD4+CD25- T cells differentiate into Foxp3+ 
suppressor/anergic T cells [229]. There is the potential for the prostaglandin content of 
seminal plasma to synergise with TGF-β in this regard, as PGE2 enhances the 
inhibitory effect and induces a regulatory phenotype in human CD4+CD25- T cells in 
vitro [230].  
 
2.1.4 Cytokine and immune mediator response to seminal plasma 
As outlined above, seminal plasma induces the expression of endometrial cytokines 
and chemokines. Chemokines are a group of small cytokines responsible for leukocyte 
chemotaxis. However for the sake of simplicity from here on in, the term cytokine will 
be used to refer to both cytokines and chemokines given that this traditional 
segregation according to their functional properties is increasingly being brought into 
question. Several cytokines have been implicated in the maternal response to seminal 
plasma, as discussed below. 
 
2.1.4.1 Colony stimulating factors 
GM-CSF, also known as colony stimulating factor (CSF)-2, was initially thought to drive 
the development of macrophages and dendritic cells from their precursors [231], 
although other research has shown it to be a key mediator of the inflammatory 
response [232-234]. Several groups have proposed that GM-CSF serves as a 
messenger between local tissue and haematopoetic cells, particularly during an 
inflammatory response [235-237]. Within the uterus, the endometrial epithelium has 
been shown to be responsible for the vast majority of GM-CSF produced in naturally 
cycling mice and women [238, 239]. This production fluctuates according to hormonal 
profile:- E2 induces GM-CSF while P4 inhibits its production [240]. This cytokine is 
thought to be a major mediator of the endometrial response to seminal plasma. Within 
12 hours of mating, seminal plasma induces a 20-fold increase in lumenal GM-CSF 
released by endometrial epithelial cells in mice [240, 241], an effect only observed 
when the seminal vesicles of the donor male remain intact [213]. GM-CSF recruits 
dendritic cells (DCs) and macrophages to the endometrium post coitum, with both cell 
types expressing the GM-CSF receptor (GM-CSFR) [242]. GM-CSF has been shown to 
have a number of effects including the regulation of glucose uptake and inhibition of 
apoptosis in the pre-implantation embryo [243]. This transient rise in GM-CSF 
abrogates before implantation in response to rising P4 levels during early pregnancy 
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[240]. There is mounting evidence that GM-CSF controls the ability of macrophages 
and DCs to elicit a T cell response during early pregnancy in mice, increasing their 
APC capacity in terms of antigen uptake, processing and presentation [48, 244-247]. In 
this respect, insufficient GM-CSF may lead to impaired T-cell activation and therefore 
reduced tolerance and altered APC profiles, which are recognised contributory factors 
in both infertility and miscarriage [48, 248, 249]. 
 
Macrophage colony stimulating factor (M-CSF, also known as CSF-1) production by 
the endometrial epithelium correlates with macrophage distribution [250]. In the mouse, 
macrophages are evenly distributed at dioestrus, while at proestrus and oestrus they 
are increasingly associated with the epithelium, driven by a peak of E2-induced M-CSF 
at proestrus [251]. However, as M-CSF is a relatively weak chemotactic agent for 
macrophages, together with the fact that M-CSF mRNA is not significantly increased 
post coitum compared to naturally cycling mice, it is unlikely to act in isolation in 
recruiting macrophages to the endometrium in response to mating [252]. 
 
2.1.4.2 IL-6 family of cytokines 
The IL-6 family (including cardiotrophin-1, IL-6, IL-11, IL-27, IL-31, LIF and 
neurotrophic factor) comprises a diverse group of mediators involved in the regulation 
of the acute phase and immune responses [253-255]. IL-6 is expressed in uterine 
epithelial cells of the naturally cycling mouse in response to E2 and P4 profiles, with 
levels highest at proestrus [212, 238]. This expression is, however, not uniform – 
expression at the luminal surface of cultured murine epithelial cells is 2.5-5 fold higher 
than at the basal surface [256], suggesting that IL-6 is primed to respond to incoming 
paternal antigens in these polarised cells. Endometrial stromal cells also produce IL-6 
in response to IL-1α, although this response occurs to a lesser extent than that seen in 
epithelium [256].  
 
IL-6 is a known mediator of the acute inflammatory response, and switches the immune 
response from a neutrophil-mediated to a monocyte/macrophage mediated event via 
induction of intracellular adhesion molecule (ICAM)-1 and MCP-1 [257]. Alongside this 
switch, IL-6 also directs the differentiation of naïve CD4+ T Cells into the Th17 lineage, 
with a concurrent inhibition of Treg cell differentiation, promoting their conversion to a 
Th17 phenotype cells via the downregulation of FoxP3 [258-260]. IL-6 mRNA is 
induced by seminal plasma proteins, including TGF-β, as seen in human cervical 
epithelial cells [211, 223, 261] and mid-cycle endometrial epithelial cells [262] in vitro. 
However, it remains to be seen if these relationships hold true in vivo.  
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Another member of the IL-6 family, LIF, has been shown to be essential for 
implantation in mice, since LIF null mice exhibit a lack of implantation and minimal 
decidualisation [263, 264]. As LIF null embryos implant normally when transferred into 
wild type recipients, this implantation defect is thought to be maternally regulated [265]. 
LIF mRNA has been reported to rise in murine glandular epithelium at day 4 post 
mating, with a concurrent spike in protein expression in response to an increase in E2 
production [266, 267]. However, the control of LIF expression varies between species: 
in the rabbit, P4 appears to be its main regulator instead [268]. Seminal plasma also 
induces LIF mRNA expression in human endometrial epithelial cells in vitro [262]. 
However, the transition through the peri-implantation period from initial semen 
deposition to implantation remains poorly defined. 
 
2.1.4.3 Interleukin-8 
Present in human endometrial epithelium and, to a lesser extent, stromal cells, IL-8 is 
thought to coordinate the recruitment of neutrophils and granulocytes to the 
endometrium [269] and drive the proliferation of endometrial stromal cells prior to 
decidualisation [270]. The ability of IL-8 to maintain stromal cell growth in a paracrine 
manner is thought to be a major factor in the pathogenesis of endometriosis [271, 272]. 
Seminal plasma (particularly the TGF-β fraction) induces the release of IL-8 from 
human non-pregnant cervical explants and stabilises IL-8 mRNA transcripts in 
endometrial stromal cells [223, 261, 273, 274]. In the mouse, the gene encoding IL-8 
has been deleted, along with its receptor CXCR1 [275]. Functional murine homologues 
to IL-8 include keratinocyte derived chemokine (KC/CXCL1) lipopolysaccharide-
inducible CXC chemokine (LIX/CXCL5) and macrophage inflammatory protein (MIP-
2/CXCL2), all of which share the extracellular loop reactive+ motif (Glu-Leu-Arg) which 
confers the chemoattractant properties of IL-8 [276]. 
 
2.1.4.4 Other identified chemokines 
MCP-1 is another chemokine thought to mediate the maternal response to seminal 
plasma. In women, MCP-1 is secreted by the endometrial epithelium into the uterine 
lumen and stroma compartments, and its levels correlate with successful implantation 
[143, 277]. A potent chemoattractant for monocytes/macrophages [278], MCP-1 mRNA 
is very highly expressed in murine endometrial epithelial cells post mating, and if this 
translates into protein levels may account for the large influx of macrophages to the 
endometrium [251, 252]. 
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Expressed on days 1 and 5 post mating in murine endometrial epithelium, RANTES is 
chemotactic for T cells, eosinophils and basophils [252, 279]. However, there is 
evidence to suggest that RANTES also recruits and activates macrophages, as uterine 
lumenal exposure to this chemokine results in a four-fold increase in macrophage 
numbers [252]. RANTES expression in the endometrium is stimulated by IFN-γ, IL-1β 
and TNF-α, with IL-4 antagonising TNF-α-induced RANTES production in vitro [280, 
281]. 
 
2.1.4.5 Prostaglandins 
Prostaglandins (PGs) are lipid mediators which are intimately linked with the immune 
system, both inducing and being induced by various cytokines. Although seminal PGs 
and prostacyclins are a major contributors to the induction of the maternal endometrial 
response, recent evidence shows that their production is also stimulated in the 
endometrium by seminal plasma, and that they are involved in the decidualisation 
process. In particular, PGE2 and PGI2 increase at the time of implantation in a localised 
manner [282-284], while PGI2 appears to be essential for blastocyst implantation and 
decidualisation in the mouse [285]. PGs are produced from arachidonic acid by the 
enzymatic action of proteins encoded by prostaglandin endoperoxide synthase genes 
(PTGS;, also known as  cyclooxygenases, COX), in conjunction with specific synthases 
[286]. Although COX-2 is generally considered to be inducible while COX-1 is 
constitutively expressed, both are inducible and developmentally controlled within the 
uterus. COX-2 is essential for successful implantation and pregnancy in mice [287] as 
highlighted by the fact that it is expressed at implantation sites within the endometrium 
and that COX-2 deficient mice exhibit multiple reproductive defects surrounding 
implantation and decidualisation [288-290]. Both COX-1 and COX-2 are transiently 
expressed post-mating in pigs [210] and mice, with COX-1 peaking at day 4 and COX-
2 peaking at day 1 post coitum in murine whole uterine preparations [288]. COX-1 
expression is governed by the prevailing hormonal milieu, being induced to its highest 
levels at day 4 by rising P4 levels originating from developing corpora lutea (CLs) [288]. 
By contrast, COX-2 production appears to be independent of hormonal control, as 
demonstrated in ovariectomised mice [288]. Subsequent studies have localised COX-2 
expression to epithelial cells in human endometrium, with expression peaking during 
the proliferative phase of the menstrual cycle in vitro [291-293].  
 
Little is known about the function of PGs in the endometrial response to seminal 
plasma. Several studies speculate that PGs, particularly PGF2α, promote epithelial cell 
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proliferation and survival, with reduced rates of apoptosis [294, 295]. PGE2 is thought 
to influence angiogenesis, particularly in conjunction with endometrial stromal cell 
activity, via the induction of VEGF in the mink and pig [296, 297], which may in turn 
induce PGF2α production [298]. However, translating these findings from mustelids to 
other species must be approached with caution, as this family has developed a unique 
reproductive strategy of delayed implantation which can last up to 10 months and 
resumes upon environmental stimuli [299-301]. More recently, studies have shown that 
PG synthesis is induced by seminal plasma in the porcine uterus, with concurrent 
angiogenesis extending throughout the preimplantation period [302, 303]. Interestingly, 
the modulation of the CL by seminal plasma may be mediated by endometrial-derived 
PGE2, which antagonises the luteolytic effect of PGF2α in gilts [304]. Further speculative 
roles in PG function include the regulation of angiogenesis/vascular function, 
mitogenesis, tissue invasion, ECM remodelling and immunosuppression, although 
these remain to be demonstrated conclusively within the endometrium [305-309]. 
 
2.1.4.6 Matrix metalloproteinases (MMPs) 
MMPs are zinc-dependent endopeptidases capable of degrading a large range of ECM 
proteins, with involvement in cell-surface receptor cleavage, cytokine 
activation/inactivation and release of apoptotic ligands (e.g. FAS-ligand) [310, 311]. 
They are traditionally grouped according to substrate specificity and cellular 
localisation, although with the emergence of new MMPs which do not fit into the current 
divisions, this categorisation may become redundant (Table 2-3). MMPs are regulated 
by circulating P4 via the transcription factor lefty [40, 312], either by inhibition of mRNA 
synthesis or modulation of MMP-inducing cytokines [40]. In addition to their role in 
ECM remodelling, MMPs are intricately linked with cytokine biology. For example, 
MMP-1, -2, -3 and -9 cleave IL-1β into biologically inactive fragments, thereby reducing 
inflammation [313]. Conversely, MMP-2, -3, and -9 can also cleave IL-1β precursors 
into an active form, providing a mechanism for both up and downregulation of protein 
activity [116]. Epidermal growth factor (EGF) and platelet derived growth factor (PGDF) 
induce the transcription of MMP-1 mRNA in human endometrial stromal cells [314]. 
This interaction with cytokines also occurs at the cell surface, where MMP-7 can cleave 
and release TNF-α from the cell membrane [315].  
 
Tissue remodelling, particularly in the endometrial stroma, occurs throughout the peri-
implantation period, both prior to and during decidualisation [312, 316]. Several MMPs 
have been shown to mediate this process, with macrophages being the main source of 
these proteases under the influence of cytokines and prostaglandins [317]. However, 
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the function of MMPs varies across species. In humans, for example, these enzymes 
are the main mediators responsible for triggering endometrial shedding; this is not seen 
in rodents, where endometrial remodelling merely causes regression [42, 312]. MMP-7 
protein expression in rat whole uterus increases sharply on day 1 post mating [318]. In 
mice, MMP-2 mRNA is expressed in the subepithelial stroma on days 3-5 post mating, 
while MMP-9 mRNA is expressed locally at the site of implantation at day 5 [319]. 
Tissue inhibitors of MMPs (TIMPs) are also induced within 12 hours of mating in the 
endometrial stroma [319].  
 
 
Category MMP 
Collagenases MMP-1, MMP-8, MMP-13 
Gelatinases MMP-2, MMP-9 
Stromelysins MMP-3, MMP-10, MMP-11 
Matrilysins MMP-7, MMP-26 
Enamelysin MMP-20 
Metalloelastase MMP-12 
Membrane bound MMPs MMP-14, MMP-15, MMP-16, MMP-17, MMP-24, MMP-25 
Other MMP-19, MMP-21, MMP-23A and B, MMP-27, MMP-28  
Table 2-3: Classification of matrix metalloproteinases 
 
2.1.4.7 Transforming growth factor (TGF) 
TGF-β is present in large quantities in seminal plasma, but is also induced within the 
maternal endometrium post mating. In humans, the three isoforms of TGF-β are 
expressed within all endometrial cells, increasing in response to rising P4 profiles [320-
323]. However, there appear to be species-specific differences in the temporal 
regulation of endometrial TGF-β expression. In rodents, TGF-β expression is high 
during late dioestrus and proestrus, possibly indicating a role in endometrial 
restructuring from one cycle to the next [324]. This is in contrast to the high expression 
in human endometrium during the late proliferative/early secretory stages which 
correspond to low levels of proliferation and high levels of differentiation [322]. 
 
Within the murine endometrium, TGF-β1 and -2 have been identified at the foeto-
maternal interface [325]. Neutralising antibodies to these cytokines reduce implantation 
rates, suggesting a pivotal role in decidualisation and the attachment of the blastocyst 
to the endometrial wall [326]. Concurrent with ECM remodelling, the signalling 
molecules (SMAD proteins) involved in the TGF-β signalling cascade are expressed 
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during the peri-implantation period concentrated at the lumenal epithelium both post 
mating and at implantation [327, 328]. The TGF-β modulation of ECM remodelling is 
thought to be achieved via the regulation of MMPs. Human endometrial stromal cell-
derived TGF-β2 has been shown to suppress epithelial cell MMP-7 production in vitro, 
thereby providing a control for erroneous ECM breakdown [329]. However, alongside 
the caveat of species differences in endometrial TGF-β function, endometrial cells 
display different expression patterns depending on the in vitro system used, rendering 
these data difficult to transfer both across species and to the in vivo setting [330]. 
 
Little remains known about the TGF-β endometrial response to seminal plasma, with 
most research focussed on the effects of exogenous TGF-β within seminal plasma 
itself, and its role in decidualisation. One study showed that TGF-β2 is expressed in 
murine endometrial epithelial cells in the pre-implantation period [325]. In human 
endometrial stromal cells TGF-β1 inhibits proliferation and induces COX-2 [331]. 
However, further evidence is required in order to elucidate the roles of TGF-β isoforms 
in the endometrial response to seminal plasma. 
 
Although individual immune mediators of the endometrial response to seminal plasma 
have been identified as discussed above, few studies have extended analyses to 
measuring large numbers of mediators in single samples to identify the global immune 
response at the level of the transcriptome. Many studies have focussed on profiling 
gene expression in the window of implantation, particularly in women following ovarian 
stimulation, in order to identify genes involved in endometrial receptivity in preparation 
for embryo transfer and in relation to implantation difficulties in endometriosis [332-
336]. Only one, however, has explored global gene expression in the cervix following 
stimulation with seminal plasma. Sharkey et al (2012) performed expression microarray 
analysis on biopsies of human cervix pre- and post- coitus, and revealed that seminal 
fluid activated pathways including the inflammatory response, immune response, 
immune cell trafficking, cellular movement, and antigen presentation [211]. Within 
these pathways, GM-CSF, IL-6 and IL-8 mRNA were prominently upregulated post 
coitum, as were COX-2 and various MMPs, suggesting active leukocyte recruitment 
and ECM remodelling [211]. However, the reporting of these findings was scant, and 
only related to a single time point, which limits the interpretation of the results. As such, 
to date, there are no gene expression studies examining the murine endometrial 
response to seminal plasma in vivo throughout the pre-implantation period. 
  
32 
 
Chapter 2. Inflammatory pathways in the murine uterine response to seminal fluid 
2.2 Aims 
The aims of this chapter were: 
 
 To identify changes in gene expression in response to seminal plasma relative 
to oestrus and dioestrus at four time points (days 1, 2, 3 and 4) throughout the 
pre-implantation period 
 To identify pathways involved in the endometrial response to seminal plasma 
 To identify differences between epithelial and stromal response in this process 
 To evaluate whether the pathway analysis approach is sufficient to describe 
immune pathway involvement in the murine endometrial response to seminal 
plasma. 
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2.3 Materials and methods 
An overview of methodology is presented in Figure 2-5. Detailed methods for each 
stage will be presented below. 
 
 
 
Figure 2-5: Methodology employed to explore immune networks within the murine 
endometrium 
 
2.3.1 Murine husbandry 
Male CD1 mice aged 10-12 weeks were individually housed while females (aged 6 
weeks) of the same strain were group housed (10 per cage) and allowed to acclimatise 
to the unit environment for 1 week. Mice had ad libitum access to water and Standard 
Expanded Beekay diet (B&K, Grimston, Aldborough, UK). The lighting cycle was 
14h:10h light:dark, (05:30 on; 19:30 off) and humidity and temperature were 
maintained at 55-65% and 21.5±1°C.  
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2.3.2 Murine mating protocol 
Oestrus synchronisation was achieved via the Whitten effect by introducing male urine 
soaked bedding to the female cage 72 hours prior to mating. Oestrus was confirmed by 
vaginal smear and receptivity to the male. Females were naturally mated to males (1 
female:1 male). Five successful copulations were observed prior to leaving the male 
and female together overnight. Females were then group housed according to time of 
mating, before being sacrificed under Schedule 1 of the Animals (Scientific 
Procedures) Act, 1986. Animals were sacrificed at 24, 48, 72 and 96 hours post initial 
mating ± 1 hour (n=3 at each time point). Controls were provided by naturally cycling 
females at the oestrus and dioestrus stages (n=3 for both), as determined by vaginal 
smear. 
 
2.3.3 Uterine tissue fixation 
Within five minutes of culling, mice were dissected and the ovaries, uterine horns and 
vagina were retrieved. Immediately after harvest, the tissue was placed on a cork block 
and coated in optimal cutting temperature (OCT) compound. The block was then 
placed in isopentane slush pre-cooled with liquid nitrogen until all the OCT became 
opaque. Once fully frozen, the blocks were stored on dry ice before transfer to -80°C 
freezer for storage. 
 
2.3.4 Uterine tissue sectioning 
Blocks were removed from -80°C storage and transported on dry ice for frozen 
sectioning using a Leica CM3050S Cryostat (Leica Biosystems, UK). The cryostat 
chamber temperature was set to -16°C, and blocks were allowed to equilibrate to this 
temperature for 30 minutes. Blocks were trimmed at 30μm section depth until sufficient 
tissue depth was achieved, with subsequent sections cut at 12μm. Sections were 
mounted onto Arcturus PEN membrane glass slides (Applied Biosystems, CA, USA), 
and kept on dry ice prior to staining. 
 
2.3.5 Uterine tissue staining 
All plasticware and staining jars were treated with RNAse-ZAP, rinsed three times in 
Milli-Q H2O, and dried thoroughly (overnight) before use. Ethanol solutions for the 
staining protocol were prepared using RNAse-free water and molecular grade absolute 
ethanol. 100% anhydrous ethanol was prepared by adding 15g molecular sieve beads 
(3 Angstrom, 1-2 mm) to 500 ml ethanol. 
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Slides were stained using buffered cresyl violet staining solution - 40μl 0.5 M Tris-HCl 
pH 8.0 was added to 1 ml cresyl violet staining solution (1g cresyl violet solubilised in 
75% ethanol and filtered) immediately prior to use. Staining with cresyl violet was 
chosen as this compound does not affect RNA quality. 
 
Slides were stained using the following protocol, adapted from Cummings et al 2011 
[337]:  
 95% ethanol, 30 seconds 
 75% ethanol, 30 seconds 
 50% ethanol, 30 seconds 
 Lay slide flat, gently wipe edges with tissue and mark with barrier pen. Add 300 
μl of buffered cresyl violet stain; 40 seconds 
 50% ethanol, seconds 
 75% ethanol, 30 seconds 
 95% ethanol, 30 seconds 
 100% ethanol, 30 seconds 
 100% ethanol, 30 seconds 
 100% ethanol, 5 minutes     
 
Ethanol was used in order to preserve RNA quality, with a minimum concentration of 
50%. All slides were blotted between each solution to reduce carry over. Solutions 
were changed after every two slides to prevent OCT saturation. Slides were stored at -
80°C. 
 
2.3.6 Laser capture microscopy 
A Zeiss Palm® Microbeam UV laser capture microscope, equipped with PALM@Robo 
software version 3.2 (Carl Zeiss, Herts, UK) was used to perform laser capture 
microscopy (LCM). Samples were captured with cut energy set at 51-60 and laser 
speed of 20. Endometrial epithelial and stromal samples were identified by morphology 
under light microscopy (20x magnification), highlighted by the in-built drawing tool, 
excised by laser and collected into adhesive caps (Carl Zeiss, Herts, UK) individually.  
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2.3.7 RNA preparation 
2.3.7.1 RNA extraction 
RNA extraction was performed using a Qiagen RNA extraction kit (Qiagen, UK). Each 
captured sample was suspended in 350μl of RLT buffer with 3.5μl β-mercaptoethanol. 
Each sample was vortexed and stored at -80°C prior to RNA extraction. The extraction 
protocol was performed as per manufacturer’s instructions with minor modifications; 
one extra RPE and 80% ethanol wash step was incorporated in order to reduce the 
carry-over of impurities and improve RNA quality. Samples were eluted from the spin 
column by immediate addition of 14μl RNAse-free H2O, with 0.5μl RNASecure 
(Ambion) to the eluate. Samples were concentrated using a Savant SpeedVac® 
concentrator (Eppendorf, Hamburg, Germany) for 30 minutes or until dry, then 
resuspended in 4μl RNAse-free water and stored at -80°C until use. 
 
2.3.7.2 Assessment of RNA quality 
RNA quality was assessed using the Agilent RNA 6000 Nano kit (Agilent, UK) on a 
2100 Bioanalyser (Agilent, UK) equipped with 2100 Expert software following the 
manufacturer’s instructions. The chip was processed using the RNA Eukaryote Total 
RNA Nano function. 
 
2.3.7.3 Fluorescent cRNA generation 
Fluorescent cRNA was prepared using the Agilent One Colour Low Input Quick AMP 
labelling kit. 10ng of RNA was added to the labelling reaction. Purification of RNA was 
performed using the RNEasy Mini kit (Quiagen UK) following the manufacturer’s 
instructions.  
 
2.3.7.4 Flourescent cRNA quality assessment 
Fluorescent cRNA quality was assessed using the NanoDrop 1000 (Thermo-Scientific 
UK). Cyanine (Cy3) concentration (pmol/μl), RNA 260/280 ratio and cRNA 
concentration (ng/μl) were recorded. The yield and specific activity were calculated for 
each sample as follows: 
 
Yield (μg cRNA) = (Concentration of cRNA x elution volume)/1000 
 
Specific Activity (pmol Cy3/μg cRNA) = (Concentration of Cy3/concentration cRNA) x 
1000 
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2.3.8 RNA hybridisation and microarray scanning 
Samples were hybridised to Agilent SurePrint G3 Mouse GE 8x60k Microarrays 
following the manufacturer’s instructions. Hybridisation was performed in an Agilent 
hybridisation oven (Agilent, UK), hybridisation time was set to 17 hours at 65°C with a 
rotation speed of 20rpm. Subsequent washes were completed within 1 hour. Slides 
were scanned immediately to reduce potential variations in signal intensities due to 
environmental contaminants. Microarrays were scanned using an Agilent ‘C’ scanner 
(Agilent, UK), with a scan resolution of 3μm.  
 
2.3.9 Data presentation and statistical analysis 
2.3.9.1 Feature extraction 
Feature extraction was performed using Feature Extraction version 11.0.1.1 (Agilent 
Technologies, UK). Sample quality was assessed utilising the inbuilt quality control 
metrics. 11 metrics were applied to the microarray, covering aspects such as 
alignment, signal intensity and reproducibility, providing a range within which a 
microarray is considered ‘good’ (Table 2-4). Microarrays falling outside of these ‘good’ 
criteria were evaluated for inclusion/exclusion from the analysis. 
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Metric name Aspect assessed ‘Good’ criteria 
Isgoodgrid Alignment of the microarray correctly detected by 
the software 
>1 
AnyColorPrcntFeatNonUn Percentage of non-uniform outliers <1 
gNegCtrlAveNetSig Negative control statistics, average net signal 
(mean signal minus scanner offset, indicates 
dynamic range) 
<40 
gNegCtrlAveBGSubSig 
 
Average background subtracted signal -10 to 5 
gNegCtrlSDevBGSubSig Standard deviation of the BG sub-signal <10 
gSpatialDetrendRMSFilter 
 
Low signal background – the higher the number, 
the more background detected and removed 
<15 
gNonCntrlMedCVProcSign Reproducibility in repeated non-control probes 
(median %CV) 
0 to 8 
gE1aMedCVProcSignal Spike-in reproducibility plot (%CV) 0 to 8 
absGE1E1aSlope Slope of spike-in dose response curve 0.9 to 1.2 
DetectionLimit Limit of detection of spike-in 0.01 to 0.2 
gDDN Direction dependent noise (background) from 
green channel 
-15 to 15 
Table 2-4: Quality control metrics applied to Agilent 1-colour gene expression 
microarrays. ‘Good’ criteria show the range of scores indicating that a particular 
microarray is of high enough quality to be included in analysis. 
 
2.3.9.2 Sample size calculation 
Sample size and desired fold difference were calculated using the Microarray Sample 
Size Computation tool available at 
http://bioinformatics.mdanderson.org/microarraysamplesize/. The calculation was 
based on 55821 entities, with an acceptable false positive rate of 5%, power 
(percentage of differentially expressed entities likely to be detected by the experiment) 
of 0.8, and a standard deviation of 0.7. 
 
2.3.9.3 Data exploration 
Data were visualised and analysed using GeneSpring version 12.5 (Agilent 
Technologies, UK). Data were normalised by dividing the signal intensity of each entity 
by 75% of the average signal intensity of all entities. Samples were examined by the 
inbuilt principal components analysis (PCA) to identify major outliers. Due to the 
sample size, a 5-fold change cut off was applied to the data. Pathway analysis was 
performed using the condition averages in order to identify immune pathways active in 
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the murine endometrium. P values were corrected for multiple comparisons using 
Benjamini and Hochberg’s false discovery rate (FDR). The results from the pathway 
analysis were used in subsequent cluster analyses. 
 
2.3.9.4 Cluster analysis 
Entities identified through pathway analysis were subjected to cluster analysis in IBM 
SPSS version 19. The analysis was performed for epithelium and stroma individually, 
based on a two-step cluster analysis using Ward linkage. At each iteration, the 
∆coefficient was calculated, with the largest ∆coefficient defining the number of 
clusters. Identified entities in each cluster were visualised and graphed in GraphPad 
Prism version 6. 
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2.4 Results 
2.4.1 Microscopic changes in the murine endometrium 
Epithelial and stromal cells differed in microscopic appearance at different points during 
the oestrus cycle and post coitum. At dioestrus, epithelial cells appeared reduced in 
height compared to oestrus, while stromal cells were round/oval (Figure 2-6). Mitotic 
bodies were evident within the epithelium. 
 
 
Figure 2-6: Endometrial epithelial and stromal cells at dioestrus. Frozen sections were 
stained with cresyl violet and visualised at 20x magnification. E – epithelium, M – 
mitotic bodies, S – rounded/oval stromal cells. 
 
Within the oestrus endometrium, the epithelial cells became very large, tall columnar 
cells (Figure 2-7). There was evidence of vacuolar degeneration and apoptotic cells 
within the epithelium, and the stromal compartment maintained a fibroblast-like 
appearance. The uterine lumen also showed evidence of dilation. 
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Figure 2-7: Endometrial epithelial and stromal cells at oestrus. Frozen sections were 
stained with cresyl violet and visualised at 20x magnification. A – apoptotic cells, E – 
epithelium, S – stromal cells, V – vacuolar degeneration. 
 
 
Post coitum, the epithelium maintained a taller appearance at days 1 and 2, 
subsequently returning to a shortened state (similar to that seen at dioestrus) at days 3 
and 4 (Figure 2-8). Stromal cells became progressively more rounded towards day 4 
post coitum. 
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Figure 2-8: Endometrial epithelial and stromal cells on days 1-4 post coitum. Frozen 
sections were stained with cresyl violet and visualised at 20x magnification. 
 
2.4.2 Sample quality control and filtering 
2.4.2.1 Epithelial samples 
Samples were assessed for hybridisation quality. Table 2-5 shows the number of 
quality control metrics passed for each epithelial sample. 
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Sample Number of metrics passed 
Dioestrus 1 2 
Dioestrus 2 11 
Dioestrus 3 7 
Oestrus 1 11 
Oestrus 2 7 
Oestrus 3 11 
Day 1-1 11 
Day 1-2 3 
Day 1-3 2 
Day 2-1 7 
Day 2-2 11 
Day 2-3 11 
Day 3-1 11 
Day 3-2 10 
Day 3-3 11 
Day 4-1 10 
Day 4-2 10 
Day 4-3 11 
Table 2-5: Quality control metrics for epithelial samples. 
 
Samples passing less than 7 quality control metrics were excluded from subsequent 
analysis. Profile plots were examined for those samples passing 7 or more metrics 
(Figure 2-9).  
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Figure 2-9: Endometrial epithelial cell sample profile plot. Normalised intensity values 
for each entity are displayed according to sample grouping. 
 
 
Samples Oestrus 2 and Day 4-2 exhibited ‘mirroring’ or ‘inversion’ of their normalised 
intensity values compared to their replicates (Figure 2-9). Extended discussions with 
the gene expression microarray supplier (Agilent, UK) suggested that these samples 
may have been contaminated, however this was not conclusive. Initial PCA of the data 
(using the in-built PCA in Genespring) identified Oestrus 2 and Day 4-2 as outliers. Due 
to the low level of confidence in the results and the lack of correlation with their 
biological replicates, these samples were excluded from subsequent analysis. The 
remaining samples were averaged, and the resultant profile plots are displayed below 
(Figure 2-10). Individual entities (mRNA) appeared to exhibit differential expression 
over time. 
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Figure 2-10: Averaged profile plots for epithelial samples. Normalised intensity values 
are displayed according to sample type. Individual entities (mRNA transcripts) are 
colour coded and exhibit differential expression over time. 
 
 
2.4.2.2 Stromal samples 
Samples were assessed for hybridisation quality. Table 2-6 shows the number of 
quality control metrics passed for each epithelial sample. As with the epithelium, 
stromal samples passing less than 7 quality control metrics were excluded from 
subsequent analysis. Profile plots were examined for those samples passing 7 or more 
metrics (Figure 2-11). Stromal profiles appeared inherently noisier than epithelial 
samples. Although some ‘mirroring’ was evident in some samples this was not as 
pronounced and limited to a small number of entities, with outliers not identified by 
PCA. Therefore all remaining samples were included in subsequent analyses. 
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Sample Number of metrics passed 
Dioestrus 1 7 
Dioestrus 2 7 
Dioestrus 3 10 
Oestrus 1 10 
Oestrus 2 11 
Oestrus 3 8 
Day 1-1 11 
Day 1-2 7 
Day 1-3 7 
Day 2-1 2 
Day 2-2 8 
Day 2-3 11 
Day 3-1 7 
Day 3-2 8 
Day 3-3 6 
Day 4-1 11 
Day 4-2 11 
Day 4-3 9 
Table 2-6: Quality control metrics for stromal samples. 
 
 
Figure 2-11: Endometrial stromal cell sample profile plot. Normalised intensity values 
for each entity are displayed according to sample grouping. 
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2.4.2.3 Sample filtering 
Of 55821 entities, 39516 displayed a 5-fold change between at least one condition/time 
point. These entities were used for subsequent analyses. 
 
2.4.3 Pathway analysis 
Pathway analysis within Genespring revealed 217 curated pathways active within the 
murine uterine tract  (Appendix I: Non-significant pathways identified by pathway 
analysis. Of these pathways, 46 were significant at p=0.05 (Table 2-7), with 
significance defined by an in-built algorithm which created a composite score of the 
number of entities matched and the extent of the response of those entities. As the 
theme of research was focussed on the role of immune pathways in the reproductive 
environment, only pathways relevant to the immune function were selected and 
examined in epithelial and stromal samples (highlighted in Table 2-7). 
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Pathway WikiPathways ID p-value 
Number of 
Matched 
Entities 
Number of 
Pathway 
Entities 
GPCRs, Class A Rhodopsin-like  WP189 62834 0.00 208 231 
GPCRs, Other  WP41 54691 0.00 150 210 
GPCRs, Other  WP41 62667 0.00 150 210 
Cytoplasmic Ribosomal Proteins  WP163 62833 0.00 77 80 
Peptide GPCRs  WP234 41308 0.00 63 70 
Metapathway biotransformation  WP1251 41349 0.00 117 143 
Monoamine GPCRs  WP570 48232 0.00 32 33 
Monoamine GPCRs  WP570 60231 0.00 32 33 
Calcium Regulation in the Cardiac Cell  WP553 47774 0.00 120 150 
Striated Muscle Contraction WP216 41273 0.00 40 45 
Complement and Coagulation Cascades  WP449 41301 0.00 53 62 
Prostaglandin Synthesis and Regulation  WP374 41394 0.00 29 31 
Small Ligand GPCRs  WP353 41279 0.00 18 18 
Selenium  WP1272 58514 0.00 22 31 
Cytokines and Inflammatory Response 
(BioCarta)  WP222 53571 0.00 26 30 
Selenium  WP1272 59028 0.00 21 31 
Complement Activation, Classical Pathway  WP200 47967 0.00 16 17 
Cytochrome P450  WP1274 48227 0.00 35 40 
Myometrial Relaxation and Contraction 
Pathways WP385 47969 0.00 120 157 
Blood Clotting Cascade  WP460 62696 0.00 19 20 
Glucocorticoid & Mineralcorticoid 
Metabolism  WP495 62838 0.00 13 13 
SIDS Susceptibility Pathways  WP1266 58254 0.00 49 61 
SIDS Susceptibility Pathways  WP1266_58281 0.00 49 61 
GPCRs, Class B Secretin-like  WP456 41317 0.01 20 22 
Nuclear receptors in lipid metabolism and 
toxicity  WP431 47744 0.01 26 30 
Glucuronidation  WP1241 59029 0.01 11 18 
Irinotecan Pathway  WP475 48258 0.01 11 11 
Matrix Metalloproteinases  WP441 41300 0.01 25 29 
Macrophage markers  WP2271 53132 0.01 10 10 
XPodNet - protein-protein interactions in the 
podocyte expanded by STRING  WP2309 58142 0.01 573 836 
XPodNet - protein-protein interactions in the 
podocyte expanded by STRING  WP2309 58143 0.01 573 836 
Oxidative Stress  WP412 41381 0.02 24 29 
GPCRs, Class C Metabotropic glutamate, 
pheromone  WP327 41361 0.02 14 15 
Folic Acid Network  WP1273 48256 0.02 20 27 
Inflammatory Response Pathway  WP458 57463 0.03 25 30 
TGFβ Signaling Pathway  WP113 41270 0.03 41 52 
Metapathway biotransformation  WP1251 59060 0.03 22 143 
Hedgehog Signaling Pathway  WP116 41332 0.03 19 22 
Folic Acid Network  WP1273 60224 0.03 19 27 
Glycolysis and Gluconeogenesis  WP157 43573 0.03 38 48 
Endochondral Ossification  WP1270 41292 0.03 48 62 
Serotonin and anxiety-related events  WP2140 58159 0.03 12 13 
Glycolysis and Gluconeogenesis  WP157 51735 0.04 39 50 
ESC Pluripotency Pathways  WP339 42897 0.04 81 111 
Retinol metabolism  WP1259 51364 0.04 31 39 
Oestrogen metabolism  WP1264 48250 0.04 11 13 
Table 2-7: Pathways in the murine endometrium which were identified by pathway 
analysis to be significant (p<0.05). Pathways highlighted were selected for examination 
in epithelial and stromal samples. P values are presented to 2 decimal places. 
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2.4.4 Endometrial response to seminal plasma – pathway analysis 
Pathway analysis within Genespring was based on pre-defined pathways described in 
disease models. For the sake of clarity and readability, these models are presented in 
Appendix II for results relating to endometrial epithelium, and Appendix III: Pathway 
analysis for LCM captured endometrial stromal cells. for pathways relating to 
endometrial stromal cells.  
 
2.4.5 Epithelial response to seminal plasma – cluster analysis 
mRNA entities encoding cytokine proteins and matrix metalloproteinases highlighted in 
the pathway analysis were selected for subsequent cluster analysis. These elements 
fell into 8 clusters, as shown in Figure 2-12. Cluster 1 was defined by peaks in 
expression on days 1 and 3 post mating with reduced expression on day 2 (Cxcl3, Il10, 
Il12a, Mmp9, Mmp20, Mmp25, Tnf). Cluster 2 exhibited a similar pattern of peaks on 
days 1 and 3, with a less dramatic reduction in expression on day 2 (Bmp4, Egf, Il7, 
Il13, Mmp1a, Mmp3, Mmp16, Mmp28). Cluster 3 generally showed a peak in 
expression at oestrus and day 2 post mating with a reduction in expression on day 1 
(Ccl5, Csf3, Il1b, Il15, Inhb1, Mmp11, Mmp14, Mmp23, Thbs). Cluster 4 demonstrated 
a slight peak at dioestrus and day 1 post mating (Ifng, Mcp1, Mmp2, Mmp19, Tgfb1, 
Tgfb2, Tgfb3). Cluster 5 showed a dip in expression at oestrus, while remaining 
relatively constant at other time points (Csf2, Cxcl2, Il2, Il4, Il5, Il12b, Itbp1, Mmp10, 
Mmp12, Mmp13, Mmp21, Mmp24). Cluster 6 exhibited minor peaks on days 2 and 4 
post mating, although many elements showed large variation (Cxcl1, Il1a, Lif, Mmp8, 
Mmp27). Cluster 7 was characterised by peaks at dioestrus, day 1 and day 4 post 
mating, with a dramatic reduction in expression at day 2 and 3 (Csf1t1, Csf1t3, Mmp7). 
Finally, cluster 8 elements exhibited huge variations in expression at each time point, 
and therefore could not be described according to any particular pattern.  
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Figure 2-12: Cluster analysis of mRNA encoding cytokine and MMP proteins in uterine 
epithelial cells. Cluster membership: Cluster 1 - Cxcl3, Il10, Il12a, Mmp9, Mmp20, 
Mmp25, Tnf; Cluster 2 - Bmp4, Egf, Il7, Il13, Mmp1a, Mmp3, Mmp16, Mmp28; Cluster 
3 - Ccl5, Csf3, Il1b, Il15, Inhb1, Mmp11, Mmp14, Mmp23, Thbs; Cluster 4 - Ifng, Mcp1, 
Mmp2, Mmp19, Tgfb1, Tgfb2, Tgfb3; Cluster 5 - Csf2, Cxcl2, Il2, Il4, Il5, Il12b, Itbp1, 
Mmp10, Mmp12, Mmp13, Mmp21, Mmp24; Cluster 6 - Cxcl1, Il1a, Lif, Mmp8, Mmp27; 
Cluster 7 - Csf1t1, Csf1t3, Mmp7; Cluster 8 - Ifnb, Il6, Il11. 
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2.4.6 Stromal response to seminal plasma: cluster analysis 
mRNA entities encoding cytokine proteins and MMPs highlighted in the pathway 
analysis were also selected for subsequent cluster analysis. These species fell into 7 
clusters, as shown in Figure 2-13. Cluster 1 comprised three mRNA species (Csf1t1, 
Csf3, Mmp23) which exhibited a peak at oestrus. Cluster 2 was characterised by a 
slight increase in expression on day 1 post mating, with a subsequent decrease on 
days 2, 3 and 4 (Bmp4, Csf1t3, Csf2, Cxcl2, Cxcl3, Egf, Ifnb1, Il1a, Il2, Il4, Il5, Il6, Il7, 
Il10, Il11, Il12a, Il12b, Il13, Mmp1a, Mmp3, Mmp8, Mmp10, Mmp13, Mmp12, Mmp16, 
Mmp20, Mmp21, Mmp24, Mmp25, Mmp28, Tnf). Cluster 3 comprised only of Mmp7, 
which showed highest expression at oestrus with lowest expression on day 3 post 
mating. Cluster 4 increased in expression post mating and remained high on days 2, 3 
and 4 (Ifng, Il15, Mmp2, Mmp19, Tgfb1, Tgfb2, Tgfb3). Cluster 5 peaked on days 1 and 
2 post mating with a subsequent decease on days 3 and 4 (Ccl5, Inhb1, Il1b, Mcp1, 
Mmp9, Thbs1). Cluster 6 peaked on day 1 with a subsequent fall to baseline levels of 
expression (Mmp11, Mmp14). Cluster 7 was characterised by peaks in expression at 
dioestrus and day 3 post mating (Cxcl1, Itbp1, Lif, Mmp27). 
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Figure 2-13: Cluster analysis of mRNA encoding cytokines and MMPs in uterine 
endometrial stromal cells. Cluster membership: Cluster 1 - Csf1t1, Csf3, Mmp23; 
Cluster 2 - Bmp4, Csf1t3, Csf2, Cxcl2, Cxcl3, Egf, Ifnb1, Il1a, Il2, Il4, Il5, Il6, Il7, Il10, 
Il11, Il12a, Il12b, Il13, Mmp1a, Mmp3, Mmp8, Mmp10, Mmp13, Mmp12, Mmp16, 
Mmp20, Mmp21, Mmp24, Mmp25, Mmp28, Tnf; Cluster 3 - Mmp7; Cluster 4 - Ifng, 
Il15, Mmp2, Mmp19, Tgfb1, Tgfb2, Tgfb3; Cluster 5 - Ccl5, Inhb1, Il1b, Mcp1, Mmp9, 
Thbs1; Cluster 6 - Mmp11, Mmp14; Cluster 7 - Cxcl1, Itbp1, Lif, Mmp27. 
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2.4.7 Endometrial epithelial and stromal differences 
Many mRNA species exhibited differences in expression between endometrial 
epithelial and stromal cells. The majority showed greater relative expression in stromal 
cells as compared to epithelial cells, with the exception of Mmp7 and elements of the 
prostaglandin pathway (as detailed below) which were consistently more highly 
expressed in epithelial cells.  
 
2.4.7.1 Colony stimulating factors 
The colony stimulating factors varied in expression in each cell type (Figure 2-14) with 
notable differences in both transcript variants of Csf1. This mRNA peaked on days 1 
and 4 post mating in the epithelium, while expression in the stroma remained relatively 
constant. Csf2 showed a slight peak in expression on day 1 post mating in both 
epithelium and stroma, with epithelial expression peaking on day 4 while stromal 
expression slowly declined. Of the colony stimulating factors, Csf3 showed the greatest 
difference in expression between epithelium and stroma, with a dramatic drop in 
epithelial expression on day 1 followed by a peak on day 2 post mating. 
 
2.4.7.2 Chemokines 
With the exception of Ccl5, the expression of chemokines rose in epithelial cells above 
the levels seen in stroma on day 4 post mating (Figure 2-15). Cxcl1 appeared to have 
opposite expression profiles in epithelial and stromal cells. Ccl5 exhibited a strong peak 
in stromal cell expression on day 2 post mating, with a subsequent dramatic fall on day 
3. Mcp1 peaked in stroma on days 1 and 2 post mating. 
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Figure 2-14: Mean CSF mRNA normalised intensity in endometrial epithelial and 
stromal cells post coitum. 
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Figure 2-15: mRNA expression of chemokines in endometrial epithelial and stromal 
cells post coitum. 
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2.4.7.3 Interleukins 
Many interleukins followed a similar pattern of expression in epithelium and stromal 
cells, being initially relatively higher in the stroma with a subsequent decrease in 
stromal expression below that seen in epithelium on days 3 and/or 4 post mating 
(Figure 2-16). Interleukins that did not follow this pattern can be seen in Figure 2-17. 
 
Of particular interest was Il1b, which demonstrated a sharp increase in stromal 
expression on days 1 and 2 post mating (Figure 2-17) with a subsequent fall below 
relative epithelial expression at days 3 and 4. This dramatic fall in stromal expression 
was also seen in Il5 and Il6 expression levels. Il11 demonstrated a strong peak in 
epithelial expression on day 4, while stromal expression dramatically decreased. Il15 
remained low in the epithelium post mating, with peaks in stromal expression on days 2 
and 4. 
 
2.4.7.4 Lif 
Lif expression varied little throughout the post mating period in endometrial epithelial 
cells, demonstrating a slight dip on day 1 (Figure 2-18). Stromal expression varied 
more, with the highest expression profiles seen in cycling endometrium at dioestrus 
and the lowest on day 4 post mating. 
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Figure 2-16: Interleukin expression in endometrial epithelium and stromal cells post 
coitum. 
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Figure 2-17: Interleukin expression in endometrial epithelial and stromal cells post 
coitum (2). 
 
 
 
Figure 2-18: Lif expression in endometrial epithelial and stromal cells post mating 
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2.4.7.5 Matrix metalloproteinases 
Many MMPs followed a similar pattern of relative expression in epithelium and stromal 
cells, initially being higher in the stroma with a subsequent increase in epithelial 
expression on days 3 and/or 4 post mating, mirroring a number of interleukins (Figure 
2-19). Three MMP transcript profiles (Mmp2, Mmp9 and Mmp13) showed a divergence 
by day 2 post mating, with a peak in stromal expression while epithelial expression 
dropped (Figure 2-20). Mmp27 was the only metalloproteinase to show a divergence 
by day 3 post mating (Figure 2-21). Mmp7 was the only MMP which exhibited 
consistently relatively higher expression in epithelial cells compared to stroma (Figure 
2-22). 
 
 
 
Figure 2-19: Matrix metalloproteinase mRNA expression in endometrial epithelial and 
stromal cells post coitum (1). 
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Figure 2-20: Matrix metalloproteinases demonstrating a divergence in expression on 
day 2 post mating. 
 
 
Figure 2-21: Mmp27 expression in endometrial epithelial and stromal cells post coitum. 
 
 
Figure 2-22: Mmp7 expression in endometrial epithelial and stromal cells post coitum. 
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2.4.7.6 Transforming growth factors 
The transforming growth factors were consistently more highly expressed (relatively) in 
stroma than in epithelium (Figure 2-23). Tgfb1 exhibited a divergence between stromal 
and epithelial expression by day 1 post mating, with stromal expression increasing 
while epithelial expression decreased. Tgfb2 showed a similar divergence by day 2 
post mating. 
 
2.4.7.7 Interferons 
Ifnb and Ifng were both detectable in endometrial epithelial and stromal cells. Ifnb 
exhibited a sharp peak in epithelial expression on day 2 post mating, elevating its 
relative expression above that noted in stromal cells (Figure 2-24). Ifng peaked on day 
2 post mating in both tissue compartments. 
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Figure 2-23: Transforming growth factor expression in endometrial epithelial and 
stromal cells post coitum. 
 
 
 
 
Figure 2-24: Expression of interferons in endometrial epithelium and stroma following 
mating. 
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2.4.7.8 Prostaglandin synthases 
Prostaglandin synthase mRNA expression was detected in both endometrial epithelial 
and stromal cells (Figure 2-25). Ptgs1 demonstrated a dramatic increase in epithelial 
expression above stromal expression on day 2 post mating, which was sustained until 
a drop on day 4. Ptgs2 peaked in the epithelium on day 2 post mating. 
 
2.4.7.9 Prostaglandin receptors 
The prostaglandin E receptors Ptger1, Ptger2, Ptger3 and Ptger4 exhibited relative 
differences in expression between endometrial epithelial and stromal cells (Figure 
2-26). Both Ptger1 and Ptger3 were relatively more highly expressed in stroma than in 
epithelium. Ptger1 showed an increase in stromal expression with a concurrent 
decrease in epithelial expression on day 2 post mating. Ptger2 and Ptger4 were 
consistently proportionally more highly expressed in epithelium than in stroma. Ptger2 
peaked on days 1 and 4 post mating, while Ptger4 peaked on day 3.  
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Figure 2-25: Prostaglandin synthase mRNA expression in endometrial epithelial and 
stromal cells post coitum. 
 
 
Figure 2-26: Prostaglandin receptor expression in endometrial epithelial and stromal 
cells following mating. 
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2.5 Discussion 
The response of the endometrium to paternal antigens and immunolological mediators 
helps to prepare the uterus for implantation and induces maternal tolerance of 
pregnancy. However, the molecular basis behind the interaction between seminal 
plasma and the endometrium as well as the subsequent immunological changes which 
it orchestrates prior to implantation remain poorly understood. This study sought to 
explore the response of the endometrium to seminal plasma throughout the 
preimplantation period. 
 
2.5.1 Immune networks within the murine endometrium following mating 
Many curated pathways identified within the murine endometrium showed differential 
expression patterns between the epithelial and stromal compartments. As might be 
expected, the Cytokines and Inflammatory Response pathway (WP222 53571) and the 
Inflammatory Response Pathway (WP458 57463) were activated in the murine 
endometrium post mating (p=0.00 and p=0.03 respectively). Although most commonly 
examined as a constituent of seminal plasma influencing the maternal reproductive 
tract, the TGF-β signalling pathway was identified as being active within the murine 
endometrium itself post mating, indicating a local role for TGF-β in the maternal 
response to seminal plasma (p=0.03). Other pathways linked to the immune system 
were also identified; Prostaglandin Synthesis and Regulation (p=0.00), Matrix 
Metalloproteinases (p=0.01), Macrophage Markers (p=0.01) and Oxidative Stress 
(p=0.02). Surprisingly, the chemokine pathways WP2292_53116 and WP2292_51127 
were not identified as being active in the murine endometrium (both p=0.08, Appendix 
I). In addition, the Complement Activation and the Blood clotting Cascade pathways 
(both p=0.00) were activated, indicating complement activation. Taken together, these 
pathways indicate that seminal plasma induced an immune response within the murine 
endometrium. For subsequent analyses, data relating to key molecular mediators 
(cytokines, MMPs and PGs) within these pathways were selected for further 
exploration. 
 
2.5.2 Cluster analysis of immune mediators 
2.5.2.1 Clusters within the endometrial epithelium 
A logical step beyond pathway analysis was to identify interactions between immune 
mediators via cluster analysis, grouping mediators into expression patterns throughout 
the pre-implantation period. Within the epithelium, eight patterns were identified, each 
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of which included elements from multiple pathways, which highlights the likely cross-
talk between each pathway. For example, the stroma cluster 2 contained elements 
from the Cytokine and Inflammatory Response, the Inflammatory response, the TGF-β 
Signalling and Matrix Metalloproteinase pathways, all of which responded to seminal 
plasma analogously with the same pattern of decreased expression over the pre-
implantation period. This likely reflects the arbitrary nature of pathway design. 
 
Of particular interest within the epithelium was cluster 2 (Bmp4, Egf, Il7, Il13, Mmp1a, 
Mmp3, Mmp16 and Mmp28), a group of mediators which rose in relative expression 
post mating above levels seen in cycling mice, and broadly remained high until day 4. 
EGF and IL-7 share a similar function, in that they induce proliferation and 
differentiation of immune effector cells [338], while BMP-4 acts as a survival factor for 
primordial follicles within the ovary [339]. IL-13 modulates the function of monocytes 
and B cells in humans [340], and also induces (and is induced by) MMPs, as 
highlighted by studies in airway disease [341-343]. The timing of expression of these 
mRNA species supports their purported role in the induction of immune tolerance as 
well as providing a signal to the underlying stroma to begin tissue remodelling, 
especially given the fact that this response is sustained over the preimplantation 
period. 
 
The mRNA species falling into cluster 1 (Cxcl3, Il10, Il12a, Mmp9, Mmp20, Mmp25 and 
Tnf) peaked at days 1 and 4 post mating; these were again above the relative 
expression levels seen in cycling mice. TNF-α is known to be involved in the acute 
inflammatory response [344], so it is unsurprising that its expression is increased early 
following semen deposition. Cxcl3 (also known as macrophage inflammatory protein, 
(MIP)-2β) controls the migration and adhesion of monocytes [345], therefore likely 
serving as a mediator of the macrophage reaction to seminal plasma. Cxcl3 has been 
shown to be induced by IL-13 [346], so it is perhaps surprising that it does not cluster 
with this cytokine despite exhibiting similar expression patterns. Again, MMPs feature 
heavily in the initial response to seminal plasma in the epithelium, indicating that the 
epithelium undergoes extensive remodelling and/or signals to the stroma to begin 
preparation for implantation in terms of neoangiogenesis to support an implanting 
blastocyst [347]. There is an inherent difficulty in interpreting MMP mRNA data, 
however. The vast majority of these proteases are secreted in an inactive form with a 
pro-peptide domain which must be cleaved in order for the protein to become active 
[348-351] such that mRNA levels may not faithfully reflect the levels of physiologically 
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active protein. The active protein is further modulated by TIMPs, creating additional 
issues in interpretation. 
 
Cluster 3 (Ccl5, Csf3, Il1b, Il15, Inhb1, Mmp11, Mmp14, Mmp23, and Thbs1) and 
cluster 6 (Cxcl1, Il1a, Lif, Mmp8, and Mmp27) exhibited a downregulation in expression 
on day 1 post mating. Interestingly, these two clusters include factors which are 
considered to be chemotactic/differentiation agents for leukocytes (Ccl5, Csf3, Cxcl1, 
and Il15). It is surprising that the expression of these elements is downregulated, given 
that leukocyte activity is evident in the endometrium post mating [252, 352-355]. This 
could be indicative of one feature of cytokine biology, that of functional redundancy, 
where many cytokines share similar actions [356]. Functional redundancy is due to the 
biology of cytokine receptors, where receptors for a family of cytokines share a 
common subunit. For example, a deficiency of IL-2 is not fatal as other cytokines in the 
same family (IL-4, IL-7, IL-9, IL-15 and IL-21) can signal through the IL-2 receptor, 
binding to the common γ-chain [357, 358]. Within the current data, this family of 
interleukins fall into clusters 3 and 5, clusters which show downregulation post mating 
or a lack of elevation above baseline levels. The exception to this is IL-7 which falls into 
cluster 2 (exhibiting a peak on days 1, 2, and 3), indicating perhaps that this cytokine 
performs the functions discussed above, rendering the remaining cytokines within the 
family functionally redundant. An alternative hypothesis is that other cytokines within 
the endometrium act as antagonists of Il4, Il9, Il15 and Il21, although this cannot be 
determined from the present data. 
 
The downregulation of Il1a and Il1b on day 1 post coitum could reflect one of two 
scenarios: firstly, that the immediate inflammatory response invoked by seminal plasma 
exposure peaks and falls prior to day 1 post mating, lying outside of the sample 
measurement in the present study. Cytokine expression has been shown to increase 
within hours of the mating stimulus, with IL-1β expression increasing within 3 hours in 
human endometrial epithelial cells in vitro [262]. Secondly, it is possible that the 
inflammatory reaction in the endometrium is modified. The function of the immune 
response to seminal plasma is to induce maternal tolerance to paternal antigens in 
preparation for implantation such that the traditional acute phase cytokine cascade may 
not accurately describe events following semen exposure. Indeed, the immune 
response may be “muted”, reflecting the physiological role of cytokines in conferring 
immune tolerance rather than a response to infection. 
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2.5.2.2 Clustering of immune mediators within the stromal compartment 
Of particular interest within the endometrial stromal cells was cluster 5 (Ccl5, Il1b, 
Inhb1, Mcp1, Mmp9 and Thbs1). These cytokines and MMPs peaked on days 1 and 2 
post mating with a subsequent fall on days 3 and 4. As previously mentioned, Il1b was 
downregulated at day 1 post mating in the epithelium, reflecting a difference in the 
epithelial and stromal compartments’ responses. The function of this cytokine within the 
endometrial stroma may not be that of a traditional acute inflammatory response – IL-
1β performs other functions such as cell proliferation and differentiation, the induction 
of COX-2 and the regulation of MMPs [359]. Indeed, within the present data, Ptgs2 
(COX-2) rises on day 2 post mating within the stromal compartment, possibly induced 
by cytokines such as IL-1β. However, it is very likely that Il1b also influences the 
steroid hormone microenviroment, as IL-1β has been shown to suppress steroid 
sulphatase (which convert E2 sulphates into active E2) activity in cycling human 
endometrial stromal cells in vitro [360]. The implication of this is that IL-1β could reduce 
the effects of E2 within the stroma, in this case perhaps preventing the progression of 
the oestrus cycle in preparation for implantation and pregnancy. The remaining 
members of this cluster mediate leukocyte recruitment and extracellular remodelling in 
preparation for implantation as previously discussed. 
 
Expression levels in cluster 4 (Ifng, Il15, Mmp2, Mmp19, Tgfb1, Tgfb2, and Tgfb3) 
overall rose on day 1 and remained high throughout the post mating period in the 
stromal compartment. Interestingly, these elements also clustered together in the 
endometrial epithelium but did not exhibit a strong temporal pattern. This is surprising 
given that many studies have shown their involvement in epithelial proliferation and 
remodelling during the human menstrual cycle [323, 361]. One murine study showed 
that Tgfb2 is expressed in epithelial but not stromal cells in the preimplantation period 
[325], which is in contrast with the present data, where TGF-β mRNA is consistently 
more highly expressed in the stromal compartment. TGF-β1 has been shown to inhibit 
proliferation and induce the expression of COX-2 and PRL in human endometrial 
stromal cells in vitro [331], indicating a role in tissue remodelling in preparation for 
decidualisation, which fits with the present data. In conjunction with the MMPs within 
this cluster, members of the TGF-β pathway may mediate the extracellular matrix 
remodelling in preparation for implantation and decidualisation. At the protein level, 
MMP-2 and MMP-9 are known to cleave latent TGF-β into its activated form [362], and 
Mmp2 clusters with all three TGF-β isoforms within both endometrial compartments, 
indicating that MMPs may in part interact with the TGF-β signalling pathway to create 
an immunopermissive environment. 
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Both Ifng and the TGF-β isoform transcripts cluster together, which is expected given 
that in a number of other systems these cytokines demonstrate an antagonistic 
relationship, for example in lung and dermal fibroblasts [363-365]. Within murine and 
human endometrial epithelial cells, IFN-γ has been shown to exhibit a potent inhibitory 
effect on TGF-β [147], although this research focused on the high levels of IFN-γ found 
in seminal plasma rather than physiologically relevant intra-endometrial levels. The 
antagonistic effect of IFN-γ on TGF-β is due to downregulation of the TGF-β type II 
receptor (Tgfb2) [365], which in the present study is upregulated at day 1 post mating 
in the stroma (data not shown). If Ifng were performing an autocrine antagonistic role 
within this cell type, the expected outcome would be a downregulation of Tgfbr2. There 
is, however, a reduction in expression of Tgfbr2 at day 1 within the epithelium, which 
could indicate a paracrine interaction. One likely role of both of these cytokines within 
the endometrium revolves around regulation of T cells. IFN-γ induces apoptosis in T 
cells and inhibits proliferation, while TGF-β promotes the differentiation of naïve T cells 
into Tregs [366]. IFN-γ has been shown to have an anti-proliferative effect on human 
endometrial epithelial cells in vitro [367], and an inhibitory effect on VEGF production 
by endometrial stromal cells [368], which seems in conflict with the events occurring 
within the endometrium post mating. IFN-γ has also been shown to antagonise 
prostaglandin responses in the endometrium, inhibiting P4 receptor-dependent 
transcription [369]. Taken together, this may indicate that the in vitro responses of 
endometrial cells does not reflect the in vivo situation, and therefore merits further 
investigation in the physiological setting. 
 
2.5.3 Previously identified mediators of immune tolerance and implantation 
2.5.3.1 CSFs  
Within the literature, several mediators of the uterine response to seminal plasma have 
been suggested, as highlighted in the introduction. GM-CSF (CSF-2) is known to be 
released by endometrial epithelial cells in response to seminal plasma within hours of 
coitus [240, 241]. Indeed, in the present study, Csf2 rises between oestrus and day 1 
post mating in both epithelial and stromal compartments. However, stromal expression 
of Csf2 exceeds the relative epithelial expression at all time points except day 4, which 
raises the question as to whether the stroma is the primary source for the lumenal 
secretion of this protein. The notion that the epithelium is the primary source of GM-
CSF arises from the fact that the studies which have examined this have been mostly 
conducted in vitro with trypsinised cell cultures which consist mostly of epithelial cells, 
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or panning techniques involving separation of cell types using antibodies – these are all 
techniques which potentially alter the phenotype and response of the cells collected 
[238, 240, 241]. One study in primary cultures of epithelial and stromal cells from 
human endometrium found that GM-CSF mRNA was more highly expressed in 
epithelium than in stroma, although this was examined in cycling uteri and not in 
response to mating [370]. When mRNA was collected from intact murine uteri following 
mating, Csf2 was upregulated on days 1 and 2 post coitum [213], while the present 
study demonstrated a decline on day 2 post mating. It is feasible that this difference in 
response could be explained by the strain of mice used in the experiments: the present 
study used CD1 mice, an outbred strain with high fertility while the Robertson (1996) 
study [213] used (Balb/c x C57B1) females mated to (CBA x C57B1), hybrid strains 
which minimize genetic variability. To the author’s knowledge, there have been no 
studies comparing the response to seminal plasma in mice from different strains which 
presents an opportunity for future study. 
 
GM-CSF exhibits species differences at the biological level, which may explain the 
disparity between studies – human and mouse GM-CSF share 70% sequence 
homology at the nucleotide level and 60% homology at the protein level [371, 372]. 
This is highlighted by the lack of inter-specific cross-reactivity of these proteins and the 
differential gene expression in response to GM-CSF stimulation in mice and humans 
[373]. GM-CSF exhibited a peak on day 1 post mating in both epithelial and stromal 
cells, indicating a role in the response of the endometrium to seminal plasma. 
However, the epithelial expression of GM-CSF was highest on day 4 post coitum, 
indicating a potential role in endometrial receptivity to implantation. In human in vitro 
models, endometrial cell lines produce GM-CSF in response to hCG in a dose-
dependent manner [374]. Under normal conditions GM-CSF recruits leukocytes to the 
endometrium in order to facilitate implantation, with DCs, Tregs and NK cells both 
directing and limiting the invasion of the trophoblast [375-382]. Although GM-CSF may 
not be essential for implantation in mice as demonstrated by experiments conducted in 
GM-CSF null mice, these animals exhibit late gestational pregnancy loss and retarded 
foetal growth, indicating potential placentation defects [383]. The cellular expression of 
GM-CSF in the endometrium within this study was unexpected; however, the temporal 
expression patterns are consistent with findings in the literature. 
 
Csf1 is thought to be a low potency recruitment agent for macrophages to the 
endometrial epithelium [252], and M-CSF protein levels correlate with macrophage 
numbers [250]. In the present study, Csf1 peaked in the epithelium on days 1 and 4 
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post mating, suggesting that macrophages are recruited to the murine endometrial 
epithelium in two distinct waves. The main role of macrophages in the endometrium is 
thought to be tissue remodelling and increasing epithelial cell adhesiveness in 
preparation for implantation [384]. This notion is supported by a rise in Csf1 levels on 
day 4 post mating, where tissue remodelling would take place just prior to implantation. 
By contrast, the rise on day 1 post mating is most likely indicative of the role of 
macrophages as APCs in the induction of maternal tolerance to pregnancy, alongside 
the phagocytosis of semen constituents within the uterine lumen [385].   
 
2.5.3.2 Interleukins 
Although IL-6 has been shown to be induced by seminal plasma constituents in human 
cervical epithelial cells in vitro [211, 223, 261], the in vivo response remains to be 
characterised. Interestingly, in the present study, Il6 was shown to rise on day 1 in the 
stromal compartment while epithelial cells lagged in their response, rising on day 2. IL-
6 expression has been shown to be induced by IL1-β in human endometrial epithelial 
cells [386-388], and in the present study the pattern of expression of Il1b and Il6 were 
similar in stromal cells, albeit with differences in epithelial cells. Il6 is induced very early 
in the response to seminal plasma (within 4 hours) in human ectocervical cell lines 
[223], but the present data indicates that this response is maintained for days following 
mating in mice. IL-6 is a known mediator of the acute inflammatory response, and 
switches the immune response from a neutrophil-mediated to a monocyte/macrophage 
mediated event via induction of ICAM-1 and MCP-1 [257, 389]. Indeed, in the present 
data Mcp1 follows a similar expression pattern to Il6. In the current context, the rise in 
epithelial and stromal Il6 is consistent with the resolution of the initial neutrophil 
response prior to implantation. 
 
Another member of the IL-6 family, LIF, has been shown to be essential for successful 
implantation in mice [263, 390], and is induced by seminal plasma in human 
endometrial epithelial cells in vitro [262]. However, the present data do not support the 
findings in the literature, with endometrial expression of Lif showing little variation in 
response to mating, and relative stromal expression exceeding that of the epithelium at 
most time points. Stromal expression peaked on day 3, potentially initiating the start of 
decidualisation in preparation for implantation. However, one study showed that murine 
endometrial stromal cells produce LIF protein with higher concentrations inhibiting 
decidualisation [391]. Within the present study, a fall in stromal expression of Lif on day 
4 could indicate a release of the inhibition on decidualisation, thereby enabling 
successful implantation. This paradox in findings across different studies could be 
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explained by the differences between in vitro and in vivo environments, as well as the 
localised nature of the decidual reaction. 
 
Interestingly, the murine IL-8 homologues Cxcl1 and Cxcl2 did not demonstrate 
dramatic changes in expression post mating, despite their postulated role in the 
recruitment of neutrophils and granulocytes to the endometrium [276]. This may be due 
in part to the timing of sample collection since cytokines have been shown to rise 
almost immediately in response to seminal plasma. Cxcl5 was not detected within the 
present study. This may be due to the restricted power of this experiment, as only 
mRNA demonstrating a minimum of a five-fold change between at least one of the 
conditions/time points were included in the analysis. However, other murine cytokines 
may perform the functions that IL-8 carries out in the human, and no direct homologue 
has been characterised in the murine genome [392]. The present data should be re-
examined once further knowledge regarding murine IL-8 homologues is attained. 
 
2.5.3.3 Chemokines  
The remaining chemokines previously identified within the literature were MCP-1 and 
RANTES (CCL5). Mcp1 was upregulated on days 1 and 2 in the stroma, but only on 
day 1 in the epithelium. This is consistent with its purported role as a potent 
chemoattractant for monocytes/macrophages [278], although previous studies have 
identified this chemokine as highly expressed in murine endometrial epithelium 
throughout the peri-implantation period [251, 252]. Ccl5 peaked in the stromal 
compartment on day 2 post mating, whereas previous studies have demonstrated a 
peak in expression on day 1 [252]. The reasons for this discrepancy are not 
immediately clear, and the findings of the present data require validation. 
 
2.5.3.4 Elements of the prostaglandin pathway 
The prostaglandin synthases Ptgs1 and Ptgs2 were expressed in the murine 
endometrium and broadly localised to the epithelium post mating which is in agreement 
with the literature [291, 292]. In contrast to previous findings where Ptgs2 was seen to 
increase in expression on day 1 in human endometrium [292],  this fell on day 1 post 
mating, with a peak in expression on day 2 in the present study. It is possible that this 
may represent species-specific differences in the response to seminal plasma with 
regards to prostaglandin pathways. 
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2.5.4 Limitations of the study and future directions 
Examination of the transcriptome can be highly informative, indicating the global 
response of a system to an external stimulus. However, there are many steps between 
the transcription of mRNA and the translation into protein, and these steps define 
whether the concentration of mRNA correlates with the concentration of bioactive 
protein. Those mRNA species which vary in concentration throughout the cell cycle are 
more likely to be controlled at the transcriptional level, and therefore correlate strongly 
with protein concentration and functional effect, while those which vary little may or 
may not be controlled at the post-translational level [393]. It is known that many 
cytokines are controlled at the post-transcriptional level. For example IL-1β, 
granulocyte colony stimulating factor (G-CSF) and IFN-γ are regulated by adenine and 
uridine-rich element (ARE)-mediated mRNA decay after export through the nuclear 
envelope [394]. In terms of post-translational modification, mechanisms include 
glycosylation, -NH2 and/or COOH-terminal truncation, as seen in MCP-1 and -2 [395], 
IL-6 [396], and RANTES [397]. This does not preclude the fact that a particular gene 
may be controlled at both the level of transcription and translation, in addition to post-
translational modification [398]. In the present study, there were many mRNA species 
which did not vary between conditions, and it is not possible to determine whether 
these species are important in the response of the uterine endometrium to seminal 
plasma.  
 
Pathway analysis is a useful tool for identifying ‘system’ level changes in mRNA 
expression. The Genespring microarray analysis tool enables the researcher to explore 
these pathways by mapping a set of identified mRNA species to known pathways and 
then determine which pathways are represented within a specific model. However, this 
approach has several limitations: firstly, the mRNA species are only able to be mapped 
to known curated pathways. Within the mouse, this amounts to 217 pathways within 
the wikipathways database, undoubtedly limited to present knowledge, with many 
pathways yet to be defined. Secondly, these pathways are rigidly defined structures 
without the flexibility to discover previously unknown interactions. Although there have 
been efforts to create new analytical tools to discover new pathways and interactions 
within microarray datasets, this has mainly been aimed at the level of the genome 
rather than the transcriptome [399]. As previously discussed, it is arguably more 
informative to examine interactions at the protein level, although again this kind of 
analysis is limited at present in terms of the ability to detect low abundancy proteins 
without amplification, and the relative insensitivity of techniques such as mass 
spectrometry [400].  
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This study has identified potential new markers of the endometrial response to seminal 
plasma and the coordinated preparation for implantation. However, these findings 
require validation with individual entities examined at the mRNA and protein level. 
Laser capture microscopy to enable examination of the endometrial epithelial and 
stromal compartments is time consuming and costly in terms of equipment/operator 
time and sample usage, especially with the limited material available from murine uteri. 
Therefore these findings present an opportunity for future work to explore the 
interactions between immune mediators, endometrial compartments and the 
developing embryo. 
 
In terms of this thesis, the next section will therefore focus on the development of a 
novel analytical tool to explore immune mediator networks at the protein level in a 
reproductive context. 
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3. Bayesian modelling of cytokine interactions in vivo 
 
3.1 Introduction 
3.1.1 Why model cytokine interactions? 
Traditional approaches to the interpretation the biological properties of cytokines have 
relied on treating these mediators as individual entities, commonly ascribing discrete 
physiological effects to each. However, the value of this strategy is limited by the key 
physiological features displayed by cytokines. It is increasingly recognised that these 
mediators function as networks, where physiological processes are governed by the 
combined influence of many cytokines. Within these networks, cytokines exhibit 
pleiotropy, synergy, antagonism and functional redundancy, further complicating the 
analysis of their influence on physiological processes [91, 92, 152-154]. Furthermore, 
in some cases cytokines exhibit different effects over a range of concentrations or are 
dependent upon the local hormonal environment, meaning that in vitro studies seldom 
replicate the in vivo situation meaningfully, leading to difficulties in interpreting their 
roles [95, 401].  
 
3.1.1.1 Pleiotropism 
Many cytokines exhibit pleiotropism, in that they exert multiple actions on an array of 
different target cell types. Pleiotropic actions may be governed by the presence of 
specific cytokine receptors across multiple cell types, or by the ability of a cytokine to 
activate multiple receptor signalling pathways within a single lineage. There are several 
mechanisms by which this can occur. For example, by forming a complex with its 
soluble IL-6 receptor-α, IL-6 utilises the gp130 subunit to activate signal transduction 
pathways which would otherwise be unresponsive to IL-6 alone [402]. This mechanism 
has been dubbed the receptor conversion model, and can be applied to many other 
cytokines [403].  Moreover, certain cytokines have the ability to send both positive and 
negative signals simultaneously via the same receptor signalling pathway. For 
example, TNF-α can induce both apoptotic and anti-apoptotic signals via TNFR-1 [404]. 
In this case it appears likely that the combined influence of the signals and their relative 
balance is important, a mechanism coined the orchestrating model [403]. 
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3.1.1.2 Synergy 
Synergy is the mechanism by which different cytokines act in concert to produce 
cellular responses greater than those resulting from individual cytokine types alone, or 
responses which neither cytokine could achieve in isolation. Cytokines often synergise 
to induce the production of other cytokines. For example, the combined effect of IL-1β 
and IFN-γ induces the production of MCP-3 in fibroblasts despite the fact that neither of 
these mediators can induce this response individually [153, 405]. Synergistic 
interactions are most likely to occur where the cytokines involved are functionally 
closely related, although this does not preclude interactions between cytokines with 
very different action mechanisms. Synergy may be mediated by shared signalling 
pathway components, as in the case of TNF-α and IL-1β which are both potent 
activators of the transcription factor NF-κB [406, 407]. 
 
3.1.1.3 Antagonism 
Any cytokines which exhibit opposing effects within the same system can be 
considered to be mutually antagonistic. In many cell types IFNs inhibit proliferation, the 
simultaneous presence of a mitogenic cytokine may result in mutual antagonism [408]. 
Two cytokines which exhibit mutual antagonism are IFN-γ and IL-4 [409-411]. In this 
respect, IL-4-induced Th2 T cell differentiation and stability is antagonised by IFN-γ, 
while IFN-γ induced Th1 T cell differentiation and stability is antagonised by IL-4 [412-
415]. This antagonism provides a mechanism for maintaining balance within the 
immune system, ensuring that neither Th1 nor Th2 responses become uncontrolled. 
Indeed, where this balance is disrupted, tissue damage can occur, as seen in diseases 
such as multiple sclerosis and Crohn’s disease (Th1 dominant), as well as atopic 
asthma and allergy (Th2 dominant) [416-419]. Antagonism can occur at any point in the 
signalling cascade, from interactions at the receptor level to modified patterns of gene 
activation, and range from subtle modulatory responses to the complete abrogation of 
an effect  [409, 420, 421].  
 
3.1.1.4 Functional redundancy 
Given that cytokine networks are crucial to the regulation of many physiological 
processes, it is unsurprising that there is an in-built redundancy in the system. Many 
distinct cytokines perform the same biological function; such that the lack of a given 
cytokine does not always confer a lack of response. The molecular basis for functional 
redundancy lies in shared receptor components in a manner not dissimilar to pleiotropy 
[422]. For example, the IL-6 family of cytokines exhibits functional redundancy between 
78 
 
Chapter 3. Bayesian modelling of cytokine interactions in vivo 
cardiotrophin (CT)-1, ciliary neurotrophic factor (CNTF), IL-6, IL-11, leukaemia 
inhibitory factor (LIF) and oncostatin M (OSM) [423]. All of these cytokines feature a 
similar helical structure, and share the gp30 subunit which enables compensation 
within the network [424-429]. Murine knockout models have demonstrated that mice 
null for IL-6 develop into normal healthy adults, while gp30 knockout mice fail to survive 
gestation [430]. 
 
3.1.2 Common approaches to modelling gene/protein interactions 
To date, many of the studies detailing the spectrum of actions displayed by cytokines 
have been based on the analysis of recombinant cytokine interactions in in vitro 
systems. Whilst providing a useful starting point, this approach does not provide a 
realistic representation of cytokine networks either in the whole organism nor at a 
cellular level. Along with pleiotropy and redundancy, cytokine action is contextual, 
influenced by the surrounding milieu containing other biologically active agents (for 
example other cytokines, hormones and prostaglandins) in a synergistic or antagonistic 
manner [431, 432]. Furthermore, many cytokines can act indirectly, either by 
stimulating or inhibiting other cytokines via receptor transmodulation. For example, IL-
1β-induced MMP-1 expression is mediated by transmodulation of the EGF receptor 
[433]. Incorporating such complex interactions provides a significant challenge to 
current modelling techniques aimed at understanding the regulation of cytokine 
networks. 
 
With the advent of high throughput analytical platforms (e.g. fluid-phase multiplex 
immunoassays and microarrays) which can profile large numbers of analytes in a small 
sample, the potential has arisen to examine complex mediator interactions. Many 
studies have utilised statistical methods to identify groups of mediators which work 
together either to result in a particular effect, or to distinguish between clinical 
groupings. Techniques such as correlation, Discriminant Factor Analysis (DFA), cluster 
analysis and PCA have proved useful in identifying groups of analytes which best 
discriminate between clinical groups/outcomes, but these provide scant information 
about how those mediators interact and function as a network [434-439]. 
 
Recent studies analysing microarray data have utilised weight matrices and Boolean 
networks in order to elucidate underlying gene expression profiles, with varying 
degrees of success [440, 441]. However, these methods operate on the basis that all 
interactions can be treated as independent events. This is clearly an assumption which 
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is untrue in the case of cytokines, rendering these approaches unsuitable for modelling 
cytokine interactions. 
 
In terms of defining cytokine networks at the protein level, very few studies have 
attempted the complex analysis required to account for multiple interactions. The 
majority have either focussed on qualitatively and visually comparing a relatively small 
number of network components [442], or on the very broad descriptive analysis of 
shifts in overall network structure [443]. Neither of these approaches provides 
quantitative or directional (i.e. which factor influences the other) information regarding 
individual cytokine interactions and, as such, have fallen short of providing a method to 
understand their networks.  
 
Broderick et al [444] performed a study in chronic fatigue syndrome in humans which 
extended the above methods by employing mutual information (MI) criteria association 
networks to construct a visual representation of cytokine interactions.  This technique 
enables quantitative comparison of networks generated from experimentally derived 
protein data, with the analytes (in this case cytokines) displayed as ‘nodes’ connected 
by ‘edges’ (Figure 3-1).  
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Figure 3-1: Example network generated using mutual information (MI) criteria 
association networks. Cytokines are displayed as nodes (circles), interconnected by 
edges (lines). The depth of colour in the edges demonstrates the strength of the 
association between the connected nodes (adapted from Broderick et al (2010)) [444].  
 
 
In this particular method, the edges are shaded according to the strength of the 
association (the deeper the colour, the stronger the association). Although this is a step 
forward in terms of visually representing cytokine interactions, there are significant 
limitations to this approach. Firstly, the edges simply represent associations, with no 
indication of the direction of the interaction. Secondly, it is not possible to define the 
nature of the interaction. As stated above, cytokines exhibit synergy, antagonism and 
functional redundancy, all features which cannot be defined by utilising an association 
method to discover underlying networks; pairwise mutual information method simply 
does not allow for multivariate analysis in order to explore these essential aspects of 
cytokine function [444]. 
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3.1.3 Bayesian approaches to cytokine network analysis 
3.1.3.1 Frequentist and Bayesian approaches 
Statistical inference approaches to the analysis of complex data sets fall broadly into 
two categories: frequentist and Bayesian [445]. The methods discussed so far have 
fallen into the former category. The frequentist approach is the method taught 
throughout scientific education where significance tests, unbiased estimators and 
confidence intervals are used to test a null hypothesis against an alternative. These 
tests are based on repetition, i.e. the frequency of a particular result if the experiment is 
repeated multiple times. This approach treats parameters as fixed but unknown 
quantities, without a distribution. 
 
By contrast, the Bayesian approach treats parameters as random variables which have 
a probability distribution. It differs from the frequentist approach by taking into account 
prior knowledge about the parameters – either in the form of known values (e.g. from 
previous experiments) or as a strength belief that a certain event will happen (personal 
uncertainty). The use of prior knowledge is controversial in the frequentist approach, 
given that there is the belief that prior knowledge is subjective and therefore has no 
place in scientific analyses. However, whilst the Bayesian approach agrees that prior 
knowledge is subjective, it argues that its use is essential to the interpretation of results 
providing that the knowledge used is as objective as possible, which can be ensured by 
robust literature searching [445].   
 
3.1.3.2 Basic Bayesian analysis 
Bayesian analysis follows several core steps: 
 
 Capture the data of interest 
 Link the data to parameters via a statistical model 
 Collect prior information about the parameters 
 Combine the statistical model and prior information using Bayes’ theorem to 
form a posterior distribution 
 Utilise the resulting posterior distribution to make inference about the 
parameters 
 
The first two steps are common to both Bayesian and frequentist approaches, with the 
remaining steps being unique to the Bayesian method. 
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There are many ways in which to collect data for the prior information, and the quality 
of this information influences the strength of the posterior distribution [446]. Prior 
information can be qualitative, for example the belief of a particular doctor that a 
treatment will have an effect on disease duration, or quantitative where knowledge/data 
gained from other experiments is incorporated. Bayesian methodology states that no 
genuinely informative prior knowledge should be discarded, although there must be an 
endeavour to ensure that this prior knowledge used is as objective as practicable. 
 
Combining the data collected (the evidence or ‘likelihood’) and the prior knowledge (the 
prior distribution) via the Bayes’ theorem results in the posterior (post-evidence) 
distribution [447]. In reality, Bayes’ theorem provides a compromise between the two 
sets of data, with the posterior distribution falling between the two (Figure 3-2). The 
posterior distribution reflects the strength of either the prior or the likelihood: if the data 
are very strong (with large sample size and a narrow distribution) then the posterior will 
be very close to the likelihood; however, if the data are weak with low sample numbers 
and a wide distribution, then the posterior distribution will be closer to the prior 
distribution. In simple terms, Bayes’ theorem states that the posterior distribution is 
proportional to the prior multiplied by the likelihood distribution, which is expressed as: 
 
 (
 
 
)  
 (
 
 ) 
( )
 ( )
 
 
Where, for proposition (A) and data/likelihood (B): 
 p(A) - the prior distribution, is the initial degree of belief in/evidence supporting 
the proposition 
 p(A/B) - the posterior distribution, is the degree of belief in/evidence supporting 
the proposition having accounted for the data 
 p(B/A)/p(B) - represents the amount of support the data provides for the prior 
knowledge 
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Figure 3-2: Formation of the posterior distribution. Graph demonstrating the effect of 
combining the prior distribution (blue) with the likelihood/observed data (green) to 
discover the posterior distribution (red). Adapted from Bink et al (2008) [448]. 
 
 
3.1.3.3 Advanced Bayesian analysis with multiple parameters  
Although Bayes’ theorem provides a simple equation for situations with single 
variables, it becomes mathematically more challenging to take into account multiple 
parameters. The majority of biological situations involve multiple variables, and in this 
case, the posterior distribution for a particular variable is influenced by one or more 
other variables, such that advanced algorithms are required to integrate the effects of 
large numbers of parameters into a network. Although recent advances in 
computational technology have enabled multiple variables to be taken into account, 
Bayesian analysis remains computationally very expensive and is therefore limited to 
researchers with appropriate resources [399].  
 
Computational approaches such as machine learning algorithms and data/text mining 
tools enable the exploration of previously unknown relationships within biological 
systems in order to allow for influences on posterior distributions. These approaches 
have proved particularly useful in genomics and proteomics [449, 450]. Within 
genomics, the location and structure of genes can be extracted from the rapidly 
expanding database of sequences [451]. Other areas of genomics being tackled from a 
computational perspective are the identification of regulatory elements [452-454] and 
non-coding RNA genes [455]. Protein structure prediction remains a key outcome in 
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terms of proteomics [449], and the methods used provide a basis for the exploration of 
protein interactions at a functional level. 
 
3.1.3.4 Probabilistic graphical models 
A probabilistic graphical model represents joint probabilities between multiple variables 
in a visual and intuitive manner [456]. These models may be undirected, as in the case 
of Markov networks and region-based approximation, where interactions are limited to 
associated probability in a similar way to the MI criteria association networks discussed 
above, without an indication of the direction of that interaction [457-459]. However, 
more informative models are generated using directed graphs - so-called directed 
acyclic graphs (DAGs) – where the probabilities between each variable are conditional 
upon the state of other variables and give directionality to the interaction. This gives 
rise to a Bayesian network which provides an efficient model to conduct probabilistic 
inference [449]. The network itself comprises a series of overlapping Markov blankets, 
defined as the connectivity between a parent node, it’s children and any subsequent 
descendants. 
 
3.1.3.5 Probabilistic graphical model Bayesian network analysis from experimental 
data 
The pioneers of Bayesian network analysis, Nir Friedman and Dana Pe’er, first applied 
probabilistic graphical models to experimentally-derived gene expression data in order 
to analyse the yeast cell cycle, thereby creating a predictive model of cell cycle 
machinery [460]. However, Djebbari and Quackenbush report that subsequent 
(unpublished) application to clinically related questions (for example treatment group 
versus control) proved less insightful and resulted in this form of analysis falling out of 
favour [399]. Moreover, many of the early studies used general purpose search 
algorithms which resulted in a failure to learn accurate or realistic Bayesian networks 
[399]. Such limitations have been overcome by introducing network ‘seeds’, wherein 
preliminary topologies discovered through prior knowledge are introduced as soft 
constraints in order to bias the search for the best Bayesian network [461, 462]. 
Although providing slight restrictions on the learned Bayesian network, this approach 
does not preclude the discovery of new interactions between mediators [463], and 
provides an optimal approach for network generation [464]. 
 
Learning probabilistic graphical models from experimental data provides its own 
challenges. Firstly, as outlined previously, learning Bayesian networks is 
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computationally expensive. Secondly, the causality of interactions between variables 
has proved an interesting problem requiring the development of advanced algorithms 
which aim to accurately represent the biological interactions involved [465, 466]. This 
approach must therefore be adapted for each experimental scenario, and as such 
requires expert knowledge of algorithm development. 
 
Bayesian analysis has been most widely applied to experimentally-derived expression 
microarray data. In this case, the principal outcomes have been the identification of 
expression patterns and the construction of resultant genetic networks [399, 467-471]. 
However, while analysis of the genome and transcriptome are useful, functional 
cytokine effects are at the level of the proteome. Significantly, many genes, including 
those encoding cytokines, are subject to post-transcriptional and post-translational 
modifications which restricts the functional interpretation of genomic and transcriptomic 
analyses [472-475]. To date, there has been no attempt to utilise Bayesian techniques 
to model in vivo protein interactions and effects within a hormonally driven 
environment, thus development of a Bayesian network solution to examine in vivo 
cytokine networks provides an opportunity to expand on existing statistical techniques 
and extend the current knowledge surrounding cytokine interactions. 
 
3.1.4 Murine lactation as a model to investigate cytokine networks 
Murine lactation provides a unique opportunity to explore the interrelationships 
between cytokines on a background of hormonal changes. Upon receiving the suckling 
stimulus, the lactating mother produces PRL and oxytocin via the hypothalamus and 
the pituitary gland (Figure 3-3). PRL has documented immunoregulatory effects on 
Th1/Th2-type cytokine responses and the survival/differentiation of immune effector 
cells in both mice and humans [476-479], and also acts as a cytokine in certain 
physiological states such as haematopoiesis [480]. This physiological perturbation of 
cytokine networks therefore provides the opportunity to explore interrelationships 
without a disease background which may in itself alter cytokine responses. 
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Figure 3-3: Hormones involved in lactation. Stimulation provided by suckling results in 
the reduction of PRL inhibiting hormone and the release of PRL and oxytocin. 
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3.2 Aims 
The aims of this chapter were: 
 
 To generate cytokine data at the protein level using murine lactation as a 
physiological system where cytokine/hormone interactions can be examined in 
vivo 
 To develop a Bayesian network solution suitable for the interpretation of 
cytokine interactions at the protein level 
 To describe causal relationships between cytokines and other inflammatory 
mediators (hormones) in murine lactation 
 To utilise in silico perturbations to predict and validate changes in cytokine 
networks when lactation is prevented from becoming established. 
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3.3 Methods 
3.3.1 Animals 
3.3.1.1 Data set 1 
Eight to ten-week old virgin CD1 female mice were group housed (10 per cage) with ad 
libitum access to water and Standard Expanded Beekay diet (B&K, Grimston, 
Aldborough, UK). The lighting cycle was 14h:10h light:dark, (05:30 on; 19:30 off). 
Humidity and temperature were maintained at 55-65% and 21.5±1°C. Oestrus 
synchronisation was achieved via the Whitten effect, whereby bedding impregnated 
with male urine was introduced to the female’s cage 48 hours prior to mating. Oestrous 
females were identified by vaginal cytology [176]. Females in oestrous were naturally 
mated with 12 week old CD1 stud males of proven fertility (1 female:1 male), with 
pregnancy confirmed on day 15 by manual palpation. Females were group housed until 
late pregnancy, at which point they were caged individually to litter down and nurse 
their pups Each dam received 8 pups (via culling/cross-fostering) in order to 
standardise the suckling stimulus. Animals were sacrificed under Schedule 1 of the 
Animals (Scientific Procedures) Act, 1986 on the following days post partum: 
 
 Day 1 (<24h of littering), n=8 
 Day 2, n=8 
 Day 4, n=8 
 Day 10, n=7  
 Day 16, n=8 
 Day 21, n=7  
 Day 24 (post lactation), n=7 
 
Weaning was performed on day 21 (at the light cycle midpoint), when the independent 
pups were removed from their mothers. 
 
3.3.1.2 Data set 2 
Lactation was abrogated in a further two groups of dams whose pups were all 
culled/allocated to different mothers at birth; these females were then sacrificed on 
days 2 and 4 (time-matched to lactating females) (n = 8 in both groups).  
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3.3.1.3 Negative controls 
Negative (baseline) controls were provided by naturally cycling virgin females of the 
same age and strain (n=7). 
 
3.3.2 Sample collection and analysis 
3.3.2.1 Sample collection 
Mice were sacrificed at 12.00pm 1h (half way through the lighting cycle) to minimise 
the impact of circadian rhythms on any of the analytes measured. Whole blood 
samples were collected by cardiac puncture using a 23G needle mounted on a 2ml 
syringe. Blood was transferred into Eppendorfs and placed on ice to clot. Serum was 
isolated by centrifugation at 5000rpm for 3 minutes, and then stored in aliquots at -80oC 
for subsequent analysis.  
 
3.3.2.2 Cytokine analysis 
Serum was assayed for IL-1, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), 
IL-12 (p70), IL-13, IL-17, eotaxin, G-CSF, GM-CSF, IFN-, keratinocyte 
chemoattractant (KC), MCP-1, MIP-1, MIP-1, RANTES and TNF- by fluid-phase 
multiplex immunoassay as per manufacturer’s instructions  (Bio-Rad Laboratories, 
Hemel Hempstead, Hertfordshire, UK). Samples were run on a Luminex-100 cytometer 
(Luminex Corporation, Austin, Texas), equipped with StarStation software (Version 2; 
Applied Cytometry Systems, Dinnington, UK). Serum diluent was used in all cases to 
avoid false positive/negatives and the serum:diluent ratio was reduced to 1:1 in order to 
maximise sensitivity [481]. All samples were run on one plate to avoid batch variation. 
 
3.3.2.3 Hormone analysis 
E2 and P4 were assayed by commercial enzyme-linked immunosorbent assay (ELISA) 
according to the manufacturer’s instructions (Alpha Diagnostic, San Antonio, Texas). 
Absorbance was measured at 450nm using a MultiScan Ascent plate reader 
(ThermoFisher Scientific, Loughborough, UK) with standard curves produced by the 
plate reader Ascent software programme using a 4 parameter logistic curve. 
 
PRL assays were outsourced to a specialist external laboratory and levels were 
determined by homologous specific radioimmunoassay, as previously described [482].  
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3.3.3 Data analysis and presentation  
3.3.3.1 Basic data analysis 
All data were expressed as pg/ml (cytokines, E2) or ng/ml (PRL, P4) ±SEM. Data 
distributions were assessed for normality using Anderson-Darling tests. Basic analytical 
approaches were based on subsequent Kruskall-Wallis/analysis of variance with post 
hoc Mann-Whitney-U/Fisher’s LSD tests, as appropriate. Pup removal data were 
similarly compared using t-tests or Mann-Whitney-U tests. Corrections for multiple 
comparisons were then applied using Holm’s modified Bonferroni method. Statistical 
analyses were performed in SPSS (Version 15), GraphPad Prism (Version 5.04) and in 
the freeware ‘R’. 
 
3.3.3.2 Bayesian hierarchical cluster (BHC) analysis 
BHC analysis was performed as previously described to allow the identification of 
distinct groupings of analytes based solely on input data using BHC via a flexible, non-
parametric Gaussian Process model [483]. Briefly, z-scores were computed for each 
time-series, using SEMs for each measurement, with an assumed null hypothesis that 
the variable is constant at the weighted mean value. Resultant z-score P values (with 
0.05 threshold) were corrected using Benjamini–Hochberg false discovery rate [484]. 
Time series were assigned to a specific cluster on strictly probabilistic grounds, 
wherein each cluster contained time series which behaved similarly throughout 
lactation. 
 
3.3.3.3 Generation of heatmaps 
Correlations between cytokine, steroid hormone and PRL profiles were determined 
using Pearson’s product-moment correlations, which were used as a basis for the 
generation of a correlation heat map using the freeware ‘R’.   
 
3.3.4 Construction of Bayesian network directed acyclic graphs 
In Bayesian network formalism, a network of interacting variables (e.g. genes or 
proteins) is represented as a graphical model in which the variables are nodes and 
their interactions are represented by directed edges [485]. The edge between two 
nodes (for example P1 and P2), is associated with a conditional probability, i.e. the 
probability of the state of P2 given the state of P1.  
 
Construction of the network involved several stages: 
91 
 
Chapter 3. Bayesian modelling of cytokine interactions in vivo 
 Establishment of a prior network based on information from the literature and/or 
existing datasets 
 Application of the experimental data to the prior network 
 
3.3.4.1 Construction of the prior network.  
In order to establish a ‘prior’ network containing the proteins from the present analytical 
target set, a ‘seed’ network was learned from the biomedical literature and protein-
protein interaction databases, principally using ‘MetaCore’ (GeneGo Inc., Thomson 
Reuters, http://www.genego.com) and ‘Predictionet’ (https://compbio.dfci.harvard.edu/ 
predictivenetworks) [486]. The seed network was species-restricted to the mouse. Any 
conflicting edges in the prior network causing feedback cycles were removed due to 
the acyclic nature of the DAG.  
 
3.3.4.2 Combination of the prior network with the experimental data. 
Prior to performing the Bayesian network analysis, z-score normalisations were applied 
to the raw data in Matlab in order to account for the wide variation in concentration 
dynamic ranges. A machine learning algorithm (implemented in the WEKA-based 
open-source package MeV  (http://www.tm4.org/mev/ [487]) was used to refine the 
seed network in conjunction with the experimental data derived from post-partum 
lactating and non-lactating (pup-free) mice in order to predict two high-confidence 
networks [399, 488].  
 
Following z-score normalisation, cytokine and hormone concentrations were converted 
from continuous to discrete data, and assigned to three mutually exclusive bins (low, 
medium and high concentrations) using an equal width binning approach. These 
discretised data were then used to learn the Bayesian network. Both the network 
topology and the conditional probabilities associated with each edge were learned from 
the data, starting from the initial seeded prior network. Only nodes with three parents 
were selected (as per convention in the field) as searching for the best possible 
network for a given set of moderately sized proteins is computationally expensive [399]. 
Standard non-parametric bootstrapping (100 bootstrap operations) was applied in order 
to address potential over-fitting in the Bayesian analysis [489], wherein multiple data 
sets were created by re-sampling with replacement to estimate the confidence in the 
various network features learned. For each iteration, the Tabu Search algorithm was 
used to optimise the BDe score as the Bayesian metric [490]. Altering the Bayesian 
metric to a Euclidean algorithm gave comparable results. The network directed acyclic 
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graph was then visualised using Cytoscape (http://www.cytoscape.org) [491]. Bayesian 
networks represent a ‘snapshot’ at any given time, however the networks generated 
herein reflect sustained effects or causal events seen across multiple time points. For 
Bayesian network generation, the interaction matrix between each node for each time 
point was learned and then used to initialise the inference process for the next time 
point. Therefore, the final Bayesian network visualized from the final time point 
reflected the dynamic process encoded by the previous time step. 
 
3.3.4.3 In silico perturbation of Bayesian networks 
In order to explore the DAG and the relationship between the nodes, artificial 
perturbation of the concentration of selected nodes was performed. In silico 
perturbation of eotaxin, IL-3, IL-12 (p40), IL-13, MCP-1 and PRL was performed in 
order to determine the relative importance of these nodes in the determination of 
cytokine network structure. This was achieved by artificially altering the conditional 
probability associated with the selected node and observing the effects on downstream 
nodes.  
 
3.3.4.4 In vivo perturbation of Bayesian network. 
In vivo perturbation of cytokine and hormone networks was achieved by the removal of 
pups at birth. This approach removed the suckling stimuli and therefore prevented the 
establishment of lactation. The in vivo perturbation provided a physiological validation 
for the predictions made through in silico perturbation.  
 
3.3.4.5 Variational Bayesian state space modelling (VBSSM) 
In order to further validate the robustness of this model, a VBSSM network was 
constructed. VBSSM does not take into account prior information (the ‘seed’) in 
the reconstruction of a given network, generating a network based solely on observed 
data, whilst having the advantage of taking into account ‘hidden’ nodes  [492]. An 
implementation of the VBSSM method in Matlab was used in the present 
reconstruction, and the results compared to the Bayesian network generated above 
[486]. The VBSSM algorithm employed utilized linear Gaussian state-space models to 
reverse engineer interactions between proteins from time series data, providing 
distributions over the model parameters leading to an inference of the underlying 
structure of the state-space. The algorithm allowed for the selection of a high 
significance level (measured in terms of z-score) of the network interactions. 
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3.3.4.6 Comparison of network structure 
In order to compare the two physiological networks, categorical Bayesian network 
inference was used to compute the F-score, which represents the harmonic average of 
specificity and sensitivity, and accounts for edge appearance and disappearance. The 
F-score is expressed in terms of the number of true and false positive and false 
negative edges, and provides a statistical score of similarity between any two networks. 
The F-score falls between the values of 0 and 1, with 1 representing an identical 
network. The comparative complexity of the two networks was assessed and compared 
via Catnet (http://cran.r-project.org/web/packages/catnet/index.html). 
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3.4 Results 
3.4.1 Circulatory cytokines and hormone concentrations during lactation 
Cytokine, E2, P4 and PRL concentrations were profiled across lactation and compared 
to those of virgin, naturally cycling animals (Figure 3-4 and Figure 3-5). Significant 
changes in concentration were noted for IL-1α (P<0.001), IL-2 (P<0.001), IL-3 
(P<0.01), IL-5 (P<0.01), IL-9 (P<0.001), IL-10 (P<0.01) IL-12 (p40) (P<0.001), IL-12 
(p70) (P<0.001), IFN- (P<0.01), G-CSF (P<0.05), GM-CSF (P<0.05), KC (P<0.01), 
MCP-1 (P<0.05), MIP-1α (P<0.05), MIP-1β (P<0.001) and RANTES (P<0.05) (Figure 
3-4). IL-13 approached significance (P<0.075). IL-1β, IL-4, IL-6, eotaxin, TNF-α and E2 
differed from NC animals, but did not vary across lactation.  
 
Cytokine levels on the first day of lactation were either moderately raised or 
comparable to naturally cycling levels. The concentration of over half of the cytokines 
investigated (eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1α, IL-9, IL-12 (p40), IL-12 (p70), IL-
13, KC, MIP-1α, and RANTES) decreased on day 2 of lactation, a change which was 
significant for MCP-1 (P<0.001).  
 
Most cytokine concentrations peaked on day 10 of lactation, which was particularly 
reflected in the significantly higher levels of IL-2 and MCP-1 at this time point over all 
others (P<0.05). The timing of peak levels differed for IL-1α (plateau on days 16-24), 
IL-9 (plateau on days 4-16), IL-12 (p40) (peak day 24), KC (peak day 21) and RANTES 
(peak day 16). There followed a significant decrease (IL-2, IFN-γ, MCP-1, MIP-1α 
(P<0.05) or trend towards decrease (eotaxin, G-CSF, GM-CSF, IL-3, IL-5, IL-6, IL-10, 
IL-12 (p70), IL-13, KC, MIP-1β, TNF-α) in cytokine profiles on day 16. By contrast, IL-
1β and IL-4 levels varied little throughout lactation and did not differ from naturally 
cycling levels. Whilst the levels of eotaxin, IL-5, IL-9, IL-12 (p70), IL-13, IL-17, RANTES 
and TNF-α did not differ significantly between time points, their levels did, however, 
vary in support of the above trends.  
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Figure 3-4: Circulatory cytokine concentrations during lactation (1). Line graphs 
charting the progression of circulatory cytokine concentration (pg/ml) throughout 
lactation. Panel A – TNF-α, eotaxin and MIP-1β. Panel B – IL-2, IFN-γ, MCP-1 and 
MIP-1α. Panel C – RANTES, KC, GM-CSF and IL-4. Significant differences between 
the time points are indicated by lowercase letters, where ‘a’ is significantly different to 
‘b’ and ‘c’ etc. 
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Figure 3-5: Circulatory cytokine concentrations during lactation (2). Line graphs 
charting the progression of circulatory cytokine concentration (pg/ml) throughout 
lactation. Panel A – IL-17, IL-12 (p70), IL-10 and IL-6. Panel B – IL-13, IL-12 (p40), IL-9 
and IL-1β. Panel C – IL-1α, IL-3, IL-5 and G-CSF. Significant differences between the 
time points are indicated by lowercase letters, where ‘a’ is significantly different to ‘b’ 
and ‘c’ etc. 
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Hormone profiles are displayed in Figure 3-6. PRL varied significantly across lactation, 
exhibiting a peak on day 4 (P<0.001). E2 concentrations fell early in lactation and then 
remained relatively steady, except for a small peak at the time of weaning. P4 
concentrations increased over early lactation, peaking on day 4 and falling to very low 
levels by day 16, with a subsequent increase towards weaning (P<0.001). 
Concentrations at the time of weaning for all three hormones were very similar to those 
of naturally cycling virgin animals. 
 
 
 
Figure 3-6: Circulatory hormone profiles (E2, P4 and PRL) across lactation. Significant 
differences between the time points are indicated by lowercase letters, where ‘a’ is 
significantly different to ‘b’ and ‘c’ etc. 
 
 
  
98 
 
Chapter 3. Bayesian modelling of cytokine interactions in vivo 
3.4.2 Cluster analysis 
Data clusters generated by BHC revealed analytes which followed similar patterns 
throughout lactation (Figure 3-7). Cytokine and hormone profiles fell into three distinct 
time-series clusters. Cluster 1 (eotaxin, G-CSF, GM-CSF, IL-2, IL-3, IL-4, IL-5, IL-6, IL-
10, IL-13, IFN-, KC, MCP-1, MIP-1 and TNF-) were initially low in concentration, 
followed by a broad peak centred on day 10 of lactation. Cluster 2 (IL-1, IL-1, IL-12 
(p40), IL-12 (p70), IL-17, MIP-1β and RANTES) showed a similar pattern with the 
exception of the lack of a day 10 peak. Cluster 3 (IL-9, E2, P4, and PRL) peaked around 
day 5, and tailed off steadily.  
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Figure 3-7: Bayesian Hierarchical Cluster (BHC) analysis of lactation data. Cytokines 
and hormones clustered into three patterns as described in the text. 
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3.4.3 Correlations between mediators 
Significant positive correlations were noted across the array of mediators investigated, 
except for E2, IL-1, P4 and PRL, which were negatively correlated with the majority of 
other analytes (Figure 3-8). Interestingly, these mediators also clustered together in the 
cluster analysis (Figure 3-7). 
 
 
 
Figure 3-8: Heatmap demonstrating the correlations between mediators across murine 
lactation. Red indicates a positive correlation while blue indicates a negative correlation 
(P=0.05). 
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3.4.4 Cytokine and hormone Bayesian networks during lactation 
3.4.4.1 Prior network structure 
A prior network was derived from the literature pertaining to murine cytokine 
interactions as described in the methodology. The prior network is displayed in Figure 
3-9, and shows the cytokines as ‘nodes’ connected by edges. Due to the nature of the 
generation of the prior network, the direction of the interaction is not known. As the 
knowledge within the literature was primarily limited to individual interactions, many 
cytokines  (Eotaxin, GM-CSF, IL-1α, IL-1β, IL-3, IL-9, IL-10, IL-12 (p70), IL-17 and KC) 
featured edges connecting them to only one or two cytokines. 
 
 
Figure 3-9: Prior network indicating known interactions between cytokines in the murine 
environment. 
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3.4.4.2 Bayesian network structure 
Networks were generated in a probabilistic graphical format with analytes (cytokines 
and hormones) depicted as ‘nodes’ (circles) and the interactions between them 
represented by ‘edges’ (lines). Each analyte was classified according to the probability 
of being in artificially defined concentration ranges or ‘bins’, and the nodes were colour 
coded to depict the probability of being in a low (red), medium (white) or high (green) 
concentration bin given the state of their parent nodes (thereby making the probability 
of being in a particular concentration bin ‘conditional’). Where a node had equal 
conditional probabilities across all concentration bins the node was coloured white. 
Probability ranged between 0 and 1. Each node had 3 associated probabilities (one per 
concentration bin), the sum of which added to 1 (Figure 3-10). 
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Figure 3-10: Schematic describing node colours and conditional probabilities. Node A 
has a high probability of being in the high concentration bin (0.9) therefore is coloured 
green. Node B has a high probability of being in a low concentration bin and is 
therefore coloured red. Node C has a high probability of being in a medium 
concentration bin and is therefore coloured white. In the case of equal probabilities 
across all concentration bins, the node would be coloured white. Node D has a slightly 
higher probability of being in a low concentration bin than a high concentration bin and 
is therefore coloured pink. 
 
Intensity of colour (for example red versus pink) was determined by the level of 
conditional probability, where a stronger colour represented a higher probability of 
being of low or high concentration. Edges were directional, indicating which nodes 
were parental nodes, terminal nodes and key ‘hubs’ (defined as nodes featuring at 
least 2 incoming and 1 outgoing edge) (Figure 3-11). High confidence edges (i.e. 
features appearing in more than 90% of iterations) were coloured green and lower 
confidence edges (appearing in 70-90% of iterations) were coloured grey. When nodes 
were ‘perturbed’ (artificially changed to a different conditional probability profile) the 
conditional probabilities were displayed next to the node as a bar chart relating to the 
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three concentration bins. The Bayesian networks were directed (indicating the direction 
of the interaction between nodes), acyclic (without feedback loops) graphs (DAGs). 
 
 
Figure 3-11: Schematic diagram depicting Bayesian network structure and 
nomenclature. Nodes A and B are defined as ‘parent’ nodes as they only feature 
outgoing edges. Nodes D and E feature at least 2 incoming and 1 outgoing edge, 
therefore are defined as ‘hub’ nodes. Nodes F, G and H only feature incoming edges 
and are therefore defined as terminal nodes. Node I is defined as an orphan node as it 
is unconnected to the network. Edges coloured green indicate high confidence, while 
edges coloured grey indicate low confidence interactions. 
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3.4.4.3 Core network features 
The Bayesian network generated using data from lactating mice appeared to form two 
main branches; the first with IL-3, E2 and eotaxin as parents, and the second with IL-12 
(p40) as the principal parent node (Figure 3-12). Within this structure, six core hubs 
(defined as those nodes with two or more input edges and one or more output edges) 
were identified, comprising IFN-γ, IL-13, MCP-1, MIP-1α, MIP-1β and RANTES. TNF-α 
was displayed as a major terminal node (defined as a node with parents but no 
children) and was connected, either directly or indirectly, to each of the core hubs. 
Minor terminal nodes were G-CSF, IL-2, IL-6 and KC. 42 edges (35 of high confidence) 
connected 25 of the 26 nodes, with IL-4 being the only orphan node. During lactation, 
E2, P4 and PRL demonstrated a high probability of being present at high concentration 
(green nodes) relative to the low concentration (red nodes) of cytokine network 
components, with the exception of eotaxin and IL-9. 
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Figure 3-12: Hierarchical Bayesian network DAG generated using data from lactating 
mice. The nodes (cytokines and hormones) are colour coded depicting the conditional 
probability of the node concentration being in a high (green), low (red) or medium 
(white) concentration bin given the state of their parent nodes. The depth of colour 
indicates the level of the probability of that node being in the stated concentration bin 
(e.g. red indicates a high probability of being in a low concentration bin, while pink 
indicates a slightly lower probability of being in that bin). Green edges represent those 
interactions being present in 90% of iterations, while grey edges were present in 70% 
of iterations. 
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3.4.4.4 Robustness of the network 
The Bayesian network generated from the lactating mice data set was robust, with the 
features displayed changing minimally when the bootstrapping confidence level was 
varied between 70% and 90% of the total number of iterations conducted. Furthermore, 
very few edges between nodes were of low confidence level.  
 
3.4.4.5 Variational Bayesian state space modelling (VBSSM) of lactation data 
The VBSSM (i.e. not based on prior knowledge) results generated a conserved core 
structure network similar to that obtained from the seeded Bayesian network analyses 
(Figure 3-13). Features not seen in the lactation Bayesian network were IL-10 and IL-
12 (p70) as parents, and IL-1α as a new terminal node. However, IL-2, RANTES and 
TNF-α were terminal nodes as seen in the Bayesian network. IL-13, IFN-γ and MIP-1β 
were key hubs with numerous incoming and outgoing edges as seen in the Bayesian 
network. Statistical comparison of the VBSSM and Bayesian networks for similarity 
showed high specificity (high true negatives and low false positives) and medium 
sensitivity and F-score, and this alongside retention of hub nodes suggests a high level 
of similarity between the two networks (Table 3-1). 
 
 
 
  VBSSM compared to seeded Bayesian network in lactation 
Specificity 0.94 
Sensitivity 0.30 
F-Score 0.46 
Table 3-1: Statistical comparison of VBSSM and Bayesian networks in lactation. 
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Figure 3-13: VBSSM model of data derived from lactating mice. Network was derived 
from data only without the use of prior knowledge. Due to the method of analysis, the 
colour of the nodes and edges in this method bear no relation to the concentration bin 
of the node or the strength of the relationship between nodes. IL-10 and IL-13 were 
parental nodes (those without incoming edges), while MIP-1β was a ‘hub’ (numerous 
incoming and outgoing edges). IL-1α, IL-2, RANTES and TNF-α were terminal nodes, 
only featuring incoming edges. 
 
3.4.5 In silico perturbation of cytokine and hormone Bayesian network 
3.4.5.1 PRL perturbation 
The first perturbation performed in silico was the reduction in PRL concentration, given 
the evidence that PRL is a critical immunomodulator of lactation and that its levels were 
expected to fail to rise physiologically in dams which had had their pups removed at 
birth. Perturbation was achieved by allocating a conditional probability of 1 in the low 
concentration bin, thereby reducing the conditional probability in the medium and high 
concentration bins to 0. Apart from a fall in P4 profile, in silico perturbation of PRL did 
not markedly affect downstream nodes, with the exception of IL-2 and IL-13 which both 
demonstrated a shift in conditional probability towards a medium/high concentration 
profile bin (Table 3-2). This suggests that PRL exerts a negative regulatory effect on 
these cytokines. 
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Cytokine/Hormone Low Medium High 
PRL  0.065 0.692 0.243 
P4 0.066 0.786 0.148 
P4 -PRL 0.778 0.111 0.111 
IL-13 0.400 0.499 0.101 
IL-13 -PRL 0.379 0.348 0.272 
IL-2 0.274 0.602 0.124 
IL-2 -PRL 0.274 0.481 0.246 
MCP-1 0.431 0.458 0.111 
MCP-1 -PRL 0.418 0.386 0.196 
GM-CSF 0.359 0.526 0.115 
GM-CSF -PRL 0.353 0.469 0.178 
MIP-1 0.235 0.687 0.078 
MIP-1 -PRL 0.250 0.644 0.106 
MIP-1 0.607 0.208 0.186 
MIP-1 -PRL 0.570 0.224 0.205 
KC 0.165 0.706 0.129 
KC -PRL 0.168 0.692 0.140 
IL-1 0.626 0.223 0.151 
IL-1 -PRL 0.605 0.230 0.165 
IL-10 0.648 0.230 0.122 
IL-10 -PRL 0.622 0.245 0.133 
IFN- 0.504 0.299 0.197 
IFN- -PRL 0.465 0.299 0.236 
IL-5 0.517 0.327 0.156 
IL-5 -PRL 0.487 0.336 0.177 
IL-17 0.513 0.391 0.096 
IL-17 -PRL 0.486 0.406 0.108 
IL-6 0.608 0.306 0.086 
IL-6 -PRL 0.585 0.319 0.096 
RANTES 0.483 0.276 0.241 
RANTES -PRL 0.454 0.287 0.259 
TNF- 0.372 0.317 0.311 
TNF- -PRL 0.364 0.321 0.316 
Table 3-2: Table indicating the shift in conditional probability upon PRL perturbation 
into a lower concentration bin. (Subscript indicates perturbation). 
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3.4.5.2 Perturbation of IL-13 and MCP-1 
As PRL appeared to mediate only slight changes in the downstream network, the core 
hubs immediately downstream of PRL (IL-13 and MCP-1) were selected for 
perturbation. IL-13 was in a low concentration bin in the lactation network, therefore 
perturbing this cytokine into the high concentration bin resulted in significant 
downstream network changes, with GM-CSF and MCP-1 shifting towards the high 
concentration bin, and IFN-γ becoming neutral (Table 3-3). More minor effects 
extended down to the terminal node. 
 
In a similar manner to IL-13, increasing MCP-1 concentration resulted in comparable 
downstream changes, with GM-CSF shifting towards a high concentration bin and MIP-
1β and RANTES towards a neutral profile (Table 3-3). Further downstream, effects 
included MIP-1α shifting to a high concentration bin, KC becoming medium/high, and 
IFN-γ and TNF-α becoming neutral. 
 
Combined IL-13 and MCP-1 perturbation was performed to examine the joint effects of 
these cytokines. This perturbation (on a background of low PRL) resulted in a 
significant number of downstream nodes changing colour compared to the lactation 
network (i.e. shifting from low to high concentration bins).  The remaining nodes 
demonstrated a shift in conditional probability towards the medium/high bins (Figure 
3-14). Within this combined perturbation, IFN-γ demonstrated the greatest shift in 
conditional probability – greater than the individual perturbations of IL-13 and MCP-1. 
This is suggestive of a likely synergistic effect by IL-13 and MCP-1. 
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Cytokine Low Medium High Cytokine Low Medium High 
P4 0.066 0.786 0.148 IL-10 0.648 0.230 0.122 
P4 -PRL+IL-13 0.778 0.111 0.111 IL-10 -PRL+IL-13 0.526 0.301 0.173 
P4 -PRL+MCP-1 0.778 0.111 0.111 IL-10 -PRL+MCP-1 0.448 0.348 0.204 
P4 -PRL+IL-13+MCP-1 0.778 0.111 0.111 IL-10-PRL+IL-13+MCP-1 0.448 0.348 0.204 
IL-13 0.400 0.499 0.101 IFN- 0.504 0.299 0.197 
IL-13 -PRL+IL-13 0.000 0.000 1.000 IFN-PRL+IL-13 0.325 0.337 0.338 
IL-13 -PRL+MCP-1 0.379 0.348 0.272 IFN- -PRL+MCP-1 0.352 0.325 0.323 
IL-13 -PRL+IL-13+MCP-1 0.000 0.000 1.000 IFN- -PRL+IL-13+MCP-1 0.316 0.341 0.343 
IL-2 0.274 0.602 0.124 IL-5 0.517 0.327 0.156 
IL-2 -PRL+IL-13 0.111 0.111 0.778 IL-5 -PRL+IL-13 0.377 0.386 0.237 
IL-2 -PRL+MCP-1 0.274 0.481 0.246 IL-5 -PRL+MCP-1 0.398 0.375 0.228 
IL-2 -PRL+IL-13+MCP-1 0.111 0.111 0.778 IL-5 -PRL+IL-13+MCP-1 0.370 0.390 0.240 
MCP-1 0.431 0.458 0.111 IL-17 0.513 0.391 0.096 
MCP-1 -PRL+IL-13 0.200 0.229 0.571 IL-17 -PRL+IL-13 0.390 0.467 0.144 
MCP-1 -PRL+MCP-1 0.000 0.000 1.000 IL-17 -PRL+MCP-1 0.407 0.454 0.138 
MCP-1PRL+IL-13+MCP-1 0.000 0.000 1.000 IL-17 -PRL+IL-13+MCP-1 0.384 0.470 0.146 
GM-CSF 0.359 0.526 0.115 IL-6 0.608 0.306 0.086 
GM-CSF -PRL+IL-13 0.225 0.316 0.458 IL-6 -PRL+IL-13 0.506 0.371 0.123 
GM-CSF -PRL+MCP-1 0.111 0.111 0.778 IL-6 -PRL+MCP-1 0.521 0.361 0.119 
GM-CSF -PRL+IL-13+MCP-1 0.111 0.111 0.778 IL-6 -PRL+IL-13+MCP-1 0.501 0.374 0.124 
MIP-1 0.235 0.687 0.078 RANTES 0.483 0.276 0.241 
MIP-1 -PRL+IL-13 0.250 0.521 0.229 RANTES -PRL+IL-13 0.373 0.322 0.305 
MIP-1 -PRL+MCP-1 0.270 0.360 0.370 RANTES -PRL+MCP-1 0.328 0.347 0.326 
MIP-1 -PRL+IL-13+MCP-1 0.270 0.360 0.370 RANTES -PRL+IL-13+MCP-1 0.327 0.347 0.326 
MIP-1 0.607 0.208 0.186 TNF- 0.372 0.317 0.311 
MIP-1 -PRL+IL-13 0.434 0.293 0.273 TNF- -PRL+IL-13 0.346 0.328 0.325 
MIP-1 -PRL+MCP-1 0.321 0.357 0.321 TNF- -PRL+MCP-1 0.341 0.331 0.329 
MIP-1-PRL+IL-13+MCP-1 0.321 0.357 0.321 TNF- -PRL+IL-13+MCP-1 0.340 0.331 0.329 
KC 0.165 0.706 0.129 IL-1 0.626 0.223 0.151 
KC -PRL+IL-13 0.183 0.635 0.181 IL-1 -PRL+IL-13 0.528 0.256 0.216 
KC -PRL+MCP-1 0.201 0.569 0.230 IL-1 -PRL+MCP-1 0.465 0.281 0.254 
KC -PRL+IL-13+MCP-1 0.201 0.569 0.230 IL-1 -PRL+IL-13+MCP-1 0.465 0.281 0.254 
Table 3-3: Table indicating the shift in conditional probability upon PRL/IL-13/MCP-1 
perturbation. Subscripts indicate the direction of perturbation: - indicates perturbation to 
a low concentration bin, + indicates perturbation to a high concentration bin. 
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Figure 3-14: Change in conditional probability following IL-13, MCP-1 and PRL 
perturbation. Panel A shows the cytokine and hormone Bayesian network during 
lactation with conditional probability indicators showing the allocation to low, medium or 
high concentration bins. Panel B shows the network after perturbation of IL-13, MCP-1 
and PRL, with the conditional probability indicators (small bar charts representing 
conditional probability values in low-to-high concentration bins) and node colour 
indicating the relevant shift. 
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3.4.5.3 Perturbation of network parent eotaxin 
As eotaxin in the lactating Bayesian network was in the medium/high bin, perturbation 
was taken to the extremes of high and low (Figure 3-15). Increasing eotaxin caused a 
mild shift in MIP-1β into a higher concentration bin, while decreasing eotaxin caused 
markedly greater effects. In this case IL-9 shifted to a lower concentration bin, while 
MIP-1β and MCP-1 became more medium. Most interestingly, MIP-1β shifted into a 
higher concentration bin regardless of the direction of eotaxin perturbation. 
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Figure 3-15: Eotaxin perturbation within the murine lactation network. Panel A shows 
eotaxin perturbed to a high concentration bin. Panel B shows eotaxin perturbed to a 
low concentration bin. 
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3.4.5.4 Perturbation of network parent IL-3 
In the lactating network, IL-3 was classified into a low concentration bin, with a 
conditional probability of 0.919 in this regard. When allocated to a high concentration 
bin, there were resultant changes in the conditional probability status of IL-2, IL-13 and 
MCP-1 to a small degree (Table 3-4), with IL-13, IL-2 and MCP-1 shifting to a slightly 
higher concentration bin. However, the greatest effects were seen when IL-3 was 
perturbed to a medium concentration bin status, creating a larger shift in these 
cytokines to a high concentration bin, suggesting that the effects of IL-3 were not 
related to concentration in a linear fashion. 
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  Low Medium High 
IL-3 0.919 0.024 0.057 
IL-13 0.400 0.499 0.101 
IL-13IL-3_L 0.410 0.507 0.083 
IL-13IL-3_M 0.333 0.333 0.335 
IL-13IL-3_H 0.273 0.446 0.281 
IL-2 0.274 0.602 0.124 
IL-2IL-3_L 0.278 0.610 0.111 
IL-2IL-3_M 0.252 0.456 0.292 
IL-2IL-3_H 0.215 0.526 0.258 
MCP-1 0.431 0.458 0.111 
MCP-1IL-3_L 0.437 0.462 0.102 
MCP-1IL-3_M 0.391 0.380 0.229 
MCP-1IL-3_H 0.359 0.436 0.205 
Table 3-4: Conditional probabilities associated with IL-3 perturbation. L-Low, M-
Medium, H-High, indicates the  direction of IL-3 perturbation. 
 
3.4.5.5 Perturbation of network parent IL-12 (p40) 
IL-12 (p40) was selected for perturbation due to being a parent of the second branch. 
Perturbation of IL-12 (p40) to a high concentration bin resulted in a large number of 
downstream changes (Figure 3-16). IL-1β, IL-12 (p70) and KC made major shifts to a 
high concentration bin, while MIP-1α exhibited a minor shift in this direction. MIP-1β, 
IFN-γ, RANTES and TNF-α became medium.  
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Figure 3-16:  IL-12 (p40) perturbation within the murine lactation network. Panel A 
shows the lactation Bayesian network with conditional probability indicators. Panel B 
shows the network after IL-12 (p40) perturbation. Changes in node classification were 
seen for MIP-1α (red to green), KC (pink to green), MIP-1β (red to white), IFN-γ (red to 
white), RANTES (red to pink) and TNF-α (pink to white) 
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3.4.5.6 Combined branch perturbations 
As IL-13, MCP-1, and IL-12 (p40) were identified as important driver nodes in their 
respective branches, combined perturbation of these nodes was performed. This 
perturbation affected the majority of their downstream nodes, of particular interest was 
the combined effect of IL-12 (p40) and MCP-1 on MIP-1α (Table 3-5). Combined 
perturbation of IL-12 (p40) and MCP-1 exhibited the largest shift in MIP-1α conditional 
probability towards a high concentration bin. 
 
 
Cytokines Low Medium High 
MIP-1 0.235 0.687 0.078 
MIP-1IL-12 (p40) 0.319 0.319 0.363 
MIP-1MCP-1 0.270 0.360 0.370 
MIP-1IL-12 (p40)+MCP-1 0.200 0.200 0.600 
Table 3-5: Conditional probabilities indicating the synergistic relationship between IL-12 
(p40) and MCP-1. 
 
3.4.6 Physiological perturbation of lactation networks by pup removal 
3.4.6.1 Cytokine and hormone profile changes 
Pup removal at birth resulted in a significant fall in maternal serum concentrations of IL-
17 on day 2 (P<0.05) (Figure 3-17). By contrast, KC concentrations were significantly 
higher in mice without pups on day 2 (P<0.05). By day 4 of lactation, the differences in 
cytokine profiles between females with and without pups were more pronounced: IL-1α, 
IL-12 (p40), IL-17, IFN-γ, G-CSF, E2 and PRL concentrations were significantly higher 
in nursing dams (P<0.05). Similar trends were noted for IL-2, IL-5, IL-9, and IL-12 
(p70). 
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Figure 3-17: Graphs depicting the change in cytokine and hormone concentration 
following pup removal. Panel A shows cytokine profiles at day 2 with/without pups, 
while panel B shows cytokine profiles at day 4 with/without pups. 
 
3.4.6.2 Bayesian network generated from pup free dams 
The Bayesian network generated from pup free dams (Figure 3-18) retained the same 
core hubs as the lactation network (IFN-γ, IL-13, MCP-1, MIP-1α, MIP-1β and 
RANTES), IL-12 (p40) remained as the principal parent and TNF-α as the terminal 
node, while IL-10 became an additional parent. 42 edges (32 of high confidence) 
connected 23 of the 26 nodes with G-CSF and IL-6 as orphan nodes. PRL became a 
terminal node.  
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Figure 3-18: Bayesian network generated using data from pup free dams. Colour 
coding is as described for Figure 3-12.  
 
3.4.6.3 Variational Bayesian state space modelling (VBSSM) of pup-free data 
VBSSM modelling of the pup free data revealed a network of striking similarity to the 
pup-free Bayesian network. IL-10 and IL-12 (p40) featured as parent nodes, while PRL 
became a terminal node. When compared statistically, the networks demonstrated high 
specificity (high true negatives and low false positives), however sensitivity (high true 
positives and low false negatives) and the corresponding F-score were low. This led to 
a high level of confidence that the networks were structurally similar. 
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Figure 3-19: VBSSM model of pup-free data. 
 
 
  VBSSM compared with seeded Bayesian Pup-free 
Network Specificity 0.95 
Sensitivity 0.14 
F-Score 0.25 
Table 3-6: Statistical comparison of VBSSM and Bayesian networks in pup-free 
scenario. 
 
3.4.6.4 Comparison of the physiological Bayesian networks 
Structural comparisons of the two physiological networks (lactation and pup free) were 
performed to assess the closeness of fit. Despite being produced from two independent 
data sets, the two networks shared striking similarity, with an F-score of 0.861. The 
total complexities of the lactation and pup free dam networks were 379 and 375 
respectively, indicating a close match despite some differences in topology. The most 
striking difference was that over half of the cytokines (GM-CSF, IFN-γ, IL-1β, IL-4, IL-5, 
IL-8, IL-12 (p70), IL-13, MCP-1, MIP-1α, MIP-1β, RANTES and TNF-α) moved to 
higher concentration bins in the pup free dam setting. 
 
3.4.6.5 Comparison of predicted (in silico) and monitored (in vivo) effects 
The node status shown in the pup free dam network closely resembles the cytokine 
concentration predicted by combined PRL/IL-13/MCP-1 perturbation, despite 
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differences in network topology (Figure 3-20). This perturbation correctly predicted the 
nodal status of IL-1α, IL-10, RANTES, TNF-α, IFN-γ, and GM-CSF. In the case of IL-5, 
IL-6, IL-17, MIP-1α and MIP-1β close categorisation was noted.  
 
MIP-1α, MIP-1β and IFN-γ featured as common children of IL-12 (p40) and MCP-1 in 
the lactation network. Combined perturbation of IL-12 (P40) and MCP-1 led to correct 
prediction of all three. Therefore, perturbation of key cytokines within the lactation 
network in silico predicted the vast majority of cytokine concentration ranges within the 
pup-free network in vivo. Only KC could not be correctly predicted via in silico 
perturbation.  
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Figure 3-20: Comparison of in silico and in vivo perturbations. Panel A depicts the 
lactation network with IL-13, MCP-1 and PRL perturbation. Panel B depicts the pup-
free in vivo network. For panel B, symbols indicate if the nodal concentration bin was 
correctly categorized by in silico perturbation.   - Correctly/closely categorized by 
PRL perturbation alone.   - Correctly/closely categorized by PRL perturbation in 
combination with IL-12 (p40), IL-13 and MCP-1, or by any other single mediator 
perturbation. X – Not correctly categorized by any perturbation. * - Could not be 
evaluated due to being upstream of the perturbations performed. 
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3.5 Discussion 
3.5.1 Bayesian network analysis is a robust method 
The networks generated were statistically robust. Despite changing the search 
algorithm and scoring metric with which the network was learned from BDe to a 
Euclidean algorithm, the networks generated proved to be consistent even with 
bootstrap confidence set to 0.9 (i.e. displayed features occurring in ≥90% of iterations). 
In comparison to other studies, this level of confidence is particularly high, as 50-70% 
is typically used [399]. Edges between nodes were also consistently of high 
confidence. This robustness was further demonstrated by the fact that VBSSM 
networks (i.e. those which did not take prior knowledge into account in their 
construction), despite comprising fewer nodes, revealed core nodes and an overall 
structure similar to those obtained from the seeded models. 
 
3.5.2 Key cytokine identification using Bayesian networks 
The lactation Bayesian network identified principal parents (IL-3, IL-12 (p40) and 
eotaxin), core hubs (IFN-γ, IL-13, MCP-1, MIP-1α, MIP-1β and RANTES) and TNF-α 
as a terminal node. These core cytokines were also evident in the pup-free dam 
network which was generated from an independent data set, indicating that they may 
form an integral network common to the lactating and non-lactating systemic 
environment. Several of these nodal relationships were preserved when the networks 
were generated through a VBSSM approach which does not take into account prior 
knowledge. These observations suggest that these relationships are robust and are 
likely reflect the physiological environment. 
 
Perhaps the most unexpected result was that PRL did not feature either as a parent or 
a core hub, despite evidence accrued since the early 1980s which portrays PRL as a 
critical immunomodulator [476, 493-495]. For example, hypophysectomised rats exhibit 
restored immune cell function upon administration of PRL [496, 497], and enhances 
mitogenesis in T and B cells [498]. However, these immunomodulatory properties may 
not be fully cytokine-mediated. The cluster analysis in the present study revealed that 
IL-9 was the only cytokine clustering with the hormones investigated. IL-9 is a 
pleiotropic cytokine, produced by CD4+ T helper cells [499], and demonstrates pro-
inflammatory actions in murine models of inflammation [500, 501]. Although there are 
no documented links between PRL and IL-9, it is feasible that this cytokine in part 
mediates the immunomodulatory properties of PRL in inflammation. Within the lactation 
network, IL-9 and PRL did not feature a direct link, but they were connected via a 
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downstream node, IL-13, which is suggestive of an indirect relationship between these 
mediators, and may merit further investigation. 
 
The observation that many cytokine profiles peaked at a later time point post-partum 
than PRL, and the fact that the latter was connected to the lactation network by a low 
confidence edge via P4, suggested that this hormone may have a more peripheral role 
to play in modulating cytokine networks. Nevertheless, perturbation of PRL did 
influence some downstream cytokines including IL-2 and IL-13, indicating that although 
this hormone is not a key driver of the cytokine networks in lactation it does influence 
the networks at a lower level. 
 
3.5.3 Bayesian network portrayal of established and novel cytokine/hormone 
relationships 
The highest cytokine concentrations generally coincided with maximal suckling/milk 
production, and their subsequent decrease followed the reduction in suckling/milk yield 
as lactation neared completion. This trend is supported in the literature, where 
mammary gland tissue expands and differentiates towards maximal suckling, followed 
by a sharp decline as lactation draws to an end [502, 503]. However, although cytokine 
profiles during murine pregnancy are believed to be regulated by the coordinated 
activities of PRL, E2 and P4 [504], the absence of correlation between cytokines and 
these hormones highlighted in the heatmap suggests that hormones do not have as 
major a role in the regulation of cytokine profiles during lactation as anticipated. The 
failure of PRL perturbation to affect global Bayesian network cytokine profiles suggests 
that serum cytokine profiles may be governed through other lactation-related agents.  
 
In this respect, other mediators associated with suckling, such as oxytocin, may be 
involved with the regulation of cytokine networks [505-507]. Oxytocin exhibits cytokine-
like properties, including mimicking IL-2 activity in T-cell induction of IFN-γ [508], 
mediation of IL-1β induction of adrenocorticotrophic hormone [509], and modulation of 
immune responsiveness [510-512]. Oxytocin also contributes to lactational 
amenorrhoea in humans [83, 513], potentially via IFN-γ producing T-cells [514], 
supporting the notion that oxytocin may affect ovarian function through cytokine 
network alterations. Sample volume restricted the ability to assess the role of oxytocin 
within this model system, although it remains a potential investigative target for the 
future. 
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The lactation Bayesian network constructed highlighted the presence of IL-12 (p40) as 
a parent to one of the main branches. IL-12 (p40) acts through IL-12 (p70) to modulate 
MIP-1β, a relationship which has been well documented, whilst also antagonising IL-12 
(p70) heterodimer activity as part of a self-regulating cytokine response [515-518]. 
Although this relationship was not particularly evident in the present Bayesian 
networks, there were high confidence edges between all these mediators in the pup-
free network. In turn, IL-12 (p70) has been shown to modulate RANTES expression 
through the induction of MIP-1β [519], as illustrated in the present Bayesian network by 
strong edges between IL-12 (p70), MIP-1β and RANTES. The interactions between IL-
12 (p40) and (p70), MIP-1β and RANTES induce the differentiation and recruitment of 
T cells and other leukocytes [520]. Given that T cells account for a significant 
proportion of the cellular composition of breast milk, it is unsurprising to note that this 
system is activated during lactation [521].  
 
IL-13 appears to have a specific role in integrating the influence of all three hormones 
measured, as well as eotaxin (via IL-9) and IL-3. The markedly divergent hormonal (E2, 
P4 and PRL) and IL-13 profiles suggest that elevated levels of the former may 
contribute to IL-13 underexpression. E2 and IL-13 have been shown to have opposing 
effects on macrophages, downregulating and upregulating MHC II molecule 
expression, respectively [522]. Furthermore, PRL induces PRL-induced protein (PIP), 
which is co-stimulated by IL-13 and its close relative, IL-4 [523, 524]. Through PIP, IL-
13 has been shown to inhibit E2-induced biological effects, as highlighted by in vitro 
studies on breast cancer cell proliferation [523]. In humans, E2 and P4 induce IL-13 in 
peripheral blood cells, indicating that regulation of IL-13 profile may be species-specific 
and/or relate to physiological context (and thus the balance of regulatory mediators 
governing its expression) [525]. Interestingly, the ‘traditional’ role of IL-13 in inhibiting 
inflammatory cytokine production is not supported by the present data, although this 
may simply reflect its broader range of physiological functions which are increasingly 
being recognised [526-528].  
 
Both IFN-γ and GM-CSF appeared to be key molecules in the cytokine network 
involved in lactation. Despite the fact that cytokine concentrations are relatively high at 
the end of pregnancy, most cytokine concentrations during lactation were similar to 
those of cycling mice suggesting a relatively rapid correction of high peripartum levels. 
GM-CSF concentrations, however, were higher and akin to those reported in mid-
pregnancy [101]. GM-CSF is embryoprotective, potentially supporting the viability of 
diapausing embryos, a common reproductive strategy in rodents [529, 530]. By 
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contrast, high systemic IFN-γ levels have been shown to be detrimental to embryo 
survival in mice [531]. They have also been linked with recurrent miscarriage in women 
[532], although conversely IFN-γ has been shown to contribute to the maintenance of 
early gestation in mice [533, 534]. Within the current networks, IFN-γ appeared to be 
antagonised by IL-10, a finding reflected in the literature [535, 536]. 
 
Eotaxin is reported to antagonise MCP-1, as indicated by its action resulting in a 
decreased response of monocytes to MCP-1 signalling [537]. This relationship is 
upheld by the present network, wherein moderately elevated eotaxin is connected by a 
high confidence edge to low MCP-1. MCP-1 and GM-CSF (linked by a low confidence 
edge in the lactation network) both recruit macrophages to sites of inflammation, and 
correlate with IL-6, TNF-α and IL-1β [538]. This relationship is in part supported by the 
present data, which highlight a strong positive correlation between IL-6 and TNF-α.  
High confidence edges between MCP-1 and MIP-1α/RANTES are also noted in both of 
the present principal networks, which may reflect the role of these cytokines in 
recruiting T cells, as demonstrated in both humans and murine models [539-543]. 
Thus, many of the nodal interrelationships highlighted by this study have been 
independently reported within the literature, lending credence to the biological 
relevance of these Bayesian networks. Although this begs the question as to whether 
the incorporation of prior networks in terms of the seeding approach introduces bias 
towards the discovery of nodal interrelationships, the presence of many of these 
relationships in the unseeded VBSSM model indicates that seeding did not bias the 
present results unduly. As outlined, the aim of seeding was to enrich the data with a 
view to providing a more complete network with which to identify key mediators. 
 
3.5.4 Identification of synergy, antagonism and functional redundancy  
3.5.4.1 Synergy 
Despite a previous report that IL-13 is an inducer of MCP-1 [544], the synergistic effect 
of IL-13 and MCP-1 on IFN-γ highlighted during this study is previously unidentified. 
When IL-13 and MCP-1 were perturbed together, IFN-γ exhibited a greater increase in 
concentration compared to individual perturbations. Interestingly, IFN-γ has been 
shown to influence both IL-13 and MCP-1, a situation not reflected in the present 
network. IFN-γ modulates of IL-13 responses via IL-13Rα2 in human primary cells and 
cell lines [545], and induces MCP-1 in human astrocytoma cells [546, 547]. However, 
these relationships may reflect a feedback loop in response to the synergistic 
relationship, a feature which cannot be demonstrated within a Bayesian network. 
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Further previously unidentified synergistic relationships were noted through in silico 
perturbation between IL-12 (p40) and MCP-1 (synergising to boost MIP-1α 
concentrations), and IL-12 (p40) and IL-13 (synergising to raise IFN-γ concentrations). 
Although many studies report that these cytokines co-exist in biological fluids, there are 
no studies exploring the direct relationships between them. However, IL-12 has been 
shown to synergise with mycobacteria in a murine model of inflammation to drastically 
increase IFN-γ production by macrophages [548], highlighting that synergy identified 
within the present networks my involve intermediary processes. 
 
3.5.4.2 Antagonism 
Within the Bayesian networks generated, PRL and IL-3 were identified as having 
opposing/modulatory effects on IL-13, and when perturbed together, resulted in 
intermediate effects on concentration compared to individual perturbations. PRL and 
IL-3 both induce the STAT5 signalling pathway, which is evident in the lactating mouse 
[549, 550]. This may provide a mechanism for antagonism if there is competition for the 
signalling pathway and the cytokines providing the initial signal exhibit opposing effects 
despite utilising the same signalling pathway. However, the nature of the antagonistic 
effect of PRL and IL-3 on IL-13 is puzzling, as signalling by both of these cytokines via 
STAT5 results in proliferation and differentiation of cells in numerous systems [551-
559]. These highlighted antagonistic relationships merit further investigation to identify 
if they are direct or mediated by cytokines not included in the present study, beyond 
which mechanisms can be derived. 
 
3.5.4.3 Functional redundancy 
In both the Bayesian networks generated, IL-4 remained peripheral and unconnected 
to any other node. Despite this, IL-4 tracked IL-13 levels (as demonstrated by the 
cluster analysis), a feature which may be indicative of the functional redundancy in the 
system given that IL-4 and IL-13 are known to operate through the same receptor [91, 
560, 561]. Functional redundancy between these two cytokines is widely reported in 
the literature [358, 562], and the fact that this relationship was highlighted in the 
Bayesian network is indicative of its relevance to the physiological situation. 
 
3.5.5 In vivo perturbation of PRL  
Pup removal at birth was associated with a failure in the circulatory concentrations of 
all the cytokines studied to rise as seen in lactating dams which, while evident by day 
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2, was most marked by day 4. The exception to this global inflammatory depression 
was eotaxin, whose levels actually increased in the first 4 days post partum. The 
reasons for this are unclear, although this may reflect a process of eosinophil 
recruitment to the uterus and/or mammary glands [4, 563]. The overall depression in 
cytokine levels in pup-free dams was largely independent of PRL concentrations, which 
failed to rise due to the absence of suckling stimulus, again suggesting an independent 
regulation of PRL and cytokines. Interestingly, even by day 4 post partum, cytokine 
levels had not entirely returned to the pre-gestational levels of the naturally cycling 
group, suggesting that cytokine profiles are to some degree maintained post partum, 
independent of whether dams are nursing. The reasons for this are unclear, and may 
possibly reflect ongoing uterine involution in conjunction with oxytocin and 
prostaglandin (PG)F2α [564-566]. Although embryos ensuing from post partum oestrus 
matings would risk developing in an environment where cytokine levels are higher than 
those encountered in virgin animals, a combination of immunological 
compartmentalisation of the intrauterine environment and embryo diapause may 
contribute to overcoming this problem [567]. Dams that had their pups removed post 
partum had lower levels of abortifacient mediators such as IFN-γ [101], in line with a 
notion of return to cyclicity (as in the present case) or preparation for implantation of 
diapaused embryos (as would occur in the wild/presence of a stud male).  
 
3.5.6 In silico perturbation and prediction of physiological changes 
In silico perturbation is a valuable tool for exploring cytokine interactions as shown 
above. However, it also has the potential to predict responses to altered physiological 
scenarios. Despite the original premise that PRL would feature as a key regulator of 
cytokine networks, in silico perturbation of this hormone (to reflect a non-suckling 
environment) resulted in correct categorisation of only three nodes (IL-1α, IL-2 and IL-
10). More detailed perturbation of other nodes in combination with PRL was required in 
order to correctly categorise the majority of nodes to the concentration bins seen in the 
pup-free network. Allocation of the driver nodes IL-13 and MCP-1 to high concentration 
bins in silico correctly (or closely) predicted the concentration status of 13 out of their 
14 downstream cytokines in vivo when pups were removed. MIP-1 and MIP-1, 
whose conditional probabilities were less accurately predicted by IL-13 and MCP-1 
perturbation, were correctly categorised when their direct driver node parents (IL-12 
(p40) and MCP-1) were perturbed. This shows a high level of predictive capability by in 
silico perturbation which, in future, may reduce the need for experimental validation, 
with early and less costly identification of research targets. The only cytokine which 
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could not be correctly categorised by in silico perturbation was the peripheral terminal 
cytokine KC. This could be explained by the fact that KC may be modulated by other 
mediators not included in this study and therefore not featured in the presented 
network, or as a potential artefact of Bayesian network analysis.  
 
Although the cytokine concentration status between the lactation and pup removed 
networks may have differed markedly, the essential six network core hubs around 
which both networks assembled were conserved, suggesting that these structural 
elements form an integral part of cytokine network regulation. Much of this structure 
was retained when the analytical process was repeated using a VBSSM approach, 
indicating that the hierarchical structure established in the standard Bayesian model 
was not due to introduced bias in the seeding process. The identification of core hubs 
infers the possibility of identifying lynchpins within a given physiological scenario which 
may be relevant to the identification of therapeutic targets. 
 
3.5.7 Study limitations and future directions 
Bayesian networks have proved useful in revealing the structure of cytokine and 
hormone networks, and in describing the likely causal relationships between mediators. 
However, bringing order to these causal inferences comes at a price. For example, the 
networks generated within this study present TNF- as the terminal node, despite 
studies indicating that, for example, TNF-α can induce MIP-1β expression in order to 
increase the number of activated leukocytes present in milk [568-570]. Thus, the 
biological interpretation of these relationships must be made with the caveat that 
Bayesian networks are necessarily incomplete by virtue of the fact that that they cannot 
possibly represent all possible edges between nodes as the methodology precludes 
the portrayal of structural loops [571]. As such, they are also unable to account for 
mediators which have autoregulatory function on their own production, either in 
isolation or through the intermediary of other signalling molecules. Furthermore, 
although this study was based on the broadest commercially available cytokine panel 
available for multiplex immunoassay, the resultant networks will inevitably have failed 
to include all possible mediators. However, despite these considerations, Bayesian 
networks represent a significant step forward in terms of defining the nature of cytokine 
and hormone interactions when compared to the traditional and increasingly outmoded 
practice of defining cytokine interactions according to the Th1:Th2 dichotomy. The 
present methodology also precluded the incorporation of the influence of ‘hidden’ 
Markov blankets, unmeasured nodes which could change the topology of the networks 
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discovered. This could be achieved by using a VBSSM approach with modifications. 
VBSSM incorporates the advantage of taking into account hidden nodes, but 
traditionally this algorithm does not incorporate a prior network. Development of such a 
method forms the basis of the networks in Chapter 4. 
 
Key areas for future development include exploring whether the generic network 
structure (i.e. the nature/composition of core hubs) and the previously unreported 
synergistic/antagonistic cytokine interactions revealed as part of this study, are 
conserved across multiple physiological processes and/or species. This is particularly 
valuable in light of the fact that the present networks have been studied in vivo, in 
contrast to most modelling endeavours which are typically performed on cell lines in 
vitro.  While in vitro approaches may provide a wealth of information on the functional 
regulation of one or more cell types under highly controlled conditions, they commonly 
fall short of presenting a realistic depiction of physiological events in vivo. The ‘top 
down’ method developed herein will also prove useful in investigating immune 
privileged organs (e.g. the eye, testes and conceptus), solid tumours, specific body 
compartments (e.g. ovarian follicles and uterus), although it can just as readily be 
applied to tissue explants, organ cultures and cell co-/monocultures. Furthermore, 
focussing on protein levels rather than differential gene expression profiles (as most 
other studies) offers the added benefit of overcoming the inferential interpretation 
problems ensuing from the fact that many signalling proteins such as cytokines are 
known to be extensively regulated at the post-transcriptional level as previously 
discussed [91]. Since the interactions identified within this chapter have been identified 
in silico, in vivo validation is still required as a gold standard validation in order to be 
confident that these are both real and biologically meaningful. However, the application 
of Bayesian networks to immunological disorders could identify those cytokines which 
orchestrate the imbalance which creates tissue destruction, enabling targeting of 
therapies. Current work is undertaking the application of these networks to human 
endometrial cancer in order to identify novel molecular mediators. 
 
In terms of this thesis, the next section will apply the Bayesian network methodology 
developed herein to the physiological environment of human oocyte maturation. This 
approach will aim to identify candidate regulators of oocyte maturation, alongside a 
‘fingerprint’ of cytokines which identify the oocytes most likely to fertilise, developing 
the Bayesian methodology to include classifier analysis. 
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4. Modelling follicular fluid cytokines in relation to oocyte 
maturation 
 
4.1 Introduction       
4.1.1 Overview of folliculogenesis  
In order to appreciate the nature of the impact of assisted conception treatment 
regimes on oocyte maturation and viability, it is first necessary to understand the 
development of the oocyte in relation to the physiological process of folliculogenesis. 
For the purposes of this Chapter, follicular development and oocyte maturation will be 
considered from a human perspective, with inferences drawn from animal models 
where species-specific data are wanting. Follicular development in humans is essential 
for the ovary to fulfil its two main functions: (i) to generate a single dominant follicle 
containing an oocyte with competence for fertilisation and development, and (ii) to 
secrete hormones required to prepare the reproductive tract for pregnancy. Follicle 
development up to the point ovulation is a complex series of events, including: 
primordial follicle recruitment; proliferation of granulosa and theca cells; oocyte 
maturation; and steroidogenesis, as detailed in the following sections. 
 
The generation of mature, competent oocytes is a complex, dynamic process involving 
an intricate dialogue between the oocyte and its surrounding somatic cells. In humans, 
folliculogenesis involves recruitment of follicles from the primordial pool, growth of the 
follicle/development of a fluid filled antrum, and concurrent oocyte maturation, a 
process lasting approximately 290 days in humans [572]. Folliculogenesis occurs within 
the ovarian cortex, and is generally considered to be divided into two stages (Figure 
4-1). The first, or ‘pre-antral’, stage is where the primordial follicle develops into a 
larger, non-cavitated follicle, with concurrent oocyte growth. This stage is governed by 
local mediators and is gonadotrophin-independent. The second, ‘antral’ stage features 
the development of a fluid-filled antrum and further growth which is follicle stimulating 
hormone (FSH)-dependent. 
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Figure 4-1: Development of the ovarian follicle from resting to the dominant 
preovulatory (Graafian) stage. 
 
4.1.2 Pre-antral follicle development 
4.1.2.1 The primordial follicle 
The primordial follicle consists of a small (25μm) oocyte which is arrested in the 
dictyate stage of meiosis (prophase I), surrounded by a single layer of 
flattened/squamous pre-granulosa cells (GCs) and a basal lamina which creates a 
barrier between the follicle and other surrounding stromal cell types. Multiple activator 
and repressor signalling pathways are active in the primordial follicle in order to 
balance dormancy and activation. For example, neurotropin and nerve growth factor 
(NGF) are important in follicle activation [573], yet the phosphatidylinositol 3 kinase 
(PI3K) pathway acts as a repressor [574].  Primordial follicles do not have their own 
vascular supply such that the external influence from the endocrine system remains 
low [575-577]. Indeed, circulatory gonadotrophins do not influence recruitment as 
primordial follicles do not express follicle stimulating hormone (FSH) receptors [578]. 
Upon recruitment from the primordial pool, GC morphology changes from a squamous 
to cuboidal phenotype. Continuous recruitment of follicles in this manner continues 
throughout the first four decades of life, until the onset of menopause. Initially, the vast 
majority of follicles leave the resting pool due to atresia, with small numbers entering 
the growth phase [579]. After the age of 30, more follicles enter the growth phase, a 
process which accelerates from approximately 38 years of age, resulting in an overall 
loss of ovarian reserve [579, 580]. This decline in ovarian reserve is indicated by falling 
anti-Müllerian hormone (AMH), a mediator produced by small growing follicles which 
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inhibits the recruitment of primordial follicles, such that lower AMH levels are indicative 
of a reduced ovarian reserve [581]. 
 
 
4.1.2.2 The primary follicle 
The primary follicle consists of a layer of proliferating cuboidal GCs surrounding the 
oocyte. At this stage, growth remains gonadotrophin-independent as follicle 
development progresses in the absence of FSH [582] and FSH receptors [583]. The 
oocyte continues its growth, increasing in size to 120 µm, and develops a 
glycoproteinaceous zona pellucida (ZP) which separates it from the GC layer. At this 
stage, transcriptional activation within the oocyte facilitates communication with 
surrounding somatic cells and allows it to support its own growth [572, 584, 585]. The 
development of an intimate paracellular dialogue between the oocyte and GCs via 
mediators such as cytokines facilitates follicle growth and oocyte development [586, 
587]. Moreover, cell-cell contacts are established between the oocyte and GC cells via 
cytoplasmic projections and microvilli in order to allow diffusion of ions, metabolites and 
signalling molecules [588, 589]. Once the follicle has attained a layer of GCs 
approximately 4 cells thick, FSH receptors are expressed on their surface in 
preparation for the gonadotrophin responsiveness of the antral phase [578]. 
 
4.1.2.3 The secondary follicle 
Secondary follicles acquire a layer of theca cells (TC) which surround the oocyte and 
GC, which subsequently differentiates into two primary layers: the theca interna 
(closest to the GCs), which form interstitial cells; and the theca externa, which forms a 
smooth muscle cell-like layer that facilitates ovulation [590]. Alongside TC 
development, perifollicular blood flow is improved by neoangiogenesis, while GCs 
proliferate [591].  The oocyte completes its growth during the pre-antral stage, but does 
not resume meiosis. This is potentially due to the inhibitory effects of oocyte- and GC-
derived cyclic nucleotides, since a decrease in the concentration of cAMP in the oocyte 
is associated with resumed meiosis [592, 593]. 
 
4.1.3 Antral follicle development 
4.1.3.1 The antral follicle 
The antral follicle is characterised by a cavity (antrum) which contains follicular fluid 
(FF). FF is an ultrafiltrate, containing both free and protein-bound steroid hormones, 
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plasma and locally derived proteins, proteoglycans and electrolytes [594, 595]. A 
recent review of the theories behind the formation of follicular fluid postulates that the 
formation of hyaluronan and chondroitin sulphate proteoglycan by granulosa cells 
provides the osmotic gradient required to draw fluid from surrounding extracellular 
matrix and, in turn, local blood capillaries [596]. This may involve remodelling of cell-
cell junctions in the stromal and thecal layers, although little is known about the 
process. Initially, small pockets of fluid form within the GC layer, eventually coalescing 
to form a single antrum. Antral follicles are heterogeneous in size, ranging between 0.4 
- 25 mm in diameter, which is largely determined by the volume of FF within the antrum 
(0.2 - 7ml) [597, 598]. In parallel with antral growth, GCs and TCs proliferate 
extensively, with the former differentiating into distinct phenotypes: the membrana, the 
periantral area and the cumulus oophorus. The cumulus oophorus extends to surround 
the oocyte within the antrum (Figure 4-2).  
 
 
 
Figure 4-2: Structure of granulosa cells within an antral follicle. Adapted from Erickson 
(2004) [599] 
 
Within antral follicles, the oocyte resumes meiosis in response to the pre-ovulatory LH 
surge, progressing to metaphase I and arresting at this point [600]. LH binds to 
receptors on GC cells, reversing the inhibition of meiosis by cAMP and cGMP [592, 
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593], and initiating a cascade of communication between the oocyte and the 
surrounding granulosa to induce meiotic maturation [601, 602]. The antral phase also is 
characterised by the presence of a large number of atretic follicles, wherein the 
formation of FF and proliferation of GCs is vastly reduced or non-existent.  
 
Throughout the antral phase, follicles are recruited for growth in subsequent cycles. 
Recruitment can be considered as the rescue of a cohort of antral follicles from atresia 
[603], and it is accepted that follicles reaching 2-5mm in diameter are recruited for 
further growth at the end of each luteal phase. It has been estimated that the cohort of 
recruited follicles is 3-11 follicles per ovary [603], from a potential pool of 6-46 antral 
follicles per ovary [604]. From this pool of recruited follicles a single follicle is selected 
for preferential growth and subsequent ovulation, while the others undergo atresia. 
 
4.1.3.2 Dominant follicle selection 
Following the decrease in E2 at the end of the luteal phase, there is a second rise in 
FSH. This marks the selection of a dominant follicle from the available pool of antral 
follicles for development in the follicular phase [572], with the mechanism of selection 
relying on the follicle’s sensitivity to FSH [605]. The selected dominant follicle then 
grows rapidly in contrast to its remaining cohort counterparts; this growth can typically 
be monitored by ultrasound [606]. As many as 99.9% of all available follicles in the 
ovary are destined to undergo atresia [607], a process is thought to be initiated by GC 
apoptosis that is controlled by a delicate balance between pro- and anti-apoptotic 
mediators [608]. Growth factors and gonadotrophins support the dominant follicle 
through to ovulation. Concurrent with this stage of follicle development, the oocyte 
completes meiosis I and progresses to meiosis II, where it remains arrested until 
fertilisation. 
 
4.1.4 Ovulation 
The process of folliculogenesis culminates in the ovulation of the cumulus-oocyte 
complex (COC) from the dominant follicle, making the mature oocyte available for 
fertilisation. Ovulation involves active remodelling of the extracellular matrix in order to 
facilitate follicle rupture prior to luteinisation, alterations to follicular microcirculation, 
formation of an avascular area at the follicular apex and extrusion of the oocyte-
cumulus complex [609]. This process is considered to be an inflammatory, cytokine-
mediated event associated with well-recognised histological markers such as an influx 
of leukocytes, which are believed to be derived from the spleen [16, 610-612]. These 
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leukocytes (comprising lymphocytes, granulocytes and macrophages) favour ovulation 
through their secretion of an array of proteases and vasoactive agents [2, 610]. 
Macrophages perform a number of functions in ovulation, including the secretion of 
MMPs to mediate extracellular matrix remodelling [112, 613] and the phagocytosis of 
GCs from atretic follicles [25, 614, 615]. Lymphocytes also contribute to follicular 
function through their selective production of an array of cytokines [16].  
 
4.1.5 The corpus luteum 
The follicular life cycle is completed by luteinisation, resulting in a highly vascularised 
corpus luteum (CL) which serves to support the resulting pregnancy. Latin for “yellow 
body”, the CL is a temporary endocrine structure producing high levels of P4 and 
moderate levels of E2 and inhibin. The E2 component serves to inhibit GnRH production 
[616], thereby reducing FSH and LH production to halt further follicular growth and 
ovulation in preparation for an impending pregnancy, while P4 helps establish and 
maintain a pregnancy. The formation, function and regression of the CL is mediated by 
the large resident and temporary populations of leukocytes, the composition of which 
changes according to the stage of CL development. In the initial formation stages, 
granulocytes such as neutrophils and eosinophils and various phenotypes of T cells 
are abundant, facilitating angiogenesis [617, 618]. Mid-cycle up to the point of luteal 
regression, an influx of macrophages dominates and the granulocyte population 
diminishes, these immune cells serving to modulate steriodogenesis within the CL 
[619-621]. In women, the CL regresses to become the corpus albicans approximately 
14 day after ovulation in the absence of pregnancy 
 
4.1.6 Oocyte maturation 
4.1.6.1 Nuclear maturation 
Concurrent with folliculogenesis, the oocyte undergoes meiotic and maturation (Figure 
4-3). In contrast to spermatozoa, oocytes arrest at various points in the meiotic 
process, awaiting signals to progress to the next stage in development, under the 
control of maturation promoting factor (MPF). Meiotic maturation, stimulated by LH and 
mediated by MPF, has been defined as the progression of the oocyte from the dictyate 
phase of prophase I to the metaphase I stage of meiosis, and is accompanied by 
germinal vesicle/nuclear envelope breakdown [622], cytoskeletal rearrangement and 
spindle assembly [623, 624]. In humans, a second meiotic arrest occurs between 
metaphase I and metaphase II, with the metaphase II oocyte being capable of 
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fertilisation. Subsequent fertilisation initiates the transition from metaphase II to 
anaphase II, completing meiosis and initiating the first mitotic divisions in the embryo. 
 
 
Figure 4-3: Nuclear maturation of the human oocyte. Red lines indicate points of arrest. 
 
4.1.6.2 Cytoplasmic maturation 
In general terms, oocyte cytoplasmic maturation comprises the accumulation of mRNA, 
proteins, substrates, and nutrients that are required to achieve oocyte developmental 
competence and successful embryo development [625], alongside redistribution of 
cytoplasmic organelles and cytoskeletal filaments [626-628]. Prior to germinal vesicle 
breakdown, the oocyte accumulates maternal mRNA through transcription in order to 
support the oocyte through the early stages of embryogenesis [629, 630]. This pauses 
until the maternal-zygotic transition, when a burst of transcription signals the activation 
of the embryonic genome [631]. 
 
Structural changes within the cytoplasm, such as the migration of mitochondria to 
areas of high energy consumption [632], alongside a peak in protein synthesis at the 
metaphase I stage [633] occur concurrently with but distinct from nuclear maturation. 
Relocation of cortical granules, uniquely present in an oocyte, from a diffuse 
cytoplasmic distribution at the germinal vesicle stage to primarily underlying the inner 
surface of the plasma membrane at metaphase II indicates that the oocyte is ready to 
ward off polyspermy via alterations to the oocyte ECM [634, 635]. However, much of 
this work has been completed in bovine oocytes which may not translate to the human 
situation. Human cytoplasmic maturation remains undefined, and reliable markers of 
this aspect are scarce. 
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4.1.7 Molecular regulators of folliculogenesis 
Historically, it was thought that ovarian somatic cells such as GCs drove 
folliculogenesis, with the oocyte merely being a passenger and receiving signals to 
develop at the appropriate time. More recently, however, it has become apparent that 
the oocyte participates in a complex dialogue with its GC complement, adjacent 
theca/interstitial cells, as well as with other surrounding follicles [636]; the nature of this 
dialogue changes according to the stage of follicular development [637]. This interplay 
is essential not only for oocyte maturation, but also for follicular development, from the 
primordial to primary follicle transition, and subsequent growth and differentiation 
through to ovulation [587]. The nature of this dialogue influences the quality of the 
resultant oocyte, which impacts on subsequent embryo viability [638]. Mediators of this 
process include cytokines, hormones, growth factors, eicosanoids and MMPs, although 
many more agents are still probably unidentified [586, 636, 639-644]. These mediators 
are both intra- and inter-follicular, and are influenced by the steroidal milieu [645]. They 
may influence the oocyte either directly or indirectly via the intermediary of both 
cumulus and GCs [646]. For the purposes of this thesis, the mediators which will be 
focussed upon are cytokines. 
 
4.1.8 The role of cytokines in folliculogenesis 
The importance of cytokines in ovarian physiology is increasingly being recognised, 
although our understanding of their precise roles and interactions remains limited. 
Specific signalling pathways/paracrine dialogues have been identified for a number of 
these mediators [647], although much of the data are fragmented and relate to 
individual aspects of ovarian function. Cytokines such as interleukins and those of the 
TGF-β family participate in the intercellular communication between the oocyte and its 
surrounding somatic cells, as well as in the regulation of follicle survival and apoptosis 
[104, 648-653]. Ovarian immune effector cells such as macrophages and lymphocytes 
also secrete cytokines, including IFN-γ, TNF-α, G-CSF, GM-CSF, IL-1, IL-6, IL-8 and 
MCP-1, all of which have been implicated in oocyte development, ovulation and 
steroidogenesis [2, 16, 637, 654]. Cytokines within the ovarian follicle are for the most 
part locally produced, often at low concentrations where, once secreted, they diffuse to 
create chemotactic gradients or to act locally in a paracrine/autocrine manner. 
Cytokines have a short half-life, the implication of this being that even major local 
inflammatory perturbations are unlikely to result in marked systemic effects affecting 
circulatory profiles. In this regard, the physiological concentration of intrafollicular 
cytokines typically exceeds that of the circulation, although this is not always the case 
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with reproductive disorders such as endometriosis and pelvic inflammatory disease 
[149, 655-658]. A review of the known roles of cytokines in folliculogenesis will follow, 
with inferences drawn from animal models where human data are not available. 
 
4.1.8.1 The primordial to primary follicle transition 
Follicular recruitment from the primordial pool is driven by a complex interplay between 
the oocyte, pre-theca and pre-GCs, mostly mediated by cytokines and growth factors 
[584, 659]. Pre-granulosa cells express many cytokines, such as stem cell factor (SCF; 
kit ligand), basic fibroblast growth factor (bFGF, a.k.a. FGF-2) and LIF, which have 
been shown to promote the primordial to primary follicle transition in vitro in goats, 
hamsters and rodents [339, 660-665]. FGF-7 (produced by pre-theca cells and the 
oocyte) and LIF have been shown to upregulate pre-granulosa cell SCF expression 
and promote the transition from primordial to primary follicles in the mouse [660, 666]. 
However, species-specific differences are apparent: for example, SCF promotes 
recruitment from the primordial follicle pool in mice but not in rabbits [667-669]. 
 
Another group of cytokines, bone morphogenic proteins (BMPs), modulates 
gonadotrophin receptor expression, follicular development and steroid production [104, 
650, 670]. BMPs utilise the SMAD signalling cascade [671], which leads to the 
activation and nuclear translocation of an array of transcriptional co-factors, 
subsequently mediating cellular responses to BMPs, such as the regulation of TGF-β 
expression [672, 673]. During folliculogenesis, regulation of this signalling cascade 
determines cell responsiveness to different BMPs, thereby providing a mechanism for 
recruitment of specific primordial follicles [673]. Rodent models suggest that pre-theca 
cell derived BMP-4 and BMP-7 promote primordial to primary follicle transition via 
stimulation of pre-granulosa cell proliferation, as demonstrated in vitro by a pre-mitotic 
increase in DNA synthesis [339, 674, 675]. In humans, both the primordial follicles and 
corpora lutea of the adult ovary express BMP-15 while foetal and peri-pubertal ovary 
primordial follicles do not, suggesting that it may participate in recruitment from the 
primordial pool [676, 677]. Moreover, mutations in the BMP-15 gene are associated 
with hypergonadotrophic ovarian failure in women, suggesting that this cytokine is 
essential for the progression of folliculogenesis [678].  
 
Stromal cell-derived factor (SDF)-1α and its receptor (C-X-C chemokine receptor type 
4; CXCR4) have been detected in immature oocytes and pre-granulosa of mouse 
neonatal ovaries [679]. In vitro exposure of these ovaries to SDF-1α results in an 
increase in follicular recruitment, although this occurs at the expense of follicular 
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diameter and follicular activation at the primary stage [679]. SDF-1α has a chemotactic 
function, as highlighted by its involvement in assisting primordial germ cell gonad 
colonisation [680]. In the mature ovary, SDF-1α is highly chemotactic for lymphocytes 
which produce cytokines, proteases and various vasoactive substances throughout 
folliculogenesis [353, 681-683].  
 
Oocyte-derived growth differentiation factor (GDF)-9 is closely related to BMPs, and is 
critical for oocyte, granulosa and theca cell development [684-686]. Mice with gdf-9 
mutations exhibit a failure of folliculogenesis to progress beyond the primary follicle 
stage coupled with an incomplete development of the TC layer which renders them 
infertile [687, 688]. The early expression of GDF-9 appears to be consistent across all 
species studied to date, including humans [676, 689, 690]. Ovarian culture techniques 
employ GDF-9 to rescue human primordial follicles from atresia based on the evidence 
that GDF-9 is involved in early folliculogenesis [691, 692].  
 
By contrast, AMH has been shown to inhibit primordial follicle growth [693, 694]. 
Primordial follicles are recruited at a higher rate in the absence of AMH in murine 
models, causing a premature depletion of the ovarian primordial follicle pool [694]. 
Human AMH levels fall with age, reaching undetectable levels by the menopause 
concurrent with a depletion of the primordial follicle population [695-697]. However, 
AMH receptors are expressed on primordial follicle pre-GCs, suggesting that growing 
follicles may use AMH as a signalling molecule to suppress resting primordial follicles 
[694, 698-700].  
 
4.1.8.2 Primary to antral follicle development 
Cytokines involved in regulating preantral follicle growth include GDF-9 and BMP-15 of 
oocyte origin, GC-derived activins, BMP-4 and BMP-7 of TC origin, and TGF-β 
produced by both theca and GCs [104, 339, 675, 691, 700-702]. Of these mediators, 
BMP-15 promotes GC proliferation in rat primary follicles in conjunction with granulosa-
derived SCF [703]. These mediators are believed to govern GC expansion via a 
negative feedback loop, providing a mechanism for the oocyte to regulate its own 
follicular growth [701, 703]. Selection for further growth and development from the 
primary follicle pool is dependent upon GDF-9, which increases the number of medium-
sized antral follicles in mice, especially in conjunction with VEGF [704-706]. These 
cytokines synergise when administered together, as highlighted by the fact that 
combined intra-ovarian injections of each cytokine cDNA results in more oocytes being 
ovulated [704]. GDF-9 also stimulates preantral follicle growth, promoting granulosa-
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cumulus cell phenotypic transition and, suppressing GC P4 production in mice, rats and 
cattle [686, 707-711]. These effects may be achieved through an upregulation of COX-
2, hyalurononan synthase (Has)-2 and steroidogenic acute regulatory protein (StAR) 
expression, which in turn induce/produce steriodogenic factors and prostaglandins 
[709, 712]. 
 
Neoangiogenesis accompanies theca development in secondary follicles prior to 
antrum formation. This is promoted by follicular mediators such as bFGF, leptin and 
follicular and circulatory VEGF [713-717]. In this respect, angiogenesis is regulated 
independently across different follicles, possibly via the selective local production of 
pro- and anti-angiogenic isoforms of VEGF, a mechanism achieved through alternative 
mRNA splicing [718, 719]. 
 
EGF, in addition to its role in angiogenesis, appears to mediate primary to antral follicle 
development [720]. Moreover, EGF regulation of TGF-β via alterations in receptor 
levels in hamster and human ovaries at the primary to antral stage of development, 
suggests a role for TGF-β in primary follicle selection for antrum development [721, 
722]. Both GC-derived EGF and FGFs increase GC SCF expression and, in turn, 
promote proliferation of thecal interstitial cells and oocyte growth via the mitogen 
activated protein kinase (MAPK) signalling pathway, as demonstrated in rats [721, 723-
726]. In bovine models, FGF-18 is thought to inhibit theca-induced GC proliferation via 
alterations in cell cycle progression, thereby participating in follicle atresia [715]. 
Oocyte-derived FGF-8 modulates cumulus expansion [727], while FGF-7 and FGF-10 
mediate GC/TC proliferation [728]. bFGF has been shown to promote pre-antral follicle 
growth in humans and goats [729-731]. However, FGFs are known to have disparate 
roles in mono- and polyovulatory species, which may lead to functional 
misinterpretations [732].  
 
The primary to antral follicle transition may also be partially mediated by macrophage 
migration inhibitory factor (MIF). Intraperitoneal injections of anti-MIF antibodies in vivo 
reduce GC and TC proliferation in mice, an effect potentially mediated by modulation of 
macrophage cytokine production [733]. Macrophages are found in the ovary throughout 
folliculogenesis, localising to the TC layer in murine and human primary follicles where 
the array of cytokines they produce (IL-1α/β, IL-6, GM-CSF and TNF-α amongst 
others) stimulates cell proliferation and inhibits apoptosis [654, 734, 735].  
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4.1.8.3 Antral follicle growth and selection 
In addition to the FSH-dependence of the antral stage, growth and selection of antral 
follicles may also involve autocrine/paracrine roles for GC-derived activin and BMP-6, 
and a paracrine role for oocyte-derived GDF-9, BMP-6 and BMP-15. These agents 
promote GC proliferation and modulate FSH-dependent follicle development [104, 736, 
737]. In contrast to the positive effects exerted by these cytokines in dominant follicle 
selection, AMH plays an inhibitory role by reducing the sensitivity of pre-antral and 
small antral follicles to FSH [738]. 
 
BMP-15 supports follicular development through to the point of ovulation [707, 739]. In 
vivo inhibition of BMP-15 and GDF-9 in mice results in fewer antral/preovulatory 
follicles, larger oocyte size and decreased GC mitogenesis [712, 740]. Moreover, BMP-
15 plays a role in follicle selection, reducing the recruitable pool of follicles in rats by 
inhibiting the expression of GC FSH receptors [701, 741]. By contrast, BMP-2, 5 and 6, 
appear to support follicle survival by maintaining GC and TC proliferation rates in 
bovine follicles [742]. Theca-derived BMP-4 and BMP-7 act as species-specific 
paracrine regulators of GC function, interacting with the activin/inhibin system and E2 to 
select and rescue antral follicles from atresia [104, 743, 744]. Oocyte-derived IL-7 
promotes oocyte maturation in rats concurrently with the suppression of GC apoptosis, 
lending further credence to the notion that the oocyte governs its own fate [745]. 
 
All three isoforms of TGF-β are expressed in the ovary with specific intrafollicular 
localisation. TGF-β1 and 2 expressions localise to the GC and TC compartments 
respectively in rats and pigs [746, 747]. Mice express both TGF-β1 and 2 in GCs, with 
TC expression of both isoforms decreasing with advancing maturity [748]. TGF-β3 
localises to the theca interna throughout the oestrus cycle in swine, increasing towards 
ovulation [749]. These isoforms have similar effects although their potency differs 
according to their target cell [750]. GC FSH-receptor expression is upregulated by 
TGF-β1 and 2, and the former synergises with FSH to stimulate VEGF thereby 
promoting angiogenesis [751, 752]. Furthermore, TGF-β1 inhibits E2 production in 
FSH-stimulated follicles in bovine ovaries, with a reduction in this inhibition enabling the 
selection of a single dominant follicle [753]. TGF-β3 mRNA expression increases post-
hCG injection in pigs, modulating preovulatory follicle development [746].  
 
SCF is involved in preovulatory follicle growth, stimulation of oocyte nuclear maturation 
and steroidogenesis [754-756]. Indeed, the interplay between theca and GC 
compartments may be modulated by the concerted action of SCF and hepatocyte 
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growth factor (HGF), promoting TC proliferation and GC steroid hormone production 
[757, 758]. SCF is a requisite factor for antrum formation and subsequent expansion, 
its pivotal role highlighted by a murine study [759].  
 
TNF-α is believed to promote GC proliferation in the mouse through the insulin-like 
growth factor (IGF) system and/or the acute phase protein serum amyloid A3 [760, 
761]. However, the follicular response to TNF-α is complex. TNF-α knock-out mice 
exhibit reduced oocyte apoptosis as well as increased GC proliferation [762]. The 
effects of TNF- likely involve the input of other mediators, as highlighted by the fact 
that nerve growth factor (NGF) levels stimulate TNF-α-mediated apoptosis of murine 
GCs [761]. The mechanism by which TNF-α balances proliferation versus apoptosis 
and atresia remains unclear, although several hypotheses have been put forward: 
TNF-α is expressed in the human oocyte from the primary stage, increasing as the 
follicle reaches ovulation [763], suggesting that the follicular response may be dose-
dependent. This may be further refined by the ratio of receptors TNF-R1 and 2 since 
TNF-R1 activation results in cytotoxicity while TNF-R2 results in proliferation [764]. This 
may also explain theeffects of TNF-α induction of nitric oxide (NO), which have a 
dichotomous effect on the apoptosis pathway [765-768]. Indeed, TNF-α induces NO 
nitric oxide synthase (NOS)-II, leading to NO-induced GC proliferation and/or 
differentiation via the EGF signalling pathway [769]. Interestingly, both TNF-related 
apoptosis-inducing ligand (TRAIL) and its pro- and anti-apoptotic receptors are 
expressed in GCs, thereby potentially modulating their apoptotic rate and, in turn, 
follicular atresia [770]. 
 
The importance of IL-6 signalling in folliculogenesis has been noted in swine, where IL-
6 receptors have been shown to promote GC survival [771]. IL-6 and its soluble 
receptor IL-6(sR) have been proposed to be essential in the regulation of follicle growth 
and atresia in humans [772]. Leporine models have shown that IL-8 mediates follicular 
maturation via granulocyte chemotaxis and activation [773], and that its production is 
upregulated by both EGF and TGF-α in humans [774]. IL-8 is a CXC chemokine, a 
potent chemoattractant, particularly for neutrophils, and an angiogenic factor [775-777]. 
IL-8 is induced by hypoxia, potentially influencing angiogenesis given that ovarian 
follicles can represent a hypoxic environment [778]. In line with this observation, rat 
models have shown that IL-8 may act as an angiogenic factor during late 
folliculogenesis [778-781]. IL-8 is stimulated by VEGF in bovine TCs, promoting 
angiogenesis and improving perifollicular blood flow, and thus potentially contributing to 
supporting oocyte viability [782, 783]. 
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Recently classified as a cytokine [784], leptin appears to play an role in reproductive 
function, since leptin/leptin receptor deficient mice are infertile [785]. Produced by 
adipocytes, leptin influences the hypothalamo-pituitary-gonadal axis, stimulating GnRH 
and luteinising hormone (LH) production and providing a metabolic signal to the 
reproductive system [786, 787]. Leptin inhibits antral follicle steroidogenesis in GC and 
TCs in human and animal in vitro models, although these findings should be interpreted 
with caution given that these studies were conducted using supraphysiological levels of 
leptin [788-793]. This is underscored by a porcine study demonstrating that the STAT-3 
mediated response of GCs to leptin is dose-dependent: physiological levels increase 
steroidogenesis while artificially increased concentrations have the opposite effect 
[794]. 
 
4.1.8.4 Peri-ovulatory oocyte maturation 
The events involved in folliculogenesis culminate in ovulation which, as outlined earlier, 
involves active remodelling of the extracellular matrix, microcirculatory vasomotion, 
formation of an avascular area at the follicular apex and expulsion of the oocyte-
cumulus complex [795]. Although the process of ovulation falls outwith the scope of this 
thesis, the accumulation of cytokines within FF immediately prior to ovulation likely 
continues to influence oocyte viability and, by inference, ability to fertilise and generate 
a successful pregnancy.  
 
IL-1β mRNA levels increase in FF macrophages and GCs in mice and humans as the 
follicle nears rupture, most likely in response to changing gonadotrophin profiles [796-
803]. This points to a role for IL-1β in ovulation - a notion supported by in vivo studies 
in horses and humans [799, 804, 805]. IL-1β reduces LH receptor expression in rat 
GCs in vitro [806], and signals for GCs to switch from proliferation to differentiation 
[807], indicating that this cytokine participates in determining whether follicles undergo 
atresia or progress to ovulation. IL-1β also upregulates macrophage NO production, 
thus mediating the growth/apoptosis decision [767-769, 808], and improves 
perifollicular blood flow via an upregulation in VEGF gene expression [800, 809, 810].  
 
The resumption of oocyte meiosis, cumulus cell expansion and ovulation are events 
mediated by several members of the EGF-like cytokine family, stimulated by the pre-
ovulatory LH surge [811]. LH induces the expression of amphiregulin (AREG), 
epiregulin (EREG), and betacellulin (BTC) in mural GCs in mice [812, 813]. These 
factors induce the expression of prostaglandin-endoperoxide synthase 2 (PTGS2) in 
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mural GCs and cumulus cells, leading to an increase in PGE2 production [814-816]. 
PGE2 then exhibits positive feedback by stimulating AREG and EREG production in 
cumulus cells, which bind in an autocrine/paracrine manner to the cumulus cells’ EGF 
receptor (EGFR) to stimulate cumulus expansion directly, and meiotic resumption 
indirectly [816]. Cumulus cell EGFR expression is stimulated by oocyte-derived GDF-9 
and BMP-15 in the mouse, effectively enabling the cumulus oophorus to respond to 
LH-induced EGF-like peptides [817, 818]. 
 
Several interleukins are thought to mediate pre-ovulatory changes in the oocyte. IL-6 is 
an autocrine regulator of ovarian function, responsible for orchestrating cumulus cell 
expansion in mice by the induction of genes specifically involved in extracellular matrix 
formation/stability (Has2, Ptx3, Ptgs2, Tnfaip6 [819]. Monocytes/macrophages as well 
as mast, theca and GCs have all been reported to produce another interleukin, IL-8 
[820, 821]. IL-8 levels are highest in the TC of late follicular/early ovulatory follicles, 
followed by an increase in the GC layer close to the time of ovulation [780, 822, 823]. 
Neutrophil numbers rise in the TC layer with increasing IL-8 concentrations towards 
ovulation, consistent with a chemotactic role for this cytokine in leukocyte recruitment 
[2, 3, 681, 824]. 
 
4.1.9 Ovarian Stimulation 
Most treatment regimes for COH rely on gonadotrophins in order to compensate for low 
pregnancy rates, overriding the natural selection of one dominant follicle. Multiple 
follicles are recruited each cycle, in theory maximising the number of oocytes available 
for fertilisation and therefore increasing the likelihood of a pregnancy. However, ovarian 
stimulation may in itself be detrimental to oogenesis, embryo quality and endometrial 
receptivity [825].  
 
The influence of exogenous gonadotrophins promotes the growth of multiple follicles to 
the pre-ovulatory stage by bypassing physiological regulatory mechanisms. Urinary-
derived or recombinant FSH are administered, occasionally in conjunction with LH, to 
increase serum FSH concentrations above the threshold required for follicle 
development, ensuring that the entire cohort of recruited follicles for that cycle attains 
pre-ovulatory status [826]. In the long protocol (Figure 4-4), GnRH agonists from cycle 
day (CD) 21 suppress pituitary FSH and LH in order to promote even follicle growth 
and prevent premature luteinisation. This is followed by administration of exogenous 
gonadotrophins at CD2, which is continued for 8-12 days depending on follicle growth. 
Once at least two follicles have attained at least 18mm diameter, a single dose of hCG 
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is administered 36 hours before oocyte retrieval to ‘trigger’ the final stages of oocyte 
maturation. After oocyte retrieval, fertilisation is attempted via IVF or ICSI, with 
resultant embryos being typically (albeit not exclusively) transferred on day 3 or day 5. 
 
 
Figure 4-4: Ovarian stimulation utilising the long protocol. CD indicates the cycle day at 
which interventions occur, with CD1 being the first day of menses. 
 
4.1.10 Assessment of oocyte maturation in the clinic 
Oocyte maturity/quality is typically evaluated using morphological criteria in assisted 
conception laboratories, despite evidence that this method of assessment may not be 
optimal in its current form [827]. The methodology for assessing oocyte morphology 
varies between laboratories, but often includes assessment of appearance of the 
cumulus oocyte complex, zona pellucida and the meiotic spindle (Table 4-1). Although 
the reliability of morphological assessment can be improved by denuding the oocyte, a 
process which is essential in ICSI treatment, allied assessment techniques remain 
highly subjective, open to inaccuracy, and inherently render the oocyte incapable of 
further development by removing its cumulus support [828-832].  
 
Despite improving the identification of mature oocytes, denuding the oocyte and 
observation of the polar body does not guarantee fertilisation. IVF and ICSI success 
rates in terms of live births remain very similar, despite overcoming the physical 
barriers to fertilisation. An average ICSI fertilisation rate of 67.5% has recently been 
reported [833], meaning that even oocytes identified as mature do not always fertilise. 
This, in conjunction with failure of live birth rates to rise rapidly in assisted conception 
protocols, has lead researchers to search for alternative methods to determine which 
are the best oocytes from a collected cohort. 
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Identifying novel molecular markers of oocyte maturation presents an opportunity for 
the improvement of assisted conception success rates. However the technology and 
expertise required are often out of the reach of clinics outside of a research situation. 
For example, examination of the first polar body using fluorescence in-situ hybridisation 
(FISH), comparative genomic hybridisation (array-CGH) and gene expression 
microarray may yield cytogenetic information but these approaches are cumbersome, 
rely heavily on expertise and may not give results in a time frame which is clinically 
informative [834, 835]. By contrast, profiling the FF which provides the oocyte with its 
developmental milieu remains an attractive proposition for the discovery of markers of 
oocyte maturation given that it is non-invasive beyond routine assisted conception 
interventions and therefore presents no developmental risk to the oocyte itself. 
 
154 
 
Chapter 4. Modelling follicular fluid cytokines in relation to oocyte maturation 
 Factor Marker Outcome References 
N
o
n
-i
n
v
a
s
iv
e
 
Cumulus 
oocyte 
complex 
Expansion of cumulus 
and corona radiata 
Correlation between dense 
corona radiata and immature 
oocytes 
[836, 837] 
Zona pellucida 
(ZP) 
Thickness and 
darkness of ZP 
Reduced ZP thickness 
correlates with increased 
fertilisation rates. Increased 
birefringence associated with 
increase fertilisation rates 
[838-841] 
In
v
a
s
iv
e
 
Perivitelline 
space 
Size of perivitelline 
space/granularity  
Increased space and 
granularity correlates with 
embryo quality. Presence of 
coarse granules predicts lower 
implantation rates 
[842-844] 
First polar 
body 
Shape, fragmentation 
and size 
Correlation between abnormal 
shape, enlarged size and low 
fertilisation rates 
[844, 845] 
Ooplasm 
appearance 
Density and granulation ‘Dark’ ooplasm associated with 
compromised embryo quality. 
Absence of granularity 
correlates with low fertilisation 
rates  
[638, 846-848] 
Vacuoles 
and/or 
cytoplasmic 
inclusions 
Presence of absence of 
vacuoles 
Decreased clinical pregnancy 
rates following transfer of 
embryos derived from oocytes 
containing vacuoles. 
Cytoplasmic inclusions may 
affect fertilisation, although this 
is controversial 
[847, 849-853] 
Meiotic spindle Presence and 
appearance of the 
meiotic spindle 
Presence of meiotic spindle 
and proximity to the first polar 
body associated with 
increased fertilisation rates. 
[854-857] 
Table 4-1: Commonly used morphological criteria for the assessment of oocyte 
maturity/quality. 
 
4.1.11 Impact of ovarian stimulation 
4.1.11.1 Oocyte maturation 
The fact that that COH has a negative impact on oocyte development has been 
increasingly recognised in recent years [858, 859]. Based on the appearance of the 
COC, fertilisation rate, embryo morphology and implantation rate, one study found that 
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higher egg retrieval rates correlated with lower quality oocytes [860]. Similarly, another 
study reported that increasing the number of oocytes collected above 13 resulted in a 
fall in pregnancy rates [861]. In this respect, excessively high numbers of poor quality 
oocytes are seen in ovarian hyperstimulation syndrome (OHSS), which suggests that 
overriding the physiological mechanism for follicle selection may be counterproductive. 
Studies in rodents demonstrate a delay in embryo development and impaired 
implantation following gonadotrophin stimulation [862, 863]. 
 
COH may have an impact on the ability of the oocyte to complete meiosis, leading to 
aneuploid oocytes and embryo mosaicism [139, 864]. Previous studies have shown 
that as many as 20% of all oocytes retrieved in these cycles are classed as immature, 
being at a nuclear maturation stage of metaphase I or earlier, despite the follicle having 
Graafian appearance [865]. Mouse embryos from stimulated cycles show evidence of 
induced-DNA lesion [866], and zygotes show an increased rate of chromosomal 
defects in the pronucleus with corresponding compromised embryo development [867]. 
Similarly, in vitro matured oocytes exposed to FSH exhibit accelerated nuclear 
maturation with significant levels of aneuploidy [868]. 
 
4.1.11.2 Cytokine profiles 
During ovarian stimulation, FF composition changes as individual cells of the ovarian 
follicle respond to exogenous gonadotrophins by secreting altered profiles of signalling 
molecules, likely including cytokines. As FF bathes the oocyte and provides the milieu 
in which it matures, such changes may have profound effects of maturation, fertilisation 
and early embryo development [869]. There is a suggestion that FF composition differs 
between the long protocol and the short protocol for ovarian stimulation, with the 
implication that the choice of stimulation regime could improve maturation rates and 
oocyte quality [870]. One recent study characterised the cytokine profiles in natural 
cycles, and demonstrated that cytokines are compartmentalised between plasma and 
FF, with certain cytokines such as IL-8 and VEGF varying between the follicular and 
luteal phases [871]. However, direct comparisons between ovarian stimulation and 
natural cycles are lacking, such that it is not possible to say how the cytokine profile is 
altered compared to normal physiology. Although this area of research falls outwith the 
remit of this thesis, it warrants further investigation. 
 
4.1.12 Potential markers of oocyte maturity 
As cytokines mediate many stages of folliculogenesis, they present attractive targets 
for the discovery of biomarkers of oocyte maturation and quality. Analysing the cytokine 
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profiles of FF collected (and usually discarded) at the time of oocyte retrieval offers a 
non-invasive analytical strategy for assessing oocyte developmental potential. Although 
several research groups have adopted this strategy, few have analysed the fate of 
individual follicles, or focussed on a wide panel of cytokines. Nevertheless, FF 
cytokines have been associated with fertilisation potential, oocyte maturational status 
and embryo quality as discussed below. 
 
4.1.12.1 FF cytokines associated with positive outcomes 
FF G-CSF concentration is positively correlated with oocyte quality/maturity, fertilisation 
success and subsequent pregnancy [872-875]. Ageing patients and higher responders 
to ovarian stimulation exhibit lower FF G-CSF levels, factors which are associated with 
decreased oocyte quality based on fertilisation rates and embryo development [151]. 
High FF G-CSF concentrations, in conjunction with IL-15, have been linked to 
increased implantation potential and a successful live birth [151, 876-878]. Related to 
G-CSF, FF M-CSF levels appear to follow the same patterns, with circulatory levels 
being touted as a marker of successful outcome in assisted conception cycles across a 
range of studies [875, 879-882].  
 
Increased FF SCF concentrations at the time of oocyte retrieval have been associated 
with increased pregnancy rates following IVF [883], although this has not been 
demonstrated in ICSI programmes [884]. SCF is critical at various stages of murine 
oocyte development, correlating with normal oocyte nuclear maturation and polar body 
extrusion [754, 885]. Similar observations have been made for SDF-1α, whose FF 
concentrations increase in line with follicle diameter [886].  
 
EGF and EGF-like peptides have been implicated in oocyte maturation in vivo, and 
these cytokines are frequently used as culture medium supplements to promote in vitro 
maturation of GV stage oocytes [887-897]. Given their role in oocyte maturation, 
AREG, EREG and BTC may thus serve as suitable markers of oocyte maturation [897]. 
AREG is the most abundant EGF-like protein in FF from stimulated ovaries, and 
although the evidence in favour of its potential role as a biomarker remains 
inconclusive at present, FF AREG may prove valuable in predicting oocyte 
maturational status [898-900]. 
 
Follicles containing mature oocytes have higher FF concentrations of MIP-1α, IL-6 and 
IL-6sR [772, 901]. However, IL-6 concentrations are increased following ovarian 
stimulation compared with natural cycles, such that this apparent increase could be 
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artefactual [902, 903]. LIF, a member if the IL-6 family modulates cumulus expansion in 
humans and mice [904], and enhances fertilisation of ovine oocytes in vitro [905]. LIF is 
present at much higher concentrations in Graafian compared to secondary follicles 
[906], and although FF LIF levels correlate with oocyte quality and implantation 
potential in humans [907], this observation is inconsistent across studies [908, 909]. 
 
Of the TGF-β family, FF TGF-β1 levels correlate positively with fertilisation and 
pregnancy rates following ovarian stimulation in humans [910, 911]. TGF-β1 production 
is sensitive to different ovarian stimulation regimes: stimulation with pure FSH results in 
higher FF TGF-β1 concentrations than stimulation with human menopausal 
gonadotrophins (HMG), suggesting differential regulation by FSH and LH [911]. BMP-
15 and GDF-9 are also detectable in human FF. Oocytes from follicles with high FF 
BMP-15 concentrations exhibit higher fertilisation rates, with improved cleavage and 
preimplantation development [912]. Similarly, high concentrations of GDF-9 are 
positively associated with oocyte nuclear maturation and embryo development [913].  
 
Embryo cleavage and implantation rates may be improved by higher FF IL-1β 
concentrations, and several observational studies in humans have linked FF IL-1β 
concentrations with successful pregnancy following assisted conception [149, 914-
916]. However, other studies in humans and horses have found no correlation between 
FF IL-1β and oocyte maturation, fertilisation or embryo cleavage rates, such that further 
studies are very much needed to determine if this is indeed a potential marker of 
oocyte maturity [804, 916-918]. 
 
4.1.12.2 FF cytokines associated with negative outcomes 
High TNF-α concentrations in FF may inhibit oocyte development and maturation [919, 
920], although the clinical value of this remains to be demonstrated. Elevated FF TNF-
α levels in swine result in fewer oocytes progressing from GV to MII, with increased 
incidence of chromosomal abnormalities at the MII stage [921, 922]. This has 
implications for women with inflammatory disorders such as endometriosis, who have 
elevated FF TNF-α concentrations and lower success rates in assisted conception 
[923-927]. There are also implications for assisted conception generally, as there is 
evidence that exogenous gonadotrophins raise FF TNF-α concentrations and perturb 
the profile of other cytokines, thereby reducing the fertilisation potential of oocytes 
when compared to natural cycles [139, 140, 799, 865, 928-932]. The detrimental 
effects of TNF-α appear to be determined by its concentration in combination with the 
local cytokine milieu [401, 933].  
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Poor outcomes following assisted conception, higher rates of OHSS and premature 
luteinisation correlate with high FF VEGF concentrations [706, 925, 934-947]. Although 
low FF VEGF levels have been associated with improved maturity status at the time of 
oocyte recovery [948], the presence of VEGF is known to positively correlate with 
perifollicular blood, and oocytes from well vascularised follicles exhibit increased 
fertilisation and pregnancy rates in humans [949-954]. Animal studies have shown that 
VEGF is beneficial to oocyte maturation both in vivo and in vitro [955-959]. This 
seemingly dichotomous situation could reflect three scenarios: (i) that there is a 
‘window’ of VEGF concentration, below which there is inadequate angiogenesis and 
above which pathological processes develop; (ii) that the physiological effects of VEGF 
depend on the contribution of other cytokines; and/or (iii) that high VEGF levels are a 
marker of a poor vascularisation, with the follicle attempting to compensate. It is also 
possible that the varying effects are mediated by different isoforms of VEGF, although 
the majority of studies have not distinguished between its pro- and anti-angiogenic 
forms [718]. As noted for TNF-α, the ovarian stimulation regimes used in assisted 
conception are reported to alter VEGF production [706, 938, 960].  
 
Elevated FF leptin concentrations in humans have been associated with a reduced 
ovarian response, poor embryo quality and reduced likelihood of pregnancy [925, 943, 
946, 961-963], despite the fact that leptin is positively correlated with oocyte nuclear 
maturation and fertilisation success in humans, mice and cattle [964]. Other studies, 
however, have shown no correlation between FF leptin concentration and assisted 
reproduction outcome [655, 656, 965-971]. The ovary has been shown to exhibit a 
biphasic response to leptin, and FF concentrations may by altered by its complex 
interaction with the metabolome given that many studies do not control for weight/BMI 
or metabolic status  [972-975]. 
 
Many other cytokines (including GM-CSF, HGF, IFN-α, IFN-γ, IL-2, IL-4, IL-7, IL10, IL-
12, IL-18, MCP-1, MIP-1β, and platelet derived growth factor (PDGF)) have been 
identified in FF [151, 877, 935, 948, 976-988]. One recent study showed that IL-8, IL-18 
and MIP-1β positively correlated with pregnancy outcome in IVF cycles, while total IL-
12 reflected oocyte fertilisation and subsequent embryo development [985]. By 
contrast, IL-4 and IL-7 have been associated with poor outcomes following assisted 
conception [978]. However, given the general paucity of information regarding these 
cytokines, their role and effectiveness as biomarkers remains to be conclusively 
demonstrated. 
159 
 
Chapter 4. Modelling follicular fluid cytokines in relation to oocyte maturation 
 
4.1.13 Identified opportunities 
Most studies to date are based on pooled FF rather than relating individual follicle 
profiles to oocyte maturity or pregnancy outcome. While this may be informative in 
terms of the immunological environment, this approach only allows general conclusions 
to be reached regarding the impact of ovarian stimulation on oocyte maturation, and 
ignores the follicle-specific physiology described above [989]. This potentially impacts 
on treatment cycle outcome, as there is significant variation in the developmental 
potential of oocytes retrieved from the same patient during the same cycle. 
 
Many groups looking for markers of oocyte maturation have focussed on nuclear 
maturation, i.e. the presence/absence of a polar body and germinal vesicle [844]. 
Suitable markers of cytoplasmic maturation remain scarce, and the cytokines within 
follicular fluid offer a non-invasive milieu to explore for potential indicators that an 
oocyte is ready for fertilisation. 
 
Although many studies have examined either individual or small groups of cytokines 
within the ovarian follicle, no studies have examined the networks which influence 
oocyte maturatity status in assisted conception cycles. It is clear from the review above 
that cytokines influence oocyte quality, but there is much still to be learned about how 
cytokine networks change within the follicle following ovarian stimulation, and whether 
any changes within these networks can identify good quality mature oocytes which will 
subsequently fertilise. This will form the basis of this Chapter, by using modelling 
techniques akin to those employed in Chapter 3. However, one of the limitations 
identified within that approach was the inability of the algorithm to take in to account 
‘hidden’ Markov blankets. A potential strategy to address the limitations identified 
involves utilising VBSSM networks with the novel application of prior networks, and will 
be explored within this experimental chapter. 
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4.2 Aims 
The aims of this section of the thesis were therefore: 
 to use the mathematical methodologies developed in Chapter 3 as a basis for 
improved modelling strategies 
 to discover, display and explore cytokine networks within human follicular fluid 
surrounding oocytes in follicles subjected to ovarian stimulation, thereby 
highlighting their likely involvement in maturation 
 to identify potential markers of cytoplasmic maturation 
 to classify maturation and the developmental viability of those oocytes based 
on their follicular fluid cytokine profile. 
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4.3 Materials and Methods 
4.3.1 Subjects 
4.3.1.1 Ethical approval 
Ethical approval was obtained from the Leeds (East) Regional Ethics Committee and 
all recruited participants gave written informed consent. Inclusion criteria were broad, 
and included any age group, subfertility aetiology and ethnicity who complied with 
Assisted Conception Unit (ACU) protocols and any IVF or IVF/ICSI cycle.  
 
4.3.1.2 Patient selection 
Patients were selected from the MPD ICSI category as during the ICSI process the 
maturity of the oocyte can be accurately assessed. Exclusion criteria were applied in 
order to eliminate patients with identified inflammatory conditions which may affect 
results. Exclusion criteria included non-Caucasian ethnicity, polycystic ovary syndrome 
(determined using Rotterdam Consensus Group criteria), pelvic inflammatory disease 
>Grade 1, tubal disease >Grade 1 (French Tubal Score), endometriosis >Grade 1 
(American Society for Reproductive Medicine Revised Classification of Endometriosis), 
smoking, extremes of BMI (<19 and >30kg/m2) and any other identified medical 
condition/medication potentially affecting patient inflammatory/immune responses. 
 
4.3.1.3 Ovarian stimulation and oocyte collection 
Ovarian stimulation, oocyte collection and embryo transfer were performed by the 
clinical team at St James’s University Hospital ACU under the direction of Mrs Vinay 
Sharma. The stimulation protocol utilised was unchanged from the unit standard and 
included pituitary down regulation with leuprorelin acetate SR (Prostap®) followed by 
stimulation with daily human menopausal gonadotrophin (hMG; Menopur®).  Follicles 
were identified 35 to 37 hours after hCG injection via transvaginal ultrasound guidance. 
Each follicle was individually aspirated and flushed, and FF examined for an oocyte. 
 
4.3.1.4 Oocyte preparation and identification of maturity 
Once retrieved, the oocytes were mechanically stripped of the cumulus oophorus and 
corona radiata cells by pipetting and assessed for maturity. Mature (metaphase II 
(MII)), immature (germinal vesicle (GV) or metaphase I (MI)) were distinguished using 
the following criteria: 
 
 MII oocytes – presence of an extruded polar body 
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 MI oocytes – determined by default, displaying neither a polar body or germinal 
vesicle 
 GV oocytes – presence of a germinal vesicle containing a single and large 
nucleolus, eccentrically located. 
 
Only mature MII oocytes were subjected to ICSI, and were injected with a single sperm 
according to unit protocols for ICSI. Fertilisation success was assessed 16-20 hours 
after ICSI. Fertilisation was considered normal when the oocytes contained 2 pro-nuclei 
(PN). For data analysis, MII oocytes were further differentiated into MII-F (those which 
fertilised) and MII-NF (those which did not fertilise). 
 
4.3.1.5 Data collection 
FFs were processed and labelled with their unique follicle and oocyte number which 
enabled longitudinal tracking (i.e. fertilised/non-fertilised, transferred/frozen as an 
embryo, developmental stage attained and embryo grade). All patients had pregnancy 
tests (biochemistry, 2 weeks) and monitoring of early pregnancy (ultrasound scan, 6 
weeks) as per unit protocols. A comprehensive database of 110 clinical parameters 
was completed for each participant (by Drs Nadia Gopichandran and Ellissa Baskind), 
detailing specific demographics, lifestyle, treatment regime and the outcome for each 
individual follicle, including the presence of an oocyte, its maturity and fate.   
 
4.3.2 Preparation of FF and serum/plasma 
FF aspirates were collected from individual follicles and examined for the presence of 
an oocyte. The aspirate was transferred into a 15ml centrifuge tube (Greiner Bio, UK) 
on ice and labelled with the corresponding follicle number. Each follicle aspirated and 
each oocyte retrieved was assigned a sequential number in the order of aspiration and 
retrieval. The follicle/oocyte number was carried forward to the embryo and linked to its 
ultimate fate (e.g. fertilised or not, pregnant or not). Blood was collected in 6ml lithium 
heparin tubes (Beckton, Dickinson and Company, UK) for plasma separation and 6ml 
EDTA tubes for serum separation (Beckton, Dickinson and Company, UK). 
 
FF aspirates were centrifuged at 2,000 rpm for 5 minutes at 4oC in a Sanyo Harrier 
18/80 MSE refrigerated Centrifuge (Sanyo, UK). The supernatant fluid was then divided 
into 1ml aliquots and stored in 1.5ml microfuge tubes (Starlab, UK). Whole blood was 
centrifuged at 2,000 rpm for 10 minutes and the supernatant serum and plasma were 
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placed in aliquots in 1.5ml microfuge tubes. All samples were processed and stored at -
80oC within 1 hour of collection. 
 
 
4.3.3 Sample analysis 
4.3.3.1 Cytokines 
Cytokines were measured by fluid phase multiplex immunoassay using 23-plex and 27-
plex kits (Bio-Rad, Hercules, CA, USA) according to the manufacturer’s instructions 
with minor modifications (original instructions available at http://tinyurl.com/korjr9s). 
Briefly, FF and plasma samples were thawed on ice, then microfuged for 2 minutes at 
8000rpm to remove any possible debris that may affect the assay filter plates. The 
supernatant was then diluted 1:1 with assay buffer and mixed with the relevant bead 
sets in a 96 well filter plate (Millipore, UK). Recombinant cytokines were serially diluted 
according to kit instructions and provided a standard curve. Following 30 minutes’ 
incubation at room temperature, the plate was washed 3 times with vacuum extraction 
of the wash buffer. Biotinylated secondary antibodies were added followed by a 30 
minute incubation and 3 washes. The streptavidin-phycoerythrin detection complex 
was added and incubated for 10 minutes, followed by a further 3 washes. The wells 
were then resuspended in 125l assay buffer ready for analysis. All incubations were 
performed on an orbital shaker at 300rpm with an initial 30 seconds at 1000rpm. The 
plate was shaken for 30 seconds at 1000rpm before analysis. Fluorescence was 
measured on a twin laser Luminex 100 cytometer platform (Luminex, Texas, USA). 
Unknown cytokine concentrations were automatically calculated by Bio-Plex Manager 
software (version 4.1) using a 5 parameter logistic calibration curve. 
 
4.3.3.2 von Willebrand Factor (vWF) 
The concentration of vWF in plasma and follicular fluid samples was measured using a 
commercially available enzyme-linked immunosorbent assay (ELISA) kit (Diagnostica 
Stago UK LTD, Reading, UK) following the manufacturer’s instructions. Absorbance 
was measured at 450nm using a MultiScan Ascent plate reader (ThermoFisher 
Scientific, Loughborough, UK) with standard curves produced by the plate reader 
Ascent software programme using a 4 parameter logistic curve. vWF was solely used 
for the purposes of accounting for the occasional blood contamination of FF that occurs 
during oocyte collection.  
 
 
164 
 
Chapter 4. Modelling follicular fluid cytokines in relation to oocyte maturation 
4.3.3.3 C-reactive protein (CRP) 
CRP is one of the most sensitive acute phase proteins, and its raised concentrations in 
blood are traditionally associated with inflammatory processes. The analysis of CRP 
utilised an enhanced latex-turbidometric immunoassay performed on an automated 
clinical chemical autoanalyser (COBAS MIRA, Roche, Basel, Switzerland) using a 
commercially available kit (Thermo Electron Corporation, Alpha Laboratories, 
Hampshire, UK). 20μl of follicular fluid or plasma was aliquoted into a MIRA sample 
cup (Alpha Laboratories, Hampshire, UK). Calibration curves and samples were run 
according to the reaction parameters detailed in Table 4-2. Calibration was performed 
at each start up using the Thermo Extended Range Calibration set (Thermo Electron 
Corporation, Alpha Laboratories, Hampshire, UK). 
 
Variable Defined condition 
Temperature 37
o
C 
Primary wavelength 570nm 
Secondary wavelength 800nm 
Assay type 2 point endpoint 
Direction Increase 
Sample:Reagent ratio 1:100 
Delay time 300 seconds 
Incubation time 265 seconds 
Reagent blank limits 
(570nm / 800nm, 1cm light path) 
Low 0.000 AU 
High 0.015 AU 
Linearity 0.12 – 320 mg/ml 
Limit of quantification 
(570nm / 800nm, 1cm light path) 
0.12 mg/ml 
Final absorbance Absorbance (test) – absorbance (blank) 
Table 4-2: Reaction conditions for CRP measurement. 
 
4.3.3.4 Protein analysis 
The concentration of protein was measured using a commercially available kit (Bio-Rad 
DC-Protein assay, Bio-Rad) in all FF and plasma samples in order to standardise for 
the protein-free medium flush component within collected fluids. All cytokine 
concentrations were expressed in pg cytokine/mg protein to account for any dilution 
effects. Prior pilot analysis of clean catch FF indicated that clean catch fluid protein 
levels were subject to minimal variability, making protein-based standardisation a 
reasonable correction method. Absorbance was measured at 630nm using a MultiScan 
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Ascent plate reader (ThermoFisher Scientific, Loughborough, UK) with standard curves 
produced by the plate reader Ascent software programme using a linear curve. 
 
4.3.4 Statistics and data analysis 
4.3.4.1 Pre-processing of FF cytokine concentrations 
When collecting FF samples, a needle is required to traverse the vaginal mucosa and 
ovarian tunica albuginea and cortex to aspirate the follicles. During this process, 
vasculature may be disrupted and blood, either macroscopic or microscopic may 
contaminate the FF. Furthermore, washes between follicular aspirations with protein 
free flush medium formulated with Gentamicin (Enhanced HTF Culture Medium with 
HEPES, Conception Technologies, San Diego, California, USA) had the potential to 
provide a mild dilution factor. The cytokine concentrations measured in the FF may 
therefore not be an accurate representation of the genuine follicular content and 
therefore such contamination must be accounted for and factored in to the analysis. 
This entailed cytokine analysis of both FF and plasma together with the measurement 
of von Willebrand Factor (vWF) and protein concentrations within blood and FF. 
 
As vWF is present in the circulation but not in FF, an equation was designed (by Drs 
Michele Cummings and Nic Orsi) to allow the relative blood contamination of FF to be 
taken into account, and therefore adjust the cytokine values based on their blood 
profiles. Equation 1 corrected the FF sample for blood contamination.  
 
 
                          
  
(                              )   (                              )
                  
 
Equation 1: Correction of cytokine values for blood contamination 
 
 
The resulting corrected FF cytokine concentrations were then expressed as a function 
of total protein to mitigate dilution effects (Equation 2). 
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Equation 2: Correction of FF cytokine concentrations for dilution effects 
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4.3.4.2 Missing data 
Forty eight out of the 8,651 data points were missing (circa 0.55% of the total) and, as 
such, these values were imputed using the regularized expectation-maximization 
(RegEM) algorithm [990] via Matlab (Tapio Schneider, California Institute of 
Technology, California, USA), wherein the algorithm was used to compute iteratively 
maximum log-likelihood estimates of missing values based on presumptive 
relationships between the complete and incomplete data sets. This was deemed to be 
a fair assumption based on the recognised physiological cytokine relationships 
highlighted by in vivo studies [481, 560, 991, 992]. Each iteration was based on a two 
(E and M) step process, where the algorithm determines the expectation of log-
likelihood of the complete data based on the incomplete data and the current 
parameter in the first step: 
 
Q(|(t)) = E (log p(X,Y|)|X,(t)) 
 
where the available observations X are drawn from a distribution parameterized by , 
and Y corresponds to the missing (but additional) data (i.e. the values to impute). The 
second step involves the algorithm determining a new parameter maximising Q (which 
then converges to a likelihood function local maximum with subsequent iterations): 
 
 
(t+1) = arg max Q(|(t)) 
               
 
4.3.4.3 Data analysis 
Data were analysed using GraphPad Prism version 5 (GraphPad Software Inc., San 
Diego, California, USA). Normality was determined by visualising normal Q-Q plots and 
testing for normality using Shapiro-Wilk. As the data was not normally distributed non-
parametric analysis was applied. Mann-Whitney U was applied, using a significance 
level of p=0.05, for initial data exploration. P values were adjusted for multiple 
comparisons using Holm’s sequentially selective Bonferroni modification.  
 
4.3.5 Advanced analysis 
In order to mitigate the effects of uneven sample size on the advanced analysis 
techniques described below, data were randomly truncated (via a random number 
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generator) to meet the smallest sample size. In the present dataset this was equivalent 
to the 26 samples in the GV category. This truncated dataset was used in the PCA 
analysis and in the generation of the modified VBSSM networks. 
 
4.3.6 Principal components analysis 
Data were normalised prior to PCA in order to reduce the effect of the dynamic range 
of each cytokine. First, each data point was divided by the maximum value in that 
particular dataset. Then data were then scaled by subtracting the mean. This approach 
rendered the data dimensionless and removed outliers. Subsequent individual and 
pairwise PCA was performed in Matlab (http://www.mathworks.com/products/matlab/) 
using Singular Value Decomposition (SVD). 
 
4.3.7 Modified variational Bayesian network analysis 
Data from each of the maturation categories were selected and randomly truncated in 
order to create equal sample sizes in each group. Variational Bayesian state space 
models (VBSSM) were used as described by Beal et al [486] with modifications. The 
original VBSSM algorithm utilised data only in order to approximate the underlying 
network. In the present study, a prior network was generated and applied to the 
VBSSM structure in order to refine the search process. The prior network was 
generated using information from human models only and was based on a text learning 
algorithm developed by Benjamin Haibe-Kains in conjunction with the Quackenbush 
laboratory (available at https://compbio.dfci.harvard.edu/predictivenetworks/). The 
initialisation fields were set to 10 seeds, with the number of iterations set to 1000. As 
VBSSM takes into account hidden Markov models with latent variables, the maximum 
hidden state dimension was limited to 20 [486]. A confidence check was performed, 
wherein a z score of 2.33 was selected (equivalent to a significance threshold of 98%) 
in order to demonstrate the number of edges reaching significance [492]. Cytokines not 
reaching the required level of significance were considered orphaned from the network 
and therefore not represented in the final visualisation. 
 
Networks were visualised using the open graph Viz platform Gephi version 0.8.2-beta 
(available at https://gephi.github.io/). The spatialisation technique selected was the 
force-directed Yifan Hu algorithm [993]. This algorithm is both efficient and high quality 
in combining a multilevel approach (aimed at effectively overcoming local minima); it 
uses the Barnes and Hut octree technique, which approximates short- and long-range 
force efficiently. A community detection algorithm was used to detect the modular 
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structure in the graph topology, as previously described [994, 995]. Communities were 
delineated by colour within the final graphical representation, and represented groups 
of cytokines which demonstrated the strongest relationships. 
 
4.3.8 Classifier analysis 
4.3.8.1 Multinomial modelling and Akaike Information Criterion (AIC) 
Multinomial modelling (logistic regression) and Akaike Information Criterion (AIC) were 
performed in ‘R’ with the categories defined as GV, MI, MII-NF and MII-F. The correct 
classification rate (CRC) was determined by removing the data for one oocyte, building 
the multinomial/AIC model then using the model to predict the correct maturity status of 
the the removed oocyte based on its cytokine profile. Accordingly, each oocyte was 
ascribed a probability of being allocated to each of the GV, MI, MII-NF and MII-F 
categories. 
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4.4 Results 
4.4.1 Demographics 
Demographics and relevant clinical data for participants in the ICSI only oocyte 
maturity data exploration are shown in (Table 4-3). After applying the exclusion criteria, 
212 representative FF samples were collected. Following cumulus cell stripping prior to 
ICSI, oocytes were allocated to the following groups: GV, (n=26), MI, (n=51), 
metaphase II not fertilised (MII-NF, n=51) and metaphase II fertilised (MII-F, n=84). 
 
 
Parameter Average 
(Range/±SEM) 
Age (years) 34 (21–42) 
MPD starting dose (IU) 300 (150–750) 
Total ampoules MPD 45 (24–100) 
Total follicles collected 15.3±0.86 
FSH (IU/l) 6.78±0.23 
LH (IU/l) 4.49±0.23 
Oestradiol (pmol/l) 158.0±12.54 
 
Table 4-3: Demographics and clinical data for included participants. Age, MPD starting 
dose and total ampules are presented as median (range). All other data presented as 
mean±SEM. 
 
4.4.2 Cytokine analysis 
4.4.2.1 Exclusions from study 
Upon analysis of the standard curves for each cytokine, the concentrations of several 
cytokines fell outwith the linear portion of the standard curve (Table 4-4). These 
cytokines were excluded from any further analysis. 
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Below limits of detection Above linear portion of standard curve 
IL-1β HGF 
IL-2 VCAM-1 
IL-4 ICAM-1 
IL-5  
IL-17  
MIP-1α  
IL-1α  
Table 4-4: Cytokines in FF lying outwith the detection range of the assay 
 
4.4.2.2 Differences between plasma and FF 
FF cytokine concentrations were measured and compared to plasma values. Of the 40 
cytokines measured, 16 demonstrated significant differences between plasma and FF 
(Figure 4-5). PDGF, IL-12 (p70), IL-9, IL-6 and GM-CSF were significantly lower in FF 
compared to plasma (P<0.001). However VEGF, CTACK, GRO-α, M-CSF, SDF-1α, 
TRAIL, IP-10, G-CSF, IL-1ra, MIF and SCGF-β all showed concentrations above those 
noted in plasma (P<0.001). 
 
 
 
Figure 4-5: Concentration of cytokines in FF normalised to plasma. 
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4.4.3 Cytokine profiles in follicles containing oocytes of differing maturity 
4.4.3.1 Cytokines increasing in concentration with advanced maturity 
FF eotaxin, VEGF and IL-8 levels demonstrated trends towards increasing with 
advancing oocyte maturity (Figure 4-6). Both VEGF and IL-8 were high in FF from GV 
oocytes, decreasing at the MI stage and then increasing to MII-F. Significant 
differences were noted across maturation statuses, as indicated in Figure 4-6. Data for 
all cytokines not demonstrating significant differences between maturity states are 
presented in Table 4-5. 
 
172 
 
Chapter 4. Modelling follicular fluid cytokines in relation to oocyte maturation 
 
Figure 4-6: Cytokines showing an increasing FF concentration trend with advancing 
oocyte maturity status. Asterisks indicate significant differences between follicles 
containing oocytes of differing maturity (*p<0.05, **p<0.01, ***p<0.001). 
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 GV MI MII-NF MII-F 
bFGF 6.61±5.10 3.46±2.25 1.03±0.58 1.31±1.10 
GM-CSF -0.20±0.48 0.08±0.04 0.06±0.03 0.74±0.57 
IFN- 0.09±0.39 0.42±0.16 0.25±0.11 0.14±0.05 
IL-1ra 10.15±10.33 1.49±0.53 16.41±8.42 4.69±1.20 
IL-6 -0.12±0.44 0.15±0.05 0.05±0.01 0.05±0.01 
IL-7 1.91±1.13 0.50±0.21 0.33±0.25 0.10±0.03 
IL-8 0.81±0.35 0.46±0.05 0.70±0.09 0.94±0.12 
IL-9 1.80±1.25 0.60±0.37 0.11±0.08 0.00±0.01 
IL-10 0.03±0.02 0.01±0.00 0.01±0.00 0.02±0.00 
IL-12 (p70) 0.41±0.23 0.22±0.12 0.03±0.03 0.07±0.02 
IL-13 0.05±0.02 0.03±0.01 0.02±0.00 0.02±0.01 
IL-15 0.23±0.23 0.11±0.11 0.02±0.02 0.17±0.13 
IL-18  0.92±0.25 0.71±0.10 0.61±0.05 0.78±0.10 
IP-10 4.56±1.34 5.69±0.83 5.95±0.78 4.67±0.62 
LIF  3.18±3.00 3.16±3.06 0.11±0.03 0.70±0.60 
MCP-1 1.16±0.28 0.76±0.08 0.82±0.12 0.85±0.09 
MIG  3.54±0.54 4.32±0.57 3.50±0.39 4.29±0.61 
MIP-1β 0.43±0.13 0.36±0.05 0.46±0.07 0.34±0.03 
PDGF 4.93±2.76 8.18±3.31 3.62±1.89 1.37±0.32 
SCF 1.22±0.16 1.58±0.19 1.50±0.14 1.46±0.23 
SCGF-β  233.31±41.84 237.00±50.44 271.48±32.04 349.68±40.10 
Table 4-5: Concentrations of cytokines without significant differences according to 
oocyte maturation stage. Data presented as pg cytokine/mg protein ±SEM. 
 
4.4.3.2 Cytokines decreasing in concentration with advanced maturity 
The remaining FF cytokines demonstrated a trend to decrease in concentration relative 
to oocyte advancing maturity status. Figure 4-7 shows cytokines (CTACK, MCP-3, -
NGF, M-CSF, TRAIL, SDF-1α, IL-12 (p40), IFN-α2, and IL-2ra) which were lowest in 
concentration in follicles containing MII-F oocytes, which were significantly different to 
follicles containing less mature oocytes. Similarly, Figure 4-8 shows other cytokines 
which decreased in FF with advancing oocyte maturity status, albeit less significantly 
(IL-3, TNF-β, IL-16, G-CSF, RANTES, GRO-α, MIF, IL-7 and TNF-α). 
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Figure 4-7: Cytokines showing a decreasing concentration trend with increasing 
maturity status.  
Asterisks indicate significant differences between follicles containing oocytes of 
differing maturity (*p<0.05, **p<0.01, ***p<0.001). 
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Figure 4-8: Further cytokines showing a decreasing concentration trend with maturity.  
Asterisks indicate significant differences between follicles containing oocytes of 
differing maturity (*p<0.05, **p<0.01, ***p<0.001). 
 
4.4.4 CRP 
Variation in CRP concentration was large across follicles (Figure 4-9). CRP was 
significantly lower in follicles containing MII-F oocytes when compared with the other 
maturity levels (P<0.001). Plasma CRP levels were similar to those in FF in follicles 
yielding a MII-F oocyte. 
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- 
Figure 4-9: CRP concentration in follicles yielding oocytes of different maturity status. 
 
4.4.5 Principal components analysis 
Data were processed by principal components analysis (PCA). Each individual stage 
was analysed, then subsequently each maturity status was compared to the others, i.e. 
MII-F versus MII-NF, MII-F vs MI, MII-NF versus MI, MI versus GV.  
 
4.4.5.1 GV 
PCA of the GV stage revealed 7 principal components (PCs), with the first 2 PCs 
describing 75% of the variance (Appendix V). Within these PCs, GM-CSF and IL-6 
were highlighted as important by PC1 (50% of variance), and G-CSF, MCP-1 and 
CTACK by PC2 (25% of variance, Figure 4-10). 
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Figure 4-10: PC Coefficients for the GV stage of oocyte maturity. 
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4.4.5.2 MI 
In follicles containing an MI oocyte, PCA revealed 10 PCs, with 65% of variance 
accounted for by the first 3 PCs (Appendix V). PC1 (35% of variance) denoted MIF, 
bFGF, TRAIL and IFN-α2 as important; PC2 (20% of variance) pointed to IL-16, βNGF, 
SCF and IL-18 while PC3 highlighted VEGF, IL-10, IL-8 and MIP-1β. 
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Figure 4-11: PC coefficients for oocytes at the MI stage of maturity. 
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4.4.5.3 MII-NF 
Variation within the PCA for FF containing MII-NF oocytes was explained by the first 2 
PCs of 10 generated (60%). PC1 revealed several cytokines which explained the 
variation to a greater degree than others (IL-12 (p40), M-CSF, IL-2ra, β-NGF, SDF-1α, 
IFN-α2 and IL-6) while PC2 highlighted just LIF and VEGF (Figure 4-12). 
 
 
Figure 4-12: PC Coefficients for MII-NF oocyte FF 
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4.4.5.4 MII-F 
60% of the variation within FF containing an MII-F oocyte was explained by PCs 1, 2 
and 3. IFN-α2, IL-13, MCP-3 and TRAIL were highlighted by PC1, with PDGF, IL-7 and 
IL-12 (p70) dominating in PC2. PC3 showed the importance of IP-10 and MIP-1β. 
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Figure 4-13: MII-F oocyte FF PC coeffiecients 
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4.4.5.5 MII-F versus MII-NF 
The analysis of MII-F versus MII-NF revealed ten PCs, the first three describing 60% of 
the total variance (Appendix VI). Discrimination was observed between MII-NF and MII-
F oocytes, when plotting PC1 versus PC2 (Figure 4-14), and to a much lesser extent 
when plotting PC1 versus PC3 and PC2 versus PC3 (Appendix VI). Principal 
component 1, which described 36% of the total variance, highlighted IFN-α2, TRAIL, M-
CSF, SDF-1α and IL-13 (in order of importance) as explaining a large proportion of the 
variation (Figure 4-15). PC2 included IL-12 (p70), TRAIL, GM-CSF, LIF and TNF-β. 
 
 
 
Figure 4-14: Principal components analysis plot for MII-F versus MII-NF oocytes.  
MII-F oocytes are displayed as purple spots, while MII-NF oocytes are displayed as 
black crosses. A marginal separation can be seen between MII-F and MII-NF oocytes. 
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Figure 4-15: Combined coefficients for MII-NF and MII-F oocytes.  
Relative importance of cytokines within PC1 (Panel A) and PC2 (Panel B). 
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4.4.5.6 MII-F versus MI 
Pairwise comparisons between FF containing MII-F and MI oocytes revealed a 
separation between these maturity states (Figure 4-16). Of the 10 PCs, 60% of the 
variance was explained by PC 1, 2 and 3 (Appendix VI). PC1 revealed that IFN-α2, IL-
13, TRAIL and FGF basic were influential in the separation of these maturity states 
(Figure 4-17). PC2 highlighted MIP-1β, SCGF-β and IP-10, while PC3 yielded IP-10 as 
its most influential cytokine. 
 
 
Figure 4-16: Pairwise PCA of FF containing MII-F and MI oocytes. 
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Figure 4-17: PCs associated with the pairwise comparison of MII-F and MI oocytes 
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4.4.5.7 MII-NF versus MI 
PCA was unable to differentiate between MII-NF and MI oocytes (Figure 4-18). Of the 
ten principal components, 62% of the variation was explained by PC1, PC2 and PC3 
(Appendix VI). Samples were equally distributed when plotting PC1 versus PC2, 
suggesting that these maturity states share a similar cytokine profile (Figure 4-18). 
Plotting PC3 did not improve separation (Appendix VI). 
 
 
 
Figure 4-18: MI versus MII-NF principal components analysis. 
Principal components analysis plots for MII-NF (black crosses) versus MI (green 
circles) oocytes. No distinct separation was noted between these maturity states. 
 
4.4.5.8 MII-NF versus GV 
PCA was unable to differentiate between the cytokine profiles of FF containing MII-NF 
and GV oocytes (Figure 4-19). 65% of the variation was explained by PCs 1 and 2 
(Appendix VI). 
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Figure 4-19: PCA plot of FF containing MII-NF versus GV oocytes. 
No separation was seen between MII-NF (purple crosses) and GV oocytes (green 
plusses). 
 
4.4.5.9 MI versus GV 
As for MII-NF and MI, PCA was unable to differentiate between MI and GV oocytes 
(Figure 4-20). Of the ten principal components, 65% of the variation was explained by 
PC1 and PC2 (Appendix VI). Equal distribution was noted for both maturity states 
suggesting that these samples shared a similar cytokine profile. 
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Figure 4-20: MI versus GV principal components analysis. 
PCA for MI (green circles) versus GV (green plusses) oocytes. No distinct separation 
was noted between these maturity states. 
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4.4.6 Cytokine networks within FF 
 
4.4.6.1 Networks in follicles containing a GV oocyte 
A modified VBSSM network was generated from the data acquired from FF containing 
a GV oocyte (Figure 4-21). The network contained 30 cytokines, grouped into 5 
communities. IL-1ra, IL-9, IL-13, IL-18, IP-10, M-CSF, MCP-3, MIF, β-NGF, RANTES 
and TNF-β appeared as parents within the different communities. IL-10 and VEGF 
appeared as hubs. Terminal nodes for each of the communities were represented by 
G-CSF, IFN-γ, TNF-α and TRAIL. Cytokines orphaned from this network were CTACK, 
eotaxin, bFGF, GM-CSF, GRO-α, IFN-α2, MIP-1β, monokine induced by gamma-
interferon (MIG), PDGF, SCGF-β and SDF-1α. 
 
 
Figure 4-21: Gephi network generated from cytokines within the FF of follicles 
containing a GV oocyte.  
Nodes are depicted in circles, which are colour coded according to community. 
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4.4.6.2 Network generated from follicles containing an MI oocyte 
The network generated from FF containing an MI oocyte depicted 24 cytokines 
grouped into 4 communities (Figure 4-22). Eotaxin, IL-9, IL-13, IP-10 and RANTES 
appeared as parent nodes, while IL-2ra, IL-7, IL-12 (p40), IL-15, IL-16, M-CSF, β-NGF, 
PDGF, and TRAIL featured as terminal nodes. Hubs were represented by IL-6, IL-10 
and VEGF. Orphaned nodes were CTACK, bFGF, G-CSF, GM-CSF, GRO-α, IFN-α2, 
IFN-γ, IL-3, IL-8, IL-12 (p70), LIF, MCP-3, MIG, SCGF-β, SDF-1α, TNF-α and TNF-β. 
 
 
 
Figure 4-22: Gephi network generated from cytokines in the FF from follicles containing 
an MI oocyte. 
 
4.4.6.3 Cytokine networks within follicles containing an MII-NF oocyte 
The network generated from follicles containing an MII-NF oocyte contained 18 
cytokines grouped into 4 communities (Figure 4-23). CRP, IL-9, IL-13, IL-18, IP-10, LIF 
and RANTES featured as parent nodes. The terminal nodes within each of the 
communities were represented by IL-2ra, IL-7, IL-15 and TRAIL, with IL-6, IL-10 and 
VEGF as hubs. Cytokines orphaned from this network were CTACK, eotaxin, bFGF, G-
CSF, GRO-α, IFN-α2, IFN-γ, IL-3, IL-8, IL-12 (p40), IL-12 (p70), IL-16, IL-17, M-CSF, 
MCP-3, MIG, MIP-1β, β-NGF, PDGF, SCGF-β, SDF-1α, TNF-α and TNF-β. 
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Figure 4-23: Cytokine network generated from follicles containing an MII-NF oocyte. 
 
4.4.6.4 Cytokine networks in follicles containing an MII-F oocyte 
The network generated from follicles containing an MII-F oocyte contained 22 cytokines 
grouped into 5 communities (Figure 4-24). Parent nodes were provided by IL-9, IL-18 
and RANTES, with terminal nodes including IFN-α2, IL-3, IL-12 (p40) IL-12 (p70), IL-
15, MCP-3, MIG, SCF and TRAIL. CRP, IL-10 and VEGF were hubs, while CTACK, 
eotaxin, bFGF, G-CSF, GRO-α, IFN-α2, IL-8, IL-16, LIF, M-CSF, MIF, β-NGF, PDGF, 
SCGF-β, SDF-1α, TNF-α and TNF-β were orphaned from the network. 
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Figure 4-24: Gephi network provided by cytokines within follicles containing an MII-F 
oocyte. 
 
4.4.6.5 Cytokines preserved across all networks 
A number of cytokines were preserved across all networks, with many retaining 
relationships within communities. IL-1ra, IL-6 and IL-7 were connected with IL-13 in all 
networks (with the exception of IL-1ra in the GV oocyte containing follicles). IL-9 
featured an outgoing edge to VEGF in all networks, and was also connected to SCF via 
an incoming edge. IL-10 was presented as a hub in all networks. IL-15 was always 
represented as a child of MCP-1, which also featured a connection with RANTES (a 
parent node in all networks). IL-2ra was connected with IL-18 in all networks, either as 
an independent community or embedded into another subnetwork. IP-10 featured as a 
parent in all networks except for MII-F, with an outgoing edge connecting this cytokine 
to VEGF. TRAIL featured as a terminal node in all networks. 
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4.4.6.6 MII-NF and MII-NF network comparison 
As the result which may make the most difference clinically was the differentiation 
between MII-NF and MII-F oocytes, this section will concentrate in the similarities and 
differences between those networks. The networks generated from FF containing MII-F 
and MII-NF oocytes displayed both conserved cytokine relationships as well as having 
unique network component signatures. IL-1ra, IL-2ra, IL-6, IL-7, IL-9, IL-10, IL-13, IL-
15, IL-18, IP-10, MCP-1, RANTES, SCF, TRAIL and VEGF were all present in both 
networks (Table 4-6). Cytokines present in the MII-NF network only were LIF and MIF, 
while the MII-F network was characterised by IFN-α2, IL-3, IL-12 (p40), IL-12 (p70), 
MCP-3 and MIG. CRP was present in both networks, as a parent in the MII-NF 
network, and as a hub in the MII-F network. Cytokines not present in either network 
were CTACK, eotaxin, bFGF, G-CSF, GRO-α, IFN-γ, IL-16, IL-17, M-CSF, β-NGF, 
PDGF, SCGF-β, SDF-1α, TNF-α and TNF-β, many of which were also absent from GV 
and MI networks. 
 
 
Cytokines common to 
MII-F and MII-NF 
Networks 
Cytokines present in 
MII-NF network only 
Cytokines present in 
MII-F network only 
Cytokines not 
present in either 
network 
IL-1ra LIF IFN-α2 CTACK 
IL-2ra MIF IL-3 Eotaxin 
IL-6  IL-12 (p40) bFGF 
IL-7  IL-12 (p70) G-CSF 
IL-9  MCP-3 GRO-α 
IL-10  MIG IFN-γ 
IL-13   IL-16 
IL-15   M-CSF 
IL-18   β-NGF 
IP-10   PDGF 
MCP-1   SCGF-β 
RANTES   SDF-1α 
SCF   TNF-α 
TRAIL   TNF-β 
VEGF    
Table 4-6: Cytokines common to and differing across the MII-F and MII-NF networks 
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4.4.7 Classification of oocytes 
4.4.7.1 Multinomial modelling 
Using a multinomial modelling approach across all 4 maturity states, a model 
generated by the inclusion of all cytokines detectable within the standard range 
correctly predicted 58% of the oocytes according to maturity stage (i.e. when taking 
into account the concentrations of all analytes). The best prediction was that of MII-F 
oocytes where 87.34% of oocytes were correctly categorised (Table 4-7). 
 
 
 
 
 
 Predicted maturity 
A
c
tu
a
l 
m
a
tu
ri
ty
  GV MI MII-NF MII-F 
GV 10.53 21.05 57.89 10.53 
MI 14.71 35.29 32.35 17.65 
MII-NF 27.27 20.45 43.18 9.09 
MII-F 1.27 6.33 5.06 87.34 
Table 4-7: Classification of oocyte maturity status by multinomial modelling. For each 
stage, the actual maturity versus predicted maturity is presented as a percentage 
through the CCR. 
 
4.4.7.2 Cytokine selection 
When cytokines were grouped and selected for their ability to predict oocyte maturity 
status by the Akaike Information Criterion (AIC), several cytokines were retained 
(CTACK eotaxin, FGF, IFN-α2, IL-1ra, IL-2ra, IL-3, IL-6, IL-7, IL-8, IL-12 (p40), IL-12 
(p70), IL-16, MCP-1, MCP-3, M-CSF, MIF, MIP-1β, βNGF, PDGF, RANTES, SCF, 
SCGF-β, SDF-1α, TNF-α, TNF-β, TRAIL and VEGF). Correct classification was 
increased for all oocytes to 64%. Again, the best prediction was seen in MII-F oocytes, 
with 89.87% being correctly predicted as falling into their category (Table 4-8).  
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 Predicted maturity 
A
c
tu
a
l 
m
a
tu
ri
ty
  GV MI MII-NF MII-F 
GV 36.84 10.53 47.37 5.26 
MI 2.94 44.12 29.41 23.53 
MII-NF 27.27 18.18 45.45 9.09 
MII-F 1.27 3.80 5.06 89.87 
Table 4-8: Classification of oocytes maturity status by Akaike Information Criterion. For 
each maturity, the actual maturity versus predicted maturity is presented as a 
percentage (CCR). 
 
4.4.7.3 Prediction capability of groups of two and three cytokines 
Cytokines were grouped into pairs in order to identify which cytokines give the best 
CCR and therefore may provide the basis for a diagnostic test. When taking pairs of 
cytokines, VEGF and TRAIL provided the best CCR of 57.3% (Table 4-9). This was 
comparable to the 58% CCR using the multinomial modelling approach. 
 
Cytokine 1 Cytokine 2 CCR (%) 
VEGF TRAIL 57.3 
IL-8 TRAIL 56.5 
Eotaxin TRAIL 55.6 
G-CSF TRAIL 55.6 
IL-12 (p70) TRAIL 55.2 
MIP-1β TRAIL 55.1 
RANTES TRAIL 54.8 
IL-3 TRAIL 54.1 
Table 4-9: CCR of oocyte maturity status by pairs of cytokines. 
 
When triplets of cytokines were grouped and examined to determine the best CCR, IL-
12 (p70), IL-18 and TRAIL provided a CCR of 59% (Table 4-10). This exceeded the 
CCR provided by multinomial modelling, but did not reach the level of prediction 
provided by AIC (64%). Further exploration of groups of 4, 5 or 6 cytokines did not 
improve the CCR. 
 
197 
 
Chapter 4. Modelling follicular fluid cytokines in relation to oocyte maturation 
Cytokine 1 Cytokine 2 Cytokine 3 CCR (%) 
IL-12 (p70) IL-18 TRAIL 59.0 
Eotaxin IL-18 TRAIL 58.9 
Eotaxin IL-8 TRAIL 58.9 
IL-8 VEGF TRAIL 58.7 
IL-15 VEGF TRAIL 58.7 
IL-1ra Eotaxin TRAIL 58.5 
IL-8 GM-CSF TRAIL 58.4 
IL-8 SCF TRAIL 58.4 
Table 4-10: Triplets of cytokines and their CCR of oocyte maturation. 
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4.5 Discussion 
4.5.1 Oocyte maturation 
The fact that cytokines are involved in oocyte maturation, folliculogenesis and ovulation 
is increasingly well-recognised, although likely perturbations in their profiles allied to 
assisted conception protocols are overlooked despite their putative impact on oocyte 
viability. Indeed, most methods of ovulation induction aim to maximise oocyte 
availability, with little regard to the quality of those oocytes and the environment in 
which they have matured.  
 
In natural cycles, where a woman is monitored through her menstrual cycle for a 
dominant oocyte which is collected prior to ovulation for ICSI, it is highly unlikely that 
the oocyte will be assessed to be GV or MI (and therefore immature) in terms of 
nuclear maturation as the single dominant follicle often contains a mature oocyte [136, 
996]. By contrast, in instances when women are subjected to COH regimens, many 
oocytes are retrieved in one session, a proportion of which will be immature. In the 
present study, this was highlighted by the high numbers of GV (8%) and MI (17%) 
oocytes collected from the women included in this study, which slightly exceeds the 
published combined proportion of between 15-20% [997]. Why not all oocytes respond 
to the maturation signals of exogenous gonadotrophins in the same manner is unclear, 
although this may be influenced by age, clinical condition, ovarian reserve and/or 
perifollicular vascularisation. However, in the present study, exclusion criteria would 
have limited the impact of many of these potential confounders, which suggests that 
the proportion of immature oocytes retrieved truly reflects the impact of ovarian 
hyperstimulation protocols. 
 
To the best of the author’s knowledge, this is the first study to examine the FF collected 
from individual follicles during assisted conception which has considered nuclear 
maturity as an outcome measure, and discovered a difference between MII oocytes 
which do/don’t fertilise. These follicles used as part of this study appeared to have the 
features consistent with those yielding a mature oocyte, such as being of large size 
(>17mm diameter) and ample volume. The fact that many harboured an immature 
oocyte points to a dysregulation (likely anachronistic) of folliculogenesis and oocyte 
maturation, processes which are intricately linked in natural cycles. 
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4.5.2 FF cytokine composition 
FF cytokine composition varied according to oocyte maturity. In general terms, cytokine 
concentrations fell (with the exception of eotaxin, VEGF and IL-8) in parallel with 
increasing oocyte maturity. This was not due to a dilution effect as all samples were 
normalised to total protein levels and adjusted for peripheral blood contamination, and 
therefore represented a physiologically relevant dynamic change. Little is known about 
the role of eotaxin in the ovary, although the presence of its ovarian transcripts has 
been reported in the rat [998]. Eotaxin has been shown to rise sharply in ovarian 
tissues in response to the preovulatory LH surge in mice; this observation supports the 
present data where those oocytes which exhibited the highest level of nuclear maturity 
had the highest relative FF eotaxin concentration.  
 
Although low FF VEGF levels have been associated with improved maturational status 
at the point of oocyte recovery [948], the opposite relationship was found in the present 
study. The presence of VEGF is essential, however, as this cytokine positively 
correlates with perifollicular blood flow [949], which contributes to the creation of a 
favourable environment for oocyte maturation, as demonstrated by the fact that 
oocytes from well-vascularised follicles exhibit increased fertilisation and pregnancy 
rates [949-954], which would tie in better with the present findings. However, high 
VEGF levels can also contribute to pathological follicular developmental processes and 
correlate with reduced pregnancy rate [944]. This apparent discrepancy likely reflects 
the delicate balance required between having sufficient VEGF to induce adequate 
angiogenesis which keeps pace with follicular development, while excessively high 
levels may simply reflect an inadequate attempt at supporting this process in 
compromised/hypoxic follicles. The disparate angiogenic properties of the various 
VEGF isoforms (which are not typically resolved in most studies) likely further 
contribute to the lack of clarity in this picture [718]. This presents an opportunity for 
future study, particularly given that the ovarian stimulation regimes utilised in assisted 
conception reportedly alter VEGF production [706, 938, 960].  
 
The present observation that FF IL-8 levels increase with oocyte maturity is supported 
in the literature only in relation to follicle size. IL-8 concentrations increase with follicle 
size, promoting the recruitment of the leukocytes required to mediate ovulation [2, 681, 
824]. IL-8 has been shown to be stimulated by VEGF in bovine theca cells, promoting 
angiogenesis and improving perifollicular blood flow, and the previously discussed rise 
in VEGF may thus account for the observed concomitant increase in IL-8 [782, 783]. 
Interestingly, rat models have shown that IL-8 may act as an angiogenic factor during 
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late folliculogenesis [778-781]. In this regard, IL-8 was only represented within the GV 
network and not within those of more mature categories. Moreover, IL-8 did not share a 
community with VEGF. Other pro-angiogenic cytokines include bFGF and TNF-α, 
which were orphaned from all networks. This may point to a degree of functional 
redundancy within the system, in that other cytokines may also participate in 
supporting/regulating angiogenesis. In the present data, RANTES (present in all 
networks) may offer this redundancy, as this cytokine exhibits pro-angiogenic 
properties in pathological scenarios such as atherosclerosis [999]. 
 
4.5.3 Cytokine profile differences between maturity states 
The greatest differences in cytokine profiles were seen between the most mature 
oocytes (MII) and the other maturity stages, which supports the notion that cytokines 
are intricately involved in coordinating oocyte maturation. What was most surprising 
was the striking difference between MII-F and MII-NF oocytes. These oocytes had 
reached nuclear maturity and were morphologically identical, yet they were 
distinguished by their FF cytokine profiles as demonstrated by profile plots and PCA. 
This could be due to a lack of cytoplasmic maturity, since nuclear and cytoplasmic 
aspects of maturation are considered to be asynchronous in stimulated cycles, with 
oocytes acquiring the ability to fertilise throughout the MII arrest phase [1000]. Although 
not formally assessed for cytoplasmic maturity, the operator selecting oocytes for the 
ICSI procedure made a visual check of the cytoplasm (for ‘graininess’ and irregularity, 
presence of vacuoles and refractile bodies) and upon mechanical stripping ensured 
that cumulus cells were not compact and stripped away easily, suggesting that these 
MII oocytes were all competent for fertilisation. However, the ‘progressive’ nature of the 
changes in cytokine profiles suggests that perhaps these MII oocytes were not fully 
competent at the time of ICSI, such that cytokines may present a useful point-of-care 
biomarker-based assay to aid embryologists in selecting which oocytes most likely to 
fertilise should undergo ICSI first (since the process is reasonably labour-intensive and 
exposes denuded oocytes to in vitro-related insults, rapid handling of those oocytes 
most likely to fertilise would likely improve cycle outcome). An alternative hypothesis is, 
of course, that MII-NF oocytes may never reach a stage where fertilisation is possible; 
i.e. that their fate has already been predicated earlier in their maturation/development. 
 
Figure 4-25 displays the potential routes open to an oocyte in terms of maturation. 
Scenario 1 is a linear progression from GV to MII-F, a process which is accepted in 
present IVF circles and forms the basis of in vitro maturation (IVM) of immature oocytes 
[1001]. However, IVM remains a very inefficient process, with few oocytes fertilising 
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and implanting to produce a viable pregnancy which has been postulated to be caused 
by the lack of support from the follicular environment to maintain adequate nuclear and 
cytoplasmic maturation [1002]. However, these low success rates could also be 
explained by the fact that some oocytes may never be destined to become competent 
following COH (either through a flaw in development or through an inherent inability to 
complete nuclear/cytoplasmic maturation). Scenario 2 proposes instead that 
development progresses normally to the MI phase, but experiences a divergence at 
this point to create MII-F and MII-NF oocytes. The implications of this being are that 
those oocytes which progress down the MII-NF route at this stage would not be able 
gain the ability to fertilise (and would therefore not benefit from IVM). Indeed, IVM of 
human oocytes is still considered to be experimental due to the low fertilisation rates 
[1003, 1004]. Finally, Scenario 3 takes the divergence back even further, in that an 
oocyte’s fertilisation potential may be decided upon at the GV stage. This is highly 
speculative, and would require extensive research to elucidate which pathway (or 
pathways) are most likely to be involved. 
 
 
 
Figure 4-25: Hypothetical oocyte maturation pathways. 
 
4.5.4 Advantages of the variational Bayesian approach  
Within the lactation data set presented in Chapter 3, Bayesian networks were 
constructed using a prior network generated using TabuSearch in order to bias the 
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heuristic search/optimisation algorithm. These were structurally robust and enabled the 
exploration of cytokine interactions within the networks themselves. However, further 
scientific advances since completing that work revealed that other experimental 
approaches may provide a more accurate approximation of the underlying networks. 
The VBSSM approach used in Chapter 3 was based on data only. However, a method 
of combining a VBSSM network with prior knowledge was developed in conjunction 
with Dr Tathagata Dasgupta (University of Harvard), based upon an extension of the 
work developed by Dr Matthew J. Beal [486]. This approach offered several 
advantages over the previous Bayesian approach, chief amongst which that VBSSM 
takes into consideration ‘hidden factors’ whereas the previous Bayesian approach did 
not. In any network, there is the potential that various unmeasured factors could 
influence the connections between the measured nodes, given that it is experimentally 
difficult to measure every conceivable factor in any one system. The search algorithm 
used in this Chapter took into account these ‘hidden’ nodes, and presented a network 
which represented their influence but compressed it into a known network of those 
measured factors. The addition of a prior network to VBSSM network learning is wholly 
novel, and served to refine the network to give a very strong approximation of the true 
network. This approach does have limitations, in that VBSSM networks generally only 
indicate the structure of the network i.e. the direction of the relationships between 
nodes and the structure of the communities or subnetworks. This novel method is now 
being modified to include node-specific conditional probabilities with a view to initiating 
in silico network challenges to reveal more about the nature of cytokine interactions.  
 
4.5.5 Cytokine networks within FF containing immature oocytes 
The networks discovered by the present study were conserved across all of the stages 
of maturation, with some communities retaining consistent membership. This 
suggested that there may be core cytokine interactions which are preserved and tightly 
regulated within the ovarian follicle, in much the same manner as conserved systemic 
networks were identified in murine lactation. For example, the present study 
demonstrated that IL-13, along with IL-1ra, IL-6 and IL-7, did not vary significantly 
across FF from different maturity states. However, elevated IL-13 concentrations in FF 
have been shown to correlate with poor pregnancy rates [978], while increased IL-6 
and IL-13, and decreased IL-7 are indicative of PCOS [1005-1007]. Therefore, it is 
perhaps not surprising that this group of cytokines should be under tight regulation and 
vary little between follicles in women without a tendency towards the PCOS spectrum. 
Indeed, IL-13 could be considered as a parent node across all networks, and 
demonstrated connections within a community with IL-1ra, IL-6 and IL-7.  
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Other examples of cytokines preserved in communities across all networks were IL-9, 
VEGF and SCF. SCF has been shown to be critical to various stages of murine oocyte 
development, with recognised associations with normal nuclear maturation and the 
promotion of polar body extrusion [754, 885]. As described earlier, VEGF plays a 
central role in folliculogenesis too such that it is not an unexpected finding that these 
two cytokines should be preserved across networks. Data remain scarce regarding the 
role played by IL-9 in folliculogenesis, although this mediator is known to promote cell 
proliferation and repress apoptosis such that it may be involved in follicular growth 
[1008]. 
 
TRAIL was featured in all networks as a terminal node, and was the only cytokine to be 
present in all cytokine sets when classifying oocytes into their maturation state. TRAIL 
and its pro- and anti-apoptotic receptors are expressed in GCs where they may 
regulate apoptosis and follicular atresia [770], as highlighted by porcine studies[1009]. 
This particular cytokine is known to induce apoptosis (specifically in tumour cells) via 
the death receptors DR4 and DR5 [1010-1012], although very little is known about its 
physiological role. However, GC resistance to TRAIL has been shown to be a major 
factor in GC ovarian cancer, where the regulation of apoptosis is dysregulated, 
resulting in unchecked proliferation [1013, 1014]. Therefore, it would be anticipated that 
this cytokine should be tightly regulated across all stages of follicular development in 
COH (indeed, the risk of developing ovarian cancer following COH is low according to 
a recent Cochrane review) [1015]. The terminal node status afforded to TRAIL in the 
networks herein suggests that it is an ‘endpoint’ to a communicative process. As with 
the networks generated in Chapter 3, these networks preclude the display of feedback 
loops which may exist within the signalling pathways. Therefore, two possibilities exist, 
TRAIL could either be the culmination of the signalling process and provide the ultimate 
regulatory node of follicle growth/atresia, or it could be an artefact of the network 
assembly. Although the latter is a possibility, evidence from the statistical-based 
modelling approach which aimed to correctly classify oocyte maturity status based on 
cytokine profiles also highlighted TRAIL as a significant component present in all 
cytokine groupings. Thus, this is the first study to demonstrate that TRAIL 
concentrations are raised in follicles containing immature oocytes or those which have 
attained nuclear maturity but have a low fertilisation potential. This suggests that raised 
FF TRAIL concentrations in Graafian follicles during COH could indicate a follicle which 
may otherwise have been destined for atresia and thus contains an oocyte with 
reduced viability.  
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Many other cytokines, such as IL-10 (a hub in all networks), RANTES (in a community 
with IL-15 and MCP-1), IL-2ra (connected to IL-18) and IP-10 were conserved across 
the networks. However, the roles of these FF cytokines have yet to be elucidated in 
their present context. Their conserved nature across the present networks suggests 
that these agents should be the focus of future study. There were also several 
cytokines which were orphaned from all of the networks (CTACK, eotaxin, bFGF, G-
CSF, GRO-α, IL-16, M-CSF, β-NGF, PDGF, SCGF-β, SDF-1α, TNF-α and TNF-β) 
which was perhaps surprising given that a number of these showed a statistical trend 
to differentiating between oocyte maturity status (CTACK, eotaxin, G-CSF, GRO-α, IL-
16, M-CSF, β-NGF and SDF-1α). However, as has been noted in many scientific 
studies, correlation does not always imply causation [1016] such that drawing 
conclusions from basic statistical inferences can be misleading. This is one particular 
advantage of using causal networks based on prior information which can ‘filter out’ 
those nodes which may essentially be ‘noise’ in the system [490, 1017]. 
 
For each maturation stage, the networks revealed novel relationships between 
cytokines. The GV network was the most complex, perhaps reflecting the efforts of the 
follicle to stimulate maturation in an unresponsive oocyte, or indicating that follicular 
atresia is at an advanced stage. PCA analysis identified GM-CSF and IL-6 as cytokines 
which are responsible for much of the variance within the data, despite the fact that 
both of these cytokines did not differ significantly across maturity levels. In fact, GM-
CSF is orphaned from all of the networks presented, and this discrepancy could be 
explained as an artefact of the PCA analysis. PCA is an unsupervised pattern 
recognition technique which reduces large datasets into a small number of PCs, which 
in turn represent the variation in the data [1018]. In general, PCA reduces ‘noisy’ data 
into components which filter out that noise and highlight important factors [1019], 
although it does have its limitations. If the variables are not correlated in the first 
instance, then PCA simply ranks variables according to their variance rather than their 
relative importance to other variables. PCA is also very sensitive to scale and 
normalisation, such that the correct preparation of the data is paramount to the 
outcome. It also does not offer the advantage of taking into account prior knowledge, 
thus ranking the influence of variables according to known relationships. Despite this, 
there was a certain level of agreement between PCA and network analysis for each 
stage of maturation. At the GV stage, some of the most influential variables highlighted 
by PCA were also represented in the network (IL-6, IL-10 and IP-10). Although IL-6 is 
known to influence oocyte quality at the later stages (MII and cumulus expansion) 
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[819], information as to its role in early oocyte maturation is lacking. IL-6 is both anti-
inflammatory and anti-apoptotic [1020], so its importance in follicles containing a GV 
oocyte following COH could reflect a rescue mechanism whereby a follicle which would 
normally have become atretic is saved by exogenous hormones. Indeed, IL-6 has been 
shown to be induced in pre-ovulatory follicles in response to gonadotrophins [799]. 
Similarly, little is known about the role of IP-10 in folliculogenesis, although it featured 
in all networks and always with an outgoing edge to VEGF. The relationship between 
IP-10 and VEGF is inhibitory, in that IP-10 is anti-angiogenic [1021-1023], and could 
indicate that angiogenesis is under tight regulatory control. In the present networks, IP-
10 is featured as a parent node at all maturity stages except MII-F, possibly reflecting a 
release on the control on angiogenesis in follicles which contain oocyte with the highest 
potential to fertilise. 
 
At the MI stage, both MIF and TRAIL were highlighted as being important in explaining 
the variance in PCA, and featured prominently within the network. MIF mediates the 
primary to antral follicle transition via stimulation of GC and TC proliferation, such that it 
is unsurprising that this cytokine should be prominent at the MI stage [733]. The 
implications of this cytokine differentiating between immature and MII-F oocytes are 
discussed below. 
 
4.5.6 Differentiation between MII-NF and MII-NF oocytes 
Of particular interest were the network cytokines which differentiated MII-NF and MII-F 
oocytes. LIF and MIF were only present in the MII-NF network, while IFN-α2, IL-3, IL-
12 (p40), IL-12 (p70), MCP-3 and MIG were present in the MII-F network. LIF, 
highlighted by both PCA and network analyses, is known to promote the primordial to 
primary follicle transition in the mouse [660, 666], and appears to modulate cumulus 
expansion in both humans and mice [904]. Previous studies have shown that LIF is 
present at much higher concentrations in preovulatory follicles compared to immature 
follicles [906], which is supported by the present data (although the findings are not 
statistically significant). Although FF LIF levels have been linked with oocyte quality 
and subsequent implantation potential in humans [907], this correlation remains 
inconsistent across studies [908, 909], and is not supported by the present networks. 
MIF is a cytokine which promotes GC proliferation and differentiation [1024, 1025], and 
is present in all networks except MII-F. Indeed, MIF was measured at higher 
concentrations in GV and MI follicles, although there was little difference between MII-
NF and MII-F stages. The presence of both of these cytokines in the MII-NF network 
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may suggest that these follicles containing less mature oocytes are still expending 
energy in order to reach ovulatory status in response to COH. 
 
The MII-F network was more complex and contained more components than its MII-NF 
counterpart. The presence of IFN-α2, IL-3, IL-12 (p40), IL-12 (p70), MCP-3 and MIG in 
the MII-F network indicated that additional relationships were at play. Interestingly, IL-3, 
IL-12 (p70), MCP-1 and MIG also featured in the cytokine selection classification model 
as part of the pairs and triplets of cytokines giving the highest CCR. Total IL-12 has 
previously been shown to correlate with successful oocyte fertilisation and subsequent 
embryo development [985], making the presence of IL-12 (p70) in the MII-F (but not 
MII-NF) network an interesting observation. IL-12 forms two proteins, IL-12 (p40) which 
is the monomeric/homodimeric protein product of the IL-12B gene, and IL-12 (p70) 
which is the heterodimeric protein formed from the combination of the IL-12A (p35) and 
IL-12B (p40) gene products. Only the p70 entire protein (highlighted in both the 
network analysis and PCA) has biological activity, while the p40 subunit appears to 
have an antagonistic effect on the p70 protein by blocking its receptor interactions. IL-
12 (p70) has a number of biological effects, but the most interesting in this context is its 
indirect anti-angiogenic role. This cytokine is known to induce IFN-γ which, in turn, 
induces IP-10 which is then responsible for mediating its anti-angiogenic effect [1026]. 
Although IL-12 (p70) and IP-10 are present in the MII-F network, they are not 
connected: IL-12 (p70) features as a terminal node. However, IP-10 is connected with 
VEGF in all networks, featuring as a parent node, except in the MII-F network. This 
could indicate that the angiogenic process in ongoing in follicles containing GV, MI and 
MII-NF oocytes, but complete in follicles containing MII-F oocytes. Unfortunately, the 
present networks do not reveal the nature of the interaction (e.g. if there is an 
antagonistic effect) which would enable evaluation of this hypothesis. Work is ongoing 
to develop the present modelling method further in order to discover the true nature of 
these interactions. 
 
4.5.7 Classification based on cytokine profiles 
Traditional methods of classification such as multinomial modelling, AIC and CCR 
revealed that FF cytokines can predict oocyte maturational status with a reasonable 
degree of accuracy, certainly above that expected by chance. When looking for small 
groups of cytokines which could predict this difference, the best classification rate was 
59% with a group of cytokines comprising IL-12 (p70), IL-18 and TRAIL. While IL-12 
(p70) and TRAIL have been discussed above, there is a paucity of information 
regarding the role played by IL-18 in the ovary. IL-18 has previously been found in FF 
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[981, 983], and a recent study has shown that together with IL-8 and MIP-1β, IL-18 
positively correlated with pregnancy outcome in IVF cycles [985]. These cytokines, 
alongside those highlighted by modified VBSSM network analysis, may serve as 
markers of cytoplasmic maturation, thereby adding to the toolkit of assays to identify 
the best oocytes. 
 
4.5.8 Study limitations and future directions 
The network approach used herein represents a very significant step forward in terms 
of understanding cytokine behaviour in ovarian follicles following COH. There are, 
however, a number of caveats. Firstly, although the present networks represent an 
efficient method of discovering the structure/topology of cytokine networks (whilst even 
including underlying ‘hidden’ nodes), it is not possible to determine the nature of these 
interactions. The next steps towards addressing this issue involves allocating 
conditional probabilities to each network node in the same manner as seen in Chapter 
3. In turn, this will enable a meaningful in silico manipulation of these various networks.  
 
Although the maturation networks were generated with a high level of confidence (as 
demonstrated by stringency testing), the possibility of further refining them in order to 
differentiate between background noise and truly important interactions remains. Much 
of the evidence presented in this Chapter has indicated that the relationships seen in 
the networks are likely to be biologically representative. Moreover, from a classification 
perspective, the identified differences between MII-F and MII-NF oocytes may well be 
definable by using a smaller number of cytokines. Although the classifier analysis 
achieved this with a degree of success, it is likely that a combination of the classifier 
and network approaches may improve prediction rates even further. In particular, 
within-network feature selection may be a method by which this can be achieved, and 
work is also ongoing to explore this option. The inclusion of other significant cytokines 
such as additional members of the TGF-β family may also further improve correct 
classification rates. Once such a classification system has been fully refined, specific 
FF cytokine signatures could be used to identify MII-NF and MII-F oocytes before ICSI. 
The drive for the implementation of such a prospective clinical trial rests with improving 
success rates and reducing wastage in the clinic. The reliable identification of the most 
viable oocytes for fertilisation and subsequent embryo transfer, and development of a 
fast, bedside test would be key to achieve that aim. 
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5. Conclusions 
 
Immune networks are active in a large number of reproductive processes, including the 
ovarian menstrual/oestrus cycle [6, 43], pregnancy [50-52], parturition [57, 58, 64], 
lactation [68, 76] and the menopause [84-86]. Within those immune networks, 
cytokines are key orchestrators of physiological processes ranging from cell 
proliferation and apoptosis [1027] to the communication between oocytes and their 
surrounding complement of somatic cells [586, 643, 1028-1030]. Although it is now 
recognised that cytokines function as networks, very few studies have taken an 
alternative approach to examining these interactions, preferring instead to attribute 
given physiological effects to the action of single or small groups of mediators. 
 
The original research hypothesis of this thesis was that cytokine-based immune 
networks underpin the processes in a number of reproductive physiological scenarios, 
and that the structure of those networks could be revealed, displayed and explored 
using both traditional and machine-learning data handing methodologies. In order to 
explore this in more detail, several physiological reproductive scenarios were 
employed, namely the response of the murine endometrium to seminal plasma, murine 
lactation and human oocyte maturation following COH. The aims and findings of each 
of these is briefly summarised below. 
 
5.1 Pathway analysis of the murine endometrial response to seminal plasma 
The aim of the studies contained in Chapter 2 was to characterise the 
inflammatory/immune-related pathways involved in the endometrial response to 
seminal plasma in the mouse by using traditional methods of pathway analysis. A 
number of pathways relevant to this context were found to be transiently activated 
within the endometrium for up to 4 days post coitum. Moreover, there was a degree of 
specificity in response noted across the endometrium’s epithelial and stromal 
compartments. The multiple curated pathways identified included: 
 
 Cytokines and Inflammatory Response pathway 
 Inflammatory Response Pathway 
 TGF-β Signalling Pathway 
 Prostaglandin Synthesis and Regulation 
 Matrix Metalloproteinases  
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 Macrophage Markers 
 Oxidative Stress  
 
The cluster analysis demonstrated that elements of each of these pathways behaved in 
similar and tightly coordinated manner, as highlighted by the results of the cluster 
analysis. The use of pathway analysis is an accepted methodology for handling large 
datasets, particularly microarray work, and in this instance this has been particularly 
successful in identifying previously unknown modulators of the endometrial response to 
seminal plasma.  
 
Although this approach offered the benefit of facilitating the identification of the broad 
areas of physiology/cell biology, curated pathways are by their very nature restrictive 
and, as such, preclude the discovery of novel interactions between individual mediators 
(since they operate on the basis of rigidly established and well-characterised 
interactions).  This led on to the next experimental Chapter wherein novel 
methodologies were developed in order to better characterise the specific interactions 
between different inflammatory network mediators. 
 
5.2 Bayesian methodology in cytokine network discovery 
The studies contained within Chapter 3 aimed to develop a novel approach of 
discovering, displaying and exploring mediator (specifically cytokine and 
peptide/steroid hormone) interactions in the in vivo setting. In order to address the 
inherent limitations highlighted in Chapter 2, a machine learning-based method for 
describing protein interaction networks was developed, applied and biologically 
validated in a physiological model of murine lactation. This Bayesian network-based 
method was highly successful in revealing previously unknown interactions between 
mediators, including their directionality, as well as in providing relative quantitative 
measures of their effects on downstream mediators. In turn, this enabled the 
characterisation of some of the more elusive features of cytokine biology. The networks 
generated were statistically very robust and attached a high level of confidence to the 
interactions they described. In brief, this approach enabled the identification of key 
cytokines (principal parents - IL-3, IL-12 (p40) and eotaxin; hubs - IFN-γ, IL-13, MCP-1, 
MIP-1α, MIP-1β and RANTES; terminal node – TNF-α) around which other cytokines 
assembled. Many of these relationships were conserved across physiological 
scenarios (i.e. even with pup removal) and were maintained even when prior 
knowledge was disregarded during network construction (i.e. using variational 
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Bayesian state space models). Bayesian networks offered the opportunity to 
numerically define the very nature of cytokine interactions through in silico perturbation 
of the networks generated. Relationships such as synergy (MCP-1 and IL-13), 
antagonism (PRL and IL-3) and functional redundancy (IL-4) were revealed, all of 
which would otherwise have remained in the domain of speculation if a reductionist 
approach alone had been applied. Perhaps the most surprising conclusion from this 
work was that PRL did not feature as a key node, despite the widely held belief that 
PRL is a critical immunomodulator, as highlighted by an array of in vitro studies . To the 
best of the author’s knowledge, this is the first instance of protein network modelling 
ever performed in a whole animal system in vivo.  
 
 
Comparisons between in vivo perturbation (i.e. preventing the establishment of 
lactation) and in silico perturbation of the cytokine network showed that the latter 
perturbation could accurately predict system responses in the former. Should this 
useful feature of Bayesian network analysis be widely conserved across 
pathophysiological settings has significant ramifications insofar as in silico network 
manipulation could be used for initial screening assessments of viable experiments 
prior to their empirical implementation. In the context of work involving in vivo models, 
this could significantly reduce the number of animals used, while in the in vitro setting 
this could streamline experimental plans and offer cost and labour-saving benefits. 
Despite these advantages, however, Bayesian network analytical methods had some 
lacunae. Firstly, the networks generated precluded the display of feedback loops and, 
secondly, the methodology did not account for ‘hidden’ Markov blankets. As such, a 
further, more refined machine-learning approach to cytokine network modelling was 
developed, which formed the core of Chapter 4.  
 
5.3 Cytokine networks in FF during COH 
In this Chapter, the targets were the ovarian follicular fluid cytokine networks and their 
relation to oocyte maturation in the assisted conception arena. This model was chosen 
as it offered a real-life compartmentalised in vivo study system wherein the results of 
this investigation may have a clinical impact. As such, the aims of Chapter 4 were to 
extend the methodology developed in Chapter 3 to discover, display and explore 
cytokine networks within human follicular fluid surrounding oocytes exposed to ovarian 
stimulation, as well as to develop classifier models to ascribe oocyte maturity and 
fertilisability status based solely on their follicular fluid cytokine profile. 
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In this final endeavour, machine learning-based network analysis was successfully 
adapted to include the influence of hidden Markov blankets and applied to determining 
the role played by inflammatory cytokine/growth factor networks in human oocyte 
maturation. The networks grouped cytokines into communities or subnetworks based 
on cytokines which demonstrate a stronger interaction – a significant advance from the 
methodology utilised in Chapter 3. The application of this methodology successfully 
revealed complex networks at each stage of oocyte maturation, with a strongly 
conserved cytokine community membership (IL-1ra, IL-2ra, IL-6, IL-7, IL-9, IL-10, IL-13, 
IL-15, IL-18, IP-10, MCP-1, RANTES, SCF, TRAIL and VEGF). Moreover, their 
interrelationships were strongly maintained such that it appeared that these mediators 
formed a tightly regulated core network within the ovarian follicle. However, there were 
significant divergences in network composition noted between follicles which contained 
MII-NF and MII-F oocytes. More specifically, LIF and MIF were present only in the MII-
NF network, while IFN-α2, IL-3, IL-12 (p40), IL-12 (p70), MCP-3 and MIG were present 
in the MII-F network, suggesting that the presence or absence of these cytokines from 
the final network structure had a bearing on oocyte maturity. This opens up new 
avenues of research into their specific roles in both cytoplasmic and nuclear 
maturation. 
 
 
5.4 Future directions 
The various facets of this thesis (semen-induced immunomodulation, hormone-
responsive inflammatory network regulation and cytokine/growth factor-dependent 
oocyte maturation) have highlighted the key role played by cytokines across a breadth 
of reproductive processes. Bayesian theory-based machine learning methodologies 
have very much been at the centre of this iterative process which has offered intuitive 
and biologically relevant insights into the complexity of immune network regulation. 
While this project has highlighted a sequential process in refining the first application of 
this methodology to in vivo acquired protein data, there remains much work in devising 
optimised ways for utilising these networks and their underlying algorithms to the best 
of their potential. Firstly, the methodology used in Chapter 4 requires expanding, to 
include ways of identifying the relationship between the nodes beyond that which is 
directional. An ideal network would represent the influence of all nodes, both measured 
and hidden, at any one snapshot in time. It would be flexible enough to manipulate in 
order to explore the effects of individual and groups of mediators on hypothetical and 
real physiological scenarios, with an emphasis on the pathophysiological changes 
underpinning disease. The accurate representation of feedback loops would be 
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essential to the structure of the network, informing new biologically relevant 
discoveries.  
 
Although the application of Bayesian network analysis to the datasets within this thesis 
involves considerably larger numbers of cytokines than seen in traditional reductionist 
studies, these remain modest in light of the hundreds involved in many biological 
processes in vivo interactions. Of particular note would be the involvement of cytokine 
cell-bound receptors, soluble receptors, and receptor antagonists. Although not 
included in the final draft of this thesis, work to characterise FF eicosanoid profiles was 
performed to understand the involvement of these non-protein inflammatory mediators 
in oocyte maturation. It would have potentially been very interesting to include these in 
the Bayesian network analysis in order to extend the spectrum of agents involved. 
Similarly, there are known interactions which take place between the metabolome and 
the proteome: for example, leptin influences the hypothalamo-pituitary-gonadal axis, 
stimulating GnRH and luteinising hormone (LH) production and providing a metabolic 
signal to the reproductive system [786, 787]. The networks generated in Chapter 4 
indicated communities which may be of use in analysing interactions between 
metabolic, immune and other molecules within the system, i.e. networking of networks. 
This may also improve correct classification rates, as it is likely that multiple factors 
influence oocyte maturation. Expanding this concept even further, interactions between 
the genome, transcriptome, proteome and metabolome, as well as an array of immune 
effector cell subtypes and patient demographics could be incorporated into these 
models with a high level of accuracy. It is only by making inroads into the development 
of such integrated, complex data modelling that we can hope to get a fuller and 
biologically more meaningful understanding of inflammatory networks and the various 
pathophysiologies they underpin. At the dawn of the Big Data era, machine learning-
based methodologies are increasingly become commonplace in the analytical steps 
supporting the new advances of tomorrow’s science. There is no need to establish a 
timeline for applying these developments to reproductive biology. That time is now. 
 
 
 
 
213 
 
 
6. References 
 
1. Best, C.L., et al., Localization and characterization of white blood cell 
populations within the human ovary throughout the menstrual cycle and 
menopause. Hum Reprod, 1996. 11(4): p. 790-7. 
2. Brannstrom, M. and A. Enskog, Leukocyte networks and ovulation. J Reprod 
Immunol, 2002. 57(1-2): p. 47-60. 
3. Chang, R.J., A. Gougeon, and G.F. Erickson, Evidence for a neutrophil-
interleukin-8 system in human folliculogenesis. Am J Obstet Gynecol, 1998. 
178(4): p. 650-7. 
4. Gouon-Evans, V., E.Y. Lin, and J.W. Pollard, Requirement of macrophages and 
eosinophils and their cytokines/chemokines for mammary gland development. 
Breast Cancer Res, 2002. 4(4): p. 155-64. 
5. Hunt, J.S. and S.A. Robertson, Uterine macrophages and environmental 
programming for pregnancy success. J Reprod Immunol, 1996. 32(1): p. 1-25. 
6. Abrams, E.T. and E.M. Miller, The roles of the immune system in women's 
reproduction: evolutionary constraints and life history trade-offs. Am J Phys 
Anthropol, 2011. 146 Suppl 53: p. 134-54. 
7. Robertson, S.A., et al., Cytokine-leukocyte networks and the establishment of 
pregnancy. Am J Reprod Immunol, 1997. 37(6): p. 438-42. 
8. Seamark, R.F., M. Hadjisavas, and S.A. Robertson, Influence of the immune 
system on reproductive function. Animal Reproduction Science, 1992. 28(1-4): 
p. 171-178. 
9. Muehlenbein, M.P., et al., Toward quantifying the usage costs of human 
immunity: Altered metabolic rates and hormone levels during acute immune 
activation in men. Am J Hum Biol, 2010. 22(4): p. 546-56. 
10. Baird, D.T. and A. Mitchell, Hormonal control of folliculogenesis: the key to 
successful reproduction. Ernst Schering Res Found Workshop, 2002(41): p. 1-
9. 
11. Berkholtz, C.B., L.D. Shea, and T.K. Woodruff, Extracellular matrix functions in 
follicle maturation. Semin Reprod Med, 2006. 24(4): p. 262-9. 
12. Drummond, A.E., The role of steroids in follicular growth. Reprod Biol 
Endocrinol, 2006. 4: p. 16. 
13. Field, S.L., et al., Cytokines in ovarian folliculogenesis, oocyte maturation and 
luteinisation. Mol Reprod Dev, 2013. 81(4): p. 284-314. 
214 
 
 
14. Fritz, M.A. and L. Speroff, The endocrinology of the menstrual cycle: the 
interaction of folliculogenesis and neuroendocrine mechanisms. Fertil Steril, 
1982. 38(5): p. 509-29. 
15. Chua, A.C., et al., Dual roles for macrophages in ovarian cycle-associated 
development and remodelling of the mammary gland epithelium. Development, 
2010. 137(24): p. 4229-38. 
16. Bukulmez, O. and A. Arici, Leukocytes in ovarian function. Hum Reprod 
Update, 2000. 6(1): p. 1-15. 
17. Espey, L.L., Ovulation as an Inflammatory Reaction--A Hypothesis. Biol 
Reprod, 1980. 22(1): p. 73-106. 
18. Richards, J.S., et al., Ovulation: new dimensions and new regulators of the 
inflammatory-like response. Annu Rev Physiol, 2002. 64: p. 69-92. 
19. Dahm-Kahler, P., et al., Monocyte chemotactic protein-1 (MCP-1), its receptor, 
and macrophages in the perifollicular stroma during the human ovulatory 
process. Fertil Steril, 2009. 91(1): p. 231-9. 
20. Johnson, M.L., et al., Tumor necrosis factor alpha regulates collagenolytic 
activity in preovulatory ovine follicles: relationship to cytokine secretion by the 
oocyte-cumulus cell complex. Biol Reprod, 1999. 61(6): p. 1581-5. 
21. Matousek, M., et al., Inhibition of ovulation in the rat by a leukotriene B(4) 
receptor antagonist. Mol Hum Reprod, 2001. 7(1): p. 35-42. 
22. Guerriero, S., S. Ajossa, and G.B. Melis, Luteal dynamics during the human 
menstrual cycle: new insight from imaging. Ultrasound Obstet Gynecol, 2005. 
25(5): p. 425-7. 
23. Milvae, R.A., S.T. Hinckley, and J.C. Carlson, Luteotropic and luteolytic 
mechanisms in the bovine corpus luteum. Theriogenology, 1996. 45(7): p. 
1327-49. 
24. Neuvians, T.P., et al., Involvement of pro-inflammatory cytokines, mediators of 
inflammation, and basic fibroblast growth factor in prostaglandin F2alpha-
induced luteolysis in bovine corpus luteum. Biol Reprod, 2004. 70(2): p. 473-80. 
25. Pate, J.L. and P. Landis Keyes, Immune cells in the corpus luteum: friends or 
foes? Reproduction, 2001. 122(5): p. 665-76. 
26. Nishimura, R. and K. Okuda, Hypoxia is important for establishing 
vascularization during corpus luteum formation in cattle. J Reprod Dev, 2010. 
56(1): p. 110-6. 
27. Antoniazzi, A.Q., et al., Endocrine delivery of interferon tau protects the corpus 
luteum from prostaglandin F2 alpha-induced luteolysis in ewes. Biol Reprod, 
2013. 88(6): p. 144. 
215 
 
 
28. Galvao, A.M., et al., Role of tumor necrosis factor-alpha, interferon-gamma and 
Fas-ligand on in vitro nitric oxide activity in the corpus luteum. Cytokine, 2013. 
64(1): p. 18-21. 
29. Miyamoto, A., et al., Impact of angiogenic and innate immune systems on the 
corpus luteum function during its formation and maintenance in ruminants. 
Reprod Biol, 2013. 13(4): p. 272-8. 
30. Galvao, A., et al., Cytokines tumor necrosis factor-alpha and interferon-gamma 
participate in modulation of the equine corpus luteum as autocrine and 
paracrine factors. J Reprod Immunol, 2012. 93(1): p. 28-37. 
31. Szostek, A.Z., et al., Tumor necrosis factor-alpha inhibits the stimulatory effect 
of luteinizing hormone and prostaglandin E(2) on progesterone secretion by the 
bovine corpus luteum. Domest Anim Endocrinol, 2011. 40(4): p. 183-91. 
32. Levy, C., et al., Estradiol and progesterone receptors in human endometrium: 
normal and abnormal menstrual cycles and early pregnancy. Am J Obstet 
Gynecol, 1980. 136(5): p. 646-51. 
33. Shah, D. and N. Nagarajan, Luteal insufficiency in first trimester. Indian J 
Endocrinol Metab, 2013. 17(1): p. 44-9. 
34. Siklosi, G., Luteal insufficiency as the primary cause of habitual abortion--its 
successful treatment. Acta Biomed Ateneo Parmense, 1992. 63(1-2): p. 101-11. 
35. Focchi, G.R., et al., Ultrastructural aspects of the remodeling process of the 
Corpus albicans in the recent postmenopausal period. Sao Paulo Med J, 1996. 
114(3): p. 1173-6. 
36. Katabuchi, H., et al., Distribution and fine structure of macrophages in the 
human ovary during the menstrual cycle, pregnancy and menopause. Endocr J, 
1997. 44(6): p. 785-95. 
37. Whitacre, C.C., S.C. Reingold, and P.A. O'Looney, A gender gap in 
autoimmunity. Science, 1999. 283(5406): p. 1277-8. 
38. Beagley, K.W. and C.M. Gockel, Regulation of innate and adaptive immunity by 
the female sex hormones oestradiol and progesterone. FEMS Immunol Med 
Microbiol, 2003. 38(1): p. 13-22. 
39. Robertson, S.A., et al., Peri-conceptual cytokines--setting the trajectory for 
embryo implantation, pregnancy and beyond. Am J Reprod Immunol, 2011. 66 
Suppl 1: p. 2-10. 
40. Gaide Chevronnay, H.P., et al., Regulation of matrix metalloproteinases activity 
studied in human endometrium as a paradigm of cyclic tissue breakdown and 
regeneration. Biochim Biophys Acta, 2012. 1824(1): p. 146-56. 
216 
 
 
41. Horne, A.W., J.O. White, and E.N. Lalani, The endometrium and embryo 
implantation. A receptive endometrium depends on more than hormonal 
influences. BMJ, 2000. 321(7272): p. 1301-2. 
42. Marbaix, E., et al., Menstrual breakdown of human endometrium can be 
mimicked in vitro and is selectively and reversibly blocked by inhibitors of matrix 
metalloproteinases. Proc Natl Acad Sci U S A, 1996. 93(17): p. 9120-5. 
43. Salamonsen, L.A. and L.J. Lathbury, Endometrial leukocytes and menstruation. 
Hum Reprod Update, 2000. 6(1): p. 16-27. 
44. Engelhardt, H., B.A. Croy, and G.J. King, Role of uterine immune cells in early 
pregnancy in pigs. J Reprod Fertil Suppl, 1997. 52: p. 115-31. 
45. Gangnuss, S., et al., Seminal plasma regulates corpora lutea macrophage 
populations during early pregnancy in mice. Biol Reprod, 2004. 71(4): p. 1135-
41. 
46. Johansson, M., et al., Semen activates the female immune response during 
early pregnancy in mice. Immunology, 2004. 112(2): p. 290-300. 
47. Moldenhauer, L.M., J.D. Hayball, and S.A. Robertson, Utilising T cell receptor 
transgenic mice to define mechanisms of maternal T cell tolerance in 
pregnancy. J Reprod Immunol, 2010. 87(1-2): p. 1-13. 
48. Moldenhauer, L.M., et al., GM-CSF is an essential regulator of T cell activation 
competence in uterine dendritic cells during early pregnancy in mice. J 
Immunol, 2010. 185(11): p. 7085-96. 
49. Robertson, S.A., et al., Activating T regulatory cells for tolerance in early 
pregnancy - the contribution of seminal fluid. J Reprod Immunol, 2009. 83(1-2): 
p. 109-16. 
50. Trowsdale, J. and A.G. Betz, Mother's little helpers: mechanisms of maternal-
fetal tolerance. Nat Immunol, 2006. 7(3): p. 241-6. 
51. Adams Waldorf, K.M. and J.L. Nelson, Autoimmune disease during pregnancy 
and the microchimerism legacy of pregnancy. Immunol Invest, 2008. 37(5): p. 
631-44. 
52. Khosrotehrani, K. and D.W. Bianchi, Multi-lineage potential of fetal cells in 
maternal tissue: a legacy in reverse. J Cell Sci, 2005. 118(Pt 8): p. 1559-63. 
53. Lissauer, D.M., et al., Fetal microchimerism: the cellular and immunological 
legacy of pregnancy. Expert Rev Mol Med, 2009. 11: p. e33. 
54. Aluvihare, V.R., M. Kallikourdis, and A.G. Betz, Regulatory T cells mediate 
maternal tolerance to the fetus. Nat Immunol, 2004. 5(3): p. 266-71. 
55. Mor, G. and I. Cardenas, The immune system in pregnancy: a unique 
complexity. Am J Reprod Immunol, 2010. 63(6): p. 425-33. 
217 
 
 
56. Roberts, C.W., W. Walker, and J. Alexander, Sex-associated hormones and 
immunity to protozoan parasites. Clin Microbiol Rev, 2001. 14(3): p. 476-88. 
57. Ness, R.B., The consequences for human reproduction of a robust 
inflammatory response. Q Rev Biol, 2004. 79(4): p. 383-93. 
58. Golightly, E., H.N. Jabbour, and J.E. Norman, Endocrine immune interactions in 
human parturition. Mol Cell Endocrinol, 2011. 335(1): p. 52-9. 
59. Condon, J.C., et al., Surfactant protein secreted by the maturing mouse fetal 
lung acts as a hormone that signals the initiation of parturition. Proc Natl Acad 
Sci U S A, 2004. 101(14): p. 4978-83. 
60. Lannon, S.M., et al., Synergy and Interactions Among Biological Pathways 
Leading to Preterm Premature Rupture of Membranes. Reprod Sci, 2014. 
61. Behrman, R.E. and A.S. Butler, eds. Preterm Birth: Causes, Consequences, 
and Prevention. 2007, National Academies Press: Washington DC. 
62. Whittle, W.L., et al., Glucocorticoid regulation of human and ovine parturition: 
the relationship between fetal hypothalamic-pituitary-adrenal axis activation and 
intrauterine prostaglandin production. Biol Reprod, 2001. 64(4): p. 1019-32. 
63. Gomez-Lopez, N., et al., Maternal circulating leukocytes display early 
chemotactic responsiveness during late gestation. BMC Pregnancy Childbirth, 
2013. 13 Suppl 1: p. S8. 
64. Gomez-Lopez, N., et al., Evidence for a role for the adaptive immune response 
in human term parturition. Am J Reprod Immunol, 2013. 69(3): p. 212-30. 
65. Shynlova, O., et al., Myometrial immune cells contribute to term parturition, 
preterm labour and post-partum involution in mice. J Cell Mol Med, 2013. 17(1): 
p. 90-102. 
66. Goldenberg, R.L., J.C. Hauth, and W.W. Andrews, Intrauterine infection and 
preterm delivery. N Engl J Med, 2000. 342(20): p. 1500-7. 
67. Goldberg, G.R., et al., Longitudinal assessment of the components of energy 
balance in well-nourished lactating women. Am J Clin Nutr, 1991. 54(5): p. 788-
98. 
68. Butte, N.F., W.W. Wong, and J.M. Hopkinson, Energy requirements of lactating 
women derived from doubly labeled water and milk energy output. J Nutr, 2001. 
131(1): p. 53-8. 
69. Jason, J.M., P. Nieburg, and J.S. Marks, Mortality and infectious disease 
associated with infant-feeding practices in developing countries. Pediatrics, 
1984. 74(4 Pt 2): p. 702-27. 
70. Popkin, B.M., et al., Breast-feeding and diarrheal morbidity. Pediatrics, 1990. 
86(6): p. 874-82. 
218 
 
 
71. Morrow, A.L. and J.M. Rangel, Human milk protection against infectious 
diarrhea: implications for prevention and clinical care. Semin Pediatr Infect Dis, 
2004. 15(4): p. 221-8. 
72. van Odijk, J., et al., Breastfeeding and allergic disease: a multidisciplinary 
review of the literature (1966-2001) on the mode of early feeding in infancy and 
its impact on later atopic manifestations. Allergy, 2003. 58(9): p. 833-43. 
73. Grabenhenrich, L.B., et al., Early-life determinants of asthma from birth to age 
20 years: A German birth cohort study. J Allergy Clin Immunol, 2014. 
74. Guibas, G.V., et al., Breastfeeding and wheeze prevalence in pre-schoolers and 
pre-adolescents: the Genesis and Healthy Growth studies. Pediatr Allergy 
Immunol, 2013. 24(8): p. 772-81. 
75. Fooladi, A.A., et al., Impact of altered early infant gut microbiota following 
breastfeeding and delivery mode on allergic diseases. Inflamm Allergy Drug 
Targets, 2013. 12(6): p. 410-8. 
76. Ouwehand, A., E. Isolauri, and S. Salminen, The role of the intestinal microflora 
for the development of the immune system in early childhood. Eur J Nutr, 2002. 
41 Suppl 1: p. I32-7. 
77. Jeppesen, D.L., et al., T-lymphocyte subsets, thymic size and breastfeeding in 
infancy. Pediatr Allergy Immunol, 2004. 15(2): p. 127-32. 
78. Ogra, S.S., D. Weintraub, and P.L. Ogra, Immunologic aspects of human 
colostrum and milk. III. Fate and absorption of cellular and soluble components 
in the gastrointestinal tract of the newborn. J Immunol, 1977. 119(1): p. 245-8. 
79. Gregory, K.E. and W.A. Walker, Immunologic Factors in Human Milk and 
Disease Prevention in the Preterm Infant. Curr Pediatr Rep, 2013. 1(4). 
80. Kainonen, E., S. Rautava, and E. Isolauri, Immunological programming by 
breast milk creates an anti-inflammatory cytokine milieu in breast-fed infants 
compared to formula-fed infants. Br J Nutr, 2013. 109(11): p. 1962-70. 
81. Fanaro, S., et al., Intestinal microflora in early infancy: composition and 
development. Acta Paediatr Suppl, 2003. 91(441): p. 48-55. 
82. Hasselbalch, H., et al., Decreased thymus size in formula-fed infants compared 
with breastfed infants. Acta Paediatr, 1996. 85(9): p. 1029-32. 
83. McNeilly, A.S., C.C. Tay, and A. Glasier, Physiological mechanisms underlying 
lactational amenorrhea. Ann N Y Acad Sci, 1994. 709: p. 145-55. 
84. Cramer, D.W., et al., Mumps, menarche, menopause, and ovarian cancer. Am J 
Obstet Gynecol, 1983. 147(1): p. 1-6. 
85. Dorman, J.S., et al., Menopause in type 1 diabetic women: is it premature? 
Diabetes, 2001. 50(8): p. 1857-62. 
219 
 
 
86. Hadjidakis, D.J., et al., Diabetes and premature menopause: is their co-
existence detrimental to the skeleton? Eur J Endocrinol, 2005. 152(3): p. 437-
42. 
87. Pikwer, M., et al., Early menopause is an independent predictor of rheumatoid 
arthritis. Ann Rheum Dis, 2012. 71(3): p. 378-81. 
88. Pikwer, M., et al., Early menopause and severity of rheumatoid arthritis in 
women older than 45 years. Arthritis Res Ther, 2012. 14(4): p. R190. 
89. Ghosh, M., M. Rodriguez-Garcia, and C.R. Wira, The immune system in 
menopause: Pros and cons of hormone therapy. J Steroid Biochem Mol Biol, 
2013. 142: p. 171-5. 
90. Jang, M.H., J.Y. Seoh, and M. Miyasaka, Cytokines, chemokines, and their 
receptors: targets for immunomodulation. Conference report: International 
Cytokine Society Conference 2005. J Leukoc Biol, 2006. 80(2): p. 217-9. 
91. Orsi, N.M., Cytokine networks in the establishment and maintenance of 
pregnancy. Hum Fertil (Camb), 2008. 11(4): p. 222-30. 
92. Orsi, N.M. and R.M. Tribe, Cytokine networks and the regulation of uterine 
function in pregnancy and parturition. J Neuroendocrinol, 2008. 20(4): p. 462-9. 
93. Crivellato, E., The role of angiogenic growth factors in organogenesis. Int J Dev 
Biol, 2011. 55(4-5): p. 365-75. 
94. Kopf, M., et al., Averting inflammation by targeting the cytokine environment. 
Nat Rev Drug Discov, 2010. 9(9): p. 703-18. 
95. Lopez-Pedrera, C., et al., Cardiovascular risk in systemic autoimmune 
diseases: epigenetic mechanisms of immune regulatory functions. Clin Dev 
Immunol, 2012. 2012: p. 9746–9748. 
96. Ma, S. and C.C. Ma, Recent development in pleiotropic effects of statins on 
cardiovascular disease through regulation of transforming growth factor-beta 
superfamily. Cytokine Growth Factor Rev, 2011. 22(3): p. 167-75. 
97. Nowsheen, S., et al., Molecular markers for cancer prognosis and treatment: 
have we struck gold? Cancer Lett, 2011. 327(1): p. 142-152. 
98. Modugno, F., et al., Inflammation and endometrial cancer: a hypothesis. Cancer 
Epidemiol Biomarkers Prev, 2005. 14(12): p. 2840-7. 
99. Oertelt-Prigione, S., The influence of sex and gender on the immune response. 
Autoimmun Rev, 2012. 11(6-7): p. A479-85. 
100. Remmers, N., et al., Molecular pathology of early pancreatic cancer. Cancer 
Biomark, 2011. 9(1-6): p. 421-40. 
101. Orsi, N.M., et al., Murine serum cytokines throughout the estrous cycle, 
pregnancy and post partum period. Anim Reprod Sci, 2006. 96(1-2): p. 54-65. 
220 
 
 
102. Rostene, W., et al., Neurochemokines: a menage a trois providing new insights 
on the functions of chemokines in the central nervous system. J Neurochem, 
2011. 118(5): p. 680-94. 
103. Pangas, S.A., Growth factors in ovarian development. Semin Reprod Med, 
2007. 25(4): p. 225-34. 
104. Knight, P.G. and C. Glister, TGF-beta superfamily members and ovarian follicle 
development. Reproduction, 2006. 132(2): p. 191-206. 
105. Arsenescu, R., V. Arsenescu, and W.J. de Villiers, TNF-alpha and the 
development of the neonatal immune system: implications for inhibitor use in 
pregnancy. Am J Gastroenterol, 2011. 106(4): p. 559-62. 
106. Forbes, K. and M. Westwood, Maternal growth factor regulation of human 
placental development and fetal growth. J Endocrinol, 2010. 207(1): p. 1-16. 
107. Witkin, S.S., et al., Unique alterations in infection-induced immune activation 
during pregnancy. BJOG, 2011. 118(2): p. 145-53. 
108. Olson, D.M., The role of prostaglandins in the initiation of parturition. Best Pract 
Res Clin Obstet Gynaecol, 2003. 17(5): p. 717-30. 
109. Kniss, D.A., et al., Interleukin-1 receptor antagonist blocks interleukin-1-induced 
expression of cyclooxygenase-2 in endometrium. Am J Obstet Gynecol, 1997. 
177(3): p. 559-67. 
110. Molnar, M., R. Romero, and F. Hertelendy, Interleukin-1 and tumor necrosis 
factor stimulate arachidonic acid release and phospholipid metabolism in 
human myometrial cells. Am J Obstet Gynecol, 1993. 169(4): p. 825-9. 
111. Hirsch, E., Y. Filipovich, and M. Mahendroo, Signaling via the type I IL-1 and 
TNF receptors is necessary for bacterially induced preterm labor in a murine 
model. Am J Obstet Gynecol, 2006. 194(5): p. 1334-40. 
112. Parks, W.C., C.L. Wilson, and Y.S. Lopez-Boado, Matrix metalloproteinases as 
modulators of inflammation and innate immunity. Nat Rev Immunol, 2004. 4(8): 
p. 617-29. 
113. McQuibban, G.A., et al., Inflammation dampened by gelatinase A cleavage of 
monocyte chemoattractant protein-3. Science, 2000. 289(5482): p. 1202-6. 
114. McQuibban, G.A., et al., Matrix metalloproteinase processing of monocyte 
chemoattractant proteins generates CC chemokine receptor antagonists with 
anti-inflammatory properties in vivo. Blood, 2002. 100(4): p. 1160-7. 
115. Shull, M.M., et al., Targeted disruption of the mouse transforming growth factor-
beta 1 gene results in multifocal inflammatory disease. Nature, 1992. 
359(6397): p. 693-9. 
221 
 
 
116. Schonbeck, U., F. Mach, and P. Libby, Generation of biologically active IL-1 
beta by matrix metalloproteinases: a novel caspase-1-independent pathway of 
IL-1 beta processing. J Immunol, 1998. 161(7): p. 3340-6. 
117. Ledger, W.L., et al., The costs to the NHS of multiple births after IVF treatment 
in the UK. BJOG, 2006. 113(1): p. 21-5. 
118. Reddy, U.M., et al., Infertility, assisted reproductive technology, and adverse 
pregnancy outcomes: executive summary of a National Institute of Child Health 
and Human Development workshop. Obstet Gynecol, 2007. 109(4): p. 967-77. 
119. MacKay, A.P., et al., Pregnancy-related mortality among women with multifetal 
pregnancies. Obstet Gynecol, 2006. 107(3): p. 563-8. 
120. Sutcliffe, A.G. and C. Derom, Follow-up of twins: health, behaviour, speech, 
language outcomes and implications for parents. Early Hum Dev, 2006. 82(6): 
p. 379-86. 
121. HFEA. Facts and Figures 2011/12 Fertility Problems and Treatment. 2012  
14/09/2014]; Available from: http://www.hfea.gov.uk/381.Html. 
122. Wilkes, S., et al., Epidemiology and management of infertility: a population-
based study in UK primary care. Fam Pract, 2009. 26(4): p. 269-74. 
123. Hull, M.G., et al., Population study of causes, treatment, and outcome of 
infertility. Br Med J (Clin Res Ed), 1985. 291(6510): p. 1693-7. 
124. Philippov, O.S., et al., Estimation of the prevalence and causes of infertility in 
western Siberia. Bull World Health Organ, 1998. 76(2): p. 183-7. 
125. Chiamchanya, C. and W. Su-angkawatin, Study of the causes and the results of 
treatment in infertile couples at Thammasat Hospital between 1999-2004. J 
Med Assoc Thai, 2008. 91(6): p. 805-12. 
126. Isaksson, R. and A. Tiitinen, Present concept of unexplained infertility. Gynecol 
Endocrinol, 2004. 18(5): p. 278-90. 
127. Templeton, A., C. Fraser, and B. Thompson, The epidemiology of infertility in 
Aberdeen. BMJ, 1990. 301(6744): p. 148-52. 
128. Sirmans, S.M. and K.A. Pate, Epidemiology, diagnosis, and management of 
polycystic ovary syndrome. Clin Epidemiol, 2013. 6: p. 1-13. 
129. Patrelli, T.S., et al., Can the impact of pelvic inflammatory disease on fertility be 
prevented? Epidemiology, clinical features and surgical treatment: evolution 
over 8 years. J Reprod Med, 2013. 58(9-10): p. 425-33. 
130. Holoch, K.J. and B.A. Lessey, Endometriosis and infertility. Clin Obstet 
Gynecol, 2010. 53(2): p. 429-38. 
131. Leyland, N., et al., Endometriosis: diagnosis and management. J Obstet 
Gynaecol Can, 2010. 32(7 Suppl 2): p. S1-32. 
222 
 
 
132. Sutcliffe, A.G., Health risks in babies born after assisted reproduction. BMJ, 
2002. 325(7356): p. 117-8. 
133. Kulkarni, A.D., et al., Fertility treatments and multiple births in the United States. 
N Engl J Med, 2013. 369(23): p. 2218-25. 
134. SOGC-CFAS, Guidelines for the number of embryos to transfer following in 
vitro fertilization No. 182, September 2006. Int J Gynaecol Obstet, 2008. 102(2): 
p. 203-16. 
135. Nargund, G., et al., The ISMAAR proposal on terminology for ovarian 
stimulation for IVF. Hum Reprod, 2007. 22(11): p. 2801-4. 
136. Aboulghar, M.A., et al., In vitro fertilization in a spontaneous cycle: a successful 
simple protocol. J Obstet Gynaecol (Tokyo 1995), 1995. 21(4): p. 337-40. 
137. Paulson, R.J., et al., In vitro fertilization in unstimulated cycles: the University of 
Southern California experience. Fertil Steril, 1992. 57(2): p. 290-3. 
138. Baart, E.B., N.S. Macklon, and B.J. Fauser, Ovarian stimulation and embryo 
quality. Reprod Biomed Online, 2009. 18 Suppl 2: p. 45-50. 
139. Baart, E.B., et al., Milder ovarian stimulation for in-vitro fertilization reduces 
aneuploidy in the human preimplantation embryo: a randomized controlled trial. 
Hum Reprod, 2007. 22(4): p. 980-8. 
140. Fauser, B.C., et al., Mild ovarian stimulation for IVF: 10 years later. Hum 
Reprod, 2010. 25(11): p. 2678-84. 
141. Verberg, M.F., et al., Mild ovarian stimulation for IVF. Hum Reprod Update, 
2009. 15(1): p. 13-29. 
142. de Mouzon, J., et al., Assisted reproductive technology in Europe, 2006: results 
generated from European registers by ESHRE. Hum Reprod, 2010. 25(8): p. 
1851-62. 
143. Boomsma, C.M., et al., Endometrial secretion analysis identifies a cytokine 
profile predictive of pregnancy in IVF. Hum Reprod, 2009. 24(6): p. 1427-35. 
144. Huisman, G.J., et al., Implantation rates after in vitro fertilization and transfer of 
a maximum of two embryos that have undergone three to five days of culture. 
Fertil Steril, 2000. 73(1): p. 117-22. 
145. Muasher, S.J., et al., Controlled preparation of the endometrium with 
exogenous steroids for the transfer of frozen-thawed pre-embryos in patients 
with anovulatory or irregular cycles. Hum Reprod, 1991. 6(3): p. 443-5. 
146. Lelaidier, C., et al., Controlled preparation of the endometrium with exogenous 
oestradiol and progesterone: a novel regimen not using a gonadotrophin-
releasing hormone agonist. Hum Reprod, 1992. 7(10): p. 1353-6. 
223 
 
 
147. Robertson, S.A., Seminal plasma and male factor signalling in the female 
reproductive tract. Cell and Tissue Research, 2005. 322(1): p. 43-52. 
148. Koot, Y.E., et al., Molecular aspects of implantation failure. Biochim Biophys 
Acta, 2012. 1822(12): p. 1943-50. 
149. Asimakopoulos, B., et al., Concentrations of inflammatory cytokines and the 
outcome in ICSI cycles. In Vivo, 2010. 24(4): p. 495-500. 
150. de Cassia, S.F.R., et al., Metaphase II human oocyte morphology: contributing 
factors and effects on fertilization potential and embryo developmental ability in 
ICSI cycles. Fertil Steril, 2010. 94(3): p. 1115-7. 
151. Ledee, N., et al., Cytokines and chemokines in follicular fluids and potential of 
the corresponding embryo: the role of granulocyte colony-stimulating factor. 
Hum Reprod, 2008. 23(9): p. 2001-9. 
152. Balkwill, F.R. and F. Burke, The cytokine network. Immunol Today, 1989. 10(9): 
p. 299-304. 
153. Gouwy, M., et al., Synergy in cytokine and chemokine networks amplifies the 
inflammatory response. Cytokine Growth Factor Rev, 2005. 16(6): p. 561-80. 
154. Kelso, A., Cytokines: principles and prospects. Immunol Cell Biol, 1998. 76(4): 
p. 300-17. 
155. Nip, M.M., et al., Autoantibodies and antisperm antibodies in sera and follicular 
fluids of infertile patients; relation to reproductive outcome after in-vitro 
fertilization. Hum Reprod, 1995. 10(10): p. 2564-9. 
156. Carroll, M., et al., Testing for hypersensitivity to seminal fluid-free spermatozoa. 
Hum Fertil (Camb), 2013. 16(2): p. 128-31. 
157. Sublett, J.W. and J.A. Bernstein, Seminal plasma hypersensitivity reactions: an 
updated review. Mt Sinai J Med, 2011. 78(5): p. 803-9. 
158. Tan, J. and J.A. Bernstein, Fertility and human seminal plasma (HSP) 
hypersensitivity. Ann Allergy Asthma Immunol, 2013. 111(2): p. 145-6. 
159. Carp, H.J., et al., Effect of paternal leukocyte immunization on implantation after 
biochemical pregnancies and repeated failure of embryo transfer. Am J Reprod 
Immunol, 1994. 31(2-3): p. 112-5. 
160. Elram, T., et al., Treatment of recurrent IVF failure and human leukocyte 
antigen similarity by intravenous immunoglobulin. Reprod Biomed Online, 2005. 
11(6): p. 745-9. 
161. Penn, D.J., The scent of genetic compatibility: sexual selection and the major 
histocompatiblity complex. Ethology, 2002. 801: p. 1-21. 
224 
 
 
162. Penn, D.J., K. Damjanovich, and W.K. Potts, MHC heterozygosity confers a 
selective advantage against multiple-strain infections. Proc Natl Acad Sci U S 
A, 2002. 99(17): p. 11260-4. 
163. Chaix, R., C. Cao, and P. Donnelly, Is mate choice in humans MHC-
dependent? PLoS Genet, 2008. 4(9): p. e1000184. 
164. Wedekind, C., et al., MHC-dependent mate preferences in humans. Proc Biol 
Sci, 1995. 260(1359): p. 245-9. 
165. Yamazaki, K. and G.K. Beauchamp, Genetic basis for MHC-dependent mate 
choice. Adv Genet, 2007. 59: p. 129-45. 
166. Shufaro, Y. and J.G. Schenker, Implantation Failure, Etiology, Diagnosis and 
Treatment. International Journal of Infertility & Fetal Medicine 2011. 2(1): p. 1-7. 
167. Mohlin, F.C., et al., Analysis of genes coding for CD46, CD55, and C4b-binding 
protein in patients with idiopathic, recurrent, spontaneous pregnancy loss. Eur J 
Immunol, 2013. 43(6): p. 1617-29. 
168. Wirstlein, P., M. Mikolajczyk, and J. Skrzypczak, Assessment of the 
transcription levels for the complement activation control system in eutopic 
endometrium in women with two or more consecutive miscarriages of unknown 
etiology. Folia Histochem Cytobiol, 2010. 48(3): p. 328-32. 
169. Foxman, B., et al., Mycoplasma, bacterial vaginosis-associated bacteria 
BVAB3, race, and risk of preterm birth in a high-risk cohort. Am J Obstet 
Gynecol, 2014. 210(3): p. 226 e1-7. 
170. Nelson, D.B., et al., Early pregnancy changes in bacterial vaginosis-associated 
bacteria and preterm delivery. Paediatr Perinat Epidemiol, 2014. 28(2): p. 88-
96. 
171. Oliver, R.S. and R.F. Lamont, Infection and antibiotics in the aetiology, 
prediction and prevention of preterm birth. J Obstet Gynaecol, 2013. 33(8): p. 
768-75. 
172. Urman, B., K. Yakin, and B. Balaban, Recurrent implantation failure in assisted 
reproduction: how to counsel and manage. A. General considerations and 
treatment options that may benefit the couple. Reprod Biomed Online, 2005. 
11(3): p. 371-81. 
173. Salamonsen, L.A., et al., Society for Reproductive Biology Founders' Lecture 
2009. Preparing fertile soil: the importance of endometrial receptivity. Reprod 
Fertil Dev, 2009. 21(7): p. 923-34. 
174. Robertson, S.A., et al., Seminal fluid and the generation of regulatory T cells for 
embryo implantation. Am J Reprod Immunol, 2013. 69(4): p. 315-30. 
225 
 
 
175. Allen, E., The oestrus cycle in the mouse. American Journal of Anatomy, 1922. 
30: p. 297-371. 
176. Caligioni, C.S., Assessing reproductive status/stages in mice. Curr Protoc 
Neurosci, 2009. Appendix 4: p. Appendix 4I. 
177. Champlin, A.K., D.L. Dorr, and A.H. Gates, Determining the stage of the estrous 
cycle in the mouse by the appearance of the vagina. Biol Reprod, 1973. 8(4): p. 
491-4. 
178. Evans, G.S., et al., Proliferative changes in the genital tissue of female mice 
during the oestrous cycle. Cell Tissue Kinet, 1990. 23(6): p. 619-35. 
179. Quarmby, V.E. and K.S. Korach, The influence of 17 beta-estradiol on patterns 
of cell division in the uterus. Endocrinology, 1984. 114(3): p. 694-702. 
180. McMaster, M.T., et al., Lactoferrin in the mouse uterus: analyses of the 
preimplantation period and regulation by ovarian steroids. Mol Endocrinol, 
1992. 6(1): p. 101-11. 
181. Zheng, Y., et al., Immunohistochemical characterization of the estrogen-
stimulated leukocyte influx in the immature rat uterus. J Leukoc Biol, 1988. 
44(1): p. 27-32. 
182. Tchernitchin, A., et al., Dramatic early increase in uterine eosinophils after 
oestrogen administration. Nature, 1974. 248(444): p. 142-3. 
183. Lee, Y.H., et al., Estrogen regulation of an eosinophil chemotactic factor in the 
immature rat uterus. Endocrinology, 1989. 125(6): p. 3022-8. 
184. Green, E.L., ed. Biology of the laboratory mouse. 2nd Ed ed. 1966, DOVER 
PUBLICATIONS, INC.: New York. 
185. Walmer, D.K., et al., Lactoferrin expression in the mouse reproductive tract 
during the natural estrous cycle: correlation with circulating estradiol and 
progesterone. Endocrinology, 1992. 131(3): p. 1458-66. 
186. Parkening, T.A., T.J. Collins, and E.R. Smith, Plasma and pituitary 
concentrations of LH, FSH, and prolactin in aging C57BL/6 mice at various 
times of the estrous cycle. Neurobiol Aging, 1982. 3(1): p. 31-5. 
187. Wood, G.A., et al., Circulating hormones and estrous stage predict cellular and 
stromal remodeling in murine uterus. Reproduction, 2007. 133(5): p. 1035-44. 
188. Grant, E.C. and J.H. Mackintosh, A comparison of the social postures of some 
common laboratory rodents. Behavior, 1963. 21: p. 246-259. 
189. McGill, T.E., Sexual behavior in three inbred strains of mice. Behaviour, 1962. 
19: p. 341-350. 
190. Parkes, A.S., Observations on the oestrous cycle of the albino mouse. 
Proceedings of the Royal Society of Biology 1926. 100: p. 151-170. 
226 
 
 
191. Robertson, S.A. Seminal fluid signaling in the female reproductive tract: 
Lessons from rodents and pigs. in 2006 ADSA/ASAS Joint Annual Meeting. 
2006. Minneapolis, MN: Amer Soc Animal Science. 
192. Rodriguez-Martinez, H., et al., Seminal plasma proteins: what role do they play? 
Am J Reprod Immunol, 2011. 66 Suppl 1: p. 11-22. 
193. Ramm, S.A. and P. Stockley, Ejaculate allocation under varying sperm 
competition risk in the house mouse, Mus musculus domesticus. Behavioural 
Ecology, 2007. 18(2): p. 491-495. 
194. Lundwall, A., et al., Chemical characterization of the predominant proteins 
secreted by mouse seminal vesicles. Eur J Biochem, 1997. 249(1): p. 39-44. 
195. Zhang, Y., et al., Prostaglandin E synthase is regulated in postnatal mouse 
testis. Front Biosci (Elite Ed), 2012. 4: p. 1071-80. 
196. Leblond, E., L. Desnoyers, and P. Manjunath, Phosphorylcholine-binding 
proteins from the seminal fluids of different species share antigenic 
determinants with the major proteins of bovine seminal plasma. Mol Reprod 
Dev, 1993. 34(4): p. 443-9. 
197. Tremellen, K.P., R.F. Seamark, and S.A. Robertson, Seminal transforming 
growth factor beta1 stimulates granulocyte-macrophage colony-stimulating 
factor production and inflammatory cell recruitment in the murine uterus. Biol 
Reprod, 1998. 58(5): p. 1217-25. 
198. Fujimoto, N., et al., Identification of prostatic-secreted proteins in mice by mass 
spectrometric analysis and evaluation of lobe-specific and androgen-dependent 
mRNA expression. J Endocrinol, 2006. 190(3): p. 793-803. 
199. Pang, S.F., P.H. Chow, and T.M. Wong, The role of the seminal vesicles, 
coagulating glands and prostate glands on the fertility and fecundity of mice. J 
Reprod Fertil, 1979. 56(1): p. 129-32. 
200. Beyler, S.A. and L.J.D. Zaneveld, The male accessory sex glands., in 
Biochemistry of mammalian reproduction, L.J.D. Zaneveld and R.T. Chatterton, 
Editors. 1982, John Wiley & Sons: New York, USA. p. 65-88. 
201. Druart, X., et al., Proteomic characterization and cross species comparison of 
mammalian seminal plasma. J Proteomics, 2013. 91C: p. 13-22. 
202. Kelly, V.C., et al., Characterization of bovine seminal plasma by proteomics. 
Proteomics, 2006. 6(21): p. 5826-33. 
203. Watson, J.G., J. Carroll, and S. Chaykin, Reproduction in mice: The fate of 
spermatozoa not involved in fertilization. Gamete Research, 1993. 7(1): p. 75-
84. 
227 
 
 
204. Bromfield, J.J., C.T. Roberts, and S.A. Robertson. Seminal plasma programs 
uterine receptivity and pregnancy outcome. in 37th Annual Meeting of the 
Society for the Study of Reproduction. 2004. Vancouver, Canada: Biology of 
Reproduction. 
205. Carp, H.J., et al., Influence of insemination on the implantation of transferred rat 
blastocysts. Gynecol Obstet Invest, 1984. 18(4): p. 194-8. 
206. Peitz, B. and P. Olds-Clarke, Effects of seminal vesicle removal on fertility and 
uterine sperm motility in the house mouse. Biol Reprod, 1986. 35(3): p. 608-17. 
207. Cukierski, M.A., et al., Effects of seminal vesicle and coagulating gland ablation 
on fertility in rats. Reprod Toxicol, 1991. 5(4): p. 347-52. 
208. Queen, K., C.B. Dhabuwala, and C.G. Pierrepoint, The effect of the removal of 
the various accessory sex glands on the fertility of male rats. J Reprod Fertil, 
1981. 62(2): p. 423-6. 
209. O, W.S., H.Q. Chen, and P.H. Chow, Effects of male accessory sex gland 
secretions on early embryonic development in the golden hamster. J Reprod 
Fertil, 1988. 84(1): p. 341-4. 
210. O'Leary, S., et al., Seminal plasma regulates endometrial cytokine expression, 
leukocyte recruitment and embryo development in the pig. Reproduction, 2004. 
128(2): p. 237-47. 
211. Sharkey, D.J., et al., Seminal fluid induces leukocyte recruitment and cytokine 
and chemokine mRNA expression in the human cervix after coitus. J Immunol, 
2012. 188(5): p. 2445-54. 
212. Sanford, T.R., M. De, and G.W. Wood, Expression of colony-stimulating factors 
and inflammatory cytokines in the uterus of CD1 mice during days 1 to 3 of 
pregnancy. J Reprod Fertil, 1992. 94(1): p. 213-20. 
213. Robertson, S.A., et al., Role of high molecular weight seminal vesicle proteins 
in eliciting the uterine inflammatory response to semen in mice. J Reprod Fertil, 
1996. 107(2): p. 265-77. 
214. Pandya, I.J. and J. Cohen, The leukocytic reaction of the human uterine cervix 
to spermatozoa. Fertil Steril, 1985. 43(3): p. 417-21. 
215. Taylor, N.J., Investigation of sperm-induced cervical leucocytosis by a double 
mating study in rabbits. J Reprod Fertil, 1982. 66(1): p. 157-60. 
216. McMaster, M.T., et al., Activation and distribution of inflammatory cells in the 
mouse uterus during the preimplantation period. J Immunol, 1992. 148(6): p. 
1699-705. 
228 
 
 
217. Lovell, J.W. and R. Getty, Fate of semen in the uterus of the sow: histologic 
study of endometrium during the 27 hours after natural service. Am J Vet Res, 
1968. 29(3): p. 609-25. 
218. Claus, R., Physiological role of seminal components in the reproductive tract of 
the female pig. J Reprod Fertil Suppl, 1990. 40: p. 117-31. 
219. Rozeboom, K.J., M.H. Troedsson, and B.G. Crabo, Characterization of uterine 
leukocyte infiltration in gilts after artificial insemination. J Reprod Fertil, 1998. 
114(2): p. 195-9. 
220. Robertson, S.A., Seminal fluid signaling in the female reproductive tract: 
lessons from rodents and pigs. J Anim Sci, 2007. 85(13 Suppl): p. E36-44. 
221. De, M., R. Choudhuri, and G.W. Wood, Determination of the number and 
distribution of macrophages, lymphocytes, and granulocytes in the mouse 
uterus from mating through implantation. J Leukoc Biol, 1991. 50(3): p. 252-62. 
222. Bischof, R.J., et al., Inflammatory response in the pig uterus induced by seminal 
plasma. J Reprod Immunol, 1994. 26(2): p. 131-46. 
223. Sharkey, D.J., et al., Seminal plasma differentially regulates inflammatory 
cytokine gene expression in human cervical and vaginal epithelial cells. Mol 
Hum Reprod, 2007. 13(7): p. 491-501. 
224. Moldenhauer, L.M., et al., Cross-presentation of male seminal fluid antigens 
elicits T cell activation to initiate the female immune response to pregnancy. J 
Immunol, 2009. 182(12): p. 8080-93. 
225. Robertson, S.A., et al., Seminal Fluid Drives Expansion of the CD4+CD25+ T 
Regulatory Cell Pool and Induces Tolerance to Paternal Alloantigens in Mice. 
Biol Reprod, 2009. 80(5): p. 1036-1045. 
226. Tafuri, A., et al., T cell awareness of paternal alloantigens during pregnancy. 
Science, 1995. 270(5236): p. 630-3. 
227. Shima, T., et al., Regulatory T cells are necessary for implantation and 
maintenance of early pregnancy but not late pregnancy in allogeneic mice. J 
Reprod Immunol, 2010. 85(2): p. 121-9. 
228. Politch, J.A., et al., Concentrations and significance of cytokines and other 
immunologic factors in semen of healthy fertile men. Hum Reprod, 2007. 
22(11): p. 2928-35. 
229. Chen, W., et al., Conversion of peripheral CD4+CD25- naive T cells to 
CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor 
Foxp3. J Exp Med, 2003. 198(12): p. 1875-86. 
229 
 
 
230. Baratelli, F., et al., Prostaglandin E2 induces FOXP3 gene expression and T 
regulatory cell function in human CD4+ T cells. J Immunol, 2005. 175(3): p. 
1483-90. 
231. Burgess, A.W. and D. Metcalf, The nature and action of granulocyte-
macrophage colony stimulating factors. Blood, 1980. 56(6): p. 947-58. 
232. Sheridan, J.W. and D. Metcalf, Studies on the bone marrow colony stimulating 
factor (CSF): relation of tissue CSF to serum CSF. J Cell Physiol, 1972. 80(1): 
p. 129-40. 
233. Kay, A.B., et al., Messenger RNA expression of the cytokine gene cluster, 
interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating 
factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J 
Exp Med, 1991. 173(3): p. 775-8. 
234. Williamson, D.J., et al., The detection and initial characterization of colony-
stimulating factors in synovial fluid. Clin Exp Immunol, 1988. 72(1): p. 67-73. 
235. Leizer, T., et al., Cytokine regulation of colony-stimulating factor production in 
cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF 
production by interleukin-1 and tumor necrosis factor. Blood, 1990. 76(10): p. 
1989-96. 
236. Hamilton, J.A., Rheumatoid arthritis: opposing actions of haemopoietic growth 
factors and slow-acting anti-rheumatic drugs. Lancet, 1993. 342(8870): p. 536-
9. 
237. Xing, Z., et al., Human upper airway structural cell-derived cytokines support 
human peripheral blood monocyte survival: a potential mechanism for 
monocyte/macrophage accumulation in the tissue. Am J Respir Cell Mol Biol, 
1992. 6(2): p. 212-8. 
238. Robertson, S.A., G. Mayrhofer, and R.F. Seamark, Uterine epithelial cells 
synthesize granulocyte-macrophage colony-stimulating factor and interleukin-6 
in pregnant and nonpregnant mice. Biol Reprod, 1992. 46(6): p. 1069-79. 
239. Zhao, Y. and N. Chegini, The expression of granulocyte macrophage-colony 
stimulating factor (GM-CSF) and receptors in human endometrium. Am J 
Reprod Immunol, 1999. 42(5): p. 303-11. 
240. Robertson, S.A., G. Mayrhofer, and R.F. Seamark, Ovarian steroid hormones 
regulate granulocyte-macrophage colony-stimulating factor synthesis by uterine 
epithelial cells in the mouse. Biology of Reproduction, 1996. 54(1): p. 183-196. 
241. Robertson, S.A. and R.F. Seamark, Granulocyte macrophage colony 
stimulating factor (GM-CSF) in the murine reproductive tract: stimulation by 
seminal factors. Reprod Fertil Dev, 1990. 2(4): p. 359-68. 
230 
 
 
242. Robertson, S.A., et al., Granulocyte-macrophage colony-stimulating factor (GM-
CSF) targets myeloid leukocytes in the uterus during the post-mating 
inflammatory response in mice. J Reprod Immunol, 2000. 46(2): p. 131-54. 
243. Robertson, S.A., et al., Granulocyte-macrophage colony-stimulating factor 
promotes glucose transport and blastomere viability in murine preimplantation 
embryos. Biol Reprod, 2001. 64(4): p. 1206-15. 
244. Higgins, D.M., et al., Relative levels of M-CSF and GM-CSF influence the 
specific generation of macrophage populations during infection with 
Mycobacterium tuberculosis. J Immunol, 2008. 180(7): p. 4892-900. 
245. Ozawa, H., et al., Granulocyte-macrophage colony-stimulating factor gene 
transfer to dendritic cells or epidermal cells augments their antigen-presenting 
function including induction of anti-tumor immunity. J Invest Dermatol, 1999. 
113(6): p. 999-1005. 
246. Larsen, C.P., et al., Regulation of immunostimulatory function and costimulatory 
molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol, 
1994. 152(11): p. 5208-19. 
247. Stumbles, P.A., et al., Resting respiratory tract dendritic cells preferentially 
stimulate T helper cell type 2 (Th2) responses and require obligatory cytokine 
signals for induction of Th1 immunity. J Exp Med, 1998. 188(11): p. 2019-31. 
248. Askelund, K., et al., CD83(+)dendritic cells in the decidua of women with 
recurrent miscarriage and normal pregnancy. Placenta, 2004. 25(2-3): p. 140-5. 
249. Scholz, C., et al., Distribution and maturity of dendritic cells in diseases of 
insufficient placentation. Am J Reprod Immunol, 2008. 60(3): p. 238-45. 
250. Pollard, J.W., et al., Apparent role of the macrophage growth factor, CSF-1, in 
placental development. Nature, 1987. 330(6147): p. 484-6. 
251. Wood, G.W., E.H. Hausmann, and K. Kanakaraj, Expression and regulation of 
chemokine genes in the mouse uterus during pregnancy. Cytokine, 1999. 
11(12): p. 1038-45. 
252. Wood, G.W., E. Hausmann, and R. Choudhuri, Relative role of CSF-1, MCP-
1/JE, and RANTES in macrophage recruitment during successful pregnancy. 
Mol Reprod Dev, 1997. 46(1): p. 62-9; discussion 69-70. 
253. Heinrich, P.C., et al., Principles of interleukin (IL)-6-type cytokine signalling and 
its regulation. Biochem J, 2003. 374(Pt 1): p. 1-20. 
254. Dillon, S.R., et al., Interleukin 31, a cytokine produced by activated T cells, 
induces dermatitis in mice. Nat Immunol, 2004. 5(7): p. 752-60. 
255. Zhang, Q., et al., Structures and biological functions of IL-31 and IL-31 
receptors. Cytokine Growth Factor Rev, 2008. 19(5-6): p. 347-56. 
231 
 
 
256. Jacobs, A.L., et al., Secretion and hormonal regulation of interleukin-6 
production by mouse uterine stromal and polarized epithelial cells cultured in 
vitro. Endocrinology, 1992. 131(3): p. 1037-46. 
257. Romano, M., et al., Role of IL-6 and its soluble receptor in induction of 
chemokines and leukocyte recruitment. Immunity, 1997. 6(3): p. 315-25. 
258. Bettelli, E., T. Korn, and V.K. Kuchroo, Th17: the third member of the effector T 
cell trilogy. Curr Opin Immunol, 2007. 19(6): p. 652-7. 
259. Bettelli, E., et al., Reciprocal developmental pathways for the generation of 
pathogenic effector TH17 and regulatory T cells. Nature, 2006. 441(7090): p. 
235-8. 
260. Yang, X.O., et al., Molecular antagonism and plasticity of regulatory and 
inflammatory T cell programs. Immunity, 2008. 29(1): p. 44-56. 
261. Sharkey, D.J., et al., TGF-beta mediates proinflammatory seminal fluid 
signaling in human cervical epithelial cells. J Immunol, 2012. 189(2): p. 1024-
35. 
262. Gutsche, S., et al., Seminal plasma induces mRNA expression of IL-1beta, IL-6 
and LIF in endometrial epithelial cells in vitro. Mol Hum Reprod, 2003. 9(12): p. 
785-91. 
263. Cheng, J.G., C.I. Rodriguez, and C.L. Stewart, Control of uterine receptivity and 
embryo implantation by steroid hormone regulation of LIF production and LIF 
receptor activity: towards a molecular understanding of "the window of 
implantation". Rev Endocr Metab Disord, 2002. 3(2): p. 119-26. 
264. Stewart, C.L., The role of leukemia inhibitory factor (LIF) and other cytokines in 
regulating implantation in mammals. Ann N Y Acad Sci, 1994. 734: p. 157-65. 
265. Sherwin, J.R., et al., Identification of genes regulated by leukemia-inhibitory 
factor in the mouse uterus at the time of implantation. Mol Endocrinol, 2004. 
18(9): p. 2185-95. 
266. Bhatt, H., L.J. Brunet, and C.L. Stewart, Uterine expression of leukemia 
inhibitory factor coincides with the onset of blastocyst implantation. Proc Natl 
Acad Sci U S A, 1991. 88(24): p. 11408-12. 
267. Chen, J.R., et al., Leukemia inhibitory factor can substitute for nidatory estrogen 
and is essential to inducing a receptive uterus for implantation but is not 
essential for subsequent embryogenesis. Endocrinology, 2000. 141(12): p. 
4365-72. 
268. Yang, Z.M., et al., Differential hormonal regulation of leukemia inhibitory factor 
(LIF) in rabbit and mouse uterus. Mol Reprod Dev, 1996. 43(4): p. 470-6. 
232 
 
 
269. Arici, A., et al., Interleukin-8 in the human endometrium. J Clin Endocrinol 
Metab, 1998. 83(5): p. 1783-7. 
270. Arici, A., et al., Interleukin-8 induces proliferation of endometrial stromal cells: a 
potential autocrine growth factor. J Clin Endocrinol Metab, 1998. 83(4): p. 1201-
5. 
271. Arici, A., Local cytokines in endometrial tissue: the role of interleukin-8 in the 
pathogenesis of endometriosis. Ann N Y Acad Sci, 2002. 955: p. 101-9; 
discussion 118, 396-406. 
272. Kayisli, U.A., N.G. Mahutte, and A. Arici, Uterine chemokines in reproductive 
physiology and pathology. Am J Reprod Immunol, 2002. 47(4): p. 213-21. 
273. Denison, F.C., et al., Seminal plasma components stimulate interleukin-8 and 
interleukin-10 release. Mol Hum Reprod, 1999. 5(3): p. 220-6. 
274. Arici, A., P.C. MacDonald, and M.L. Casey, Modulation of the levels of 
interleukin-8 messenger ribonucleic acid and interleukin-8 protein synthesis in 
human endometrial stromal cells by transforming growth factor-beta 1. J Clin 
Endocrinol Metab, 1996. 81(8): p. 3004-9. 
275. Modi, W.S. and T. Yoshimura, Isolation of novel GRO genes and a phylogenetic 
analysis of the CXC chemokine subfamily in mammals. Mol Biol Evol, 1999. 
16(2): p. 180-93. 
276. Watanabe, K., et al., Chemoattractants for neutrophils in lipopolysaccharide-
induced inflammatory exudate from rats are not interleukin-8 counterparts but 
gro-gene-product/melanoma-growth-stimulating-activity-related factors. Eur J 
Biochem, 1993. 214(1): p. 267-70. 
277. Meter, R.A., C.R. Wira, and J.V. Fahey, Secretion of monocyte chemotactic 
protein-1 by human uterine epithelium directs monocyte migration in culture. 
Fertil Steril, 2005. 84(1): p. 191-201. 
278. Deshmane, S.L., et al., Monocyte chemoattractant protein-1 (MCP-1): an 
overview. J Interferon Cytokine Res, 2009. 29(6): p. 313-26. 
279. Alam, R., et al., RANTES is a chemotactic and activating factor for human 
eosinophils. J Immunol, 1993. 150(8 Pt 1): p. 3442-8. 
280. Altman, G.B., et al., RANTES production by cultured primate endometrial 
epithelial cells. Am J Reprod Immunol, 1999. 42(3): p. 168-74. 
281. Arima, K., et al., Effects of lipopolysaccharide and cytokines on production of 
RANTES by cultured human endometrial stromal cells. Mol Hum Reprod, 2000. 
6(3): p. 246-51. 
233 
 
 
282. Bany, B.M., X. Zhang, and T.G. Kennedy, Effects of epidermal growth factor 
and interleukin-1alpha on plasminogen activator secretion and decidualization 
in rat endometrial stromal cells. Biol Reprod, 1998. 59(1): p. 131-5. 
283. Ushikubi, F., et al., Impaired febrile response in mice lacking the prostaglandin 
E receptor subtype EP3. Nature, 1998. 395(6699): p. 281-4. 
284. Bany, B.M. and T.G. Kennedy, Role of interleukin 1 in the regulation of 
cyclooxygenase gene expression in rat endometrial stromal cells. J Reprod 
Fertil, 1999. 115(1): p. 125-31. 
285. Lim, H., et al., Cyclo-oxygenase-2-derived prostacyclin mediates embryo 
implantation in the mouse via PPARdelta. Genes Dev, 1999. 13(12): p. 1561-
74. 
286. Coleman, R.A., W.L. Smith, and S. Narumiya, International Union of 
Pharmacology classification of prostanoid receptors: properties, distribution, 
and structure of the receptors and their subtypes. Pharmacol Rev, 1994. 46(2): 
p. 205-29. 
287. Wang, H., et al., Rescue of female infertility from the loss of cyclooxygenase-2 
by compensatory up-regulation of cyclooxygenase-1 is a function of genetic 
makeup. J Biol Chem, 2004. 279(11): p. 10649-58. 
288. Chakraborty, I., et al., Developmental expression of the cyclo-oxygenase-1 and 
cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their 
differential regulation by the blastocyst and ovarian steroids. J Mol Endocrinol, 
1996. 16(2): p. 107-22. 
289. Lim, H. and S.K. Dey, Prostaglandin E2 receptor subtype EP2 gene expression 
in the mouse uterus coincides with differentiation of the luminal epithelium for 
implantation. Endocrinology, 1997. 138(11): p. 4599-606. 
290. Reese, J., et al., COX-2 compensation in the uterus of COX-1 deficient mice 
during the pre-implantation period. Mol Cell Endocrinol, 1999. 150(1-2): p. 23-
31. 
291. Rees, M.C., et al., Immunohistochemical localisation of cyclooxygenase in the 
human uterus. Prostaglandins, 1982. 23(2): p. 207-14. 
292. Rees, M.C., et al., Endometrial and myometrial prostaglandin release during the 
menstrual cycle in relation to menstrual blood loss. J Clin Endocrinol Metab, 
1984. 58(5): p. 813-8. 
293. Jones, R.L., R.W. Kelly, and H.O. Critchley, Chemokine and cyclooxygenase-2 
expression in human endometrium coincides with leukocyte accumulation. Hum 
Reprod, 1997. 12(6): p. 1300-6. 
234 
 
 
294. Milne, S.A. and H.N. Jabbour, Prostaglandin (PG) F(2alpha) receptor 
expression and signaling in human endometrium: role of PGF(2alpha) in 
epithelial cell proliferation. J Clin Endocrinol Metab, 2003. 88(4): p. 1825-32. 
295. Milne, S.A., et al., Expression, localization, and signaling of PGE(2) and 
EP2/EP4 receptors in human nonpregnant endometrium across the menstrual 
cycle. J Clin Endocrinol Metab, 2001. 86(9): p. 4453-9. 
296. Lopes, F.L., et al., Transcriptional regulation of uterine vascular endothelial 
growth factor during early gestation in a carnivore model, Mustela vison. J Biol 
Chem, 2006. 281(34): p. 24602-11. 
297. Kaczmarek, M.M., et al., Assessment of VEGF-receptor system expression in 
the porcine endometrial stromal cells in response to insulin-like growth factor-I, 
relaxin, oxytocin and prostaglandin E2. Mol Cell Endocrinol, 2008. 291(1-2): p. 
33-41. 
298. Tasaki, Y., et al., Expression of VEGF and its receptors in the bovine 
endometrium throughout the estrous cycle: effects of VEGF on prostaglandin 
production in endometrial cells. J Reprod Dev, 2010. 56(2): p. 223-9. 
299. Lefevre, P.L. and B.D. Murphy, Differential gene expression in the uterus and 
blastocyst during the reactivation of embryo development in a model of delayed 
implantation. Methods Mol Biol, 2009. 550: p. 11-61. 
300. Murphy, B.D., Embryonic diapause: advances in understanding the enigma of 
seasonal delayed implantation. Reprod Domest Anim, 2012. 47 Suppl 6: p. 
121-4. 
301. Thom, M.D., D.D. Johnson, and D.W. MacDonald, The evolution and 
maintenance of delayed implantation in the mustelidae (mammalia: carnivora). 
Evolution, 2004. 58(1): p. 175-83. 
302. Kaczmarek, M.M., et al., Seminal plasma affects prostaglandin synthesis in the 
porcine oviduct. Theriogenology, 2010. 74(7): p. 1207-20. 
303. Kaczmarek, M.M., K. Krawczynski, and J. Filant, Seminal plasma affects 
prostaglandin synthesis and angiogenesis in the porcine uterus. Biol Reprod, 
2013. 88(3): p. 72. 
304. Christenson, L.K., et al., Luteal maintenance during early pregnancy in the pig: 
role for prostaglandin E2. Prostaglandins, 1994. 47(1): p. 61-75. 
305. Sales, K.J. and H.N. Jabbour, Cyclooxygenase enzymes and prostaglandins in 
pathology of the endometrium. Reproduction, 2003. 126(5): p. 559-67. 
306. Sales, K.J. and H.N. Jabbour, Cyclooxygenase enzymes and prostaglandins in 
reproductive tract physiology and pathology. Prostaglandins Other Lipid Mediat, 
2003. 71(3-4): p. 97-117. 
235 
 
 
307. Kennedy, T.G., C. Gillio-Meina, and S.H. Phang, Prostaglandins and the 
initiation of blastocyst implantation and decidualization. Reproduction, 2007. 
134(5): p. 635-43. 
308. Van Ly, D., et al., Prostaglandins but not leukotrienes alter extracellular matrix 
protein deposition and cytokine release in primary human airway smooth 
muscle cells and fibroblasts. Am J Physiol Lung Cell Mol Physiol, 2012. 303(3): 
p. L239-50. 
309. Weinreb, R.N., et al., Prostaglandins increase matrix metalloproteinase release 
from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci, 1997. 
38(13): p. 2772-80. 
310. Van Lint, P. and C. Libert, Chemokine and cytokine processing by matrix 
metalloproteinases and its effect on leukocyte migration and inflammation. J 
Leukoc Biol, 2007. 82(6): p. 1375-81. 
311. Mitsiades, N., et al., Matrix metalloproteinase-7-mediated cleavage of Fas 
ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer 
Res, 2001. 61(2): p. 577-81. 
312. Tang, M., et al., Lefty is expressed in mouse endometrium in estrous cycle and 
peri-implantation period. Hum Reprod, 2005. 20(4): p. 872-80. 
313. Ito, A., et al., Degradation of interleukin 1beta by matrix metalloproteinases. J 
Biol Chem, 1996. 271(25): p. 14657-60. 
314. Singer, C.F., et al., Local cytokines induce differential expression of matrix 
metalloproteinases but not their tissue inhibitors in human endometrial 
fibroblasts. Eur J Biochem, 1999. 259(1-2): p. 40-5. 
315. Haro, H., et al., Matrix metalloproteinase-7-dependent release of tumor necrosis 
factor-alpha in a model of herniated disc resorption. J Clin Invest, 2000. 105(2): 
p. 143-50. 
316. Aplin, J.D., Adhesion molecules in implantation. Rev Reprod, 1997. 2(2): p. 84-
93. 
317. Goetzl, E.J., M.J. Banda, and D. Leppert, Matrix metalloproteinases in 
immunity. J Immunol, 1996. 156(1): p. 1-4. 
318. Feng, J., J.F. Woessner, Jr., and C. Zhu, Matrilysin activity in the rat uterus 
during the oestrous cycle and implantation. J Reprod Fertil, 1998. 114(2): p. 
347-50. 
319. Das, S.K., et al., Expression of matrix metalloproteinases and tissue inhibitors 
of metalloproteinases in the mouse uterus during the peri-implantation period. 
Dev Genet, 1997. 21(1): p. 44-54. 
236 
 
 
320. Chegini, N., et al., Human uterine tissue throughout the menstrual cycle 
expresses transforming growth factor-beta 1 (TGF beta 1), TGF beta 2, TGF 
beta 3, and TGF beta type II receptor messenger ribonucleic acid and protein 
and contains [125I]TGF beta 1-binding sites. Endocrinology, 1994. 135(1): p. 
439-49. 
321. Tang, X.M., et al., Expression of transforming growth factor-beta (TGF beta) 
isoforms and TGF beta type II receptor messenger ribonucleic acid and protein, 
and the effect of TGF beta s on endometrial stromal cell growth and protein 
degradation in vitro. Endocrinology, 1994. 135(1): p. 450-9. 
322. Marshburn, P.B., A.M. Arici, and M.L. Casey, Expression of transforming growth 
factor-beta 1 messenger ribonucleic acid and the modulation of 
deoxyribonucleic acid synthesis by transforming growth factor-beta 1 in human 
endometrial cells. Am J Obstet Gynecol, 1994. 170(4): p. 1152-8. 
323. Gold, L.I., et al., Increased expression of transforming growth factor beta 
isoforms and basic fibroblast growth factor in complex hyperplasia and 
adenocarcinoma of the endometrium: evidence for paracrine and autocrine 
action. Cancer Res, 1994. 54(9): p. 2347-58. 
324. Chegini, N., L.I. Gold, and R.S. Williams, Localization of transforming growth 
factor beta isoforms TGF-beta 1, TGF-beta 2, and TGF-beta 3 in surgically 
induced endometriosis in the rat. Obstet Gynecol, 1994. 83(3): p. 455-61. 
325. Das, S.K., et al., Expression of transforming growth factor-beta isoforms (beta 2 
and beta 3) in the mouse uterus: analysis of the periimplantation period and 
effects of ovarian steroids. Endocrinology, 1992. 130(6): p. 3459-66. 
326. Slager, H.G., et al., Transforming growth factor-beta in the early mouse embryo: 
implications for the regulation of muscle formation and implantation. Dev Genet, 
1993. 14(3): p. 212-24. 
327. Lin, H.Y., et al., Expression of Smad2 and Smad4, transforming growth factor-
beta signal transducers in rat endometrium during the estrous cycle, pre-, and 
peri-implantation. Anim Reprod Sci, 2004. 80(3-4): p. 303-16. 
328. Zhao, K.Q., et al., Maternal Smad3 deficiency compromises decidualization in 
mice. J Cell Biochem, 2012. 113(10): p. 3266-75. 
329. Bruner, K.L., et al., Transforming growth factor beta mediates the progesterone 
suppression of an epithelial metalloproteinase by adjacent stroma in the human 
endometrium. Proc Natl Acad Sci U S A, 1995. 92(16): p. 7362-6. 
330. Streuli, C.H., et al., Extracellular matrix regulates expression of the TGF-beta 1 
gene. J Cell Biol, 1993. 120(1): p. 253-60. 
237 
 
 
331. Chang, H.J., et al., Transforming growth factor (TGF)-beta1-induced human 
endometrial stromal cell decidualization through extracellular signal-regulated 
kinase and Smad activation in vitro: peroxisome proliferator-activated receptor 
gamma acts as a negative regulator of TGF-beta1. Fertil Steril, 2008. 90(4 
Suppl): p. 1357-65. 
332. Riesewijk, A., et al., Gene expression profiling of human endometrial receptivity 
on days LH+2 versus LH+7 by microarray technology. Mol Hum Reprod, 2003. 
9(5): p. 253-64. 
333. Kao, L.C., et al., Global gene profiling in human endometrium during the 
window of implantation. Endocrinology, 2002. 143(6): p. 2119-38. 
334. Kao, L.C., et al., Expression profiling of endometrium from women with 
endometriosis reveals candidate genes for disease-based implantation failure 
and infertility. Endocrinology, 2003. 144(7): p. 2870-81. 
335. Burney, R.O., et al., Gene expression analysis of endometrium reveals 
progesterone resistance and candidate susceptibility genes in women with 
endometriosis. Endocrinology, 2007. 148(8): p. 3814-26. 
336. Giudice, L.C., Microarray expression profiling reveals candidate genes for 
human uterine receptivity. Am J Pharmacogenomics, 2004. 4(5): p. 299-312. 
337. Cummings, M., et al., A robust RNA integrity-preserving staining protocol for 
laser capture microdissection of endometrial cancer tissue. Anal Biochem, 
2011. 416(1): p. 123-5. 
338. Niu, N. and X. Qin, New insights into IL-7 signaling pathways during early and 
late T cell development. Cell Mol Immunol, 2013. 10(3): p. 187-9. 
339. Nilsson, E.E. and M.K. Skinner, Bone morphogenetic protein-4 acts as an 
ovarian follicle survival factor and promotes primordial follicle development. Biol 
Reprod, 2003. 69(4): p. 1265-72. 
340. McKenzie, A.N., et al., Interleukin 13, a T-cell-derived cytokine that regulates 
human monocyte and B-cell function. Proc Natl Acad Sci U S A, 1993. 90(8): p. 
3735-9. 
341. Bailey, J.R., et al., IL-13 promotes collagen accumulation in Crohn's disease 
fibrosis by down-regulation of fibroblast MMP synthesis: a role for innate 
lymphoid cells? PLoS One, 2012. 7(12): p. e52332. 
342. Firszt, R., et al., Interleukin-13 induces collagen type-1 expression through 
matrix metalloproteinase-2 and transforming growth factor-beta1 in airway 
fibroblasts in asthma. Eur Respir J, 2013. 
238 
 
 
343. Wadsworth, S.J., et al., IL-13 and TH2 cytokine exposure triggers matrix 
metalloproteinase 7-mediated Fas ligand cleavage from bronchial epithelial 
cells. J Allergy Clin Immunol, 2010. 126(2): p. 366-74, 374 e1-8. 
344. Warren, J.S., P.A. Ward, and K.J. Johnson, Tumor necrosis factor: a 
plurifunctional mediator of acute inflammation. Mod Pathol, 1988. 1(3): p. 242-7. 
345. Smith, D.F., et al., GRO family chemokines are specialized for monocyte arrest 
from flow. Am J Physiol Heart Circ Physiol, 2005. 289(5): p. H1976-84. 
346. Ooi, A.T., et al., Identification of an interleukin 13-induced epigenetic signature 
in allergic airway inflammation. Am J Transl Res, 2012. 4(2): p. 219-28. 
347. Rundhaug, J.E., Matrix metalloproteinases and angiogenesis. J Cell Mol Med, 
2005. 9(2): p. 267-85. 
348. Nagase, H., Activation mechanisms of matrix metalloproteinases. Biol Chem, 
1997. 378(3-4): p. 151-60. 
349. Nagase, H., et al., Substrate specificities and activation mechanisms of matrix 
metalloproteinases. Biochem Soc Trans, 1991. 19(3): p. 715-8. 
350. Nagase, H., et al., Stepwise activation mechanisms of the precursors of matrix 
metalloproteinases 1 (tissue collagenase) and 3 (stromelysin). Biomed Biochim 
Acta, 1991. 50(4-6): p. 749-54. 
351. Nagase, H., et al., Activation mechanisms of the precursors of matrix 
metalloproteinases 1, 2 and 3. Matrix Suppl, 1992. 1: p. 237-44. 
352. Schall, T.J., et al., Selective attraction of monocytes and T lymphocytes of the 
memory phenotype by cytokine RANTES. Nature, 1990. 347(6294): p. 669-71. 
353. Bleul, C.C., et al., A highly efficacious lymphocyte chemoattractant, stromal cell-
derived factor 1 (SDF-1). J Exp Med, 1996. 184(3): p. 1101-9. 
354. Kryczek, I., et al., The chemokine SDF-1/CXCL12 contributes to T lymphocyte 
recruitment in human pre-ovulatory follicles and coordinates with lymphocytes 
to increase granulosa cell survival and embryo quality. Am J Reprod Immunol, 
2005. 54(5): p. 270-83. 
355. Ashkar, A.A., et al., Assessment of requirements for IL-15 and IFN regulatory 
factors in uterine NK cell differentiation and function during pregnancy. J 
Immunol, 2003. 171(6): p. 2937-44. 
356. Kishimoto, T., T. Taga, and S. Akira, Cytokine signal transduction. Cell, 1994. 
76(2): p. 253-62. 
357. Ozaki, K. and W.J. Leonard, Cytokine and cytokine receptor pleiotropy and 
redundancy. J Biol Chem, 2002. 277(33): p. 29355-8. 
239 
 
 
358. Lin, J.X., et al., The role of shared receptor motifs and common Stat proteins in 
the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, 
and IL-15. Immunity, 1995. 2(4): p. 331-9. 
359. Rossi, M., et al., Identification of genes regulated by interleukin-1beta in human 
endometrial stromal cells. Reproduction, 2005. 130(5): p. 721-9. 
360. Matsuoka, R., et al., Regulation of estrogen activity in human endometrium: 
effect of IL-1beta on steroid sulfatase activity in human endometrial stromal 
cells. Steroids, 2002. 67(7): p. 655-9. 
361. Godkin, J.D. and J.J. Dore, Transforming growth factor beta and the 
endometrium. Rev Reprod, 1998. 3(1): p. 1-6. 
362. Yu, Q. and I. Stamenkovic, Cell surface-localized matrix metalloproteinase-9 
proteolytically activates TGF-beta and promotes tumor invasion and 
angiogenesis. Genes Dev, 2000. 14(2): p. 163-76. 
363. Eickelberg, O., et al., Molecular mechanisms of TGF-(beta) antagonism by 
interferon (gamma) and cyclosporine A in lung fibroblasts. FASEB J, 2001. 
15(3): p. 797-806. 
364. Higashi, K., et al., Interferon-gamma interferes with transforming growth factor-
beta signaling through direct interaction of YB-1 with Smad3. J Biol Chem, 
2003. 278(44): p. 43470-9. 
365. Yu, J., et al., Pro- and antiinflammatory cytokine signaling: reciprocal 
antagonism regulates interferon-gamma production by human natural killer 
cells. Immunity, 2006. 24(5): p. 575-90. 
366. Chen, W., IDO: more than an enzyme. Nat Immunol, 2011. 12(9): p. 809-11. 
367. Tabibzadeh, S.S., P.G. Satyaswaroop, and P.N. Rao, Antiproliferative effect of 
interferon-gamma in human endometrial epithelial cells in vitro: potential local 
growth modulatory role in endometrium. J Clin Endocrinol Metab, 1988. 67(1): 
p. 131-8. 
368. Kawano, Y., et al., Effects of interferon-gamma on secretion of vascular 
endothelial growth factor by endometrial stromal cells. Am J Reprod Immunol, 
2000. 43(1): p. 47-52. 
369. Zoumpoulidou, G., et al., Convergence of interferon-gamma and progesterone 
signaling pathways in human endometrium: role of PIASy (protein inhibitor of 
activated signal transducer and activator of transcription-y). Mol Endocrinol, 
2004. 18(8): p. 1988-99. 
370. Chegini, N., X.M. Tang, and Q. Dou, The expression, activity and regulation of 
granulocyte macrophage-colony stimulating factor in human endometrial 
epithelial and stromal cells. Mol Hum Reprod, 1999. 5(5): p. 459-66. 
240 
 
 
371. Shanafelt, A.B., K.E. Johnson, and R.A. Kastelein, Identification of critical 
amino acid residues in human and mouse granulocyte-macrophage colony-
stimulating factor and their involvement in species specificity. J Biol Chem, 
1991. 266(21): p. 13804-10. 
372. Gough, N.M., et al., Structure and expression of the mRNA for murine 
granulocyte-macrophage colony stimulating factor. EMBO J, 1985. 4(3): p. 645-
53. 
373. Lacey, D.C., et al., Defining GM-CSF- and macrophage-CSF-dependent 
macrophage responses by in vitro models. J Immunol, 2012. 188(11): p. 5752-
65. 
374. Paiva, P., et al., Human chorionic gonadotrophin regulates FGF2 and other 
cytokines produced by human endometrial epithelial cells, providing a 
mechanism for enhancing endometrial receptivity. Hum Reprod, 2011. 26(5): p. 
1153-62. 
375. Bulmer, J.N., et al., Granulated lymphocytes in human endometrium: 
histochemical and immunohistochemical studies. Hum Reprod, 1991. 6(6): p. 
791-8. 
376. Hemberger, M., Immune balance at the foeto-maternal interface as the fulcrum 
of reproductive success. J Reprod Immunol, 2013. 97(1): p. 36-42. 
377. Chaouat, G., Inflammation, NK cells and implantation: friend and foe (the good, 
the bad and the ugly?): replacing placental viviparity in an evolutionary 
perspective. J Reprod Immunol, 2013. 97(1): p. 2-13. 
378. Erlebacher, A., Immunology of the maternal-fetal interface. Annu Rev Immunol, 
2013. 31: p. 387-411. 
379. Fu, B., et al., Natural killer cells promote immune tolerance by regulating 
inflammatory TH17 cells at the human maternal-fetal interface. Proc Natl Acad 
Sci U S A, 2013. 110(3): p. E231-40. 
380. Gonzalez, I.T., et al., Uterine NK cells are critical in shaping DC immunogenic 
functions compatible with pregnancy progression. PLoS One, 2012. 7(10): p. 
e46755. 
381. Hatta, K., et al., Emerging themes in uterine natural killer cell heterogeneity and 
function. Am J Reprod Immunol, 2012. 68(4): p. 282-9. 
382. Male, V., L. Gardner, and A. Moffett, Isolation of cells from the feto-maternal 
interface. Curr Protoc Immunol, 2012. Chapter 7: p. Unit 7 40 1-11. 
383. Seymour, J.F., et al., Mice lacking both granulocyte colony-stimulating factor 
(CSF) and granulocyte-macrophage CSF have impaired reproductive capacity, 
241 
 
 
perturbed neonatal granulopoiesis, lung disease, amyloidosis, and reduced 
long-term survival. Blood, 1997. 90(8): p. 3037-49. 
384. Lee, J.Y., M. Lee, and S.K. Lee, Role of endometrial immune cells in 
implantation. Clin Exp Reprod Med, 2011. 38(3): p. 119-25. 
385. Olive, D.L., J.B. Weinberg, and A.F. Haney, Sperm-macrophage interaction in 
the mouse: a quantitative assay in vitro using 111indium oxine-labeled sperm. 
Biol Reprod, 1987. 37(5): p. 1170-8. 
386. Laird, S.M., et al., Stimulation of human endometrial epithelial cell interleukin 6 
production by interleukin 1 and placental protein 14. Hum Reprod, 1994. 9(7): p. 
1339-43. 
387. von Wolff, M., et al., Endometrial expression and secretion of interleukin-6 
throughout the menstrual cycle. Gynecol Endocrinol, 2002. 16(2): p. 121-9. 
388. von Wolff, M., et al., Endometrial interleukin-6 in vitro is not regulated directly by 
female steroid hormones, but by pro-inflammatory cytokines and hypoxia. Mol 
Hum Reprod, 2002. 8(12): p. 1096-102. 
389. Hurst, S.M., et al., Il-6 and its soluble receptor orchestrate a temporal switch in 
the pattern of leukocyte recruitment seen during acute inflammation. Immunity, 
2001. 14(6): p. 705-14. 
390. Stewart, C.L., Leukaemia inhibitory factor and the regulation of pre-implantation 
development of the mammalian embryo. Mol Reprod Dev, 1994. 39(2): p. 233-
8. 
391. Fouladi Nashta, A.A., et al., Role of leukemia inhibitor factor (LIF) in 
decidualisation of murine uterine stromal cells in vitro. J Endocrinol, 2004. 
181(3): p. 477-92. 
392. Guenet, J.L., The mouse genome. Genome Res, 2005. 15(12): p. 1729-40. 
393. Greenbaum, D., et al., Comparing protein abundance and mRNA expression 
levels on a genomic scale. Genome Biol, 2003. 4(9): p. 117. 
394. Anderson, P., Post-transcriptional control of cytokine production. Nat Immunol, 
2008. 9(4): p. 353-9. 
395. Proost, P., et al., Posttranslational modifications affect the activity of the human 
monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2(6-
76) as a natural chemokine inhibitor. J Immunol, 1998. 160(8): p. 4034-41. 
396. May, L.T., et al., Synthesis and secretion of multiple forms of beta 2-
interferon/B-cell differentiation factor 2/hepatocyte-stimulating factor by human 
fibroblasts and monocytes. J Biol Chem, 1988. 263(16): p. 7760-6. 
242 
 
 
397. Kameyoshi, Y., et al., Cytokine RANTES released by thrombin-stimulated 
platelets is a potent attractant for human eosinophils. J Exp Med, 1992. 176(2): 
p. 587-92. 
398. Arava, Y., et al., Genome-wide analysis of mRNA translation profiles in 
Saccharomyces cerevisiae. Proc Natl Acad Sci U S A, 2003. 100(7): p. 3889-
94. 
399. Djebbari, A. and J. Quackenbush, Seeded Bayesian Networks: constructing 
genetic networks from microarray data. BMC Syst Biol, 2008. 2: p. 57. 
400. Garbis, S., G. Lubec, and M. Fountoulakis, Limitations of current proteomics 
technologies. J Chromatogr A, 2005. 1077(1): p. 1-18. 
401. Baud, V. and M. Karin, Signal transduction by tumor necrosis factor and its 
relatives. Trends Cell Biol, 2001. 11(9): p. 372-7. 
402. Taga, T., et al., Interleukin-6 triggers the association of its receptor with a 
possible signal transducer, gp130. Cell, 1989. 58(3): p. 573-81. 
403. Hirano, T., Molecular basis underlying functional pleiotropy of cytokines and 
growth factors. Biochem Biophys Res Commun, 1999. 260(2): p. 303-8. 
404. Liu, Z.G., et al., Dissection of TNF receptor 1 effector functions: JNK activation 
is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell, 
1996. 87(3): p. 565-76. 
405. Menten, P., et al., Differential induction of monocyte chemotactic protein-3 in 
mononuclear leukocytes and fibroblasts by interferon-alpha/beta and interferon-
gamma reveals MCP-3 heterogeneity. Eur J Immunol, 1999. 29(2): p. 678-85. 
406. Lowenthal, J.W., et al., Tumor necrosis factor-alpha activation of the IL-2 
receptor-alpha gene involves the induction of kappa B-specific DNA binding 
proteins. J Immunol, 1989. 142(9): p. 3121-8. 
407. Osborn, L., S. Kunkel, and G.J. Nabel, Tumor necrosis factor alpha and 
interleukin 1 stimulate the human immunodeficiency virus enhancer by 
activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A, 1989. 86(7): 
p. 2336-40. 
408. Hasbold, J., et al., Integrating signals from IFN-gamma and IL-4 by B cells: 
positive and negative effects on CD40 ligand-induced proliferation, survival, and 
division-linked isotype switching to IgG1, IgE, and IgG2a. J Immunol, 1999. 
163(8): p. 4175-81. 
409. Nguyen, V.T. and E.N. Benveniste, IL-4-activated STAT-6 inhibits IFN-gamma-
induced CD40 gene expression in macrophages/microglia. J Immunol, 2000. 
165(11): p. 6235-43. 
243 
 
 
410. Ritter, U. and H. Moll, Monocyte chemotactic protein-1 stimulates the killing of 
leishmania major by human monocytes, acts synergistically with IFN-gamma 
and is antagonized by IL-4. Eur J Immunol, 2000. 30(11): p. 3111-20. 
411. Paludan, S.R., Interleukin-4 and interferon-gamma: the quintessence of a 
mutual antagonistic relationship. Scand J Immunol, 1998. 48(5): p. 459-68. 
412. Kaplan, M.H., et al., Stat6 is required for mediating responses to IL-4 and for 
development of Th2 cells. Immunity, 1996. 4(3): p. 313-9. 
413. Chatelain, R., K. Varkila, and R.L. Coffman, IL-4 induces a Th2 response in 
Leishmania major-infected mice. J Immunol, 1992. 148(4): p. 1182-7. 
414. Maggi, E., et al., Reciprocal regulatory effects of IFN-gamma and IL-4 on the in 
vitro development of human Th1 and Th2 clones. J Immunol, 1992. 148(7): p. 
2142-7. 
415. Parronchi, P., et al., IL-4 and IFN (alpha and gamma) exert opposite regulatory 
effects on the development of cytolytic potential by Th1 or Th2 human T cell 
clones. J Immunol, 1992. 149(9): p. 2977-83. 
416. Mosmann, T.R. and S. Sad, The expanding universe of T-cell subsets: Th1, 
Th2 and more. Immunol Today, 1996. 17(3): p. 138-46. 
417. Strober, W., Immunology: The expanding T(H)2 universe. Nature, 2010. 
463(7280): p. 434-5. 
418. Eyerich, K. and N. Novak, Immunology of atopic eczema: overcoming the 
Th1/Th2 paradigm. Allergy, 2013. 68(8): p. 974-82. 
419. Wilczynski, J.R., Th1/Th2 cytokines balance--yin and yang of reproductive 
immunology. Eur J Obstet Gynecol Reprod Biol, 2005. 122(2): p. 136-43. 
420. Deon, D., et al., Cross-talk between IL-1 and IL-6 signaling pathways in 
rheumatoid arthritis synovial fibroblasts. J Immunol, 2001. 167(9): p. 5395-403. 
421. Alvaro-Gracia, J.M., et al., Mutual antagonism between interferon-gamma and 
tumor necrosis factor-alpha on fibroblast-like synoviocytes: paradoxical 
induction of IFN-gamma and TNF-alpha receptor expression. J Clin Immunol, 
1993. 13(3): p. 212-8. 
422. Miyajima, A., T. Hara, and T. Kitamura, Common subunits of cytokine receptors 
and the functional redundancy of cytokines. Trends Biochem Sci, 1992. 17(10): 
p. 378-82. 
423. Hibi, M., K. Nakajima, and T. Hirano, IL-6 cytokine family and signal 
transduction: a model of the cytokine system. J Mol Med (Berl), 1996. 74(1): p. 
1-12. 
424. Bazan, J.F., Haemopoietic receptors and helical cytokines. Immunol Today, 
1990. 11(10): p. 350-4. 
244 
 
 
425. Ip, N.Y., et al., CNTF and LIF act on neuronal cells via shared signaling 
pathways that involve the IL-6 signal transducing receptor component gp130. 
Cell, 1992. 69(7): p. 1121-32. 
426. Carbia-Nagashima, A. and E. Arzt, Intracellular proteins and mechanisms 
involved in the control of gp130/JAK/STAT cytokine signaling. IUBMB Life, 
2004. 56(2): p. 83-8. 
427. Kling, J., et al., Redundancy of interleukin-6 in the differentiation of T cell and 
monocyte subsets during cutaneous leishmaniasis. Exp Parasitol, 2011. 129(3): 
p. 270-6. 
428. Liu, Z., et al., Acute obstructive cholangiopathy in interleukin-6 deficient mice: 
compensation by leukemia inhibitory factor (LIF) suggests importance of gp-130 
signaling in the ductular reaction. Liver, 2000. 20(2): p. 114-24. 
429. Tanaka, T. and T. Kishimoto, Immunotherapeutic implication of IL-6 blockade. 
Immunotherapy, 2012. 4(1): p. 87-105. 
430. Alexander, W.S. Knockout Mouse Models of Cytokine Action in Hematopoietic 
Stem Cell Regulation. Madame Curie Bioscience Database [Internet] 2000  
[cited 2014 27/02/2014]; Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK6511/. 
431. Green, A.R., Peptide regulatory factors: multifunctional mediators of cellular 
growth and differentiation. Lancet, 1989. 1(8640): p. 705-7. 
432. Sporn, M.B. and A.B. Roberts, Peptide growth factors are multifunctional. 
Nature, 1988. 332(6161): p. 217-9. 
433. Wan, Y., et al., Transmodulation of epidermal growth factor receptor mediates 
IL-1 beta-induced MMP-1 expression in cultured human keratinocytes. Int J Mol 
Med, 2001. 7(3): p. 329-34. 
434. Alex, P., et al., Distinct cytokine patterns identified from multiplex profiles of 
murine DSS and TNBS-induced colitis. Inflamm Bowel Dis, 2009. 15(3): p. 341-
52. 
435. Szodoray, P., et al., Circulating cytokines in Norwegian patients with psoriatic 
arthritis determined by a multiplex cytokine array system. Rheumatology 
(Oxford), 2007. 46(3): p. 417-25. 
436. Yan, X.J., et al., Identification of outcome-correlated cytokine clusters in chronic 
lymphocytic leukemia. Blood, 2011. 118(19): p. 5201-10. 
437. van den Ham, H.J., et al., Differential cytokine profiles in juvenile idiopathic 
arthritis subtypes revealed by cluster analysis. Rheumatology (Oxford), 2009. 
48(8): p. 899-905. 
245 
 
 
438. Lvovschi, V., et al., Correction: cytokine profiles in sepsis have limited 
relevance for stratifying patients in the emergency department: a prospective 
observational study. PLoS One, 2012. 7(1). 
439. Lvovschi, V., et al., Cytokine profiles in sepsis have limited relevance for 
stratifying patients in the emergency department: a prospective observational 
study. PLoS One, 2011. 6(12): p. e28870. 
440. Weaver, D.C., C.T. Workman, and G.D. Stormo, Modeling regulatory networks 
with weight matrices. Pac Symp Biocomput, 1999: p. 112-23. 
441. Akutsu, T., S. Miyano, and S. Kuhara, Identification of genetic networks from a 
small number of gene expression patterns under the Boolean network model. 
Pac Symp Biocomput, 1999: p. 17-28. 
442. Kerr, J.R., et al., Gene expression subtypes in patients with chronic fatigue 
syndrome/myalgic encephalomyelitis. J Infect Dis, 2008. 197(8): p. 1171-84. 
443. Emmert-Streib, F., The chronic fatigue syndrome: a comparative pathway 
analysis. J Comput Biol, 2007. 14(7): p. 961-72. 
444. Broderick, G., et al., A formal analysis of cytokine networks in chronic fatigue 
syndrome. Brain Behav Immun, 2010. 24(7): p. 1209-17. 
445. O’Hagan, A., Bayesian principles, in Bayesian Methods in Health Economics: 
The Biomedical & Life Sciences Collection, Henry Stewart Talks, T. O’Hagan, 
Editor 2009, Henry Stewart Talks Ltd: London. 
446. Stevens, J.W. and A. O'Hagan, Incorporation of genuine prior information in 
cost-effectiveness analysis of clinical trial data. Int J Technol Assess Health 
Care, 2002. 18(4): p. 782-90. 
447. Lee, P.M., Bayesian statistics: an introduction. 2nd ed. 1997, London: Arnold. 
448. Bink, M.C.A.M., et al., Bayesian analysis of complex traits in pedigreed plant 
populations Euphytica, 2008. 161(1): p. 85-96. 
449. Larranaga, P., et al., Machine learning in bioinformatics. Brief Bioinform, 2006. 
7(1): p. 86-112. 
450. Krallinger, M., R.A. Erhardt, and A. Valencia, Text-mining approaches in 
molecular biology and biomedicine. Drug Discov Today, 2005. 10(6): p. 439-45. 
451. Mathe, C., et al., Current methods of gene prediction, their strengths and 
weaknesses. Nucleic Acids Res, 2002. 30(19): p. 4103-17. 
452. Aerts, S., et al., A genetic algorithm for the detection of new cis-regulatory 
modules in sets of coregulated genes. Bioinformatics, 2004. 20(12): p. 1974-6. 
453. Bockhorst, J., et al., A Bayesian network approach to operon prediction. 
Bioinformatics, 2003. 19(10): p. 1227-35. 
246 
 
 
454. Won, K.J., A. Prugel-Bennett, and A. Krogh, Training HMM structure with 
genetic algorithm for biological sequence analysis. Bioinformatics, 2004. 20(18): 
p. 3613-9. 
455. Carter, R.J., I. Dubchak, and S.R. Holbrook, A computational approach to 
identify genes for functional RNAs in genomic sequences. Nucleic Acids Res, 
2001. 29(19): p. 3928-38. 
456. Pearl, J., Graphical Models for Probabilistic and Causal Reasoning, in The 
Computer Science and Engineering Handbook, A.T. Tucker, Editor 1997, CRC 
Press: Boca Raton, Florida. p. 699-711. 
457. Schafer, J. and K. Strimmer, An empirical Bayes approach to inferring large-
scale gene association networks. Bioinformatics, 2005. 21(6): p. 754-64. 
458. Jojic, V., et al., Efficient approximations for learning phylogenetic HMM models 
from data. Bioinformatics, 2004. 20 Suppl 1: p. i161-8. 
459. Leone, M. and A. Pagnani, Predicting protein functions with message passing 
algorithms. Bioinformatics, 2005. 21(2): p. 239-47. 
460. Friedman, N., et al., Using Bayesian networks to analyze expression data. J 
Comput Biol, 2000. 7(3-4): p. 601-20. 
461. Le Phillip, P., A. Bahl, and L.H. Ungar, Using prior knowledge to improve 
genetic network reconstruction from microarray data. In Silico Biol, 2004. 4(3): 
p. 335-53. 
462. Husmeier, D. and A.V. Werhli, Bayesian integration of biological prior 
knowledge into the reconstruction of gene regulatory networks with Bayesian 
networks. Comput Syst Bioinformatics Conf, 2007. 6: p. 85-95. 
463. Gevaert, O., S. Van Vooren, and B. De Moor, A framework for elucidating 
regulatory networks based on prior information and expression data. Ann N Y 
Acad Sci, 2007. 1115: p. 240-8. 
464. Wolpurt, D.H., No free lunch theorems for optimization. IEEE Transactions on 
Evolutionary Computation, 1997. 1(1): p. 67-82. 
465. Li, Y., et al., Critical reasoning on causal inference in genome-wide linkage and 
association studies. Trends Genet, 2010. 26(12): p. 493-8. 
466. Pearl, J., Causality: Models, Reasoning and Inference. 2nd ed. 2009, 
Cambridge: Cambridge University Press. 
467. Moloshok, T.D., et al., Application of Bayesian decomposition for analysing 
microarray data. Bioinformatics, 2002. 18(4): p. 566-75. 
468. Sha, N., M.G. Tadesse, and M. Vannucci, Bayesian variable selection for the 
analysis of microarray data with censored outcomes. Bioinformatics, 2006. 
22(18): p. 2262-8. 
247 
 
 
469. Zhao, H., et al., Multivariate hierarchical Bayesian model for differential gene 
expression analysis in microarray experiments. BMC Bioinformatics, 2008. 9 
Suppl 1: p. S9. 
470. Imoto, S., et al., Bayesian network and nonparametric heteroscedastic 
regression for nonlinear modeling of genetic network. Proc IEEE Comput Soc 
Bioinform Conf, 2002. 1: p. 219-27. 
471. Kim, S., S. Imoto, and S. Miyano, Dynamic Bayesian network and 
nonparametric regression for nonlinear modeling of gene networks from time 
series gene expression data. Biosystems, 2004. 75(1-3): p. 57-65. 
472. Gracias, D.T. and P.D. Katsikis, MicroRNAs: key components of immune 
regulation. Adv Exp Med Biol, 2011. 780: p. 15-26. 
473. Stumpo, D.J., W.S. Lai, and P.J. Blackshear, Inflammation: cytokines and RNA-
based regulation. Wiley Interdiscip Rev RNA, 2010. 1(1): p. 60-80. 
474. Mortier, A., J. Van Damme, and P. Proost, Regulation of chemokine activity by 
posttranslational modification. Pharmacol Ther, 2008. 120(2): p. 197-217. 
475. Pierre, P., Immunity and the regulation of protein synthesis: surprising 
connections. Curr Opin Immunol, 2009. 21(1): p. 70-7. 
476. Buckley, A.R., Prolactin, a lymphocyte growth and survival factor. Lupus, 2001. 
10(10): p. 684-90. 
477. Brand, J.M., et al., Prolactin triggers pro-inflammatory immune responses in 
peripheral immune cells. Eur Cytokine Netw, 2004. 15(2): p. 99-104. 
478. Carreno, P.C., et al., Prolactin affects both survival and differentiation of T-cell 
progenitors. J Neuroimmunol, 2005. 160(1-2): p. 135-45. 
479. Lau, J., et al., Prolactin regulation of the expression of TNF-alpha, IFN-gamma 
and IL-10 by splenocytes in murine multiple low dose streptozotocin diabetes. 
Immunol Lett, 2006. 102(1): p. 25-30. 
480. Richards, S.M. and W.J. Murphy, Use of human prolactin as a therapeutic 
protein to potentiate immunohematopoietic function. J Neuroimmunol, 2000. 
109(1): p. 56-62. 
481. Gopichandran, N., et al., Multiplex determination of murine seminal fluid 
cytokine profiles. Reproduction, 2006. 131(3): p. 613-21. 
482. Chandrashekar, V., A. Bartke, and T.E. Wagner, Endogenous human growth 
hormone (GH) modulates the effect of gonadotropin-releasing hormone on 
pituitary function and the gonadotropin response to the negative feedback effect 
of testosterone in adult male transgenic mice bearing human GH gene. 
Endocrinology, 1988. 123(6): p. 2717-22. 
248 
 
 
483. Cooke, E., et al. Bayesian hierarchical clustering for microarray time series data 
with replicates and outlier measurements. in MASAMB 2011. 2011. Vienna. 
484. Benjamini, Y. and Y. Hochberg, Controlling the false discovery rate: a practical 
and powerful approach to multiple testing. J Royal Stat Soc B 1995. 57: p. 289-
300. 
485. Pe'er, D., Bayesian network analysis of signaling networks: a primer. Sci STKE, 
2005. 2005(281): p. pl4. 
486. Beal, M.J., et al., A Bayesian approach to reconstructing genetic regulatory 
networks with hidden factors. Bioinformatics, 2005. 21(3): p. 349-56. 
487. Jenssen, T.K., et al., A literature network of human genes for high-throughput 
analysis of gene expression. Nat Genet, 2001. 28(1): p. 21-8. 
488. Hall, M., et al., The WEKA Data Mining Software: An Update. SIGKDD 
Explorations, 2009. 11(1): p. 10-18. 
489. Friedman, N., M. Goldszmidt, and A. Wyner, Data analysis with Bayesian 
networks: a bootstrap approach, ed. K. Laskey and H. Prade. 1999: Morgan 
Kaufmann. 
490. Heckerman, D., D. Geiger, and D. Chickering, Learning Bayesian networks: the 
combination of knowledge and statistical data. Machine Learning, 1995. 20(95): 
p. 197-234. 
491. Shannon, P., et al., Cytoscape: a software environment for integrated models of 
biomolecular interaction networks. Genome Research, 2003. 13(11): p. 2498-
2504. 
492. Bishop, C., Pattern Recognition and Machine Learning. 2nd Edition ed. 
Information Science and Statistics, ed. M. Jordan, J. Kleinberg, and B. 
Scholkopf. 2007, Singapore: Springer Science and Business Media. 
493. Reber, P.M., Prolactin and immunomodulation. Am J Med, 1993. 95(6): p. 637-
44. 
494. Cejkova, P., M. Fojtikova, and M. Cerna, Immunomodulatory role of prolactin in 
diabetes development. Autoimmun Rev, 2009. 9(1): p. 23-7. 
495. Saha, S., et al., Prolactin alters the mechanisms of B cell tolerance induction. 
Arthritis Rheum, 2009. 60(6): p. 1743-52. 
496. Berczi, I., et al., Regulation of humoral immunity in rats by pituitary hormones. 
Acta Endocrinol (Copenh), 1981. 98(4): p. 506-13. 
497. Quintanar-Stephano, A., et al., Hypophysectomy and neurointermediate 
pituitary lobectomy decrease humoral immune responses to T-independent and 
T-dependent antigens. J Physiol Biochem, 2010. 66(1): p. 7-13. 
249 
 
 
498. Matera, L., et al., Modulatory effect of prolactin on the resting and mitogen-
induced activity of T, B, and NK lymphocytes. Brain Behav Immun, 1992. 6(4): 
p. 409-17. 
499. Uyttenhove, C., R.J. Simpson, and J. Van Snick, Functional and structural 
characterization of P40, a mouse glycoprotein with T-cell growth factor activity. 
Proc Natl Acad Sci U S A, 1988. 85(18): p. 6934-8. 
500. Cheng, G., et al., Anti-interleukin-9 antibody treatment inhibits airway 
inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit 
Care Med, 2002. 166(3): p. 409-16. 
501. Angkasekwinai, P., et al., Regulation of IL-9 expression by IL-25 signaling. Nat 
Immunol, 2010. 11(3): p. 250-6. 
502. Shipman, L.J., et al., Metabolic adaptations in mouse mammary gland during a 
normal lactation cycle and in extended lactation. Q J Exp Physiol, 1987. 72(3): 
p. 303-11. 
503. Wilde, C.J., C.H. Knight, and D.J. Flint, Control of milk secretion and apoptosis 
during mammary involution. J Mammary Gland Biol Neoplasia, 1999. 4(2): p. 
129-36. 
504. Basak, S., et al., Expression of pro-inflammatory cytokines in mouse 
blastocysts during implantation: modulation by steroid hormones. Am J Reprod 
Immunol, 2002. 47(1): p. 2-11. 
505. Nishimori, K., et al., Oxytocin is required for nursing but is not essential for 
parturition or reproductive behavior. Proc Natl Acad Sci U S A, 1996. 93(21): p. 
11699-704. 
506. Wagner, K.U., et al., Oxytocin and milk removal are required for post-partum 
mammary-gland development. Genes Funct, 1997. 1(4): p. 233-44. 
507. Young, W.S., 3rd, et al., Deficiency in mouse oxytocin prevents milk ejection, 
but not fertility or parturition. J Neuroendocrinol, 1996. 8(11): p. 847-53. 
508. Johnson, H.M. and B.A. Torres, Regulation of lymphokine production by 
arginine vasopressin and oxytocin: modulation of lymphocyte function by 
neurohypophyseal hormones. J Immunol, 1985. 135(2 Suppl): p. 773s-775s. 
509. Watanobe, H., S. Sasaki, and K. Takebe, Involvement of oxytocin and 
cholecystokinin-8 in interleukin-1 beta-induced adrenocorticotropin secretion in 
the rat. Neuroimmunomodulation, 1995. 2(2): p. 88-91. 
510. Clodi, M., et al., Oxytocin alleviates the neuroendocrine and cytokine response 
to bacterial endotoxin in healthy men. Am J Physiol Endocrinol Metab, 2008. 
295(3): p. E686-91. 
250 
 
 
511. Maccio, A., et al., Oxytocin both increases proliferative response of peripheral 
blood lymphomonocytes to phytohemagglutinin and reverses 
immunosuppressive estrogen activity. In Vivo, 2010. 24(2): p. 157-63. 
512. Szeto, A., et al., Oxytocin attenuates NADPH-dependent superoxide activity 
and IL-6 secretion in macrophages and vascular cells. Am J Physiol Endocrinol 
Metab, 2008. 295(6): p. E1495-501. 
513. Heinig, M.J. and K.G. Dewey, Health effects of breast feeding for mothers: a 
critical review. Nutr Res Rev, 1997. 10(1): p. 35-56. 
514. Langer-Gould, A., et al., Interferon-gamma-producing T cells, pregnancy, and 
postpartum relapses of multiple sclerosis. Arch Neurol, 2010. 67(1): p. 51-7. 
515. Hilkens, C.M., et al., Accessory cell-derived IL-12 and prostaglandin E2 
determine the IFN-gamma level of activated human CD4+ T cells. J Immunol, 
1996. 156(5): p. 1722-27. 
516. van der Pouw Kraan, T.C., et al., Regulation of IL-12 production by human 
monocytes and the influence of prostaglandin E2. Ann N Y Acad Sci, 1996. 
795: p. 147-57. 
517. Heinzel, F.P., et al., In vivo production and function of IL-12 p40 homodimers. J 
Immunol, 1997. 158(9): p. 4381-8. 
518. Tripathi, A. and A. Sodhi, Prolactin-induced production of cytokines in 
macrophages in vitro involves JAK/STAT and JNK MAPK pathways. Int 
Immunol, 2008. 20(3): p. 327-36. 
519. Wang, J., et al., Inhibition of CCR5 expression by IL-12 through induction of 
beta-chemokines in human T lymphocytes. J Immunol, 1999. 163(11): p. 5763-
9. 
520. Fahey, T.J., 3rd, et al., Macrophage inflammatory protein 1 modulates 
macrophage function. J Immunol, 1992. 148(9): p. 2764-9. 
521. Mosconi, E., et al., Breast milk immune complexes are potent inducers of oral 
tolerance in neonates and prevent asthma development. Mucosal Immunol, 
2010. 3(5): p. 461-74. 
522. Sinha, S., et al., IL-13-mediated gender difference in susceptibility to 
autoimmune encephalomyelitis. J Immunol, 2008. 180(4): p. 2679-85. 
523. Blais, Y., et al., Interleukin-4 and interleukin-13 inhibit estrogen-induced breast 
cancer cell proliferation and stimulate GCDFP-15 expression in human breast 
cancer cells. Mol Cell Endocrinol, 1996. 121(1): p. 11-8. 
524. Gooch, J.L., A.V. Lee, and D. Yee, Interleukin 4 inhibits growth and induces 
apoptosis in human breast cancer cells. Cancer Res, 1998. 58(18): p. 4199-
205. 
251 
 
 
525. Hamano, N., et al., Effect of female hormones on the production of IL-4 and IL-
13 from peripheral blood mononuclear cells. Acta Otolaryngol Suppl, 1998. 537: 
p. 27-31. 
526. Wynn, T.A., IL-13 effector functions. Annu Rev Immunol, 2003. 21: p. 425-56. 
527. Joshi, B.H., et al., Role of interleukin-13 in cancer, pulmonary fibrosis, and other 
T(H)2-type diseases. Vitam Horm, 2006. 74: p. 479-504. 
528. Wills-Karp, M. and F.D. Finkelman, Untangling the complex web of IL-4- and IL-
13-mediated signaling pathways. Sci Signal, 2008. 1(51): p. pe55. 
529. Savion, S., et al., Cytokine expression in the uterus of mice with pregnancy 
loss: effect of maternal immunopotentiation with GM-CSF. Reproduction, 2002. 
123(3): p. 399-409. 
530. Sjoblom, C., M. Wikland, and S.A. Robertson, Granulocyte-macrophage colony-
stimulating factor (GM-CSF) acts independently of the beta common subunit of 
the GM-CSF receptor to prevent inner cell mass apoptosis in human embryos. 
Biol Reprod, 2002. 67(6): p. 1817-23. 
531. Haddad, E.K., et al., Role of interferon-gamma in the priming of decidual 
macrophages for nitric oxide production and early pregnancy loss. Cell 
Immunol, 1997. 181(1): p. 68-75. 
532. Wilson, R., et al., Abnormal cytokine levels in non-pregnant women with a 
history of recurrent miscarriage. Eur J Obstet Gynecol Reprod Biol, 2004. 
115(1): p. 51-4. 
533. Ashkar, A.A. and B.A. Croy, Interferon-gamma contributes to the normalcy of 
murine pregnancy. Biol Reprod, 1999. 61(2): p. 493-502. 
534. Murphy, S.P., et al., Interferon gamma in successful pregnancies. Biol Reprod, 
2009. 80(5): p. 848-59. 
535. D'Andrea, A., et al., Interleukin 10 (IL-10) inhibits human lymphocyte interferon 
gamma-production by suppressing natural killer cell stimulatory factor/IL-12 
synthesis in accessory cells. J Exp Med, 1993. 178(3): p. 1041-8. 
536. Naundorf, S., et al., IL-10 interferes directly with TCR-induced IFN-gamma but 
not IL-17 production in memory T cells. Eur J Immunol, 2009. 39(4): p. 1066-77. 
537. Ogilvie, P., et al., Eotaxin is a natural antagonist for CCR2 and an agonist for 
CCR5. Blood, 2001. 97(7): p. 1920-4. 
538. Kobayashi, Y., et al., Levels of MCP-1 and GM-CSF mRNA correlated with 
inflammatory cytokines mRNA levels in experimental autoimmune myocarditis 
in rats. Autoimmunity, 2002. 35(2): p. 97-104. 
539. Kunstfeld, R., et al., MCP-1 and MIP-1alpha are most efficient in recruiting T 
cells into the skin in vivo. J Invest Dermatol, 1998. 111(6): p. 1040-4. 
252 
 
 
540. Alam, R., et al., Increased MCP-1, RANTES, and MIP-1alpha in 
bronchoalveolar lavage fluid of allergic asthmatic patients. Am J Respir Crit 
Care Med, 1996. 153(4 Pt 1): p. 1398-404. 
541. Yoshida, S., et al., Role of MCP-1 and MIP-1alpha in retinal neovascularization 
during postischemic inflammation in a mouse model of retinal 
neovascularization. J Leukoc Biol, 2003. 73(1): p. 137-44. 
542. Low, Q.E., et al., Wound healing in MIP-1alpha(-/-) and MCP-1(-/-) mice. Am J 
Pathol, 2001. 159(2): p. 457-63. 
543. Conti, P. and M. DiGioacchino, MCP-1 and RANTES are mediators of acute 
and chronic inflammation. Allergy Asthma Proc, 2001. 22(3): p. 133-7. 
544. Goebeler, M., et al., Interleukin-13 selectively induces monocyte 
chemoattractant protein-1 synthesis and secretion by human endothelial cells. 
Involvement of IL-4R alpha and Stat6 phosphorylation. Immunology, 1997. 
91(3): p. 450-7. 
545. Daines, M.O. and G.K. Hershey, A novel mechanism by which interferon-
gamma can regulate interleukin (IL)-13 responses. Evidence for intracellular 
stores of IL-13 receptor alpha -2 and their rapid mobilization by interferon-
gamma. J Biol Chem, 2002. 277(12): p. 10387-93. 
546. Zhou, Z.H., et al., Regulation of monocyte chemoattractant protein (MCP)-1 
transcription by interferon-gamma (IFN-gamma) in human astrocytoma cells: 
postinduction refractory state of the gene, governed by its upstream elements. 
FASEB J, 2001. 15(2): p. 383-92. 
547. Yamana, J., L. Santos, and E. Morand, Enhanced induction of LPS-induced 
fibroblast MCP-1 by interferon-gamma: involvement of JNK and MAPK 
phosphatase-1. Cell Immunol, 2009. 255(1-2): p. 26-32. 
548. Xing, Z., A. Zganiacz, and M. Santosuosso, Role of IL-12 in macrophage 
activation during intracellular infection: IL-12 and mycobacteria synergistically 
release TNF-alpha and nitric oxide from macrophages via IFN-gamma 
induction. J Leukoc Biol, 2000. 68(6): p. 897-902. 
549. Pallard, C., et al., Interleukin-3, erythropoietin, and prolactin activate a STAT5-
like factor in lymphoid cells. J Biol Chem, 1995. 270(27): p. 15942-5. 
550. Watson, C.J. and T.G. Burdon, Prolactin signal transduction mechanisms in the 
mammary gland: the role of the Jak/Stat pathway. Rev Reprod, 1996. 1(1): p. 1-
5. 
551. D'Atri, L.P., et al., The low viability of human CD34+ cells under acidic 
conditions is improved by exposure to thrombopoietin, stem cell factor, 
253 
 
 
interleukin-3, or increased cyclic adenosine monophosphate levels. 
Transfusion, 2011. 51(8): p. 1784-95. 
552. Hoshino, A., J.A. Hirst, and H. Fujii, Regulation of cell proliferation by 
interleukin-3-induced nuclear translocation of pyruvate kinase. J Biol Chem, 
2007. 282(24): p. 17706-11. 
553. Li, X., Y. Wu, and Y. Chen, Down-regulating the expression of IL-3Rbeta 
interfered with the proliferation, not differentiation in NB4 cells. Int J Hematol, 
2011. 93(1): p. 83-90. 
554. Luo, X.J., et al., The interleukin 3 gene (IL3) contributes to human brain volume 
variation by regulating proliferation and survival of neural progenitors. PLoS 
One, 2012. 7(11): p. e50375. 
555. Olazabal, I., et al., Prolactin (PRL)-PRL receptor system increases cell 
proliferation involving JNK (c-Jun amino terminal kinase) and AP-1 activation: 
inhibition by glucocorticoids. Mol Endocrinol, 2000. 14(4): p. 564-75. 
556. Nitze, L.M., et al., Reevaluation of the proposed autocrine proliferative function 
of prolactin in breast cancer. Breast Cancer Res Treat, 2013. 142(1): p. 31-44. 
557. Sengupta, A. and D.K. Sarkar, Roles of dopamine 2 receptor isoforms and g 
proteins in ethanol regulated prolactin synthesis and lactotropic cell 
proliferation. PLoS One, 2012. 7(9): p. e45593. 
558. Walker, T.L., et al., Prolactin stimulates precursor cells in the adult mouse 
hippocampus. PLoS One, 2012. 7(9): p. e44371. 
559. Wood, C.E., et al., Progestin effects on cell proliferation pathways in the 
postmenopausal mammary gland. Breast Cancer Res, 2013. 15(4): p. R62. 
560. Orsi, N.M., et al., Murine serum cytokines throughout the estrous cycle, 
pregnancy and postpartum period. Animal Reproduction Science, 2006. 96(1-
2): p. 54-65. 
561. Jiang, H., M.B. Harris, and P. Rothman, IL-4/IL-13 signaling beyond JAK/STAT. 
J Allergy Clin Immunol, 2000. 105(6 Pt 1): p. 1063-70. 
562. Fallon, P.G., et al., IL-4 induces characteristic Th2 responses even in the 
combined absence of IL-5, IL-9, and IL-13. Immunity, 2002. 17(1): p. 7-17. 
563. Gouon-Evans, V. and J.W. Pollard, Eotaxin is required for eosinophil homing 
into the stroma of the pubertal and cycling uterus. Endocrinology, 2001. 
142(10): p. 4515-21. 
564. Wakasa, T., et al., Change in morphology and oxytocin receptor expression in 
the uterine blood vessels during the involution process. Gynecol Obstet Invest, 
2009. 67(2): p. 137-44. 
254 
 
 
565. Gunduz, M.C., G. Kasikci, and H.H. Kaya, The effect of oxytocin and 
PGF2alpha on the uterine involution and pregnancy rates in postpartum 
Arabian mares. Anim Reprod Sci, 2008. 104(2-4): p. 257-63. 
566. Pitzel, L., H. Jarry, and W. Wuttke, Effects and interactions of prostaglandin F2 
alpha, oxytocin, and cytokines on steroidogenesis of porcine luteal cells. 
Endocrinology, 1993. 132(2): p. 751-6. 
567. Munoz-Suano, A., A.B. Hamilton, and A.G. Betz, Gimme shelter: the immune 
system during pregnancy. Immunol Rev, 2011. 241(1): p. 20-38. 
568. Glabinski, A.R., et al., TNF-alpha microinjection upregulates chemokines and 
chemokine receptors in the central nervous system without inducing leukocyte 
infiltration. J Interferon Cytokine Res, 2003. 23(8): p. 457-66. 
569. Liu, B., et al., Maternal hematopoietic TNF, via milk chemokines, programs 
hippocampal development and memory. Nat Neurosci, 2014. 17(1): p. 97-105. 
570. Renaud, S.J., R. Sullivan, and C.H. Graham, Tumour necrosis factor alpha 
stimulates the production of monocyte chemoattractants by extravillous 
trophoblast cells via differential activation of MAPK pathways. Placenta, 2009. 
30(4): p. 313-9. 
571. Gyftodimos, E. and P. Flach. Hierarchical Bayesian networks: a probabilistic 
reasoning model for structured domains. in Proceedings of the ICML-2002 
Workshop on Development of Representations. . 2002. 
572. Gougeon, A., Dynamics of follicular growth in the human: a model from 
preliminary results. Hum Reprod, 1986. 1(2): p. 81-7. 
573. Dissen, G.A., et al., Neurotrophic control of ovarian development. Microsc Res 
Tech, 2002. 59(6): p. 509-15. 
574. John, G.B., et al., Foxo3 is a PI3K-dependent molecular switch controlling the 
initiation of oocyte growth. Dev Biol, 2008. 321(1): p. 197-204. 
575. Brown, H.M. and D.L. Russell, Blood and lymphatic vasculature in the ovary: 
development, function and disease. Hum Reprod Update, 2014. 20(1): p. 29-39. 
576. Robinson, R.S., The critical importance of ovarian angiogenesis. Reprod Fertil 
Dev, 2013. 25(2): p. iii-v. 
577. Siu, M.K. and C.Y. Cheng, The blood-follicle barrier (BFB) in disease and in 
ovarian function. Adv Exp Med Biol, 2012. 763: p. 186-92. 
578. Oktay, K., D. Briggs, and R.G. Gosden, Ontogeny of follicle-stimulating 
hormone receptor gene expression in isolated human ovarian follicles. J Clin 
Endocrinol Metab, 1997. 82(11): p. 3748-51. 
255 
 
 
579. Hansen, K.R., et al., A new model of reproductive aging: the decline in ovarian 
non-growing follicle number from birth to menopause. Hum Reprod, 2008. 
23(3): p. 699-708. 
580. Kelsey, T.W., et al., Data-driven assessment of the human ovarian reserve. Mol 
Hum Reprod, 2012. 18(2): p. 79-87. 
581. Anderson, R.A., S.M. Nelson, and W.H. Wallace, Measuring anti-Mullerian 
hormone for the assessment of ovarian reserve: when and for whom is it 
indicated? Maturitas, 2012. 71(1): p. 28-33. 
582. Barnes, R.B., et al., The role of LH and FSH in ovarian androgen secretion and 
ovarian follicular development: clinical studies in a patient with isolated FSH 
deficiency and multicystic ovaries. Hum Reprod, 2002. 17(1): p. 88-91. 
583. Dierich, A., et al., Impairing follicle-stimulating hormone (FSH) signaling in vivo: 
targeted disruption of the FSH receptor leads to aberrant gametogenesis and 
hormonal imbalance. Proc Natl Acad Sci U S A, 1998. 95(23): p. 13612-7. 
584. Gougeon, A., Regulation of ovarian follicular development in primates: facts and 
hypotheses. Endocr Rev, 1996. 17(2): p. 121-55. 
585. Gougeon, A., Human ovarian follicular development: from activation of resting 
follicles to preovulatory maturation. Ann Endocrinol (Paris), 2010. 71(3): p. 132-
43. 
586. Wigglesworth, K., et al., Bidirectional communication between oocytes and 
ovarian follicular somatic cells is required for meiotic arrest of mammalian 
oocytes. Proc Natl Acad Sci U S A, 2013. 110(39): p. E3723-9. 
587. Albertini, D.F., et al., Cellular basis for paracrine regulation of ovarian follicle 
development. Reproduction, 2001. 121(5): p. 647-53. 
588. Makabe, S., T. Naguro, and T. Stallone, Oocyte-follicle cell interactions during 
ovarian follicle development, as seen by high resolution scanning and 
transmission electron microscopy in humans. Microsc Res Tech, 2006. 69(6): p. 
436-49. 
589. Bruzzone, R., T.W. White, and D.L. Paul, Connections with connexins: the 
molecular basis of direct intercellular signaling. Eur J Biochem, 1996. 238(1): p. 
1-27. 
590. Erickson, G.F. and D.R. Danforth, Ovarian control of follicle development. Am J 
Obstet Gynecol, 1995. 172(2 Pt 2): p. 736-47. 
591. Robinson, R.S., et al., Angiogenesis and vascular function in the ovary. 
Reproduction, 2009. 138(6): p. 869-81. 
592. Conti, M., et al., Role of cyclic nucleotide signaling in oocyte maturation. Mol 
Cell Endocrinol, 2002. 187(1-2): p. 153-9. 
256 
 
 
593. Norris, R.P., et al., Cyclic GMP from the surrounding somatic cells regulates 
cyclic AMP and meiosis in the mouse oocyte. Development, 2009. 136(11): p. 
1869-78. 
594. Edwards, R.G., Follicular fluid. J Reprod Fertil, 1974. 37(1): p. 189-219. 
595. Edwards, R.G., et al., Observations on preovulatory human ovarian follicles and 
their aspirates. Br J Obstet Gynaecol, 1980. 87(9): p. 769-79. 
596. Rodgers, R.J. and H.F. Irving-Rodgers, Formation of the Ovarian Follicular 
Antrum and Follicular Fluid. Biol Reprod, 2010. 
597. Jokubkiene, L., P. Sladkevicius, and L. Valentin, Number of antral follicles, 
ovarian volume, and vascular indices in asymptomatic women 20 to 39 years 
old as assessed by 3-dimensional sonography: a prospective cross-sectional 
study. J Ultrasound Med, 2012. 31(10): p. 1635-49. 
598. Erickson, G.F. and S. Shimasaki, The role of the oocyte in folliculogenesis. 
Trends Endocrinol Metab, 2000. 11(5): p. 193-8. 
599. Erickson, G.F. Follicle growth and development. Gynaecology and Obstetrics 
2004  [cited 2014 09/01/2014]; Available from: 
http://www.glowm.com/resources/glowm/cd/pages/v5/v5c012.html. 
600. Jones, K.T., Turning it on and off: M-phase promoting factor during meiotic 
maturation and fertilization. Mol Hum Reprod, 2004. 10(1): p. 1-5. 
601. Peng, X.R., et al., Localization of luteinizing hormone receptor messenger 
ribonucleic acid expression in ovarian cell types during follicle development and 
ovulation. Endocrinology, 1991. 129(6): p. 3200-7. 
602. Minegishi, T., et al., Expression of luteinizing hormone/human chorionic 
gonadotrophin (LH/HCG) receptor mRNA in the human ovary. Mol Hum 
Reprod, 1997. 3(2): p. 101-7. 
603. Pache, T.D., et al., Growth patterns of nondominant ovarian follicles during the 
normal menstrual cycle. Fertil Steril, 1990. 54(4): p. 638-42. 
604. Baird, D.T., Factors regulating the growth of the preovulatory follicle in the 
sheep and human. J Reprod Fertil, 1983. 69(1): p. 343-52. 
605. Oktem, O. and K. Oktay, The ovary: anatomy and function throughout human 
life. Ann N Y Acad Sci, 2008. 1127: p. 1-9. 
606. Birtch, R.L., et al., Ultrasound image attributes of human ovarian dominant 
follicles during natural and oral contraceptive cycles. Reprod Biol Endocrinol, 
2005. 3: p. 12. 
607. Celestino, J.J.H., et al., Mechanisms of atresia in ovarian follicles. Animal 
Reproduction, 2009. 6(4): p. 495-508. 
257 
 
 
608. Hussein, M.R., Apoptosis in the ovary: molecular mechanisms. Hum Reprod 
Update, 2005. 11(2): p. 162-77. 
609. Zackrisson, U., et al., Alterations of follicular microcirculation and apex structure 
during ovulation in the rat. Eur J Obstet Gynecol Reprod Biol, 2011. 
610. Oakley, O.R., et al., Periovulatory leukocyte infiltration in the rat ovary. 
Endocrinology, 2010. 151(9): p. 4551-9. 
611. Richards, J.S., Z. Liu, and M. Shimada, Immune-like mechanisms in ovulation. 
Trends Endocrinol Metab, 2008. 19(6): p. 191-6. 
612. Richards, J.S. and S.A. Pangas, New insights into ovarian function. Handb Exp 
Pharmacol, 2010(198): p. 3-27. 
613. Curry, T.E., Jr. and K.G. Osteen, The matrix metalloproteinase system: 
changes, regulation, and impact throughout the ovarian and uterine 
reproductive cycle. Endocr Rev, 2003. 24(4): p. 428-65. 
614. Penny, L.A., Monocyte chemoattractant protein 1 in luteolysis. Rev Reprod, 
2000. 5(2): p. 63-6. 
615. Duncan, W.C., The human corpus luteum: remodelling during luteolysis and 
maternal recognition of pregnancy. Rev Reprod, 2000. 5(1): p. 12-7. 
616. Knecht, M., et al., Gonadotropin-releasing hormone as a modulator of ovarian 
function. J Steroid Biochem, 1985. 23(5B): p. 771-8. 
617. Jiemtaweeboon, S., et al., Evidence that polymorphonuclear neutrophils 
infiltrate into the developing corpus luteum and promote angiogenesis with 
interleukin-8 in the cow. Reprod Biol Endocrinol, 2011. 9: p. 79. 
618. Schruefer, R., et al., Human neutrophils promote angiogenesis by a paracrine 
feedforward mechanism involving endothelial interleukin-8. Am J Physiol Heart 
Circ Physiol, 2005. 288(3): p. H1186-92. 
619. Penny, L.A., et al., Immune cells and cytokine production in the bovine corpus 
luteum throughout the oestrous cycle and after induced luteolysis. J Reprod 
Fertil, 1999. 115(1): p. 87-96. 
620. Wang, L.J., et al., Distribution of leukocyte subpopulations in the human corpus 
luteum. Hum Reprod, 1992. 7(2): p. 197-202. 
621. Castro, A., et al., Luteal leukocytes are modulators of the steroidogenic process 
of human mid-luteal cells. Hum Reprod, 1998. 13(6): p. 1584-9. 
622. Fan, H.Y. and Q.Y. Sun, Involvement of mitogen-activated protein kinase 
cascade during oocyte maturation and fertilization in mammals. Biol Reprod, 
2004. 70(3): p. 535-47. 
258 
 
 
623. Masui, Y., From oocyte maturation to the in vitro cell cycle: the history of 
discoveries of Maturation-Promoting Factor (MPF) and Cytostatic Factor (CSF). 
Differentiation, 2001. 69(1): p. 1-17. 
624. Greenstein, D., Control of oocyte meiotic maturation and fertilization. 
WormBook, 2005: p. 1-12. 
625. Krisher, R.L., The effect of oocyte quality on development. J Anim Sci, 2004. 82 
E-Suppl: p. E14-23. 
626. Ferreira, E.M., et al., Cytoplasmic maturation of bovine oocytes: structural and 
biochemical modifications and acquisition of developmental competence. 
Theriogenology, 2009. 71(5): p. 836-48. 
627. Coticchio, G., et al., Contributions of the actin cytoskeleton to the emergence of 
polarity during maturation in human oocytes. Mol Hum Reprod, 2014. 20(3): p. 
200-7. 
628. Coticchio, G., et al., Mechanistic foundations of the metaphase II spindle of 
human oocytes matured in vivo and in vitro. Hum Reprod, 2013. 28(12): p. 
3271-82. 
629. Brevini-Gandolfi, T.A., et al., Changes in poly(A) tail length of maternal 
transcripts during in vitro maturation of bovine oocytes and their relation with 
developmental competence. Mol Reprod Dev, 1999. 52(4): p. 427-33. 
630. Piccioni, F., V. Zappavigna, and A.C. Verrotti, Translational regulation during 
oogenesis and early development: the cap-poly(A) tail relationship. C R Biol, 
2005. 328(10-11): p. 863-81. 
631. Gosden, R.G., Oogenesis as a foundation for embryogenesis. Mol Cell 
Endocrinol, 2002. 186(2): p. 149-53. 
632. Krisher, R.L. and B.D. Bavister, Responses of oocytes and embryos to the 
culture environment. Theriogenology, 1998. 49(1): p. 103-14. 
633. Tomek, W., H. Torner, and W. Kanitz, Comparative analysis of protein 
synthesis, transcription and cytoplasmic polyadenylation of mRNA during 
maturation of bovine oocytes in vitro. Reprod Domest Anim, 2002. 37(2): p. 86-
91. 
634. Hosoe, M. and Y. Shioya, Distribution of cortical granules in bovine oocytes 
classified by cumulus complex. Zygote, 1997. 5(4): p. 371-6. 
635. Thibault, C., D. Szollosi, and M. Gerard, Mammalian oocyte maturation. Reprod 
Nutr Dev, 1987. 27(5): p. 865-96. 
636. Eppig, J.J., Oocyte control of ovarian follicular development and function in 
mammals. Reproduction, 2001. 122(6): p. 829-38. 
259 
 
 
637. Vinatier, D., et al., Immunological aspects of ovarian function: role of the 
cytokines. Eur J Obstet Gynecol Reprod Biol, 1995. 63(2): p. 155-68. 
638. Wilding, M., et al., An oocyte score for use in assisted reproduction. J Assist 
Reprod Genet, 2007. 24(8): p. 350-8. 
639. Oktay, K., et al., Interaction of extracellular matrix and activin-A in the initiation 
of follicle growth in the mouse ovary. Biol Reprod, 2000. 63(2): p. 457-61. 
640. Skinner, M.K., Regulation of primordial follicle assembly and development. Hum 
Reprod Update, 2005. 11(5): p. 461-71. 
641. Richards, J.S. and L. Hedin, Molecular aspects of hormone action in ovarian 
follicular development, ovulation, and luteinization. Annu Rev Physiol, 1988. 50: 
p. 441-63. 
642. Buccione, R., A.C. Schroeder, and J.J. Eppig, Interactions between somatic 
cells and germ cells throughout mammalian oogenesis. Biol Reprod, 1990. 
43(4): p. 543-7. 
643. Eppig, J.J., Oocyte-somatic cell interactions during oocyte growth and 
maturation in the mammal. Dev Biol (N Y 1985), 1985. 1: p. 313-47. 
644. Su, Y.Q., et al., Oocyte regulation of metabolic cooperativity between mouse 
cumulus cells and oocytes: BMP15 and GDF9 control cholesterol biosynthesis 
in cumulus cells. Development, 2008. 135(1): p. 111-21. 
645. Schams, D. and B. Berisha, Steroids as local regulators of ovarian activity in 
domestic animals. Domest Anim Endocrinol, 2002. 23(1-2): p. 53-65. 
646. Gilchrist, R.B., L.J. Ritter, and D.T. Armstrong, Oocyte-somatic cell interactions 
during follicle development in mammals. Anim Reprod Sci, 2004. 82-83: p. 431-
46. 
647. Sharkey, A., Cytokines and implantation. Rev Reprod, 1998. 3(1): p. 52-61. 
648. Kaipia, A. and A.J. Hsueh, Regulation of ovarian follicle atresia. Annu Rev 
Physiol, 1997. 59: p. 349-63. 
649. Bornstein, S.R., H. Rutkowski, and I. Vrezas, Cytokines and steroidogenesis. 
Mol Cell Endocrinol, 2004. 215(1-2): p. 135-41. 
650. Shimasaki, S., et al., The role of bone morphogenetic proteins in ovarian 
function. Reprod Suppl, 2003. 61: p. 323-37. 
651. Drummond, A.E., et al., Ovarian follicle populations of the rat express TGF-beta 
signalling pathways. Mol Cell Endocrinol, 2003. 202(1-2): p. 53-7. 
652. Bristol, S.K. and T.K. Woodruff, Follicle-restricted compartmentalization of 
transforming growth factor beta superfamily ligands in the feline ovary. Biol 
Reprod, 2004. 70(3): p. 846-59. 
260 
 
 
653. McNatty, K.P., et al., Oocyte-expressed genes affecting ovulation rate. Mol Cell 
Endocrinol, 2005. 234(1-2): p. 57-66. 
654. Wu, R., et al., Macrophage contributions to ovarian function. Hum Reprod 
Update, 2004. 10(2): p. 119-33. 
655. Asimakopoulos, B., et al., Cytokine and hormonal profile in blood serum and 
follicular fluids during ovarian stimulation with the multidose antagonist or the 
long agonist protocol. Hum Reprod, 2006. 21(12): p. 3091-5. 
656. Asimakopoulos, B., et al., Intrafollicular and circulating concentrations of leptin 
do not predict the outcome in IVF-ICSI cycles. Reprod Sci, 2009. 16(1): p. 113-
9. 
657. Best, C.L. and J.A. Hill, Cytokines in ovarian function, in Cytokines in human 
reproduction, J.A. Hill, Editor 2000, Wiley-Liss: New York. p. pp. 43-77. 
658. Tarrant, J.M., Blood cytokines as biomarkers of in vivo toxicity in preclinical 
safety assessment: considerations for their use. Toxicol Sci, 2010. 117(1): p. 4-
16. 
659. McLaughlin, E.A. and S.C. McIver, Awakening the oocyte: controlling primordial 
follicle development. Reproduction, 2009. 137(1): p. 1-11. 
660. Nilsson, E.E., P. Kezele, and M.K. Skinner, Leukemia inhibitory factor (LIF) 
promotes the primordial to primary follicle transition in rat ovaries. Mol Cell 
Endocrinol, 2002. 188(1-2): p. 65-73. 
661. Nilsson, E.E. and M.K. Skinner, Kit ligand and basic fibroblast growth factor 
interactions in the induction of ovarian primordial to primary follicle transition. 
Mol Cell Endocrinol, 2004. 214(1-2): p. 19-25. 
662. Wang, J. and S.K. Roy, Growth differentiation factor-9 and stem cell factor 
promote primordial follicle formation in the hamster: modulation by follicle-
stimulating hormone. Biol Reprod, 2004. 70(3): p. 577-85. 
663. Gougeon, A., et al., Kit ligand and the somatostatin receptor antagonist, BIM-
23627, stimulate in vitro resting follicle growth in the neonatal mouse ovary. 
Endocrinology, 2010. 151(3): p. 1299-309. 
664. Parrott, J.A. and M.K. Skinner, Kit-ligand/stem cell factor induces primordial 
follicle development and initiates folliculogenesis. Endocrinology, 1999. 140(9): 
p. 4262-71. 
665. da Nobrega, J.E., Jr., et al., Leukemia inhibitory factor stimulates the transition 
of primordial to primary follicle and supports the goat primordial follicle viability 
in vitro. Zygote, 2012. 20(1): p. 73-8. 
261 
 
 
666. Kezele, P., E.E. Nilsson, and M.K. Skinner, Keratinocyte growth factor acts as a 
mesenchymal factor that promotes ovarian primordial to primary follicle 
transition. Biol Reprod, 2005. 73(5): p. 967-73. 
667. Hutt, K.J., E.A. McLaughlin, and M.K. Holland, KIT/KIT ligand in mammalian 
oogenesis and folliculogenesis: roles in rabbit and murine ovarian follicle 
activation and oocyte growth. Biol Reprod, 2006. 75(3): p. 421-33. 
668. Yoshida, H., et al., Stepwise requirement of c-kit tyrosine kinase in mouse 
ovarian follicle development. Dev Biol, 1997. 184(1): p. 122-37. 
669. Packer, A.I., et al., The ligand of the c-kit receptor promotes oocyte growth. Dev 
Biol, 1994. 161(1): p. 194-205. 
670. Myers, M. and S.A. Pangas, Regulatory roles of transforming growth factor beta 
family members in folliculogenesis. Wiley Interdiscip Rev Syst Biol Med, 2010. 
2(1): p. 117-25. 
671. Massague, J. and D. Wotton, Transcriptional control by the TGF-beta/Smad 
signaling system. EMBO J, 2000. 19(8): p. 1745-54. 
672. von Bubnoff, A. and K.W. Cho, Intracellular BMP signaling regulation in 
vertebrates: pathway or network? Dev Biol, 2001. 239(1): p. 1-14. 
673. Kaivo-oja, N., et al., Smad signalling in the ovary. Reprod Biol Endocrinol, 2006. 
4: p. 21. 
674. Lee, W.S., et al., Effect of bone morphogenetic protein-7 on folliculogenesis and 
ovulation in the rat. Biol Reprod, 2001. 65(4): p. 994-9. 
675. Erickson, G.F. and S. Shimasaki, The spatiotemporal expression pattern of the 
bone morphogenetic protein family in rat ovary cell types during the estrous 
cycle. Reprod Biol Endocrinol, 2003. 1: p. 9. 
676. Sun, R.Z., et al., Expression of GDF-9, BMP-15 and their receptors in 
mammalian ovary follicles. J Mol Histol, 2010. 41(6): p. 325-32. 
677. Al-Musawi, S.L., et al., Species differences in the expression and activity of 
bone morphogenetic protein 15. Endocrinology, 2013. 154(2): p. 888-99. 
678. Di Pasquale, E., P. Beck-Peccoz, and L. Persani, Hypergonadotropic ovarian 
failure associated with an inherited mutation of human bone morphogenetic 
protein-15 (BMP15) gene. Am J Hum Genet, 2004. 75(1): p. 106-11. 
679. Holt, J.E., et al., CXCR4/SDF1 interaction inhibits the primordial to primary 
follicle transition in the neonatal mouse ovary. Dev Biol, 2006. 293(2): p. 449-
60. 
680. Ara, T., et al., Impaired colonization of the gonads by primordial germ cells in 
mice lacking a chemokine, stromal cell-derived factor-1 (SDF-1). Proc Natl 
Acad Sci U S A, 2003. 100(9): p. 5319-23. 
262 
 
 
681. Brannstrom, M. and R.J. Norman, Involvement of leukocytes and cytokines in 
the ovulatory process and corpus luteum function. Hum Reprod, 1993. 8(10): p. 
1762-75. 
682. Norman, R.J. and M. Brannstrom, White cells and the ovary--incidental invaders 
or essential effectors? J Endocrinol, 1994. 140(3): p. 333-6. 
683. Norman, R.J. and M. Brannstrom, Cytokines in the ovary: pathophysiology and 
potential for pharmacological intervention. Pharmacol Ther, 1996. 69(3): p. 219-
36. 
684. Mazerbourg, S. and A.J. Hsueh, Genomic analyses facilitate identification of 
receptors and signalling pathways for growth differentiation factor 9 and related 
orphan bone morphogenetic protein/growth differentiation factor ligands. Hum 
Reprod Update, 2006. 12(4): p. 373-83. 
685. Vitt, U.A., et al., Bone morphogenetic protein receptor type II is a receptor for 
growth differentiation factor-9. Biol Reprod, 2002. 67(2): p. 473-80. 
686. Hayashi, M., et al., Recombinant growth differentiation factor-9 (GDF-9) 
enhances growth and differentiation of cultured early ovarian follicles. 
Endocrinology, 1999. 140(3): p. 1236-44. 
687. Carabatsos, M.J., et al., Characterization of oocyte and follicle development in 
growth differentiation factor-9-deficient mice. Dev Biol, 1998. 204(2): p. 373-84. 
688. Vitt, U.A., et al., In vivo treatment with GDF-9 stimulates primordial and primary 
follicle progression and theca cell marker CYP17 in ovaries of immature rats. 
Endocrinology, 2000. 141(10): p. 3814-20. 
689. Bodensteiner, K.J., et al., Molecular cloning of the ovine Growth/Differentiation 
factor-9 gene and expression of growth/differentiation factor-9 in ovine and 
bovine ovaries. Biol Reprod, 1999. 60(2): p. 381-6. 
690. Jaatinen, R., et al., Localization of growth differentiation factor-9 (GDF-9) 
mRNA and protein in rat ovaries and cDNA cloning of rat GDF-9 and its novel 
homolog GDF-9B. Mol Cell Endocrinol, 1999. 156(1-2): p. 189-93. 
691. Hreinsson, J.G., et al., Growth differentiation factor-9 promotes the growth, 
development, and survival of human ovarian follicles in organ culture. J Clin 
Endocrinol Metab, 2002. 87(1): p. 316-21. 
692. Kedem, A., et al., Growth differentiating factor 9 (GDF9) and bone 
morphogenetic protein 15 both activate development of human primordial 
follicles in vitro, with seemingly more beneficial effects of GDF9. J Clin 
Endocrinol Metab, 2011. 96(8): p. E1246-54. 
693. Durlinger, A.L., J.A. Visser, and A.P. Themmen, Regulation of ovarian function: 
the role of anti-Mullerian hormone. Reproduction, 2002. 124(5): p. 601-9. 
263 
 
 
694. Durlinger, A.L., et al., Control of primordial follicle recruitment by anti-Mullerian 
hormone in the mouse ovary. Endocrinology, 1999. 140(12): p. 5789-96. 
695. Knauff, E.A., et al., Anti-Mullerian hormone, inhibin B, and antral follicle count in 
young women with ovarian failure. J Clin Endocrinol Metab, 2009. 94(3): p. 786-
92. 
696. Hagen, C.P., et al., Serum levels of anti-Mullerian hormone as a marker of 
ovarian function in 926 healthy females from birth to adulthood and in 172 
Turner syndrome patients. J Clin Endocrinol Metab, 2010. 95(11): p. 5003-10. 
697. Voorhuis, M., et al., Genes involved in initial follicle recruitment may be 
associated with age at menopause. J Clin Endocrinol Metab, 2011. 96(3): p. 
E473-9. 
698. Weenen, C., et al., Anti-Mullerian hormone expression pattern in the human 
ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum 
Reprod, 2004. 10(2): p. 77-83. 
699. Rajpert-De Meyts, E., et al., Expression of anti-Mullerian hormone during 
normal and pathological gonadal development: association with differentiation 
of Sertoli and granulosa cells. J Clin Endocrinol Metab, 1999. 84(10): p. 3836-
44. 
700. Grondahl, M.L., et al., Anti-Mullerian hormone remains highly expressed in 
human cumulus cells during the final stages of folliculogenesis. Reprod Biomed 
Online, 2011. 22(4): p. 389-98. 
701. Otsuka, F., et al., Bone morphogenetic protein-15 inhibits follicle-stimulating 
hormone (FSH) action by suppressing FSH receptor expression. J Biol Chem, 
2001. 276(14): p. 11387-92. 
702. Drummond, A.E., et al., Expression and localization of activin receptors, 
Smads, and beta glycan to the postnatal rat ovary. Endocrinology, 2002. 
143(4): p. 1423-33. 
703. Otsuka, F. and S. Shimasaki, A negative feedback system between oocyte 
bone morphogenetic protein 15 and granulosa cell kit ligand: its role in 
regulating granulosa cell mitosis. Proc Natl Acad Sci U S A, 2002. 99(12): p. 
8060-5. 
704. Shimizu, T., et al., Gene injections of vascular endothelial growth factor and 
growth differentiation factor-9 stimulate ovarian follicular development in 
immature female rats. Fertil Steril, 2008. 89(5 Suppl): p. 1563-70. 
705. Shimizu, T., Promotion of ovarian follicular development by injecting vascular 
endothelial growth factor (VEGF) and growth differentiation factor 9 (GDF-9) 
genes. J Reprod Dev, 2006. 52(1): p. 23-32. 
264 
 
 
706. Cerrillo, M., et al., Differential regulation of VEGF after final oocyte maturation 
with GnRH agonist versus hCG: a rationale for OHSS reduction. Fertil Steril, 
2009. 91(4 Suppl): p. 1526-8. 
707. Juengel, J.L., et al., Physiology of GDF9 and BMP15 signalling molecules. 
Anim Reprod Sci, 2004. 82-83: p. 447-60. 
708. Elvin, J.A., et al., Molecular characterization of the follicle defects in the growth 
differentiation factor 9-deficient ovary. Mol Endocrinol, 1999. 13(6): p. 1018-34. 
709. Elvin, J.A., et al., Paracrine actions of growth differentiation factor-9 in the 
mammalian ovary. Mol Endocrinol, 1999. 13(6): p. 1035-48. 
710. Spicer, L.J., et al., Growth differentiation factor 9 (GDF9) stimulates proliferation 
and inhibits steroidogenesis by bovine theca cells: influence of follicle size on 
responses to GDF9. Biol Reprod, 2008. 78(2): p. 243-53. 
711. Vitt, U.A., et al., Growth differentiation factor-9 stimulates proliferation but 
suppresses the follicle-stimulating hormone-induced differentiation of cultured 
granulosa cells from small antral and preovulatory rat follicles. Biol Reprod, 
2000. 62(2): p. 370-7. 
712. Dragovic, R.A., et al., Role of oocyte-secreted growth differentiation factor 9 in 
the regulation of mouse cumulus expansion. Endocrinology, 2005. 146(6): p. 
2798-806. 
713. Gospodarowicz, D., et al., Corpus luteum angiogenic factor is related to 
fibroblast growth factor. Endocrinology, 1985. 117(6): p. 2383-91. 
714. Brown, L.F., et al., Vascular permeability factor/vascular endothelial growth 
factor: a multifunctional angiogenic cytokine. EXS, 1997. 79: p. 233-69. 
715. Chaves, R.N., et al., The fibroblast growth factor family: involvement in the 
regulation of folliculogenesis. Reprod Fertil Dev, 2012. 24(7): p. 905-15. 
716. Joo, J.K., et al., Role of leptin in improvement of oocyte quality by regulation of 
ovarian angiogenesis. Anim Reprod Sci, 2010. 119(3-4): p. 329-34. 
717. Araujo, V.R., et al., Importance of vascular endothelial growth factor (VEGF) in 
ovarian physiology of mammals. Zygote, 2013. 21(3): p. 295-304. 
718. McFee, R.M., T.G. Rozell, and A.S. Cupp, The balance of proangiogenic and 
antiangiogenic VEGFA isoforms regulate follicle development. Cell Tissue Res, 
2012. 349(3): p. 635-47. 
719. Fraser, H.M., Regulation of the ovarian follicular vasculature. Reprod Biol 
Endocrinol, 2006. 4: p. 18. 
720. Ryan, K.J. and A. Makris, Significance of angiogenic and growth factors in 
ovarian follicular development. Adv Exp Med Biol, 1987. 219: p. 203-9. 
265 
 
 
721. Yang, P. and S.K. Roy, Epidermal growth factor modulates transforming growth 
factor receptor messenger RNA and protein levels in hamster preantral follicles 
in vitro. Biol Reprod, 2001. 65(3): p. 847-54. 
722. Roy, S.K. and A.R. Kole, Ovarian transforming growth factor-beta (TGF-beta) 
receptors: in-vitro effects of follicle stimulating hormone, epidermal growth 
factor and TGF-beta on receptor expression in human preantral follicles. Mol 
Hum Reprod, 1998. 4(3): p. 207-14. 
723. Jin, X., et al., Signal transduction of stem cell factor in promoting early follicle 
development. Mol Cell Endocrinol, 2005. 229(1-2): p. 3-10. 
724. Parrott, J.A. and M.K. Skinner, Direct actions of kit-ligand on theca cell growth 
and differentiation during follicle development. Endocrinology, 1997. 138(9): p. 
3819-27. 
725. Goritz, F., K. Jewgenow, and H.H. Meyer, Epidermal growth factor and 
epidermal growth factor receptor in the ovary of the domestic cat (Felis catus). J 
Reprod Fertil, 1996. 106(1): p. 117-24. 
726. Driancourt, M.A., et al., Roles of KIT and KIT LIGAND in ovarian function. Rev 
Reprod, 2000. 5(3): p. 143-52. 
727. Portela, V.M., et al., Expression and function of fibroblast growth factor 18 in the 
ovarian follicle in cattle. Biol Reprod, 2010. 83(3): p. 339-46. 
728. Buratini, J., Jr., et al., Expression and function of fibroblast growth factor 10 and 
its receptor, fibroblast growth factor receptor 2B, in bovine follicles. Biol Reprod, 
2007. 77(4): p. 743-50. 
729. Almeida, A.P., et al., Gene expression and immunolocalization of fibroblast 
growth factor 2 in the ovary and its effect on the in vitro culture of caprine 
preantral ovarian follicles. Reprod Domest Anim, 2012. 47(1): p. 20-5. 
730. Matos, M.H., et al., Follicle stimulating hormone and fibroblast growth factor-2 
interact and promote goat primordial follicle development in vitro. Reprod Fertil 
Dev, 2007. 19(5): p. 677-84. 
731. Matos, M.H., et al., Effects of fibroblast growth factor-2 on the in vitro culture of 
caprine preantral follicles. Cells Tissues Organs, 2007. 186(2): p. 112-20. 
732. Schams, D., et al., Expression and possible role of fibroblast growth factor 
family members in porcine antral follicles during final maturation. Reproduction, 
2009. 138(1): p. 141-9. 
733. Matsuura, T., et al., Anti-macrophage inhibitory factor antibody inhibits PMSG-
hCG-induced follicular growth and ovulation in mice. J Assist Reprod Genet, 
2002. 19(12): p. 591-5. 
266 
 
 
734. Wu, R., et al., Ovarian leukocyte distribution and cytokine/chemokine mRNA 
expression in follicular fluid cells in women with polycystic ovary syndrome. 
Hum Reprod, 2007. 22(2): p. 527-35. 
735. Tingen, C.M., et al., A macrophage and theca cell-enriched stromal cell 
population influences growth and survival of immature murine follicles in vitro. 
Reproduction, 2011. 141(6): p. 809-20. 
736. Gueripel, X., V. Brun, and A. Gougeon, Oocyte bone morphogenetic protein 15, 
but not growth differentiation factor 9, is increased during gonadotropin-induced 
follicular development in the immature mouse and is associated with cumulus 
oophorus expansion. Biol Reprod, 2006. 75(6): p. 836-43. 
737. Mottershead, D.G., L.J. Ritter, and R.B. Gilchrist, Signalling pathways mediating 
specific synergistic interactions between GDF9 and BMP15. Mol Hum Reprod, 
2012. 18(3): p. 121-8. 
738. Durlinger, A.L., et al., Anti-Mullerian hormone attenuates the effects of FSH on 
follicle development in the mouse ovary. Endocrinology, 2001. 142(11): p. 
4891-9. 
739. Juengel, J.L., et al., Growth differentiation factor 9 and bone morphogenetic 
protein 15 are essential for ovarian follicular development in sheep. Biol 
Reprod, 2002. 67(6): p. 1777-89. 
740. Myllymaa, S., et al., Inhibition of oocyte growth factors in vivo modulates 
ovarian folliculogenesis in neonatal and immature mice. Reproduction, 2010. 
139(3): p. 587-98. 
741. Otsuka, F., et al., Bone morphogenetic protein-15. Identification of target cells 
and biological functions. J Biol Chem, 2000. 275(50): p. 39523-8. 
742. Fatehi, A.N., et al., Expression of bone morphogenetic protein2 (BMP2), BMP4 
and BMP receptors in the bovine ovary but absence of effects of BMP2 and 
BMP4 during IVM on bovine oocyte nuclear maturation and subsequent embryo 
development. Theriogenology, 2005. 63(3): p. 872-89. 
743. Adashi, E.Y., The IGF family and folliculogenesis. J Reprod Immunol, 1998. 
39(1-2): p. 13-9. 
744. Scheele, F. and J. Schoemaker, The role of follicle-stimulating hormone in the 
selection of follicles in human ovaries: a survey of the literature and a proposed 
model. Gynecol Endocrinol, 1996. 10(1): p. 55-66. 
745. Cheng, Y., et al., Oocyte-expressed interleukin 7 suppresses granulosa cell 
apoptosis and promotes oocyte maturation in rats. Biol Reprod, 2011. 84(4): p. 
707-14. 
267 
 
 
746. Sriperumbudur, R., L. Zorrilla, and J.E. Gadsby, Transforming growth factor-
beta (TGFbeta) and its signaling components in peri-ovulatory pig follicles. 
Anim Reprod Sci, 2010. 120(1-4): p. 84-94. 
747. Teerds, K.J. and J.H. Dorrington, Immunohistochemical localization of 
transforming growth factor-beta 1 and -beta 2 during follicular development in 
the adult rat ovary. Mol Cell Endocrinol, 1992. 84(1-2): p. R7-13. 
748. Ghiglieri, C., et al., Immunolocalization of transforming growth factor-beta 1 and 
transforming growth factor-beta 2 in the mouse ovary during gonadotrophin-
induced follicular maturation. Hum Reprod, 1995. 10(8): p. 2115-9. 
749. Steffl, M., M. Schweiger, and W.M. Amselgruber, Expression of transforming 
growth factor-beta3 (TGF-beta3) in the porcine ovary during the oestrus cycle. 
Histol Histopathol, 2008. 23(6): p. 665-71. 
750. Juengel, J.L. and K.P. McNatty, The role of proteins of the transforming growth 
factor-beta superfamily in the intraovarian regulation of follicular development. 
Hum Reprod Update, 2005. 11(2): p. 143-60. 
751. Dunkel, L., et al., Follicle-stimulating hormone receptor expression in the rat 
ovary: increases during prepubertal development and regulation by the 
opposing actions of transforming growth factors beta and alpha. Biol Reprod, 
1994. 50(4): p. 940-8. 
752. Kuo, S.W., et al., Potential role of follicle-stimulating hormone (FSH) and 
transforming growth factor (TGFbeta1) in the regulation of ovarian 
angiogenesis. J Cell Physiol, 2011. 226(6): p. 1608-19. 
753. Ouellette, Y., C.A. Price, and P.D. Carriere, Follicular fluid concentration of 
transforming growth factor-beta1 is negatively correlated with estradiol and 
follicle size at the early stage of development of the first-wave cohort of bovine 
ovarian follicles. Domest Anim Endocrinol, 2005. 29(4): p. 623-33. 
754. Ye, Y., et al., Kit ligand promotes first polar body extrusion of mouse 
preovulatory oocytes. Reprod Biol Endocrinol, 2009. 7: p. 26. 
755. Silva, J.R., et al., The Kit ligand/c-Kit receptor system in goat ovaries: gene 
expression and protein localization. Zygote, 2006. 14(4): p. 317-28. 
756. Miyoshi, T., et al., Regulatory role of kit ligand-c-kit interaction and oocyte 
factors in steroidogenesis by rat granulosa cells. Mol Cell Endocrinol, 2012. 
358(1): p. 18-26. 
757. Ito, M., et al., Hepatocyte growth factor and stem cell factor involvement in 
paracrine interplays of theca and granulosa cells in the human ovary. Fertil 
Steril, 2001. 75(5): p. 973-9. 
268 
 
 
758. Tanikawa, M., et al., Presence of stem cell factor in follicular fluid and its 
expression in the human ovary. Fertil Steril, 2000. 73(6): p. 1259-60. 
759. Reynaud, K., et al., Effects of Kit Ligand and anti-Kit antibody on growth of 
cultured mouse preantral follicles. Mol Reprod Dev, 2000. 56(4): p. 483-94. 
760. Son, D.S., et al., Tumor necrosis factor alpha (TNF) increases granulosa cell 
proliferation: dependence on c-Jun and TNF receptor type 1. Endocrinology, 
2004. 145(3): p. 1218-26. 
761. Son, D.S., K.F. Roby, and P.F. Terranova, Tumor necrosis factor-alpha induces 
serum amyloid A3 in mouse granulosa cells. Endocrinology, 2004. 145(5): p. 
2245-52. 
762. Cui, L.L., et al., Tumor necrosis factor alpha knockout increases fertility of mice. 
Theriogenology, 2011. 75(5): p. 867-76. 
763. Kondo, H., T. Maruo, and M. Mochizuki, Immunohistochemical evidence for the 
presence of tumor necrosis factor-alpha in the infant and adult human ovary. 
Endocr J, 1995. 42(6): p. 771-80. 
764. Tartaglia, L.A., et al., The two different receptors for tumor necrosis factor 
mediate distinct cellular responses. Proc Natl Acad Sci U S A, 1991. 88(20): p. 
9292-6. 
765. Brune, B., Nitric oxide: NO apoptosis or turning it ON? Cell Death Differ, 2003. 
10(8): p. 864-9. 
766. Brunswig-Spickenheier, B. and A.K. Mukhopadhyay, Stimulation of nitric oxide-
cyclic guanosine monophosphate pathway in bovine ovarian theca cells by 
tumor necrosis factor alpha (TNF alpha). Is this pathway implicated in the TNF 
alpha-induced inhibition of luteinizing hormone-stimulated prorenin production? 
Biol Reprod, 1997. 57(4): p. 700-6. 
767. Rosselli, M., P.J. Keller, and R.K. Dubey, Role of nitric oxide in the biology, 
physiology and pathophysiology of reproduction. Hum Reprod Update, 1998. 
4(1): p. 3-24. 
768. Matsumi, H., et al., Regulation of nitric oxide synthase to promote cytostasis in 
ovarian follicular development. Biol Reprod, 2000. 63(1): p. 141-6. 
769. Hattori, M., et al., Nitric oxide: a modulator for the epidermal growth factor 
receptor expression in developing ovarian granulosa cells. Am J Physiol, 1996. 
270(3 Pt 1): p. C812-8. 
770. Jaaskelainen, M., et al., TRAIL pathway components and their putative role in 
granulosa cell apoptosis in the human ovary. Differentiation, 2009. 77(4): p. 
369-76. 
269 
 
 
771. Maeda, A., et al., Changes in expression of interleukin-6 receptors in granulosa 
cells during follicular atresia in pig ovaries. J Reprod Dev, 2007. 53(4): p. 727-
36. 
772. Kawasaki, F., et al., The clinical role of interleukin-6 and interleukin-6 soluble 
receptor in human follicular fluids. Clin Exp Med, 2003. 3(1): p. 27-31. 
773. Belayet, H.M., et al., Pharmacologic doses of interleukin 8 suppositories induce 
follicular maturation in rabbits. Cytokine, 2000. 12(4): p. 361-7. 
774. Kawano, Y., et al., The effects of epidermal growth factor and transforming 
growth factor-alpha on secretion of interleukin-8 and growth-regulated 
oncogene-alpha in human granulosa-lutein cells. Gynecol Obstet Invest, 2012. 
73(3): p. 189-94. 
775. Hebert, C.A. and J.B. Baker, Interleukin-8: a review. Cancer Invest, 1993. 11(6): 
p. 743-50. 
776. Mukaida, N., et al., Molecular mechanism of interleukin-8 gene expression. J 
Leukoc Biol, 1994. 56(5): p. 554-8. 
777. Koch, A.E., et al., Interleukin-8 as a macrophage-derived mediator of 
angiogenesis. Science, 1992. 258(5089): p. 1798-801. 
778. Yoshino, O., et al., Upregulation of interleukin-8 by hypoxia in human ovaries. 
Am J Reprod Immunol, 2003. 50(4): p. 286-90. 
779. Hickey, M.M. and M.C. Simon, Regulation of angiogenesis by hypoxia and 
hypoxia-inducible factors. Curr Top Dev Biol, 2006. 76: p. 217-57. 
780. Arici, A., et al., Interleukin-8 expression and modulation in human preovulatory 
follicles and ovarian cells. Endocrinology, 1996. 137(9): p. 3762-9. 
781. Goto, J., et al., Morphological analyses of interleukin-8 effects on rat ovarian 
follicles at ovulation and luteinization in vivo. Cytokine, 2002. 20(4): p. 168-73. 
782. Murayama, C., et al., Effect of VEGF (vascular endothelial growth factor) on 
expression of IL-8 (interleukin-8), IL-1beta and their receptors in bovine theca 
cells. Cell Biol Int, 2010. 34(5): p. 531-6. 
783. Pancarci, S.M., et al., Nitric oxide concentrations, estradiol-17beta 
progesterone ratio in follicular fluid, and COC quality with respect to 
perifollicular blood flow in cows. Anim Reprod Sci, 2012. 130(1-2): p. 9-15. 
784. Lord, G.M., Leptin as a proinflammatory cytokine. Contrib Nephrol, 2006. 151: 
p. 151-64. 
785. Serke, H., et al., Leptin-deficient (ob/ob) mouse ovaries show fatty 
degeneration, enhanced apoptosis and decreased expression of steroidogenic 
acute regulatory enzyme. Int J Obes (Lond), 2012. 36(8): p. 1047-53. 
270 
 
 
786. Magni, P., et al., Expression of a leptin receptor in immortalized gonadotropin-
releasing hormone-secreting neurons. Endocrinology, 1999. 140(4): p. 1581-5. 
787. De Biasi, S.N., L.I. Apfelbaum, and M.E. Apfelbaum, In vitro effect of leptin on 
LH release by anterior pituitary glands from female rats at the time of 
spontaneous and steroid-induced LH surge. Eur J Endocrinol, 2001. 145(5): p. 
659-65. 
788. Spicer, L.J. and C.C. Francisco, The adipose obese gene product, leptin: 
evidence of a direct inhibitory role in ovarian function. Endocrinology, 1997. 
138(8): p. 3374-9. 
789. Spicer, L.J., C.S. Chamberlain, and C.C. Francisco, Ovarian action of leptin: 
effects on insulin-like growth factor-I-stimulated function of granulosa and thecal 
cells. Endocrine, 2000. 12(1): p. 53-9. 
790. Spicer, L.J. and C.C. Francisco, Adipose obese gene product, leptin, inhibits 
bovine ovarian thecal cell steroidogenesis. Biol Reprod, 1998. 58(1): p. 207-12. 
791. Agarwal, S.K., et al., Leptin antagonizes the insulin-like growth factor-I 
augmentation of steroidogenesis in granulosa and theca cells of the human 
ovary. J Clin Endocrinol Metab, 1999. 84(3): p. 1072-6. 
792. Brannian, J.D., Y. Zhao, and M. McElroy, Leptin inhibits gonadotrophin-
stimulated granulosa cell progesterone production by antagonizing insulin 
action. Hum Reprod, 1999. 14(6): p. 1445-8. 
793. Zachow, R.J. and D.A. Magoffin, Direct intraovarian effects of leptin: impairment 
of the synergistic action of insulin-like growth factor-I on follicle-stimulating 
hormone-dependent estradiol-17 beta production by rat ovarian granulosa cells. 
Endocrinology, 1997. 138(2): p. 847-50. 
794. Ruiz-Cortes, Z.T., et al., Biphasic effects of leptin in porcine granulosa cells. 
Biol Reprod, 2003. 68(3): p. 789-96. 
795. Zackrisson, U., et al., Alterations of follicular microcirculation and apex structure 
during ovulation in the rat. Eur J Obstet Gynecol Reprod Biol, 2011. 157(2): p. 
169-74. 
796. Martoriati, A. and N. Gerard, Interleukin-1 (IL-1) system gene expression in 
granulosa cells: kinetics during terminal preovulatory follicle maturation in the 
mare. Reprod Biol Endocrinol, 2003. 1: p. 42. 
797. Martoriati, A., et al., Inhibition of in vitro maturation of equine oocytes by 
interleukin 1 beta via specific IL-1 receptors. Reproduction, 2003. 126(4): p. 
509-15. 
271 
 
 
798. Martoriati, A., et al., Expression of interleukin-1 (IL-1) system genes in equine 
cumulus-oocyte complexes and influence of IL-1beta during in vitro maturation. 
Biol Reprod, 2002. 67(2): p. 630-6. 
799. Loret de Mola, J.R., et al., Gonadotropins induce the release of interleukin-1 
beta, interleukin-6 and tumor necrosis factor-alpha from the human preovulatory 
follicle. Am J Reprod Immunol, 1998. 39(6): p. 387-90. 
800. Levitas, E., et al., Periovulatory and interleukin-1 beta-dependent up-regulation 
of intraovarian vascular endothelial growth factor (VEGF) in the rat: potential 
role for VEGF in the promotion of periovulatory angiogenesis and vascular 
permeability. J Soc Gynecol Investig, 2000. 7(1): p. 51-60. 
801. Adashi, E.Y., The potential role of interleukin-1 in the ovulatory process: an 
evolving hypothesis. Mol Cell Endocrinol, 1998. 140(1-2): p. 77-81. 
802. Machelon, V., et al., Macrophage and granulosa interleukin-1 beta mRNA in 
human ovulatory follicles. Hum Reprod, 1995. 10(8): p. 2198-203. 
803. Wang, X.F., F.Q. Xing, and S.L. Chen, Interleukin-1beta expression on ovarian 
granulosa cells and its clinical implication in women undergoing in vitro 
fertilization. Di Yi Jun Yi Da Xue Xue Bao, 2002. 22(10): p. 934-6. 
804. Caillaud, M., G. Duchamp, and N. Gerard, In vivo effect of interleukin-1beta and 
interleukin-1RA on oocyte cytoplasmic maturation, ovulation, and early 
embryonic development in the mare. Reprod Biol Endocrinol, 2005. 3: p. 26. 
805. Martoriati, A., G. Duchamp, and N. Gerard, In vivo effect of epidermal growth 
factor, interleukin-1beta, and interleukin-1RA on equine preovulatory follicles. 
Biol Reprod, 2003. 68(5): p. 1748-54. 
806. Gottschall, P.E., et al., Interleukin 1: an inhibitor of luteinizing hormone receptor 
formation in cultured rat granulosa cells. FASEB J, 1988. 2(9): p. 2492-6. 
807. Karakji, E.G. and B.K. Tsang, Regulation of rat granulosa cell plasminogen 
activator system: influence of interleukin-1 beta and ovarian follicular 
development. Biol Reprod, 1995. 53(6): p. 1302-10. 
808. Tao, M., et al., Possible contribution of follicular interleukin-1beta to nitric oxide 
generation in human pre-ovulatory follicles. Hum Reprod, 1997. 12(10): p. 
2220-5. 
809. Tanaka, T., et al., Induction of VEGF gene transcription by IL-1 beta is 
mediated through stress-activated MAP kinases and Sp1 sites in cardiac 
myocytes. J Mol Cell Cardiol, 2000. 32(11): p. 1955-67. 
810. Jung, Y.D., et al., Vascular endothelial growth factor is upregulated by 
interleukin-1 beta in human vascular smooth muscle cells via the P38 mitogen-
activated protein kinase pathway. Angiogenesis, 2001. 4(2): p. 155-62. 
272 
 
 
811. Richards, J.S., Hormonal control of gene expression in the ovary. Endocr Rev, 
1994. 15(6): p. 725-51. 
812. Ashkenazi, H., et al., Epidermal growth factor family members: endogenous 
mediators of the ovulatory response. Endocrinology, 2005. 146(1): p. 77-84. 
813. Park, J.Y., et al., EGF-like growth factors as mediators of LH action in the 
ovulatory follicle. Science, 2004. 303(5658): p. 682-4. 
814. Asano, K., et al., Interferon gamma induces prostaglandin G/H synthase-2 
through an autocrine loop via the epidermal growth factor receptor in human 
bronchial epithelial cells. J Clin Invest, 1997. 99(5): p. 1057-63. 
815. Ben-Ami, I., et al., PGE2 up-regulates EGF-like growth factor biosynthesis in 
human granulosa cells: new insights into the coordination between PGE2 and 
LH in ovulation. Mol Hum Reprod, 2006. 12(10): p. 593-9. 
816. Shimada, M., et al., Paracrine and autocrine regulation of epidermal growth 
factor-like factors in cumulus oocyte complexes and granulosa cells: key roles 
for prostaglandin synthase 2 and progesterone receptor. Mol Endocrinol, 2006. 
20(6): p. 1352-65. 
817. Su, Y.Q., et al., Mouse oocytes enable LH-induced maturation of the cumulus-
oocyte complex via promoting EGF receptor-dependent signaling. Mol 
Endocrinol, 2010. 24(6): p. 1230-9. 
818. Sugiura, K., et al., Estrogen promotes the development of mouse cumulus cells 
in coordination with oocyte-derived GDF9 and BMP15. Mol Endocrinol, 2010. 
24(12): p. 2303-14. 
819. Liu, Z., et al., Interleukin-6: an autocrine regulator of the mouse cumulus cell-
oocyte complex expansion process. Endocrinology, 2009. 150(7): p. 3360-8. 
820. Szukiewicz, D., et al., Mast cell-derived interleukin-8 may be involved in the 
ovarian mechanisms of follicle growth and ovulation. Inflamm Res, 2007. 56 
Suppl 1: p. S35-6. 
821. Runesson, E., et al., The human preovulatory follicle is a source of the 
chemotactic cytokine interleukin-8. Mol Hum Reprod, 1996. 2(4): p. 245-50. 
822. Runesson, E., et al., Gonadotropin- and cytokine-regulated expression of the 
chemokine interleukin 8 in the human preovulatory follicle of the menstrual 
cycle. J Clin Endocrinol Metab, 2000. 85(11): p. 4387-95. 
823. Ujioka, T., et al., Interleukin-8 as an essential factor in the human chorionic 
gonadotropin-induced rabbit ovulatory process: interleukin-8 induces neutrophil 
accumulation and activation in ovulation. Biol Reprod, 1998. 58(2): p. 526-30. 
273 
 
 
824. Malizia, B.A., et al., The human ovarian follicular fluid level of interleukin-8 is 
associated with follicular size and patient age. Fertil Steril, 2010. 93(2): p. 537-
43. 
825. Santos, M.A., E.W. Kuijk, and N.S. Macklon, The impact of ovarian stimulation 
for IVF on the developing embryo. Reproduction, 2009. 139(1): p. 23-34. 
826. Macklon, N.S., et al., The science behind 25 years of ovarian stimulation for in 
vitro fertilization. Endocr Rev, 2006. 27(2): p. 170-207. 
827. Rienzi, L., G. Vajta, and F. Ubaldi, Predictive value of oocyte morphology in 
human IVF: a systematic review of the literature. Hum Reprod Update, 2011. 
17(1): p. 34-45. 
828. Veeck, L.L., Oocyte assessment and biological performance. Ann N Y Acad 
Sci, 1988. 541: p. 259-74. 
829. El-Talatini, M.R., et al., Localisation and function of the endocannabinoid 
system in the human ovary. PLoS One, 2009. 4(2): p. e4579. 
830. Liu, S., et al., Evaluation of the immature human oocytes from unstimulated 
cycles in polycystic ovary syndrome patients using a novel scoring system. 
Fertil Steril, 2010. 93(7): p. 2202-9. 
831. Balaban, B. and B. Urman, Effect of oocyte morphology on embryo 
development and implantation. Reprod Biomed Online, 2006. 12(5): p. 608-15. 
832. Patrizio, P., et al., Molecular methods for selection of the ideal oocyte. Reprod 
Biomed Online, 2007. 15(3): p. 346-53. 
833. Johnson, L.N., et al., Does intracytoplasmic sperm injection improve the 
fertilization rate and decrease the total fertilization failure rate in couples with 
well-defined unexplained infertility? A systematic review and meta-analysis. 
Fertil Steril, 2013. 100(3): p. 704-11. 
834. Kuliev, A., et al., Chromosomal abnormalities in a series of 6,733 human 
oocytes in preimplantation diagnosis for age-related aneuploidies. Reprod 
Biomed Online, 2003. 6(1): p. 54-9. 
835. Bermudez, M.G., et al., Expression profiles of individual human oocytes using 
microarray technology. Reprod Biomed Online, 2004. 8(3): p. 325-37. 
836. Rattanachaiyanont, M., A. Leader, and M.C. Leveille, Lack of correlation 
between oocyte-corona-cumulus complex morphology and nuclear maturity of 
oocytes collected in stimulated cycles for intracytoplasmic sperm injection. Fertil 
Steril, 1999. 71(5): p. 937-40. 
837. Ebner, T., et al., Blood clots in the cumulus-oocyte complex predict poor oocyte 
quality and post-fertilization development. Reprod Biomed Online, 2008. 16(6): 
p. 801-7. 
274 
 
 
838. Bertrand, E., M. Van den Bergh, and Y. Englert, Does zona pellucida thickness 
influence the fertilization rate? Hum Reprod, 1995. 10(5): p. 1189-93. 
839. Shen, Y., et al., High magnitude of light retardation by the zona pellucida is 
associated with conception cycles. Hum Reprod, 2005. 20(6): p. 1596-606. 
840. Rama Raju, G.A., et al., Meiotic spindle and zona pellucida characteristics as 
predictors of embryonic development: a preliminary study using PolScope 
imaging. Reprod Biomed Online, 2007. 14(2): p. 166-74. 
841. Montag, M., et al., Oocyte zona birefringence intensity is associated with 
embryonic implantation potential in ICSI cycles. Reprod Biomed Online, 2008. 
16(2): p. 239-44. 
842. Chamayou, S., et al., Meiotic spindle presence and oocyte morphology do not 
predict clinical ICSI outcomes: a study of 967 transferred embryos. Reprod 
Biomed Online, 2006. 13(5): p. 661-7. 
843. Farhi, J., et al., Coarse granulation in the perivitelline space and IVF-ICSI 
outcome. J Assist Reprod Genet, 2002. 19(12): p. 545-9. 
844. Rienzi, L., et al., Significance of metaphase II human oocyte morphology on 
ICSI outcome. Fertil Steril, 2008. 90(5): p. 1692-700. 
845. Ebner, T., et al., Prognostic value of first polar body morphology on fertilization 
rate and embryo quality in intracytoplasmic sperm injection. Hum Reprod, 2000. 
15(2): p. 427-30. 
846. Ten, J., et al., Donor oocyte dysmorphisms and their influence on fertilization 
and embryo quality. Reprod Biomed Online, 2007. 14(1): p. 40-8. 
847. Loutradis, D., et al., Oocyte morphology correlates with embryo quality and 
pregnancy rate after intracytoplasmic sperm injection. Fertil Steril, 1999. 72(2): 
p. 240-4. 
848. Suppinyopong, S., R. Choavaratana, and C. Karavakul, Correlation of oocyte 
morphology with fertilization rate and embryo quality after intracytoplasmic 
sperm injection. J Med Assoc Thai, 2000. 83(6): p. 627-32. 
849. Otsuki, J., et al., The relationship between pregnancy outcome and smooth 
endoplasmic reticulum clusters in MII human oocytes. Hum Reprod, 2004. 
19(7): p. 1591-7. 
850. De Sutter, P., et al., Oocyte morphology does not correlate with fertilization rate 
and embryo quality after intracytoplasmic sperm injection. Hum Reprod, 1996. 
11(3): p. 595-7. 
851. Balaban, B., et al., Oocyte morphology does not affect fertilization rate, embryo 
quality and implantation rate after intracytoplasmic sperm injection. Hum 
Reprod, 1998. 13(12): p. 3431-3. 
275 
 
 
852. Xia, P., Intracytoplasmic sperm injection: correlation of oocyte grade based on 
polar body, perivitelline space and cytoplasmic inclusions with fertilization rate 
and embryo quality. Hum Reprod, 1997. 12(8): p. 1750-5. 
853. Otsuki, J., Y. Nagai, and K. Chiba, Lipofuscin bodies in human oocytes as an 
indicator of oocyte quality. J Assist Reprod Genet, 2007. 24(7): p. 263-70. 
854. Moon, J.H., et al., Visualization of the metaphase II meiotic spindle in living 
human oocytes using the Polscope enables the prediction of embryonic 
developmental competence after ICSI. Hum Reprod, 2003. 18(4): p. 817-20. 
855. Cohen, Y., et al., Spindle imaging: a new marker for optimal timing of ICSI? 
Hum Reprod, 2004. 19(3): p. 649-54. 
856. Fang, C., et al., Visualization of meiotic spindle and subsequent embryonic 
development in in vitro and in vivo matured human oocytes. J Assist Reprod 
Genet, 2007. 24(11): p. 547-51. 
857. Madaschi, C., et al., Spindle imaging: a marker for embryo development and 
implantation. Fertil Steril, 2008. 90(1): p. 194-8. 
858. Sharma, V., et al., A comparison of treatments with exogenous FSH to promote 
folliculogenesis in patients with quiescent ovaries due to the continued 
administration of an LH-RH agonist. Hum Reprod, 1987. 2(7): p. 553-6. 
859. Sharma, V., et al., Influence of superovulation on endometrial and embryonic 
development. Fertil Steril, 1990. 53(5): p. 822-9. 
860. Pellicer, A., et al., Is the retrieval of high numbers of oocytes desirable in 
patients treated with gonadotrophin-releasing hormone analogues (GnRHa) and 
gonadotrophins? Hum Reprod, 1989. 4(5): p. 536-40. 
861. van der Gaast, M.H., et al., Optimum number of oocytes for a successful first 
IVF treatment cycle. Reprod Biomed Online, 2006. 13(4): p. 476-80. 
862. Ertzeid, G. and R. Storeng, Adverse effects of gonadotrophin treatment on pre- 
and postimplantation development in mice. J Reprod Fertil, 1992. 96(2): p. 649-
55. 
863. Ertzeid, G., R. Storeng, and T. Lyberg, Treatment with gonadotropins impaired 
implantation and fetal development in mice. J Assist Reprod Genet, 1993. 
10(4): p. 286-91. 
864. Hodges, C.A., et al., Experimental evidence that changes in oocyte growth 
influence meiotic chromosome segregation. Hum Reprod, 2002. 17(5): p. 1171-
80. 
865. Imthurn, B., et al., Nuclear maturity and oocyte morphology after stimulation 
with highly purified follicle stimulating hormone compared to human 
menopausal gonadotrophin. Hum Reprod, 1996. 11(11): p. 2387-91. 
276 
 
 
866. Elbling, L. and M. Colot, Abnormal development and transport and increased 
sister-chromatid exchange in preimplantation embryos following superovulation 
in mice. Mutat Res, 1985. 147(4): p. 189-95. 
867. Vogel, R. and H. Spielmann, Genotoxic and embryotoxic effects of 
gonadotropin-hyperstimulated ovulation of murine oocytes, preimplantation 
embryos, and term fetuses. Reprod Toxicol, 1992. 6(4): p. 329-33. 
868. Roberts, R., et al., Follicle-stimulating hormone affects metaphase I 
chromosome alignment and increases aneuploidy in mouse oocytes matured in 
vitro. Biol Reprod, 2005. 72(1): p. 107-18. 
869. Hammadeh, M.E., et al., Relationship between cytokine concentration in serum 
and preovulatory follicular fluid and in vitro fertilization/intracytoplasmic sperm 
injection outcome. Chem Immunol Allergy, 2005. 88: p. 80-97. 
870. Choi, Y.S., et al., Comparison of follicular fluid IGF-I, IGF-II, IGFBP-3, IGFBP-4 
and PAPP-A concentrations and their ratios between GnRH agonist and GnRH 
antagonist protocols for controlled ovarian stimulation in IVF-embryo transfer 
patients. Hum Reprod, 2006. 21(8): p. 2015-21. 
871. Baskind, N.E., N.M. Orsi, and V. Sharma, Follicular-phase ovarian follicular fluid 
and plasma cytokine profiling of natural cycle in vitro fertilization patients. Fertil 
Steril, 2014. 
872. Ledee, N., et al., Impact of follicular G-CSF quantification on subsequent 
embryo transfer decisions: a proof of concept study. Hum Reprod, 2013. 28(2): 
p. 406-13. 
873. Salmassi, A., et al., Is granulocyte colony-stimulating factor level predictive for 
human IVF outcome? Hum Reprod, 2005. 20(9): p. 2434-40. 
874. Salmassi, A., et al., Detection of granulocyte colony-stimulating factor and its 
receptor in human follicular luteinized granulosa cells. Fertil Steril, 2004. 81 
Suppl 1: p. 786-91. 
875. Yanagi, K., et al., Cyclic changes of granulocyte colony-stimulating factor (G-
CSF) mRNA in the human follicle during the normal menstrual cycle and 
immunolocalization of G-CSF protein. Hum Reprod, 2002. 17(12): p. 3046-52. 
876. Ledee, N., et al., New pre-conception immune biomarkers for clinical practice: 
interleukin-18, interleukin-15 and TWEAK on the endometrial side, G-CSF on 
the follicular side. J Reprod Immunol, 2011. 88(2): p. 118-23. 
877. Ledee, N., et al., Levels of follicular G-CSF and interleukin-15 appear as 
noninvasive biomarkers of subsequent successful birth in modified natural in 
vitro fertilization/intracytoplasmic sperm injection cycles. Fertil Steril, 2010. 
277 
 
 
878. Ledee, N., et al., Levels of follicular G-CSF and interleukin-15 appear as 
noninvasive biomarkers of subsequent successful birth in modified natural in 
vitro fertilization/intracytoplasmic sperm injection cycles. Fertil Steril, 2011. 
95(1): p. 94-8. 
879. Salmassi, A., et al., Expression of mRNA and protein of macrophage colony-
stimulating factor and its receptor in human follicular luteinized granulosa cells. 
Fertil Steril, 2005. 83(2): p. 419-25. 
880. Salmassi, A., et al., Circulating level of macrophage colony-stimulating factor 
can be predictive for human in vitro fertilization outcome. Fertil Steril, 2010. 
93(1): p. 116-23. 
881. Nishimura, K., et al., Changes in macrophage colony-stimulating factor 
concentration in serum and follicular fluid in in-vitro fertilization and embryo 
transfer cycles. Fertil Steril, 1998. 69(1): p. 53-7. 
882. Kawano, Y., et al., The production and clinical evaluation of macrophage 
colony-stimulating factor and macrophage chemoattractant protein-1 in human 
follicular fluids. Am J Reprod Immunol, 2001. 45(1): p. 1-5. 
883. Smikle, C.B., et al., Elevated ovarian follicular fluid stem cell factor 
concentrations are associated with improved pregnancy rates in in-vitro 
fertilization cycles. Fertil Steril, 1998. 69(1): p. 70-2. 
884. Hammadeh, M.E., et al., Relationship between cytokine concentrations (FGF, 
sICAM-1 and SCF) in serum, follicular fluid and ICSI outcome. Am J Reprod 
Immunol, 2004. 51(1): p. 81-5. 
885. Klinger, F.G. and M. De Felici, In vitro development of growing oocytes from 
fetal mouse oocytes: stage-specific regulation by stem cell factor and granulosa 
cells. Dev Biol, 2002. 244(1): p. 85-95. 
886. Nishigaki, A., et al., Concentrations of stromal cell-derived factor-1 and vascular 
endothelial growth factor in relation to the diameter of human follicles. Fertil 
Steril, 2011. 95(2): p. 742-6. 
887. Goud, P.T., et al., In-vitro maturation of human germinal vesicle stage oocytes: 
role of cumulus cells and epidermal growth factor in the culture medium. Hum 
Reprod, 1998. 13(6): p. 1638-44. 
888. Merlo, B., et al., Effect of EGF on in vitro maturation of domestic cat oocytes. 
Theriogenology, 2005. 63(7): p. 2032-9. 
889. Merriman, J.A., D.G. Whittingham, and J. Carroll, The effect of follicle 
stimulating hormone and epidermal growth factor on the developmental 
capacity of in-vitro matured mouse oocytes. Hum Reprod, 1998. 13(3): p. 690-
5. 
278 
 
 
890. Ben-Ami, I., et al., In vitro maturation of human germinal vesicle-stage oocytes: 
role of epidermal growth factor-like growth factors in the culture medium. Hum 
Reprod, 2011. 26(1): p. 76-81. 
891. Bolamba, D., et al., Effects of epidermal growth factor and hormones on 
granulosa expansion and nuclear maturation of dog oocytes in vitro. 
Theriogenology, 2006. 65(6): p. 1037-47. 
892. Oyamada, T., H. Iwayama, and Y. Fukui, Additional effect of epidermal growth 
factor during in vitro maturation for individual bovine oocytes using a chemically 
defined medium. Zygote, 2004. 12(2): p. 143-50. 
893. Park, K.W., K. Iga, and K. Niwa, Exposure of bovine oocytes to EGF during 
maturation allows them to develop to blastocysts in a chemically-defined 
medium. Theriogenology, 1997. 48(7): p. 1127-35. 
894. Song, H.J., et al., Influence of epidermal growth factor supplementation during 
in vitro maturation on nuclear status and gene expression of canine oocytes. 
Res Vet Sci, 2010. 
895. Hsieh, M., K. Thao, and M. Conti, Genetic dissection of epidermal growth factor 
receptor signaling during luteinizing hormone-induced oocyte maturation. PLoS 
One, 2011. 6(6): p. e21574. 
896. Lee, H.J., et al., In vitro maturation (IVM) of murine and human germinal vesicle 
(GV)-stage oocytes by coculture with immortalized human fallopian tube 
epithelial cells. Fertil Steril, 2011. 95(4): p. 1344-8. 
897. Richani, D., et al., Mode of oocyte maturation affects EGF-like peptide function 
and oocyte competence. Mol Hum Reprod, 2013. 19(8): p. 500-9. 
898. Inoue, Y., et al., Amphiregulin is much more abundantly expressed than 
transforming growth factor-alpha and epidermal growth factor in human 
follicular fluid obtained from patients undergoing in vitro fertilization-embryo 
transfer. Fertil Steril, 2009. 91(4): p. 1035-41. 
899. Zamah, A.M., et al., Human oocyte maturation is dependent on LH-stimulated 
accumulation of the epidermal growth factor-like growth factor, amphiregulin. 
Hum Reprod, 2010. 25(10): p. 2569-78. 
900. Liu, N., et al., Comparison of follicular fluid amphiregulin and EGF 
concentrations in patients undergoing IVF with different stimulation protocols. 
Endocrine, 2012. 42(3): p. 708-16. 
901. Kawano, Y., et al., Production of macrophage inflammatory protein-3alpha in 
human follicular fluid and cultured granulosa cells. Fertil Steril, 2004. 82 Suppl 
3: p. 1206-11. 
279 
 
 
902. Loret de Mola, J.R., et al., Elevated interleukin-6 levels in the ovarian 
hyperstimulation syndrome: ovarian immunohistochemical localization of 
interleukin-6 signal. Obstet Gynecol, 1996. 87(4): p. 581-7. 
903. Geva, E., et al., Elevated levels of interleukin-6 in the follicular fluid at the time 
of oocyte retrieval for in vitro fertilization may predict the development of early-
form ovarian hyperstimulation syndrome. Fertil Steril, 1997. 68(1): p. 133-7. 
904. De Matos, D.G., et al., Leukemia inhibitory factor induces cumulus expansion in 
immature human and mouse oocytes and improves mouse two-cell rate and 
delivery rates when it is present during mouse in vitro oocyte maturation. Fertil 
Steril, 2008. 90(6): p. 2367-75. 
905. Ptak, G., et al., Leukaemia inhibitory factor enhances sheep fertilization in vitro 
via an influence on the oocyte. Theriogenology, 2006. 65(9): p. 1891-9. 
906. Coskun, S., et al., Presence of leukemia inhibitory factor and interleukin-12 in 
human follicular fluid during follicular growth. Am J Reprod Immunol, 1998. 
40(1): p. 13-8. 
907. Ledee-Bataille, N., et al., Concentration of leukaemia inhibitory factor (LIF) in 
uterine flushing fluid is highly predictive of embryo implantation. Hum Reprod, 
2002. 17(1): p. 213-8. 
908. Hsieh, Y.Y., et al., Leukemia inhibitory factor in follicular fluid is not related to 
the number and quality of embryos as well as implantation and pregnancy 
rates. Biochem Genet, 2005. 43(9-10): p. 501-6. 
909. Ozornek, M.H., et al., Epidermal growth factor and leukemia inhibitory factor 
levels in follicular fluid. Association with in vitro fertilization outcome. J Reprod 
Med, 1999. 44(4): p. 367-9. 
910. Fried, G. and H. Wramsby, Increase in transforming growth factor beta1 in 
ovarian follicular fluid following ovarian stimulation and in-vitro fertilization 
correlates to pregnancy. Hum Reprod, 1998. 13(3): p. 656-9. 
911. Fried, G., H. Wramsby, and M. Tally, Transforming growth factor-beta1, insulin-
like growth factors, and insulin-like growth factor binding proteins in ovarian 
follicular fluid are differentially regulated by the type of ovarian hyperstimulation 
used for in vitro fertilization. Fertil Steril, 1998. 70(1): p. 129-34. 
912. Wu, Y.T., et al., High bone morphogenetic protein-15 level in follicular fluid is 
associated with high quality oocyte and subsequent embryonic development. 
Hum Reprod, 2007. 22(6): p. 1526-31. 
913. Gode, F., et al., Influence of follicular fluid GDF9 and BMP15 on embryo quality. 
Fertil Steril, 2011. 95(7): p. 2274-8. 
280 
 
 
914. Bonetti, T.C., et al., Cytokine and hormonal profile in serum samples of patients 
undergoing controlled ovarian stimulation: interleukin-1beta predicts ongoing 
pregnancy. Hum Reprod, 2010. 25(8): p. 2101-6. 
915. Karagouni, E.E., et al., Interleukin-1beta and interleukin-1alpha may affect the 
implantation rate of patients undergoing in vitro fertilization-embryo transfer. 
Fertil Steril, 1998. 70(3): p. 553-9. 
916. Mendoza, C., et al., Relationship between fertilization results after 
intracytoplasmic sperm injection, and intrafollicular steroid, pituitary hormone 
and cytokine concentrations. Hum Reprod, 1999. 14(3): p. 628-35. 
917. Caillaud, M., et al., In vitro equine oocyte maturation in pure follicular fluid plus 
interleukin-1 and fertilization following ICSI. Anim Reprod Sci, 2008. 106(3-4): 
p. 431-9. 
918. Bedaiwy, M., et al., Differential expression of follicular fluid cytokines: 
relationship to subsequent pregnancy in IVF cycles. Reprod Biomed Online, 
2007. 15(3): p. 321-5. 
919. Soto, P., R.P. Natzke, and P.J. Hansen, Actions of tumor necrosis factor-alpha 
on oocyte maturation and embryonic development in cattle. Am J Reprod 
Immunol, 2003. 50(5): p. 380-8. 
920. Mendoza, C., et al., Follicular fluid markers of oocyte developmental potential. 
Hum Reprod, 2002. 17(4): p. 1017-22. 
921. Ma, C.H., et al., Effects of tumor necrosis factor-alpha on porcine oocyte 
meiosis progression, spindle organization, and chromosome alignment. Fertil 
Steril, 2010. 93(3): p. 920-6. 
922. Lee, K.S., et al., Relationships between concentrations of tumor necrosis factor-
alpha and nitric oxide in follicular fluid and oocyte quality. J Assist Reprod 
Genet, 2000. 17(4): p. 222-8. 
923. Falconer, H., et al., IVF outcome in women with endometriosis in relation to 
tumour necrosis factor and anti-Mullerian hormone. Reprod Biomed Online, 
2009. 18(4): p. 582-8. 
924. Carlberg, M., et al., Elevated expression of tumour necrosis factor alpha in 
cultured granulosa cells from women with endometriosis. Hum Reprod, 2000. 
15(6): p. 1250-5. 
925. Nikolettos, N., et al., Evaluation of leptin, interleukin-1beta, tumor necrosis 
factor-alpha and vascular endothelial growth factor in serum and follicular fluids 
of women undergoing controlled ovarian hyperstimulation as prognostic 
markers of ICSI outcome. In Vivo, 2004. 18(5): p. 667-73. 
281 
 
 
926. Bedaiwy, M.A., et al., Prediction of endometriosis with serum and peritoneal 
fluid markers: a prospective controlled trial. Hum Reprod, 2002. 17(2): p. 426-
31. 
927. Pizzo, A., et al., Behaviour of cytokine levels in serum and peritoneal fluid of 
women with endometriosis. Gynecol Obstet Invest, 2002. 54(2): p. 82-7. 
928. Buscher, U., et al., Cytokines in the follicular fluid of stimulated and non-
stimulated human ovaries; is ovulation a suppressed inflammatory reaction? 
Hum Reprod, 1999. 14(1): p. 162-6. 
929. Munne, S., et al., Treatment-related chromosome abnormalities in human 
embryos. Hum Reprod, 1997. 12(4): p. 780-4. 
930. Out, H.J., et al., A randomized, double-blind, multicentre clinical trial comparing 
starting doses of 150 and 200 IU of recombinant FSH in women treated with the 
GnRH antagonist ganirelix for assisted reproduction. Hum Reprod, 2004. 19(1): 
p. 90-5. 
931. Lashen, H., et al., Superovulation with a high gonadotropin dose for in vitro 
fertilization: is it effective? J Assist Reprod Genet, 1998. 15(7): p. 438-43. 
932. Das, S., et al., Follicular fluid expression of alpha-defensins and their role in 
ovulation. J Assist Reprod Genet, 2008. 25(2-3): p. 83-7. 
933. Trehan, P., N. Gopichandran, and N. Orsi. Cytokine preimplantation 
embryotrophism in the mouse. in Fertility 2007. 2007. York: British Fertility 
Society. 
934. Geva, E., et al., Follicular fluid levels of vascular endothelial growth factor. Are 
they predictive markers for ovarian hyperstimulation syndrome? J Reprod Med, 
1999. 44(2): p. 91-6. 
935. Artini, P.G., et al., Vascular endothelial growth factor, interleukin-6 and 
interleukin-2 in serum and follicular fluid of patients with ovarian 
hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol, 2002. 101(2): p. 
169-74. 
936. Agrawal, R., et al., Concentration of vascular endothelial growth factor released 
by cultured human luteinized granulosa cells is higher in women with polycystic 
ovaries than in women with normal ovaries. Fertil Steril, 2002. 78(6): p. 1164-9. 
937. Quintana, R., et al., Relationship of ovarian stimulation response with vascular 
endothelial growth factor and degree of granulosa cell apoptosis. Hum Reprod, 
2001. 16(9): p. 1814-8. 
938. Wang, T.H., et al., Human chorionic gonadotropin-induced ovarian 
hyperstimulation syndrome is associated with up-regulation of vascular 
endothelial growth factor. J Clin Endocrinol Metab, 2002. 87(7): p. 3300-8. 
282 
 
 
939. Babayof, R., et al., Serum inhibin A, VEGF and TNFalpha levels after triggering 
oocyte maturation with GnRH agonist compared with HCG in women with 
polycystic ovaries undergoing IVF treatment: a prospective randomized trial. 
Hum Reprod, 2006. 21(5): p. 1260-5. 
940. Chen, S.U., et al., Signal mechanisms of vascular endothelial growth factor and 
interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their 
common pathways. Hum Reprod, 2010. 25(3): p. 757-67. 
941. Pellicer, A., et al., The pathogenesis of ovarian hyperstimulation syndrome: in 
vivo studies investigating the role of interleukin-1beta, interleukin-6, and 
vascular endothelial growth factor. Fertil Steril, 1999. 71(3): p. 482-9. 
942. Savchev, S.I., et al., Follicular fluid-specific distribution of vascular endothelial 
growth factor isoforms and sFlt-1 in patients undergoing IVF and their 
correlation with treatment outcomes. Reprod Sci, 2010. 17(11): p. 1036-42. 
943. Asimakopoulos, B., et al., Follicular fluid levels of vascular endothelial growth 
factor and leptin are associated with pregnancy outcome of normal women 
participating in intracytoplasmic sperm injection cycles. Physiol Res, 2005. 
54(3): p. 263-70. 
944. Friedman, C.I., et al., Elevated level of follicular fluid vascular endothelial 
growth factor is a marker of diminished pregnancy potential. Fertil Steril, 1998. 
70(5): p. 836-9. 
945. Tokuyama, O., et al., Vascular endothelial growth factor concentrations in 
follicular fluid obtained from IVF-ET patients: a comparison of hMG, clomiphene 
citrate, and natural cycle. J Assist Reprod Genet, 2002. 19(1): p. 19-23. 
946. Barroso, G., et al., Vascular endothelial growth factor, nitric oxide, and leptin 
follicular fluid levels correlate negatively with embryo quality in IVF patients. 
Fertil Steril, 1999. 72(6): p. 1024-6. 
947. Anasti, J.N., et al., Human follicle fluid vascular endothelial growth factor 
concentrations are correlated with luteinization in spontaneously developing 
follicles. Hum Reprod, 1998. 13(5): p. 1144-7. 
948. Kawano, Y., et al., Production of vascular endothelial growth factor and 
angiogenic factor in human follicular fluid. Mol Cell Endocrinol, 2003. 202(1-2): 
p. 19-23. 
949. Monteleone, P., et al., Follicular fluid VEGF levels directly correlate with 
perifollicular blood flow in normoresponder patients undergoing IVF. J Assist 
Reprod Genet, 2008. 25(5): p. 183-6. 
283 
 
 
950. Mattioli, M., et al., Follicle activation involves vascular endothelial growth factor 
production and increased blood vessel extension. Biol Reprod, 2001. 65(4): p. 
1014-9. 
951. Van Blerkom, J., M. Antczak, and R. Schrader, The developmental potential of 
the human oocyte is related to the dissolved oxygen content of follicular fluid: 
association with vascular endothelial growth factor levels and perifollicular blood 
flow characteristics. Hum Reprod, 1997. 12(5): p. 1047-55. 
952. Borini, A., et al., Perifollicular vascularity and its relationship with oocyte 
maturity and IVF outcome. Ann N Y Acad Sci, 2001. 943: p. 64-7. 
953. Abramovich, D., F. Parborell, and M. Tesone, Effect of a vascular endothelial 
growth factor (VEGF) inhibitory treatment on the folliculogenesis and ovarian 
apoptosis in gonadotropin-treated prepubertal rats. Biol Reprod, 2006. 75(3): p. 
434-41. 
954. Yamamoto, S., et al., Expression of vascular endothelial growth factor (VEGF) 
during folliculogenesis and corpus luteum formation in the human ovary. 
Gynecol Endocrinol, 1997. 11(6): p. 371-81. 
955. Luo, H., et al., Effect of vascular endothelial growth factor on maturation, 
fertilization and developmental competence of bovine oocytes. J Vet Med Sci, 
2002. 64(9): p. 803-6. 
956. Luo, H., et al., Vascular endothelial growth factor (VEGF) promotes the early 
development of bovine embryo in the presence of cumulus cells. J Vet Med Sci, 
2002. 64(11): p. 967-71. 
957. Einspanier, R., et al., Expression of the vascular endothelial growth factor and 
its receptors and effects of VEGF during in vitro maturation of bovine cumulus-
oocyte complexes (COC). Mol Reprod Dev, 2002. 62(1): p. 29-36. 
958. Barboni, B., et al., Vascular endothelial growth factor production in growing pig 
antral follicles. Biol Reprod, 2000. 63(3): p. 858-64. 
959. Koos, R.D., Increased expression of vascular endothelial growth/permeability 
factor in the rat ovary following an ovulatory gonadotropin stimulus: potential 
roles in follicle rupture. Biol Reprod, 1995. 52(6): p. 1426-35. 
960. Artini, P.G., et al., Correlation between the amount of follicle-stimulating 
hormone administered and plasma and follicular fluid vascular endothelial 
growth factor concentrations in women undergoing in vitro fertilization. Gynecol 
Endocrinol, 1998. 12(4): p. 243-7. 
961. Anifandis, G., et al., Serum and follicular fluid leptin levels are correlated with 
human embryo quality. Reproduction, 2005. 130(6): p. 917-21. 
284 
 
 
962. Mantzoros, C.S., et al., Predictive value of serum and follicular fluid leptin 
concentrations during assisted reproductive cycles in normal women and in 
women with the polycystic ovarian syndrome. Hum Reprod, 2000. 15(3): p. 539-
44. 
963. Robins, J.C., et al., Association of leptin with poor ovarian stimulation during in 
vitro fertilization. J Reprod Med, 2005. 50(5): p. 356-60. 
964. Suzuki, H., et al., Ghrelin and leptin did not improve meiotic maturation of 
porcine oocytes cultured in vitro. Reprod Domest Anim, 2010. 45(5): p. 927-30. 
965. Almog, B., et al., Intrafollicular and serum levels of leptin during in vitro 
fertilization cycles: comparison between the effects of recombinant follicle-
stimulating hormones and human menopausal gonadotrophin. Gynecol 
Endocrinol, 2011. 27(9): p. 666-8. 
966. Chakrabarti, J., et al., Overt leptin response to controlled ovarian 
hyperstimulation negatively correlates with pregnancy outcome in in vitro 
fertilization--embryo transfer cycle. J Hum Reprod Sci, 2012. 5(2): p. 194-9. 
967. Dorn, C., et al., Leptin, VEGF, IGF-1, and IGFBP-3 concentrations in serum and 
follicular fluid of women undergoing in vitro fertilization. Arch Gynecol Obstet, 
2003. 268(3): p. 187-93. 
968. Hill, M.J., et al., The utility of serum leptin and follicular fluid leptin, estradiol, 
and progesterone levels during an in vitro fertilization cycle. J Assist Reprod 
Genet, 2007. 24(5): p. 183-8. 
969. Takikawa, S., et al., Assessment of the predictive value of follicular fluid insulin, 
leptin and adiponectin in assisted reproductive cycles. Gynecol Endocrinol, 
2010. 26(7): p. 494-9. 
970. Wunder, D.M., R. Kretschmer, and N.A. Bersinger, Concentrations of leptin and 
C-reactive protein in serum and follicular fluid during assisted reproductive 
cycles. Hum Reprod, 2005. 20(5): p. 1266-71. 
971. Wunder, D.M., et al., Steroids and protein markers in the follicular fluid as 
indicators of oocyte quality in patients with and without endometriosis. J Assist 
Reprod Genet, 2005. 22(6): p. 257-64. 
972. Butzow, T.L., et al., Serum and follicular fluid leptin during in vitro fertilization: 
relationship among leptin increase, body fat mass, and reduced ovarian 
response. J Clin Endocrinol Metab, 1999. 84(9): p. 3135-9. 
973. Chen, R., et al., Serum and follicular fluid leptin levels in patients undergoing 
controlled ovarian hyperstimulation for in vitro fertilization cycle. Clin Exp Obstet 
Gynecol, 2004. 31(2): p. 103-6. 
285 
 
 
974. Webb, R., et al., Control of follicular growth: local interactions and nutritional 
influences. J Anim Sci, 2004. 82 E-Suppl: p. E63-74. 
975. Michalakis, K., et al., The complex interaction between obesity, metabolic 
syndrome and reproductive axis: a narrative review. Metabolism, 2013. 62(4): p. 
457-78. 
976. Bili, H., et al., Cytokines in the human ovary: presence in follicular fluid and 
correlation with leukotriene B4. J Assist Reprod Genet, 1998. 15(2): p. 93-8. 
977. Orvieto, R., et al., Interleukin-2 and ovarian hyperstimulation syndrome: a pilot 
study. Hum Reprod, 1995. 10(1): p. 24-7. 
978. Ostanin, A.A., et al., Role of cytokines in the regulation of reproductive function. 
Bull Exp Biol Med, 2007. 143(1): p. 75-9. 
979. Boomsma, C.M., et al., Ovarian stimulation for in vitro fertilization alters the 
intrauterine cytokine, chemokine, and growth factor milieu encountered by the 
embryo. Fertil Steril, 2010. 94(5): p. 1764-8. 
980. Cerkiene, Z., A. Eidukaite, and A. Usoniene, Follicular fluid levels of interleukin-
10 and interferon-gamma do not predict outcome of assisted reproductive 
technologies. Am J Reprod Immunol, 2008. 59(2): p. 118-26. 
981. Kilic, S., et al., IL-18 and IL-18 binding protein concentrations in serum and 
ovarian follicular fluid do not affect in vitro fertilization outcomes in obese, 
overweight, and non-obese patients. J Reprod Immunol, 2009. 79(2): p. 211-4. 
982. Pelzer, E.S., et al., Microbial colonization of follicular fluid: alterations in 
cytokine expression and adverse assisted reproduction technology outcomes. 
Hum Reprod, 2011. 26(7): p. 1799-812. 
983. Vujisic, S., et al., Ovarian follicular concentration of IL-12, IL-15, IL-18 and p40 
subunit of IL-12 and IL-23. Hum Reprod, 2006. 21(10): p. 2650-5. 
984. Yang, Y., et al., Is interleukin-18 associated with polycystic ovary syndrome? 
Reprod Biol Endocrinol, 2011. 9: p. 7. 
985. Sarapik, A., et al., Follicular proinflammatory cytokines and chemokines as 
markers of IVF success. Clin Dev Immunol, 2012. 2012: p. 606459. 
986. Dahm-Kahler, P., et al., Monocyte chemotactic protein-1 in the follicle of the 
menstrual and IVF cycle. Mol Hum Reprod, 2006. 12(1): p. 1-6. 
987. Lamaita, R.M., et al., Inflammatory response patterns in ICSI patients: a 
comparative study between chronic anovulating and normally ovulating women. 
Reprod Sci, 2012. 19(7): p. 704-11. 
988. Hammadeh, M.E., et al., Comparison between cytokine concentration in 
follicular fluid of poor and high responder patients and their influence of ICSI-
outcome. Am J Reprod Immunol, 2003. 50(2): p. 131-6. 
286 
 
 
989. Gutman, G., et al., Interleukin-18 is high in the serum of IVF pregnancies with 
ovarian hyperstimulation syndrome. Am J Reprod Immunol, 2004. 51(5): p. 381-
4. 
990. Li, H., K. Zhang, and T. Jiang. The regularized EM algorithm. in Proceedings of 
the 20th National Conference on Artificial Intelligence. 2005. 
991. Orsi, N.M., et al., Uterine and serum cytokine arrays in the mouse during estrus. 
Anim Reprod Sci, 2007. 100(3-4): p. 301-10. 
992. Orsi, N.M., et al., Regulation of maternal serum and amniotic fluid cytokine 
profiles in the mouse: possible roles in the onset of labour. J Reprod Immunol, 
2007. 75(2): p. 97-105. 
993. Hu, Y., Efficient and high quality force-directed graph drawing. The 
Mathematica Journal, 2005. 10(1): p. 37-71. 
994. Subelj, L. and M. Bajec, Unfolding communities in large complex networks: 
combining defensive and offensive label propagation for core extraction. Phys 
Rev E Stat Nonlin Soft Matter Phys, 2011. 83(3 Pt 2): p. 036103. 
995. Blondel, V.D., et al., Fast unfolding of communities in large networks J. Stat. 
Mech., 2008: p. P10008. 
996. Son, W.Y., et al., Fertilization, embryo development, and clinical outcome of 
immature oocytes obtained from natural cycle in vitro fertilization. J Assist 
Reprod Genet, 2013. 30(1): p. 43-7. 
997. Cha, K.Y. and R.C. Chian, Maturation in vitro of immature human oocytes for 
clinical use. Hum Reprod Update, 1998. 4(2): p. 103-20. 
998. Wong, K.H., H. Negishi, and E.Y. Adashi, Expression, hormonal regulation, and 
cyclic variation of chemokines in the rat ovary: key determinants of the 
intraovarian residence of representatives of the white blood cell series. 
Endocrinology, 2002. 143(3): p. 784-91. 
999. Suffee, N., et al., RANTES/CCL5-induced pro-angiogenic effects depend on 
CCR1, CCR5 and glycosaminoglycans. Angiogenesis, 2012. 15(4): p. 727-44. 
1000. Eppig, J.J., et al., Relationship between the developmental programs controlling 
nuclear and cytoplasmic maturation of mouse oocytes. Dev Biol, 1994. 164(1): 
p. 1-9. 
1001. Coticchio, G., et al., Human oocyte maturation in vitro. Int J Dev Biol, 2012. 
56(10-12): p. 909-18. 
1002. Hardy, K., et al., In vitro maturation of oocytes. Br Med Bull, 2000. 56(3): p. 588-
602. 
287 
 
 
1003. Grondahl, C., Oocyte maturation. Basic and clinical aspects of in vitro 
maturation (IVM) with special emphasis of the role of FF-MAS. Dan Med Bull, 
2008. 55(1): p. 1-16. 
1004. Piquette, G.N., The in vitro maturation (IVM) of human oocytes for in vitro 
fertilization (IVF): is it time yet to switch to IVM-IVF? Fertil Steril, 2006. 85(4): p. 
833-5; discussion 841. 
1005. Gallinelli, A., et al., Correlations between concentrations of interleukin-12 and 
interleukin-13 and lymphocyte subsets in the follicular fluid of women with and 
without polycystic ovary syndrome. Fertil Steril, 2003. 79(6): p. 1365-72. 
1006. Amato, G., et al., Serum and follicular fluid cytokines in polycystic ovary 
syndrome during stimulated cycles. Obstet Gynecol, 2003. 101(6): p. 1177-82. 
1007. Knebel, B., et al., Increased low grade inflammatory serum markers in patients 
with Polycystic ovary syndrome (PCOS) and their relationship to PPARgamma 
gene variants. Exp Clin Endocrinol Diabetes, 2008. 116(8): p. 481-6. 
1008. Goswami, R. and M.H. Kaplan, A brief history of IL-9. J Immunol, 2011. 186(6): 
p. 3283-8. 
1009. Inoue, N., et al., Roles of tumor necrosis factor-related apoptosis-inducing 
ligand signaling pathway in granulosa cell apoptosis during atresia in pig 
ovaries. J Reprod Dev, 2003. 49(4): p. 313-21. 
1010. Song, J.J. and Y.J. Lee, Differential cleavage of Mst1 by caspase-7/-3 is 
responsible for TRAIL-induced activation of the MAPK superfamily. Cell Signal, 
2008. 20(5): p. 892-906. 
1011. Kichev, A., et al., Tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) signaling and cell death in the immature central nervous system after 
hypoxia-ischemia and inflammation. J Biol Chem, 2014. 289(13): p. 9430-9. 
1012. Falschlehner, C., et al., TRAIL signalling: decisions between life and death. Int J 
Biochem Cell Biol, 2007. 39(7-8): p. 1462-75. 
1013. Lane, D., et al., Acquired resistance to TRAIL-induced apoptosis in human 
ovarian cancer cells is conferred by increased turnover of mature caspase-3. 
Mol Cancer Ther, 2006. 5(3): p. 509-21. 
1014. Kyronlahti, A., et al., GATA4 protects granulosa cell tumors from TRAIL-induced 
apoptosis. Endocr Relat Cancer, 2010. 17(3): p. 709-17. 
1015. Rizzuto, I., R.F. Behrens, and L.A. Smith, Risk of ovarian cancer in women 
treated with ovarian stimulating drugs for infertility. Cochrane Database Syst 
Rev, 2013. 8: p. CD008215. 
1016. Aldrich, J., Correlations Genuine and Spurious in Pearson and Yule. Statistical 
Science, 1995. 10(4): p. 364-376. 
288 
 
 
1017. Spirtes, P., Introduction to Causal Inference. Journal of Machine Learning 
Research, 2010. 11: p. 1643-1662. 
1018. Manly, B.F.J., Multivariate Statistical Methods: A Primer. 2005, Boca Raton, 
Florida: Chapman and Hall. 
1019. Lee, Y.H., et al., Reducing system noise in copy number data using principal 
components of self-self hybridizations. Proc Natl Acad Sci U S A, 2012. 109(3): 
p. E103-10. 
1020. Chen, R.H., et al., Interleukin-6 inhibits transforming growth factor-beta-induced 
apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers 
and activators of transcription 3 pathways. J Biol Chem, 1999. 274(33): p. 
23013-9. 
1021. Yates-Binder, C.C., et al., An IP-10 (CXCL10)-derived peptide inhibits 
angiogenesis. PLoS One, 2012. 7(7): p. e40812. 
1022. Bodnar, R.J., et al., IP-10 induces dissociation of newly formed blood vessels. J 
Cell Sci, 2009. 122(Pt 12): p. 2064-77. 
1023. Sato, E., et al., Expression of IP-10 related to angiogenesis in uterine cervical 
cancers. Br J Cancer, 2007. 96(11): p. 1735-9. 
1024. Wada, S., et al., Macrophage migration inhibitory factor in the human ovary: 
presence in the follicular fluids and production by granulosa cells. Biochem Mol 
Biol Int, 1997. 41(4): p. 805-14. 
1025. Wada, S., et al., Induction of macrophage migration inhibitory factor in human 
ovary by human chorionic gonadotrophin. Hum Reprod, 1999. 14(2): p. 395-9. 
1026. Sgadari, C., A.L. Angiolillo, and G. Tosato, Inhibition of angiogenesis by 
interleukin-12 is mediated by the interferon-inducible protein 10. Blood, 1996. 
87(9): p. 3877-82. 
1027. Goldring, M.B. and S.R. Goldring, Cytokines and cell growth control. Crit Rev 
Eukaryot Gene Expr, 1991. 1(4): p. 301-26. 
1028. Eppig, J.J., et al., Oocyte control of granulosa cell development: how and why. 
Hum Reprod, 1997. 12(11 Suppl): p. 127-32. 
1029. Eppig, J.J., M. O'Brien, and K. Wigglesworth, Mammalian oocyte growth and 
development in vitro. Mol Reprod Dev, 1996. 44(2): p. 260-73. 
1030. Eppig, J.J., K. Wigglesworth, and F.L. Pendola, The mammalian oocyte 
orchestrates the rate of ovarian follicular development. Proc Natl Acad Sci U S 
A, 2002. 99(5): p. 2890-4. 
 
 
 
289 
 
 
7. Appendices 
7.1 Appendix I: Non-significant pathways identified by pathway analysis. 
 
Pathway Adjusted  
p-value 
Matched 
Entities 
Total Pathway 
Entities 
Fatty Acid Omega Oxidation WP33 59026 0.05 7 7 
Nucleotide GPCRs WP207 41362 0.06 10 11 
SIDS Susceptibility Pathways WP2086 52939 0.07 31 40 
PodNet protein-protein interactions in the podocyte 
WP2310 58140 
0.07 218 315 
PodNet protein-protein interactions in the podocyte 
WP2310 58138 
0.07 218 315 
Focal Adhesion WP85 59067 0.07 130 191 
SHH, FGF8, Stat3 WP1500 42211 0.08 6 6 
ErbB signaling pathway WP1261 41378 0.08 35 46 
Chemokine signaling pathway WP2292 53116 0.08 129 193 
Chemokine signaling pathway WP2292 51127 0.08 129 193 
Leptin and adiponectin WP683 45174 0.09 9 10 
Glucuronidation WP1241 41277 0.11 14 18 
Hypothetical Network for Drug Addiction WP1246 
48795 
0.11 24 32 
 Ovarian Infertility Genes WP273 41282 0.11 24 31 
 Synthesis and Degradation of Ketone Bodies  0.12 5 5 
 Wnt Signaling Pathway WP403 41302 0.12 44 60 
 Electron Transport Chain WP295 62836 0.12 72 102 
 Osteoblast WP238 41255 0.13 8 10 
 G Protein Signaling Pathways WP232 41275 0.13 65 91 
 Tryptophan metabolism WP79 54741 0.14 32 44 
 Tryptophan metabolism WP79 47759 0.14 32 44 
 Type II interferon signaling (IFNG) WP1253 48389 0.14 25 34 
 PPAR signaling pathway WP2316 52058 0.14 58 87 
 PPAR signaling pathway WP2316 53110 0.14 58 87 
  One carbon metabolism and related pathways 
WP1770 48487 
0.15 36 49 
  Eicosanoid Synthesis WP318 62829 0.16 15 19 
 Statin Pathway WP1 53530 0.16 15 20 
 Statin Pathway WP1 41296 0.16 15 20 
 Regulation of Actin Cytoskeleton WP523 47746 0.16 105 151 
 Id Signaling Pathway WP512 41335 0.18 37 52 
 Estrogen metabolism WP1264 59015 0.18 4 13 
 Polyol pathway WP1265 41264 0.18 4 4 
 Glutathione metabolism WP164 48254 0.20 14 19 
 Wnt Signaling Pathway and Pluripotency WP723 
41353 
0.21 67 97 
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Pathway Adjusted  
p-value 
Matched 
Entities 
Total Pathway 
Entities 
 Wnt Signaling Pathway and Pluripotency WP723 
59063 
0.21 67 97 
 Notch Signaling Pathway WP29 41252 0.23 33 47 
 Biogenic Amine Synthesis WP522 41322 0.23 11 15 
 Urea cycle and metabolism of amino groups WP426 
45004 
0.26 15 20 
 Hypertrophy Model WP202 41285 0.26 15 20 
 Triacylglyceride Synthesis WP386 62840 0.27 17 23 
 Ptf1a related regulatory pathway WP201 41299 0.27 8 14 
 Nicotine Activity on Dopaminergic Neurons WP2083 
58000 
0.27 8 10 
 S1P pathways and spinal cord injury WP2170 59059 0.28 3 6 
 miR-1 in cardiac development WP608 41375 0.28 3 5 
 Arachidonate Epoxygenase Epoxide Hydrolase 
WP1250 58253 
0.28 3 3 
 Steroid Biosynthesis WP55 62839 0.29 10 13 
 IL-7 Signaling Pathway WP297 41313 0.30 31 44 
 Heart Development WP2067 45788 0.30 31 47 
 Nucleotide Metabolism WP87 41363 0.31 14 19 
 Prostaglandin pathway WP1439 41354 0.33 5 6 
 Connective tissue growth factor pathway WP2442 
57984 
0.33 5 6 
 Glutathione and one carbon metabolism WP730 41399 0.33 22 31 
 neural retinal development WP535 43786 0.35 7 9 
 Alanine and aspartate metabolism WP240 62062 0.36 9 40 
 Leptin Insulin Overlap WP578 62835 0.36 11 18 
 Senescence and Autophagy WP1267 48388 0.38 66 98 
 One Carbon Metabolism WP435 42576 0.42 20 29 
 Cytochrome P450 WP1274 59077 0.43 2 40 
 Alzheimers Disease WP2075 59061 0.43 2 77 
 Phase I, non P450 WP1255 59040 0.43 2 8 
 Amino acid conjugation of benzoic acid WP1252 41304 0.43 2 2 
 miRs in Muscle Cell Differentiation WP2076 59033 0.43 2 21 
 Oxidative Damage WP1496 43789 0.43 12 42 
 Osteoclast WP454 48251 0.43 10 14 
 Keap1-Nrf2 WP1245 48229 0.43 10 14 
 Aflatoxin B1 metabolism WP1262 48257 0.44 4 5 
 Phase I, non P450 WP1255 41309 0.44 6 8 
 TLR WP2440 58153 0.44 6 8 
 Alpha6-Beta4 Integrin Signaling Pathway WP488 
41271 
0.54 44 67 
 Wnt Signaling Pathway NetPath WP539 41242 0.56 71 109 
 Oxidative phosphorylation WP1248 41278 0.62 38 59 
 Amino acid conjugation of benzoic acid WP1252 59036 0.65 1 2 
 Aflatoxin B1 metabolism WP1262 59068 0.65 1 5 
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Pathway Adjusted  
p-value 
Matched 
Entities 
Total Pathway 
Entities 
 Polyol pathway WP1265 59024 0.65 1 4 
 Cardiac Hypertrophy- miR-208 WP1526 59045 0.65 4 8 
 Nuclear Receptors WP509 41291 0.68 24 38 
 Circadian Exercise WP544 41312 0.68 31 49 
 Splicing factor NOVA regulated synaptic proteins 
WP1983 59012 
0.71 20 42 
 Amino Acid metabolism WP662 42241 0.72 60 95 
 G1 to S cell cycle control WP413 41269 0.74 38 62 
 Purine metabolism WP2185 58151 0.74 107 178 
 Purine metabolism WP2185 47829 0.74 107 178 
 miRNAs involved in DNA damage response WP2085 
59079 
0.76 6 49 
 Histone modifications WP300 41360 0.77 3 5 
 Cell cycle WP190 62828 0.80 53 88 
 Signal Transduction of S1P Receptor WP57 41348 0.80 13 22 
 Acetylcholine Synthesis WP175 42542 0.81 4 7 
 Delta-Notch Signaling Pathway WP265 41380 0.81 51 84 
 IL-4 signaling Pathway WP93 41293 0.82 37 61 
 IL-1 Signaling Pathway WP37 41331 0.82 22 37 
 IL-9 Signaling Pathway WP10 43998 0.83 14 24 
 Splicing factor NOVA regulated synpatic proteins 
WP1983 42575 
0.83 25 42 
 Integrin-mediated cell adhesion WP6 62831 0.83 60 100 
 Integrin-mediated cell adhesion WP6 41290 0.83 60 100 
 Methylation WP1247 58512 0.83 5 9 
 Mismatch repair WP1257 41257 0.83 5 9 
 T Cell Receptor Signaling Pathway WP480 41339 0.84 82 133 
 DNA Replication WP150 41336 0.86 24 41 
 Apoptosis WP1254 47965 0.86 50 83 
 TFs Regulate miRNAs related to cardiac hypertrophy 
WP2080 59071 
0.88 2 11 
 Diurnally regulated genes with circadian orthologs 
WP1268 41369 
0.88 28 48 
 Serotonin Receptor 2 and STAT3 Signaling WP2079 
45981 
0.88 1 2 
 Serotonin and anxiety-related events WP2140 59058 0.88 1 13 
 EBV LMP1 signaling WP1243 59031 0.88 1 22 
 Insulin Signaling WP65 57331 0.88 96 159 
 Toll-like receptor signaling pathway WP1271 49294 0.89 57 97 
 Proteasome Degradation WP519 62832 0.89 34 59 
 Cholesterol Biosynthesis WP103 41337 0.89 8 15 
 Fatty Acid Biosynthesis WP336 41307 0.90 12 22 
 Selenium metabolism-Selenoproteins WP108 49742 0.90 27 48 
 Translation Factors WP307 41351 0.91 28 51 
 Selenium metabolism-Selenoproteins WP108 41386 0.92 26 48 
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Pathway Adjusted  
p-value 
Matched 
Entities 
Total Pathway 
Entities 
 EPO Receptor Signaling WP1249 41283 0.92 14 26 
 IL-2 Signaling Pathway WP450 41330 0.93 44 76 
 IL-5 Signaling Pathway WP151 59065 0.93 39 69 
 IL-6 signaling Pathway WP387 41281 0.94 58 99 
 Apoptosis Modulation by HSP70 WP166 41376 0.94 9 18 
 PluriNetWork WP1763 41345 0.95 177 291 
 Sterol regulatory element binding protein related 
WP731 41316 
0.95 3 7 
 Pentose Phosphate Pathway WP63 45643 0.95 3 7 
 miRNAs and TFs in iPS Cell Generation WP2375 58155 0.95 3 11 
 Heme Biosynthesis WP18 41372 0.95 4 9 
 MAPK Cascade WP251 62830 0.96 15 29 
 Neural Crest Differentiation WP2074 59025 0.96 1 97 
 B Cell Receptor Signaling Pathway WP274 41374 0.96 92 156 
 TCA Cycle WP434 57464 0.96 16 31 
 G13 Signaling Pathway WP298 41392 0.96 20 38 
 FAS pathway and Stress induction of HSP regulation 
WP571 47743 
0.96 20 38 
 IL-3 Signaling Pathway WP373 41387 0.97 57 100 
 Kit Receptor Signaling Pathway WP407 41265 0.97 37 67 
 Mitochondrial Gene Expression WP1263 47754 0.97 9 19 
 Mitochondrial Gene Expression WP1263 49535 0.97 9 19 
 Androgen Receptor Signaling Pathway WP252 47768 0.98 63 112 
 p38 MAPK Signaling Pathway (BioCarta) WP350 41398 0.98 17 34 
 EGFR1 Signaling Pathway WP572 41396 0.98 102 176 
 MAPK signaling pathway WP493 47770 0.99 91 159 
 Homologous recombination WP1258 41350 0.99 5 13 
 Fatty acid oxidation WP2318 58160 0.99 4 11 
 TGF-beta Receptor Signaling Pathway WP258 41259 0.99 85 150 
 NLR proteins WP1256 41241 0.99 3 9 
 Signaling of Hepatocyte Growth Factor Receptor 
WP193 41367 
0.99 16 34 
 Fatty Acid Beta Oxidation WP1269 41314 0.99 16 34 
 miRNA regulation of DNA Damage Response WP2087 
59076 
0.99 2 91 
 MicroRNAs in cardiomyocyte hypertrophy WP1560 
41377 
0.99 44 104 
 Toll Like Receptor signaling WP88 41390 0.99 15 33 
 Mitochondrial LC-Fatty Acid Beta-Oxidation WP401 
47761 
0.99 6 16 
 Kennedy pathway WP1771 45176 0.99 5 14 
 EBV LMP1 signaling WP1243 41295 0.99 9 22 
 Glycogen Metabolism WP317 43575 1.00 15 34 
 TNF-alpha NF-kB Signaling Pathway WP246 41391 1.00 98 184 
 Eukaryotic Transcription Initiation WP567 41326 1.00 13 41 
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Pathway Adjusted  
p-value 
Matched 
Entities 
Total Pathway 
Entities 
 Estrogen signalling WP1244 59014 1.00 26 74 
 Estrogen signalling WP1244 48233 1.00 27 74 
 mRNA processing WP310 62837 1.00 230 551 
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7.2 Appendix II: Endometrial epithelial cell response to seminal plasma.  
7.2.1.1 Prostaglandin synthesis and regulation pathway 
The prostaglandin synthesis and regulation pathway was activated in uterine epithelial 
cells (Figure 7-1). Pgh2 synthesis via Pla2g4a and Ptgs1 appeared to increase, with 
expression of these entities increasing post mating, followed by a subsequent decrease 
at day 3 and 4. This pattern was also reflected in the PG synthase Ptgds. Prl increased 
in expression above controls, most notably at day 1 and day 3 post mating. 
 
7.2.1.2 Cytokine and inflammatory response pathway 
Members of the cytokine and inflammatory response pathway fluctuated post mating 
(Figure 7-2). Il1a demonstrated a clear increase in expression post mating, most 
notably between days 1 and 2, a relationship also reflected in Il6 and Il13 expression 
levels. Il10 and Il12a also increased post mating, with day 1 and day 3 exhibiting the 
highest levels. Csf1 peaked at dioestrus, day 1 and day 4 post mating, Cxcl3 peaked at 
days 1 and 3 and Cd4 levels peaked at dioestrus and day 4. Il13 remained high at days 
1,2 and 3 with a subsequent drop at day 4. Il1b and H2Eb1 peaked at day 2 post 
mating with all other conditions remaining low. Tgfb1 decreased post mating, day 4 
presenting the lowest levels. IL-5 dropped from an initially high level at dioestrus to a 
low level of expression at oestrus and a subsequent recovery post mating. Expression 
of Tnfa peaked at day 1 then dropped at day 2 post mating. The lowest levels of Ifng 
expression were evident at oestrus. Csf2 was lower at oestrus compared with 
dioestrus, and remained static throughout the post mating time points. 
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Figure 7-1: Elements of the prostaglandin synthesis and regulation pathway active in 
uterine epithelial cells. 
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Figure 7-2: Elements of the cytokine and inflammatory response pathway activated in 
uterine epithelial cells. 
 
 
 
 
297 
 
 
7.2.1.3 MMPs 
Uterine epithelial MMPs exhibited varied responses to mating (Figure 7-3). Several 
MMPs exhibited a peak in expression at oestrus (Mmp8, Mmp11, Mmp14, Mmp23 and 
the inhibitor Timp4). Mmp7 showed an initially high expression at dioestrus, oestrus 
and day 1 post mating with a subsequent fall at days 2, 3 and 4. A number of MMPs 
displayed a drop in expression between dioestrus and oestrus with an ensuing 
recovery post mating (Mmp2, Mmp10, Mmp12, Mmp16, Mmp19, Mmp21, Mmp25 and 
Mmp27). The MMP inhibitors Timp2 and Timp3 remained broadly low in expression 
throughout. 
 
7.2.1.4 Macrophage markers 
The macrophage markers Cd14 and Cd68 exhibited a peak in expression at oestrus 
with a subsequent drop post mating (Figure 7-4). F3 was highly expressed at dioestrus 
and day 1 post mating while Cd163 showed the lowest expression at oestrus. Lyz2 
remained low throughout. 
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Figure 7-3: MMP response to mating 
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Figure 7-4: Macrophage markers in uterine epithelial cells post mating 
 
 
7.2.1.5 Inflammatory response pathway 
Several elements of the inflammatory response pathway demonstrate their lowest 
expression at dioestrus (Cd80, Ifng, Il2, Il2ra, Il2rb, Il4, Il5, Il5ra and Zap70, Figure 7-5) 
while others peaked at dioestrus (Cd40, Cd40lg, Il4ra, Lama5, Lamc2, Thbs3 and 
Tnfrsf1b). Fibrotic response factors Col1a1 and 2 and Thbs3 initially showed increasing 
expression post mating followed by a reduction at day 4. Lamb1-1 reduced post mating 
which was most evident at day 2. 
 
7.2.1.6 TGF-β signalling pathway 
TGF-β receptors Tgfbr1 and 2 initially showed low expression at dioestrus followed by 
an increase in expression at oestrus (Figure 7-6). Tgfbr3 showed high expression at 
dioestrus with a subsequent reduction at oestrus. Expression of all receptors remained 
low following mating, with Tgfbr1 increasing in expression at day 4. Tgfb1 reduced in 
expression following mating with a subsequent increase at day 4, while inhibin beta A 
(Ihba) exhibited its lowest expression at day 4. Lif showed a dramatic reduction in 
expression at day 1 post mating, with a recovery towards day 4, and the repressor 
Spp1 and co-factor Foxh1 mirrored this trend at day 2. Wnt1 and Egf showed low 
expression in cycling mice with a peak at day 1 post mating. 
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Figure 7-5: Elements of the inflammatory response pathway activated in uterine 
epithelial cells post mating 
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Figure 7-6: TGF-β pathway elements activated in uterine epithelial cells post mating 
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7.3 Appendix III: Pathway analysis for LCM captured endometrial stromal cells. 
 
7.3.1.1 Prostaglandin synthesis and regulation pathway 
Several members of the prostaglandin synthesis and regulation pathway (Figure 7-7-) 
showed a higher expression at dioestrus compared to oestrus (Ednra, Ednrb, Hpdg, 
Hsd11b1, Hsd11b2, Prl, Ptgder, Ptger1, Ptger3, Ptgir, Ptgis and S100a6) while others 
showed the reverse (Anxa1, Anxa2, Anxa4, Anxa5, Anxa6, Anxa8, Edn1, Pla2g4a, 
Ptger2, Ptger4 and Ptgs2). Cyp11a1, Ednra, Hsd11b1, Hpgd Ptgir and Tbxas1 
exhibited a peak in expression post mating at day 1, while S100a10 showed the lowest 
expression at this time point. Elements which peaked at day 2 included Anxa2, Anxa6, 
Hsd11b2, Ptger1 and S100a10. Anxa1, Anxa4, Cyp11a1, Pla2g4a, Ptgdr, Ptgs1, 
Ptgs2, and Prl experienced a reduction in expression post mating with day 4 being the 
lowest time point. 
 
7.3.1.2 Cytokines and inflammatory response pathway 
The vast majority of elements in the cytokine and inflammatory response pathway were 
more highly expressed at dioestrus compared with oestrus (Figure 7-8), with the 
notable exception of Pgdfa which exhibited the reverse. Many cytokines peaked at day 
1 post mating with a subsequent decrease in expression over time to day 4 (Csf2, 
Cxcl3, Il2, Il6, Il10, Il11, Il12a, Il12b, Il13, Pgdfa and Tnf) with others exhibiting a peak 
at day 2 (H2-eb1, Ifng, Il1b, IL15 and Pdgfa ) or day 3 (Cd4, H2-ea and Il5). The vast 
majority of elements showed a marked reduction in expression at day 4 with the 
exceptions of Ifng, Il15 and Tgfb. 
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Figure 7-7: Prostaglandin synthesis and regulation pathway elements active in uterine 
stromal cells 
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Figure 7-8: The cytokines and inflammatory response pathway in uterine stromal cells 
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7.3.1.3 MMPs 
The stromal MMP response to seminal plasma is shown in Figure 7-9. The majority of 
MMPs were expressed more highly at dioestrous compared to oestrus (Mmp1a, Mmp2, 
Mmp3, Mmp8, Mmp9, Mmp10, Mmp12, Mmp13, Mmp16, Mmp20, Mmp21, Mmp24, 
Mmp25, Mmp27 and Mmp28). Post mating, Mmp1a, Mmp3, Mmp10 and Mmp14 
peaked at day 1, while Mmp2, Mmp9, Mmp19 and Mmp25 peaked at day 2. With the 
exception of Mmp2, Mmp7 and Mmp19, day 4 showed the lowest expression of MMPs. 
 
7.3.1.4 Macrophage markers 
Cd14 and Cd68 were both more highly expressed at oestrus compared to dioestrus, 
while F3 and Cd163 showed the reverse (Figure 7-10). Cd14 and Cd163 showed 
progressively lower expression post mating following a small peak at day1, with day 4 
showing the lowest. Cd68 and Lyz2 peaked at day 2, with a subsequent reduction in 
expression, while F3 was lowest at day 3. 
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Figure 7-9: Uterine stromal cell MMP response to seminal plasma 
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Figure 7-10: Macrophage markers in uterine stromal cells post mating 
 
7.3.1.5 Inflammatory response pathway 
With the exception of Il4ra, Lama5 and Lamc2, all elements of the inflammatory 
response pathway were more highly expressed at dioestrus compared to oestrus 
(Figure 7-11). Post mating, Cd40, Cd40lg, Cd86 and Thbs1 peaked at day 1, while 
Col1a1, Col1a2, Col3a1, Ifng and Vtn peaked at day 2.  Il2ra was initially high at days 1 
and 2 with a subsequent drop in expression at days 3 and 4. Lama5 and Lamc2 were 
progressively downregulated post mating. Il2b and Zap70 peaked at day 4, with 
Cd40lg, Il2, Il4, Il5, Il5ra and Tnfrsf1b showing their lowest expression at this time point. 
 
7.3.1.6 TGF-β signalling pathway 
The complex TGF-β signalling pathway exhibited differential responses to the mating 
stimulus (Figure 7-12). Tgfb1 was very low in expression in controls, with a dramatic 
increase post mating, sustained through days 1-4. Of the TGF-β receptors, Tgfbr1 and 
Tgfbr3 were more highly expressed at dioestrus compared to oestrus.Tgfbr3 
maintained a steady level of expression post mating, while Tgfbr1 and Tgfbr2 were 
initially high at day 1 with a subsequent reduction in expression. Inhba and Thbs1 
peaked at day 1 with a subsequent fall in expression, while Fst and Nog peaked at day 
2. Of the signal transducing SMADs, Smad1 peaked at dioestrus and day 4, Smad 9 
was highly expressed at dioestrus with its lowest expression at day 4, and Smad3 was 
low at dioestrus with a peak at day 4. Smad 7 exhibited a dramatic fall in expression at 
day 2 post mating with a subsequent recovery at days 3 and 4. 
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Figure 7-11: Inflammatory response pathway activation in uterine stromal cells 
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Figure 7-12: TGF-β signalling pathway response to mating in uterine stromal cells 
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7.4 Appendix IV: Cytokines measured via fluid phase multiplex immunoassay 
 
Cytokine Symbol 
Cutaneous T Cell attracting chemokine CTACK 
Eotaxin Eotaxin 
Fibroblast growth factor basic FGF basic 
Granulocyte colony stimulating factor G-CSF 
Growth regulated oncogene alpha GRO-α 
Hepatocyte growth factor HGF 
Intercellular adhesion molecule ICAM 
Interferon alpha 2 IFN-α2 
Interferon gamma IFN-γ 
Interferon gamma induced protein 10 IP-10 
Interleukin  12 p40 subunit IL-12 (p40) 
Interleukin 1 alpha IL-1α 
Interleukin 1 receptor antagonist IL-1ra 
Interleukin 10 IL-10 
Interleukin 12 p70 subunit IL-12 (p70) 
Interleukin 13 IL-13 
Interleukin 15 IL-15 
Interleukin 16 IL-16 
Interleukin 17 IL-17 
Interleukin 18 IL-18 
Interleukin 1β IL-1β 
Interleukin 2 IL-2 
Interleukin 2 receptor alpha IL-2rα 
Interleukin 3 IL-3 
Interleukin 4 IL-4 
Interleukin 5 IL-5 
Interleukin 6 IL-6 
Interleukin 7 IL-7 
Interleukin 8 IL-8 
Interleukin 9 IL-9 
Leukaemia inhibitory factor LIF 
Macrophage colony stimulating factor M-CSF 
Macrophage inhibitory protein 1 alpha MIP-1α 
Macrophage inhibitory protein 1 beta MIP-1β 
Macrophage migration inhibitory factor MIF 
Monocyte chemotactic protein 1 MCP-1 
Monocyte chemotactic protein 3 MCP-3 
Monokine induced by gamma interferon MIG 
Nerve growth factor beta βNGF 
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Cytokine Symbol 
Platelet derived growth factor PDGF 
Regulated upon activation T cell expressed and secreted RANTES 
Stem cell factor SCF 
Stem cell growth factor beta SCGF-β 
Stromal derive factor SDF-1α 
TNF-related apoptosis-inducing ligand TRAIL 
Tumour necrosis factor alpha TNF-α 
Tumour necrosis factor beta TNF-β 
Vascular cell adhesion molecule VCAM 
Vascular endothelial growth factor VEGF 
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7.5 Appendix V: Principal components analysis (individual data) 
 
7.5.1 Scree plots for maturity stages 
 
Figure 7-13: Scree plots for the PCA of individual maturity stages 
 
 
  
313 
 
 
7.6 Appendix VI: Principal Components Analysis (Pairwise Comparisons) 
 
7.6.1 MII-F vs MII-NF Scree plot 
 
Figure 7-14: Scree plot demonstrating the variance explained by each of the PCs when 
comparing MII-F and MII-NF oocytes. PCs 1, 2 and 3 represented 60% of the total 
variation. 
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7.6.2 MII-F vs MII-NF alternative PC plots 
 
Figure 7-15: Alternative PC plots for MII-F vs MII-NF 
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7.6.3 PC3 coefficients for MII-F vs MII-NF 
 
Figure 7-16: Relative contributions of cytokines as determined by PC3 
 
  
316 
 
 
7.6.4 MII-F vs MI Scree Plot 
 
Figure 7-17: Scree plot demonstrating the amout of variance explained by each PC 
when comparing MII-F and MI oocyte FF 
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7.6.5 MII-NF vs MI Scree plot 
 
 
Figure 7-18: Scree plot demonstrating the relative contribution of each PC to total 
variance.  
PCs 1, 2 and 3 explained 60% of the total. 
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7.6.6 MII-NF and MI PC coefficients 
 
Figure 7-19: PC coefficients for MII-NF vs MI oocytes 
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7.6.7 MII-NF vs GV Scree Plot 
 
Figure 7-20: Scree plot of combined PCs for MII-NF versus GV oocytes 
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7.6.8 MI vs GV Scree plot 
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7.6.9 MI vs GV PC Coefficients 
 
Figure 7-21: PC coefficients for MI and GV oocytes 
 
